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Abstract 
Foot and mouth disease (FMD) has significant socioeconomic importance due to its 
impact on livestock trade. Responses to outbreaks of FMD are designed to establish a 
state of freedom from the disease as quickly as possible so that normal trade can 
resume. Critical to any response plan is the ability to rapidly detect the disease with 
high confidence. Clinical symptoms of FMD are difficult to distinguish from other 
vesicular diseases and a definitive diagnosis can only be made using laboratory-based 
tests. Diagnosis of FMD is further complicated by the antigenic variation associated 
with the causative agent (FMD virus) existing as seven immunologically distinct 
serotypes, each composed of numerous strains.  
Serodiagnostic tests for FMD exploit the host immune response to either the structural 
proteins that confer serotype specificity or the non-structural proteins that are highly 
conserved across all serotypes. Most vaccines are composed of FMD virus structural 
proteins from a single serotype such that no cross-serotype protection is conferred. 
Vaccination complicates diagnosis because detection of antibodies to structural 
proteins may indicate infection or vaccination. However, sera containing antibodies to 
non-structural proteins are indicative of infection. The homology shared by non-
structural proteins across all serotypes provides an opportunity to develop serotype-
independent serodiagnostic tests for FMD that may be applied to unvaccinated and 
vaccinated animals. 
This thesis describes the development of one such prototype test. A novel approach to 
antigen design was used to derive a serotype-independent antigen, referred to as c3B, 
which best represented the non-structural protein 3B from all serotypes of FMDV. 
Abstract  
 
   
Soluble recombinant c3B proteins were produced in bacteria from a synthetic coding 
sequence and purified. Recombinant c3B antigen was used to develop a pan-
serodiagnostic competition enzyme-linked immunosorbent assay (c3B C-ELISA). The 
c3B C-ELISA positively identified each of seven bovine sera collected from individual 
animals that were each infected with one of the seven FMDV serotypes. The high 
diagnostic power of the test is shown through an analysis of its sensitivity and 
specificity as compared with an existing validated test. The c3B C-ELISA is also 
discussed in terms of its serotype-independent diagnostic capability, its application to 
differentiating infected from vaccinated animals (DIVA), and its potential as a readily 
available test suitable for use in the global plan to control and eradicate FMD. 
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CHAPTER 1  
 LITERATURE REVIEW 
1.1. INTRODUCTION 
Foot-and-mouth disease (FMD) is the most contagious viral vesicular disease affecting 
cloven-hoofed livestock species and has significant global socio-economic 
consequences. It is an important constraint to international trade of livestock and their 
derived products (1,2). FMD is a significant endemic disease that threatens the 
livestock industries of many countries (3) and remains a major threat to FMD-free 
countries, including Australia. Accurate diagnosis of infection and an ability to 
differentiate infected and vaccinated animals (DIVA) is of prime importance for 
control, surveillance and eradication strategies (4). To this end, research and 
development of bioreagents suitable for pan-serotype diagnosis of FMD virus 
(FMDV) infection remains a priority. 
FMD is included in the list of infectious diseases notifiable to the Office International 
des Epizooties/ World Organisation for Animal Health (OIE) (5). FMD was originally 
ranked first in the A list of infectious diseases of animals by OIE, defined as 
 “transmissible diseases that have the potential for very serious and rapid spread, 
irrespective of national borders, that are of serious socio-economic or public health 
consequence and that are of major importance in the international trade of animals 
and animal products.” (6) 
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FMD is exotic to Australia but it is believed to have occurred in Australia twice during 
the 1800’s. The last recorded incursion occurred in 1872-73 when five suspected 
incidents of FMD were reported. The disease was observed only in cattle and pigs on 
the index farm and originated from an imported English bull (7). Bunn and colleagues 
advocated that the outbreak in 1872 was FMD based on strong circumstantial evidence 
(8) with clinical symptoms recorded indicative of the disease. FMD is a highly 
contagious disease and its limited spread during this incident led Auty (9) to question 
the diagnosis. However, it was suggested that the lack of spread may have been due to 
a number of factors including infection by a low virulence strain; the number of 
infected animals was small and the farm was isolated; and conditions were 
unfavourable for airborne spread at that time (8). Given that FMD is clinically 
indistinguishable from other vesicular diseases, and without verification by accepted 
diagnostic tests, this occurrence of FMD in Australia cannot be confirmed. If FMDV 
was the cause of the vesicular disease in the 1800’s Australia is extremely fortunate 
that the disease did not become endemic (8) and has not occurred since. The CSIRO 
Australian Animal Health Laboratory was purpose built in 1985 as a high-containment 
facility designed to allow scientific research into the most dangerous infectious agents 
in the world, including FMD. To this day it serves Australia as a reference diagnostic 
facility conducting FMD exclusion testing. 
FMD causes enormous economic damage in countries where it is endemic and has the 
potential to cause in disease-free countries should an outbreak occur. An example of 
the devastating financial loss an FMD outbreak can cause occurred in 2001 in the 
United Kingdom. Over a period of eight months more than four million animals were 
destroyed, with an estimated amount of US $30 billion attributed to direct and indirect 
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costs (10), including compensation, lost trade and eradication measures (11). Australia 
exports approximately 60% of its livestock production to markets sensitive to FMD 
(12). The estimated financial cost of a small FMD outbreak in a single Australian state 
is US $4.0 - 4.5 billion over 10 years, depending on the control measures employed. 
In the event of a large multi-state FMD outbreak the estimated cost could be as high 
as US $36 billion over a 10 year period (12).  
The disease continues to be present in many parts of the world, although it has been 
successfully excluded from North America, Australasia and, until recently, Western 
Europe (13). Outbreaks have occurred in 2001 and 2007 in the United Kingdom and 
in 2001 in France and the Netherlands (14,15). In February 2001, FMD was detected 
in sows at a slaughterhouse in Great Britain (16). One month later, animals on a mixed 
dairy-goat/veal-calf farm showed signs of FMD in Netherlands. This farm was one of 
three that received calves imported from Ireland (15). Transmission of FMD to the 
Irish calves was believed to have occurred at a staging point in France where sheep 
from an affected farm neighbouring the incident case in the United Kingdom were also 
present (15–17). The European Union is an open market so no measures were in place 
to prevent the spread of FMD between countries (15). The outbreak of 2007 in the 
United Kingdom was found to be due to virus escape from FMDV laboratories at 
Pirbright (18). 
The global distribution of FMD closely mirrors global distribution of wealth such that 
disease is persistently endemic in low-income per capita nations (19,20). The OIE’s 
mandate is to provide official recognition of a country’s FMD status for international 
trade under an official agreement with the World Trade Organisation. As of May 2015, 
of the 180 OIE member countries, more than 100 were not FMD-free as defined by 
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the OIE Terrestrial Animal Health Code which states that an animal must be free of 
FMDV antigen, ribonucleic acid or antibodies that are not a consequence of 
vaccination (21). These FMD endemic regions remain a permanent threat to disease-
free regions. 
1.2. FOOT-AND-MOUTH DISEASE  
Believed to be the first written record of FMD, in 1546 Hieronymous Fracastorius 
described an epidemic that occurred in cattle near Verona, Italy (3). The disease was 
characteristic of FMD. Fracastorius detailed animals that refused to eat and the 
interiors of their mouths displayed redness and small vesicles which appeared to 
“descend to” the feet (22). In the centuries that passed, the disease became a notorious 
recurrent threat to domestic cattle. Perhaps the first FMD research was the 
demonstration by Loeffler and Frosch of a filterable agent as the cause of disease (23). 
Twenty years later Waldmann and Pape reproduced disease in guinea pigs by 
intradermal inoculation thus establishing, for the first time, a suitable experimental 
animal model (3). 
1.2.1. Incubation period 
A disease incubation period is defined as the time interval between initial exposure to 
an infective dose of virus and the first appearance of clinical signs of disease. The 
incubation period of FMD is highly variable and can range from 2-14 days. The 
incubation period is dependent on dose and strain of virus, route of infection, animal 
species and husbandry conditions (24–27). In naturally acquired FMD infection the 
incubation period is generally short, lasting 2-8 days (24). 
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1.2.2. Clinical signs of FMD  
FMD results in an acute febrile illness with characteristic vesicle formation within the 
stratified squamous epithelia of the oral cavity and feet (1). Disease has been observed 
in cattle, pigs, sheep, goats, camelids (camels, llamas and alpacas), bison, water 
buffalo, African buffalo, deer, antelope and gazelle, moose, impala, giraffes, 
wildebeest, eland and warthogs (19,28).  
It should be emphasised that clinical diagnosis can be difficult; for example, small 
ruminants may display mild or subclinical signs of disease (11,29–31). Clinical 
diagnosis of FMD is further complicated as it cannot be differentiated from other 
vesicular diseases such as vesicular stomatitis, swine vesicular exanthema and swine 
vesicular disease (23,30,32). A definitive diagnosis of FMD requires complimentary 
laboratory confirmation (33). 
Host species variation 
The disease predominantly affects domesticated livestock including cattle, sheep, 
goats and pigs. Susceptibility to infection, routes of virus infection, development and 
severity of clinical disease, and persistence of infection vary significantly between host 
animal species (24).  
Following incubation, initial clinical signs such as fever, anorexia and depression 
become evident (30). Vesicular lesions are apparent in and around the mouth, on the 
feet and, for lactating animals, on the mammary glands 1-3 days following initial 
clinical signs. Oral lesions occur predominantly on the tongue but may also develop 
on the dental pad, hard palate, gums and inside the lips (24). Lesions on the feet 
typically appear on coronary bands, bulbs of the heel and may extend to the interdigital 
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space (24,33,34). Fluid filled vesicular lesions can reach several centimetres in 
diameter. Vesicles rupture 1-2 days after development leaving raw erosions. This 
results in acute lameness, a tucked-up stance or a reluctance to move, inappetence and 
excessive salivation (24,30). Feet and oral lesions heal rapidly, averaging 7 days, if 
uncomplicated by secondary infection. Mortality in mature animals is rare but can be 
over 90% in young animals due to associated myocarditis (24,33,35). 
Cattle 
Susceptible cattle in contact with infected animals are predominantly infected by the 
respiratory route or skin abrasions. Initial signs of FMD are generally a sudden loss of 
milk production, depression and fever lasting 1-2 days (24). Mouth lesions often 
coalesce and rupture within 24 h of forming, displacing large portions of epithelium 
(35). Profuse drooling and ocular and nasal discharge occurs during the acute stage of 
disease. Due to these pronounced clinical signs of disease, cattle are regarded as 
indicators of disease. Persistent infection is considered a common sequel to FMDV 
infection in ruminants that may lead to a carrier state (2,36,37). 
Sheep and goats 
Sheep are susceptible to infection via the respiratory route but are more likely to be 
infected by direct contact through abrasions on the skin or mucous membranes (35,38). 
Clinical symptoms of FMD in sheep and goats are mild to subclinical and may prove 
difficult to diagnose (11,29–31). Twenty-five per cent of infected sheep fail to develop 
vesicular lesions (38). Of those animals that do, lesions are superficial in comparison 
to lesions developed by cattle and heal rapidly (39). As such, sheep and goats are 
described as disseminators of disease or maintenance hosts amongst the susceptible 
domestic species. Lesions that typically rupture rapidly can form on the feet in the 
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interdigital cleft, on heel bulbs and on the coronary band (29,38). Lesions also form in 
the mouth on the dental pad and usually occur as only shallow erosions (29,38). Other 
conditions such as footrot or bluetongue virus infection can conceal FMDV infection 
in sheep (38). FMDV has been demonstrated to persist in sheep beyond clinical disease 
for up to 20 weeks post infection (40). 
Pigs 
Pigs have been termed the amplification host of FMD as they generate greater 
quantities of aerosolised virus than other susceptible hosts [reviewed in (33,41,42)]. 
Pigs are more susceptible to infection via the gastrointestinal route by consumption of 
contaminated products (41–43). The serotype O Cathay topotype including the 
Taiwanese strain, O/TAW/9/97, has adapted to be highly virulent in pigs (44–46). Pigs 
present with fever, lameness and blanching of the skin around the coronary band in the 
acute stage of infection. Vesicular lesions that develop in the mouth or on the snout 
are not as prominent as those in cattle (24). Rather, FMD primarily affects the feet 
causing severe vesicular lesions on the coronary band (38). Lesions can also appear on 
the accessory digits and pressure points due to the animals adoption of a hobbling gait 
(24,33). Pigs typically clear virus within 3-4 weeks post infection (1). Persistent 
infection of pigs has not been observed beyond the resolution of clinical disease (47).  
Other hosts (wildlife) 
In comparison to livestock animals FMDV infection of wildlife hosts results in 
relatively mild disease (28). Natural and experimental FMDV infection has been 
reported in numerous species of free-ranging and captive wildlife [reviewed in (48)]. 
The significance of wildlife hosts is hypothesised to be the establishment of carrier 
populations that form a reservoir of disease. A case in point, the African buffalo 
Chapter 1 
 
8 
(Syncerus caffer) is believed to play an important role as a reservoir for the Southern 
African Territories serotypes of FMDV in Africa (28,33,49,50). Disease in African 
buffalos is often subclinical, as with sheep and goats (51). Transmission of FMDV 
from buffalo to domesticated livestock is believed to be the cause of a number of 
outbreaks in southern Africa (52–54) and has been demonstrated experimentally 
(55,56). 
1.2.3. Pathogenesis  
Numerous researchers have investigated the pathogenesis of FMDV and the subject 
has recently been reviewed for disease in cattle (2) and in other susceptible species (1). 
Originally it was thought that infection occurred by puncture of the epithelium with 
primary replication occurring in the tongue, mouth and feet (57). It is now generally 
accepted that the most common route of infection is via the respiratory route whereas 
the initial site of virus replication following aerosol exposure is a controversial subject. 
Several lines of evidence suggest the pharyngeal area as the primary site of virus 
replication (25,58–64) whereas others suggest the lower respiratory system (61,62). A 
consensus is forming where the lungs have an important role in late infection rather 
than as the initial site of replication (63,65). Thus, virus replication in the epithelium 
of the pharynx is generally accepted as the primary site of replication (33). One 
exception is if the virus directly enters the cornified epithelia through damaged 
integument allowing it to target the highly susceptible epithelial regions for initial 
replication (60). 
Following infection there is a period of viremia and generalised infection lasting 3-5 
days. Virus drains from the initial site of replication through the lymphatic system 
gaining entry to the bloodstream (63). All excretions and secretions from an infected 
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animal, including urine, faeces, saliva, nasal and lachrymal fluid, milk and breath, may 
become infectious over the course of disease (25). Secondary sites of replication result 
in the formation of vesicular lesions in the stratified squamous epithelium of the skin, 
oral mucosa and interdigital space (66). Development of vesicular lesions is coincident 
with the peak of viremia (63). Significant titres of circulating antibodies can be 
detected 3-5 days after the first appearance of clinical disease. The antibody response 
is usually sufficient to clear the virus from circulation (25,33). 
1.2.4. Modes of transmission 
The modes of FMDV transmission in order of common occurrence are 1) direct contact 
between infected and susceptible animals; 2) ingestion of contaminated animal 
products, usually associated with pigs, including meat, offal and milk; 3) indirect 
contact via contaminated non-susceptible vectors such as animals, humans or fomites 
(25).  
The species infected highly influences the spread of disease (67). Cattle are highly 
susceptible to infection via the respiratory route, requiring only 10 median tissue 
culture infectious dose (TCID50) units to establish infection (33). Compared with 
smaller ruminants, cattle are prone to infection via aerosolised virus due to their 
relatively large respiratory volume (25,35). In contrast, infection of cattle via the oral 
route requires 10,000 times greater viral load than for pigs (35). Sheep are also 
susceptible to infection via the respiratory route, requiring a similar infective dose to 
cattle. However, sheep are less likely to become infected by this route than cattle due 
to their lower respiratory volume (33,35). For these reasons sheep are more likely to 
be infected by direct contact through abrasions on the skin or mucous membranes or 
by contaminated food (35). Differing from ruminants, pigs are noted to be relatively 
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resistant to airborne virus and infection via the respiratory route. Pigs have been found 
to require up to 104 TCID50 to establish infection by this route (26,68,69). The reason 
cattle and sheep are more susceptible to infection by airborne virus compared to pigs 
remains unknown (1,69). However, pigs have a much smaller region of specialised 
epithelium on the dorsal soft palate than cattle (66) which may explain this difference 
in susceptibility to airborne transmission of FMDV (66,70). Pigs are more commonly 
infected via the oral route through consumption of contaminated products presenting 
an infectious dose of approximately 105 TCID50 (43). Pigs are also infected by direct 
contact with infected animals or when housed in heavily contaminated environments 
(71). In all cases, the minimum infective dose values are indicative only as they vary 
with virus strain and individual animals (33) [reviewed in (42)].   
Direct and indirect contact 
Direct contact is generally accepted as the most common and effective mode of FMDV 
transmission (2,63,72). All excretions (e.g. urine or faeces) and secretions (e.g. sweat 
or saliva) from infected animals contain virus (67). Infection can be initiated by 
inhalation of infectious droplets and droplet nuclei originating mainly from the breath 
of infected animals (41,73). Other routes of infection include mechanical transfer 
between infected and susceptible animals by physical contact with animal excretions 
or virus entry through cuts or abrasions in the skin (33). Injury to the skin or oral 
mucosa is commonly caused by feeding on rough fodder; milking machines or 
suckling calves; housing on concrete; or foot rot (74). Infection via abrasions is an 
efficient natural and a common experimental infection method. Infection is 
accomplished experimentally by damaging the cornified epithelium of the tongue by 
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scraping and inoculating with FMD. An infective dose as low as 10 TCID50 is 
sufficient for FMDV infection through abrasions of this type (74). 
Contact with infected animals may also occur indirectly by mechanical means; for 
example, through contact with contaminated milking machinery or transport vehicles, 
handlers, or fomites (26). Farming practices such as shearing, de-worming, clinical 
examination, and blood sampling increase the risk of indirect transmission (25). 
FMDV has been shown to retain infectivity in the environment for periods that vary 
with virus strain and ambient temperature on fomites such as faeces, 2-3 months; urine, 
5-7 days; slurry, 2-3 months; wool, 2 months; hay, 2 weeks to 4 months; and soil, up 
to 7 months (74,75).  
Outbreaks have originated with the feeding and ingestion of contaminated animal 
products. The epidemic in the United Kingdom in 2001 is attributed to feeding pigs 
swill (11,33,76). In March 2000, an outbreak of FMD type O in South Korea and Japan 
was traced back to the feeding of pigs uncooked swill obtained from a ship from the 
port of Durban, South Africa (14). FMD had not been present in these countries for 
over 30 years prior to these outbreaks. 
Airborne virus transmission 
Most transmission mechanisms are controllable. In the event of an outbreak, 
establishment of quarantine zones, movement restrictions and disinfection of fomites 
can prevent further spread. However, long distance aerial transmission of virus is 
considered more difficult to control, as it requires large exclusion or quarantine zones 
(70). Under certain favourable epidemiological (virus strain, host species, infectivity 
and concentration, and source of aerosolised virus) and climatic conditions (high 
relative humidity of >55% and a continuous steady wind) aerial transmission can be 
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rapid and occur over significant distances (74,77). Long distance aerial transmission 
was first suspected in the early 1970’s after outbreaks during an epidemic in the United 
Kingdom in 1967-68 could not be attributed to any other mechanism of transmission 
(27,78). Windborne transmission is believed to have a limit of approximately 10 km 
over land, yet it is suspected as the transmission route for an outbreak on the Isle of 
Wright which would require a250 km journey over water (41). Although airborne 
spread of FMDV can occur, it is dependent upon serotype and strain. Airborne spread 
has been identified as playing a role in the outbreaks in the United Kingdom in 1967-
68 (79) and 2001 (80,81) and should not be overlooked in strategies for disease control.  
Excretion 
Strain-specific differences in FMDV excretion levels have been observed for FMDV 
(82). Aerosolised virus quantities excreted by pigs per 24 h clearly demonstrate the 
variation between viral strains: 105.8 TCID50 O South Korea 2000, 106.1 TCID50 O UK 
2001, 106.4 TCID50 O Lausanne, and 107.6 TCID50 C Noville (26,68,83).  
Differences in FMDV excretion levels in breath has also been observed across animal 
species (25,70,84). In cattle and pigs excretion lasts for a period of 4-5 days with 
maximal excretion occurring during the acute phase and coinciding with development 
of clinical disease. Sheep excrete virus for up to 7 days with maximum excretion 
occurring 1-2 days before clinical signs develop (85–87). Airborne virus is excreted in 
breath originating from the upper respiratory tract initially and lower respiratory tract 
later in disease (70,86). The precise mechanism of virus release is not yet known 
(87,88) and so far only a single study (86) has demonstrated excretion of FMDV from 
the respiratory system as the source of airborne FMDV. 
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The highly contagious nature of this virus is in part due to the quantities of airborne 
virus excreted. Quantities of virus excreted vary depending upon the type of domestic 
host. As an example, ruminants have been shown to excrete approximately 104.3 
TCID50 airborne FMDV serotype O (UKG 2001) per animal in a 24 h period. However, 
pigs were shown to excrete 106.1 TCID50 of the same virus, 60-fold greater than that 
from cattle or sheep (68,83). As such, pigs are noted as potent emitters of airborne 
virus because they generate greater quantities of aerosolised virus (between 105.6 - 108.6 
virus particles per pig in a 24 h period) (33,34,42). Consequently, a high risk of 
airborne spread exists for prone species downwind of infected pigs (70). 
The carrier state: a persistent infection  
Development of an FMDV carrier state has been reviewed extensively 
(1,2,25,31,33,47,66,89); however, little is known about how this state of persistent 
infection translates to disease transmission. A carrier of FMD is characterised by the 
asymptomatic low-level excretion of FMDV from the oropharynx of ruminants for 
periods that are species- and virus strain-dependent (47). A typical host response to 
FMDV includes the production of antibodies 3-4 days post exposure which results in 
clearing of viremia within 3-4 weeks (66). Animals that develop a persistent infection 
fail to eliminate the virus in the acute stage of infection leading to presence of 
detectable virus for periods greater than 28 days post infection (47,90). Van Bekkum 
and colleagues isolated viable virus from probang oesophagopharyngeal (OP) fluid 
samples taken from convalescent cattle five months post infection (91). A subsequent 
study demonstrated tissue-specific persistent infection localised to the tonsil, pharynx 
and the dorsal surface of the soft palate (40).  
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The proportion of ruminants in a herd which develop persistent infections average 
approximately 50% with the duration of persistence varying between animals (2,33). 
This is suspected to be due to less efficient clearance of virus from peripheral sites 
such as the nasal and oral surfaces and, more so, the OP region (25). In carriers, virus 
has been intermittently detected at a low titre that declined over time. This complicates 
diagnosis using methods that detect virus and reinforces the need for serological tests. 
Maximum reported durations of the carrier state for the different species are: cattle, 
3.5 years; sheep, 9 months; goat, 4 months; and African buffalo, 5 years (40,49,66,92). 
Pigs efficiently clear FMDV and have not been demonstrated to become carriers 
[reviewed in (66,72)] as demonstrated by studies that have not detected infectious 
FMDV in pigs beyond 28 days post infection (1,25,93–95).  
Currently, trade restrictions apply to asymptomatic carriers despite inconclusive 
evidence of the their role in virus transmission (33,66). The only experimental 
demonstration of transmission of virus from carriers to susceptible hosts is that from 
African buffalo to cattle (56,96). Yet there is no experimental evidence of virus 
transmission from carrier cattle or sheep to uninfected animals. As a result, 
confirmation of the extent of the threat posed by carriers to susceptible animals is of 
critical importance for trade as well as disease control. Clearly then, further elucidation 
of the mechanisms contributing to development of persistent infection and the 
potential for transmission from carriers is required. Of interest are the anatomical sites 
conducive to persistent infection, the cellular origin of virus obtained by OP sampling 
and the mechanisms leading to the establishment of a persistent infection in ruminants 
but not in pigs.  
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1.3. FOOT-AND-MOUTH DISEASE VIRUS (FMDV) 
1.3.1. Classification 
FMDV belongs to the family, Picornaviridae. Members of this family are 
characterised by a genome consisting of one molecule of single-stranded, positive-
sense RNA ((+)ssRNA), contained within an icosahedral non-enveloped capsid 
approximately 30 nm in diameter (3,97). FMDV is the type species of the genus 
Aphthovirus, and is distinguished by its acid labile properties, becoming unstable 
below pH 6.8 (3,4,98). 
1.3.2. Serotypes 
There are seven serologically distinct types of FMDV (4,23). In the early twentieth 
century the virus was discovered to exist as more than one serotype by Vallée and 
Carré who distinguished serotypes O, originating from the Department of Oise in 
France, and A from Allemagne (the French word for Germany) (99,100). A third 
serotype, serotype C, was subsequently distinguished by Waldmann and Trautwein 
(101). In the late 1920’s, subtypes were discovered within these three serotypes (23). 
Thirty years later, Galloway, Brooksby and Henderson at the Pirbright laboratory 
described three additional serotypes isolated in South Africa, Southern African 
Territories 1 (SAT1), SAT2 and SAT3 (102). The most recent serotype to be identified, 
Asia1, was detected in India in 1951 and 1952 and in Pakistan in 1954 (103,104). 
Extensive examination of samples from around the world has not revealed any 
additional serotypes, although there are many subtypes within each serotype (105). 
Animals infected or vaccinated against one FMDV serotype remain susceptible to 
infection by all other serotypes (106). 
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Currently, FMDV serotypes are geographically distributed in clusters (Figure 1-1). 
The SAT serotypes are predominantly in sub-Saharan Africa, however, SAT1 was 
identified in Saudi Arabia in 2000 and SAT2 in Egypt and Libya in 2012. Types A and 
O are widely distributed in parts of Africa, southern Asia, the Far East, and South 
America. Type Asia1 is found in southern Asia (107). At the time of writing there have 
been no outbreaks of type C in Europe since 1989 (Italy), Asia since 1996 (India and 
the Philippines), Africa (Kenya) (108) and South America since 2004 (Amazon river) 
(109,110). Serotype C is suspected to no longer circulate in nature (105). At this time 
Australasia, North America and Europe remain FMD-free. 
1.3.3. Genome organisation 
The FMDV genome is a single, long, open-reading frame of approximately 8,500 
nucleotides in length. It can be separated into four main sections including a 5’-
untranslated region (5’-UTR), a single open-reading frame (ORF), a 3’-untranslated 
region (3’-UTR) and a polyadenylated tail. The RNA does not contain a 5’-terminal 
7-methyl-G cap structure immediately upstream of the start codon. Rather the 5’ UTR 
is covalently linked to a small protein termed the viral protein genome linked (VPg) 
or as the non-structural protein, 3B. VPg serves as a primer for RNA transcription 
(111). Translation of the ORF can be initiated at two separate start codons that are 84 
nucleotides apart, the second being dominant (4). The 5’ UTR is extraordinarily long, 
approximately 1,300 nucleotides, and is divided into five functional components 
critical for genome replication and translation; these include an S fragment, poly 
cytosine tract, cis-acting replicative element (cre), pseudo knot, and an internal 
ribosome entry site (IRES) (112,113). The IRES has a critical role in mediating and 
initiating translation of the viral genome (31,113). 
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1.3.4. Virus structure  
The FMD virion consists of sixty copies of each of the structural proteins that assemble 
to form the capsid (114). FMDV structural proteins include VP1, VP2, VP3 and VP4. 
Proteins VP0, VP1 and VP3 form a protomer, five protomers assemble into a pentamer 
and 12 pentamers form the provirion. Cleavage of the protein intermediate VP0 to 
form VP4 and VP2 results in generation of the infectious virion (115). 
1.3.5. Infectious cycle 
The FMDV infection cycle has not been studied extensively. As such, much of current 
theory is based on observations from other picornaviridae infection cycles [reviewed 
by Grubman and Baxt (31)] (Figure 1-2). 
Penetration and uncoating 
To replicate, the virus particle must enter a cell capable of transcription and translation. 
A conserved Arg-Gly-Asp (RGD) motif in the FMDV G-H loop of VP1 was shown to 
bind to cells via a number of integrin receptor isoforms (115–120). Alternative virus-
binding ligands heparan sulphate proteoglycans, also facilitate FMDV entry into cells 
(121) [reviewed by Jackson and colleagues (114)]. The mechanism for release of viral 
genome within the host cell remains unclear; however, available evidence suggests a 
process triggered by the acidic environment of endosomes (122). Unlike those of other 
picornaviruses, at pH <6.5 the FMDV capsid dissociates to 12S pentameric subunits 
(98). This instability is thought to be due to a cluster of histidine residues at the 
interface between VP2 and VP3 which become protonated at low pH (123). 
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Figure 1-1: FMDV distribution. 
Distribution of FMDV serotypes categorised into seven pools for the period 2011-2015. Adapted from FAO FMD Situation monthly 
report (107).  
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Figure 1-2: FMDV infection cycle. 
(1) Penetration and uncoating; (2) viral protein translation; (3) transcription and genome replication; (4) encapsidation and maturation. 
Positive-sense RNA is shown in purple and negative sense in blue. IRES: internal ribosome entry site. Adapted from Whitton and 
colleagues (124). 
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Viral protein translation and function 
The FMDV genome encodes all proteins required for production of infectious virions 
(Figure 1-3). Following uncoating, the viral genome is released into the cytoplasm by 
an unknown mechanism. By mimicking messenger RNA (mRNA), translation of viral 
protein commences. Translation of the FMDV ORF results in the production of a 
single polyprotein that is co- and post-translationally cleaved, leading to the production 
of both structural proteins (SP) and non-structural proteins (NSP). Each protein has a 
defined role and position on the polypeptide if known, these are summarised in Table 
1-1. Picornavirus full-length translation products are not observed due to rapid, co-
translational, intramolecular cleavages (125). Primary cleavage creates four 
fragments: Lpro, P1-2A, P2, and P3 (126). This is mediated by three non-structural 
proteinases, leader Lpro, 2Apro, 3Cpro. All subsequent cleavages are mediated by 3Cpro 
to generate the structural proteins VP0, VP1 and VP3 and NSP 2A from P1-2A as well 
as the remaining NSPs from P2 and P3. 
Leader proteinase, Lpro, is an additional protein at the N-terminus of the polyprotein of 
aphthoviruses. It is synthesised in two active forms, Lab and Lb, resulting from the 
initiation of translation at either of two AUG codons that are 84 nucleotides apart 
(127,128). Lpro is a papain-like cysteine proteinase that mediates autocatalytic cleavage 
of itself from P1. In additional Lpro cleaves host factor translation initiation factor, 
eIF4G, preventing host cap-dependent mRNA translation (122). Polyprotein cleavage 
occurs at the C-terminus of 2A at the Gly–Pro peptide bond and is mediated by an 18 
amino acid region. Fry and colleagues suggested protein 2A may function as an 
autoprotease (122). It has also been hypothesised that 2Apro acts at the ribosomal level, 
modifying translational machinery allowing release of the P1-2A region while 
Chapter 1 
 
21 
permitting downstream synthesis to continue (129). The capsid precursor P1 is 
processed on secondary cleavage to form the structural proteins VP0, VP3 and VP1 
(genome segments 1AB, 1C and 1D, respectively). FMDV structural proteins VP1-3 
are smaller than viruses in other genera of the Picornaviridae family.  
Cleavage of P2 creates NSP 2B and 2C. FMDV 2B and 2C are known to form 
membrane-associated virus-replicating complexes localised to the cell periphery 
(130). Picornaviral 2B is known to enhance membrane permeability, block protein 
secretory pathways, suppress apoptotic responses and has been implicated in virus-
induced cytopathic affects (115,131). When expressed together FMDV NSP 2B and 
2C disrupt the Golgi-ER secretory pathway and block protein secretion (132). NSP 2C 
has also been implicated in FMDV RNA synthesis, having putative helicase and 
nucleotide binding motifs (31,133). Protein 2C also has ATPase and GTPase activity 
with triphosphate-binding domains (115,134–137). These are suggested to couple 
nucleotide hydrolysis to a function necessary for viral replication (135). Recently, NSP 
2C has also be shown to modulate the fusion of lysosomes to autophagosomes by 
specific binding to protein beclin1 and the cellular intermediate filament protein 
vimentin (138,139). 
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Figure 1-3: FMDV genome organisation and translation products. 
Schematic representation of (A) the composition of FMDV (+)ssRNA genome; and (B) the processing of the polypeptide into 
structural and non-structural proteins. Arrows indicate autocleavage by proteinases. Adapted from  Mason and colleagues (115) and 
Belsham and colleagues (140).
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Table 1-1: FMDV structural and non-structural proteins and their approximate 
position, size in amino acid residues and function, based on a serotype O virus. 
Polypeptide Map position* Size (aa) Function Protein 
Polyprotein 1059-8027 2322   
LAb 1059-1661 201 Leader proteinase NSP 
VP4 1662-1916 85 Capsid protein SP 
VP2 1917-2570 218 Capsid protein SP 
VP3 2571-3230 220 Capsid protein SP 
VP1 3231-3863 211 Capsid protein SP 
2Apro 3864-3917 18 Protease NSP 
2B 3918-4379 154 Replication NSP 
2C 4380-5333 318 Replication NSP 
3A 5334-5762 143 Replication NSP 
3B1 5763-5831 23 
Viral genome 
linked protein 
(VPg) 
NSP 
3B2 5832-5904 24 NSP 
3B3 5905-5975 24 NSP 
3Cpro 5976-6614 213 Protease NSP 
3Dpol 6615-8024 470 RNA dependent polymerase NSP 
*NCBI reference sequence analysis derived from the O serotype of FMDV 
[Accession: PRJNA15378] (45); SP, structural protein; NSP, non-structural protein; 
VP, viral protein; pro, protease; pol, polymerase; aa, amino acids. 
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The P3 proteins 3A and 3B of FMDV are atypical. FMDV is distinguished from other 
picornaviruses by a longer 3A protein (152 aa compared to 87 aa for poliovirus). All 
picornavirus 3A proteins contain a 15-20 amino acid hydrophobic domain about 60-
80 residues from the N-terminus that is thought to function in binding viral RNA 
replication machinery to cellular membranes (141) and in delivery of 3B to sites of 
RNA replication (140). A deletion of 10 aa at positions 93–102 of 3A has been 
associated with altered virulence. This deletion was present in a variant of FMDV 
serotype O, isolated in Taiwan in 1997 (O/TAW/9/97), which severely affected swine 
but was attenuated in cattle (44–46). However, the PanAsia strain, O/SKR/AS/2002, 
affected pigs and cattle in the same way but contained a full length 3A protein 
suggesting factors other than this deletion are responsible for the observed differences 
in host-specific virulence of the virus (142,143). 
FMDV is the only picornavirus to encode multiple copies of the 3B protein in tandem, 
each varying slightly in amino acid sequence (3B1, 3B2, and 3B3) (140). The GPYXGP 
motif is homologous to the start of each repeat and contains the Tyr3 residue which is 
involved in the phosphodiester linkage of 3B to the 5’ end of genomic (+)ssRNA (144) 
and transcription products (31). Attachment of this peptide to the RNA genome is 
catalysed by the viral RNA polymerase (3Dpol). Each repeat has been found attached 
to genomic RNA, and is functionally equivalent (145). It is generally accepted that 3B 
(VPg) serves as a primer for the viral RNA polymerase, 3Dpol (31). Having three 
genome-associated 3B proteins appears to advantage the virus by enhancing RNA 
replication efficiency of FMDV (146).  
3Cpro is a chymotrypsin-like serine proteinase responsible for the primary cleavage of 
P2 from P3 and all secondary cleavages required for processing of capsid and 
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replicative protein precursors (125,147), except for the final cleavage of VP0 during 
maturation of the virion. All picornaviruses possess a 3C proteinase which 
demonstrates a high degree of sequence similarity across the genera. The catalytic site 
of 3Cpro is the catalytic triad: Cys163, His46, Asp84 (148). Its recognition sequence 
shows heterogeneity, with multiple dipeptides facilitating cleavage (113). 3Cpro also is 
responsible for truncation of histone H3, which has been suggested to contribute to the 
inhibition of cellular transcription (149,150). 3Cpro also cleaves several host translation 
initiation factors including eIF4A and eIF4G (151) and inhibits the type I interferon 
response by degradation of KPNA1, resulting in blockage of STAT1/STAT2 nuclear 
translocation (152). These processes may contribute to viral fitness.  
3Dpol viral RNA-dependent RNA polymerase is responsible for generating both minus- 
and plus-strands of viral RNA. 3Dpol must distinguish between viral and cellular 
mRNAs destined for translation at the ribosome and for packaging into the virion; 
however the mechanism by which this occurs remains unknown (31). Priming of RNA 
requires uridylylation of VPg which is also performed by 3Dpol (111,153). 
Transcription and genome replication 
Following plus strand translation, 3Dpol catalyses elongation of the minus strand (31). 
For this to occur, the initiation complex must translocate to the 3’ end of the plus-
strand template. The mechanism by which this occurs is unknown; however, it has 
been suggested that binding of a poly(A)-binding protein to the 3’ poly(A) tract 
facilitates circularisation of the genome (31). 3Dpol catalyses the transcription of 
minus-strand RNA to form a double stranded RNA molecule, referred to as the 
replicative form (RF).  
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The mechanism by which plus-strand synthesis from the RF is initiated is believed to 
involve uridylylation of VPg which then acts as the primer for synthesis of both plus- 
and minus-strand RNA (154). Based on studies of poliovirus uridylylated VPg 
synthesis is achieved on the cre element and uridylylated VPg then acts as the primer 
of plus-strand RNA synthesis (154,155). In contrast, there is evidence that cre 
dependent VPg uridylylation is not required for minus-strand RNA synthesis (156). 
Rather, the poly(A) tail is used as a template for the generation of uridylylated VPg 
which is then utilised for minus-strand synthesis (155,156). For plus-strand synthesis 
to proceed, the RF must be separated. The picornavirus 2C protein sequence contains 
a conserved helicase motif, unique for superfamily III helicases, and nucleotide 
binding motifs (133). However, helicase activity has not been demonstrated and the 
mechanism used by FMDV to separate the RF strands remains unclear (133).  
Encaspidation and maturation 
The viral proteins VP0, VP1 and VP3 form a structure which is antigenically very 
similar to the virus prior to final cleavage. Final steps in the replication cycle involve 
encapsidation of (+)ssRNA linked to VPg and formation of the mature virion through 
viral RNA-dependant maturation cleavage of VP0 to VP2 and VP4 (114) (Figure 1-3). 
Cleavage is thought to be autocatalytic and requires a conserved histidine residue 
(His2145) in VP2 (157–159). Each of the three surface-oriented proteins (VP1, VP2 
and VP3) has an 8-stranded E-barrel structure and is highly conserved across all 
picornaviruses. The loops joining the E-strands are exposed to the exterior surface. The 
G-H loop of VP1 is biologically important because it is central to viral antigenicity 
and receptor binding (114,131). Completing the infection cycle, approximately 
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100,000 assembled virus particles per cell are released by cell lysis between 4-6 h post 
infection in vitro (13,31).  
1.3.6. FMDV immunogenicity and antigenicity 
Previous infection with, or vaccination against, one FMDV serotype does not provide 
protection against infection by another serotype, due to differences in the 
immunogenicity of their structural proteins (106). Furthermore, within-serotype 
antigenic variation may be sufficient to prevent cross-protection between strains (160). 
Antigenic variation at the levels of serotype and strain present major obstacles in FMD 
diagnosis and detection, particularly where co-circulating strains occur in an outbreak 
(161). This antigenic heterogeneity complicates surveillance strategies through its 
impact on diagnostics, with molecular tests being more susceptible to false negative 
results than serologic tests due to the probability of the occurrence of silent mutations. 
Most antigenic variation stems from the capsid encoding region of the genome. 
Mutations in the NSP coding regions are less tolerated as these proteins encode factors 
critical for virus replication (31). Many surface features of the FMDV capsid confer 
independent immunogenic sites, where only a subset are similar across the serotypes 
and subtypes (162). For serotype O there are at least five antigenic sites that contain 
epitopes that interact with neutralising antibodies. Only one of these is continuous and 
is located in the G-H loop of VP1 [reviewed (162,163)]. These antigenic sites are 
located on the flexible loops that connect the E-sheets of VP2 and VP3 and at least two 
sites include the C-terminus of VP1 (164). The immunodominant region for this virus 
is located in the G-H loop region of VP1 (165,166). Between serotypes, this region is 
highly variable in both its length and amino acid sequence. However, common to all 
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serotypes, the G-H loop contains a conserved Arg-Gly-Asp (RGD) triplet responsible 
for host cell receptor binding.  
The immunogenicity of VP1 was established in the early 1980’s. The amino acid 
sequences responsible for its immunogenicity were identified by enzymatic or 
chemical cleavage of fragments resulting in reduced infectivity (167). Trypsin 
cleavage of VP1 within the G-H loop and at the C-terminus does not affect the integrity 
of the virus particle but removes the virus’ ability to attach to cells and greatly reduces 
immunogenicity (114). Studies also investigated VP1 immunogenicity by prediction 
of secondary structural features (168) and determination of the regions of high 
sequence variation between antigenically distinct virus isolates (169). Two regions of 
the protein were implicated as being of antigenic importance; one between residues 
141-160 of the G-H loop and another between residues 200-213 at the C-terminus. 
Synthetic peptides corresponding to these sequences were capable of generating 
neutralising antibodies (168,169), with the 141-160 amino acid sequence eliciting 
sufficient neutralizing antibody to provide protection from disease in guinea pigs 
(169). Grubman and colleagues (170) found that, to a lesser extent than VP1, VP3 and 
3C were antigenically variable proteins within the FMDV serotypes.  
In contrast to the variability observed in FMDV structural proteins, the non-structural 
proteins, 2B, 2C, 3A, 3B and 3D, appear to be largely antigenically conserved across 
the serotypes (170,171). 3D was the first FMDV antigen used as a reagent to 
distinguish vaccinated and infected animals (172). It is one of the most conserved 
FMDV proteins in both nucleotide and amino acid sequences. Additionally, 3D 
provokes the strongest immune response of the FMDV NSPs (173), containing three 
hypervariable hydrophobic antigenic regions between amino acids 1-12, 64-76, and 
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143-153 (174). However, antibodies against 3D were observed in repeatedly 
vaccinated animals (175,176) limiting its use as an NSP-based diagnostic test (177). 
Subsequently, the 3ABC precursor protein has been used in diagnostic tests due to its 
high immunoreactivity (178). The antigenic region between amino acids 141-160 of 
3ABC, found within 3B, is highly conserved in all seven FMDV serotypes (171,179).  
1.4. DIAGNOSTIC TESTS 
FMD is listed as a disease notifiable to the World Organisation for Animal Health, 
OIE. A critical factor in FMD control is the use of surveillance strategies capable of 
confirming FMDV infection or demonstrating freedom from the disease. Clinical 
symptoms of FMD are indistinguishable from other vesicular diseases such as swine 
vesicular disease and vesicular stomatitis. Hence, laboratory testing is necessary to 
confirm whether clinical signs consistent with FMD are due to FMDV infection or not. 
The OIE Terrestrial Animal Health Code (21) and the Terrestrial Manual (180) set 
out prescribed tests for FMD that are considered optimal for animal health surveillance 
for trade purposes. Prescribed tests are enzyme-linked immunosorbent assays (ELISA) 
and virus neutralisation test (VNT) with the complement fixation test (CFT) listed as 
a possible, less reliable, alternative (180). Nucleic-acid based diagnostic techniques 
for the detection of FMDV genome include reverse transcription polymerase chain 
reaction (RT-PCR), multiplex PCR and real-time RT-PCR [reviewed in (4)]. There are 
no OIE prescribed NSP-based tests for the purposes of international trade, rather these 
are suggested as confirmatory tests.  
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1.4.1. Samples 
For laboratory diagnosis and confirmation, epithelium, vesicular fluid, and OP fluid 
are preferred samples for virus identification and antigen based serotyping, while 
serum is preferred for detecting FMD-specific antibodies. The optimal detection 
period for virus or viral antigens occurs during the acute stage of disease; typically 3-
4 days post infection. For most specimens, indirect sandwich ELISAs or CFTs are 
satisfactory for detection of virus. Samples of OP fluid, and in some cases serum, may 
require more sensitive diagnostic tests such as RT-PCR or pre-amplification of virus 
in cell culture prior to testing.   
Serum samples may be used for the detection of antibodies raised against FMD virus 
or antigens by ELISA. The antibody response develops 4-7 days post infection. Anti-
FMDV and anti-structural protein antibodies can be detected in serum from 4 days 
post infection by VNT, liquid-phase blocking ELISA (LPBE), solid-phase competition 
ELISA (SPCE) and solid-phase blocking ELISA (SPBE) tests (26). Antibodies to 
NSPs are detectable as early as 7 days post infection in serum using the enzyme 
immunotransfer blot assay (EITB) and indirect ELISA (I-ELISA) tests (26). 
The OIE recommends collection of at least 1 gram of epithelial tissue from vesicular 
lesions or where epithelium is not available OP fluid should be collected by probang 
cup sampling. Samples must be transferred to buffered medium and transported at 4°C. 
Buffering of the medium is critical for transport as FMDV is labile at pH <6.5 (180).  
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1.4.1. Detection of FMDV or viral antigens 
Virus isolation 
Virus isolation in cell culture is often the reference standard test for viral diseases. For 
FMDV, 10% of the diagnostic sample in suspension is used to inoculate susceptible 
cell cultures or suckling mice. For virus isolation in cell culture, primary bovine calf 
thyroid (BTY) cells are recommended as they are highly susceptible to FMD infection 
(181). Primary pig, calf and lamb kidney cells may also be used. Continuous cell lines, 
such as baby hamster kidney (BHK-21) (182), pig kidney cells (IB-RS-2) (183) and 
foetal porcine kidney (LF-BK) (184,185), are also susceptible to FMDV infection, yet 
less susceptible than primary BTY cells (184). Foetal goat tongue cells (ZZ-R 127) 
and a modified LF-BK cell line expressing integrin αVβ6 have significantly higher 
susceptibility to FMDV than that of BHK-21 or IB-RS-2 cells (186,187). The LF-BK 
continuous porcine kidney cell line is less susceptible to several subtypes of FMDV 
than primary bovine thyroid cells but is useful for routine plaque assays or plaque 
neutralisation tests as a substitute for primary bovine kidney cells (184). Cell cultures 
are examined for cytopathic effect (CPE) over a period of 48 h (180). FMDV is 
cytocidal and induces CPE including cell rounding and redistribution of internal 
cellular membranes (31). An advantage of virus isolation methods is that amplified 
virus may be used as antigen in other tests (181).  
Complement fixation 
The complement fixation test involves binding of a specific antibody to viral antigen 
in a test sample and the presence of complement. Formation of an antibody-antigen 
complex fixes complement preventing lysis of haemolysin sensitive red blood cells 
(rbcs). Lysis of rbcs occurs in the presence of free complement and indicates a negative 
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test (188). The CFT is typically performed in microtiter plates (189) and requires 
several days for results to be acquired and a high level of biosecurity containment. As 
a highly contagious disease, urgent diagnosis of FMD is essential and this has led to 
the CFT being replaced by other methods. Immunofluorescence or serological 
techniques were developed for testing of viral infectivity to avoid delays due to tissue 
culture propagation allowing more rapid detection (190). The CFT has several 
additional drawbacks; it is a relatively insensitive and complex method that is prone 
to interpretation errors; results may be complicated by pro- or anti-complement 
activity (191,192); and it requires a high level of biosecurity containment (193). 
Despite these limitations, the CFT was the predominant method for diagnosis and 
typing of FMD until the late 1970’s (190) when ELISA methods became the preferred 
option. However, if ELISA reagents are not available or if subtyping is required the 
CFT is still a recommended approach (180). 
Indirect sandwich enzyme-linked immunosorbent assay  
Enzyme-linked immunosorbent assays are highly sensitive and specific tests that have 
replaced the CFT as routine tests for FMD in many laboratories (193). It is a diagnostic 
procedure used for identification of FMD viral antigen (146S antigen; the virus particle 
has a 146S sedimentation coefficient in a sucrose gradient), serotyping (194,195), and 
differentiation from other vesicular diseases (196). The antigen capture ELISA was 
first developed by Engvall and Perlmann in 1971 (197) and adapted to FMD antigen 
detection in 1979 (198). Subsequent refinements to this ELISA resulted in significant 
improvements over the CFT (191,193,194,199).  
Currently, an indirect sandwich ELISA is recommended to diagnose FMD in which 
the antigen to be measured is bound between two primary antibodies; the capture 
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antibodies and the detection antibodies, which are raised against each of the seven 
FMDV serotypes (180). In addition to the identification of serotypes, this test has been 
adapted to enable differentiation from other vesicular viruses (196). More recently, use 
of the antigen capture ELISA has shifted towards detection of viral antigens rather 
than whole virus for the differentiation of infected and uninfected animals. However, 
these tests require sample of large volume, they are reagent intensive and are affected 
by the short window of opportunity for antigen detection due to effective antigen 
clearance by the immune system.  
1.4.2. Identification of FMDV antibodies in serum 
Serological diagnostic tests for FMD examine serum samples for the presence of 
antibodies raised against FMDV. FMDV antibody-positive samples can result from 
natural infection, vaccination or the presence of maternal antibodies. Serological tests 
are used to confirm infection, substantiate the absence of infection and demonstrate 
efficacy of vaccination (180). For FMD, serological tests can be separated into two 
categories; those that detect antibodies to viral SPs and those that detect antibodies to 
NSPs. There are prescribed tests for international trade by the OIE that are deemed 
appropriate for use to confirm previous or ongoing infection in non-vaccinated animals 
and to monitor immunity induced by vaccination. These tests are serotype-specific 
(180). Where structural proteins in the absence of NSPs are used to formulate vaccines, 
detection of NSP antibodies can provide evidence that vaccinated animals have been 
exposed to FMDV (180). 
Structural protein antibody tests 
Infected animals produce antibodies to both structural and non-structural viral 
proteins. Structural protein-based tests are serotype-specific and detect antibodies 
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elicited by vaccination or infection; examples are the virus neutralisation test, the 
solid-phase competition ELISA, solid-phase blocking ELISA and the liquid-phase 
blocking ELISA (200–206). 
Serotype-specific structural protein-based tests require different reagents for each 
serotype adding to their cost and complexity. The OIE recommend initial screening by 
ELISA, followed by confirmation using VNT. Of the OIE prescribed tests, a known 
low frequency of false-positive reactions is expected in a small proportion of sera 
tested (180). Additionally, the consensus is to use a screening ELISA with moderate 
specificity when testing large numbers of samples, for example, during an outbreak, 
as the best alternative to testing all samples by VNT (204).  
Virus neutralisation test (OIE prescribed) 
The VNT was the international standard test for detection of FMDV antibodies for 
more than 20 years prior to the development of the ELISA technique in 1986. The 
VNT test detects and quantifies antibodies against FMDV SPs. The test depends on 
the ability of specific serum antibodies to block parts of the virus that react with host 
cell receptors, thereby blocking or limiting infectivity as indicated by degree of 
observed CPE. The VNT has several disadvantages; the test is time and labour 
intensive and it relies on cultured cells and growth of infectious virus in specialised 
high containment facilities (204). Currently, the ELISA is the preferred method to 
screen samples and the VNT is used as a confirmatory test for samples that return a 
positive result by ELISA. 
Liquid phase blocking ELISA  
A liquid-phase blocking sandwich ELISA (LPBE) for detection of FMDV was 
originally developed by McCullough and colleagues (207) to replace the VNT. It was 
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subsequently modified for the quantitation of FMDV serotype-specific antibodies 
(202,203,208). The modified assay showed a positive correlation with the VNT 
although this relationship was poor for sera from animals that had been vaccinated 
against more than one FMDV serotype (202). The LPBE measures anti-FMDV 
antibody titre and can be used to estimate the level of expected protection of a 
vaccinated animal and/or herd immunity (209,210). However, the test can prove 
variable due to quality and derivation of reagents used (205). Further, the rate of false-
positive reactions varies depending on the animal population tested, which can be 
particularly high in non-vaccinated and stressed animals (211). In addition, due to this 
test having several reaction steps it is not ideal for high-throughput serodiagnosis 
(204).  
Solid-phase ELISAs 
A solid-phase competition ELISA (SPCE) based on the LPBE (212,213) was 
developed to measure levels of anti-FMDV antibodies in sera (205). The SPCE is more 
specific than the VNT or LPBE but has a similar limit of detection when compared to 
LPBE (205,206). Like the LPBE, the complexity of the SPCE precludes it from high-
throughput screening. In addition, although this assay detects a wide variety of strains 
within serotypes, it does not currently have complete strain coverage and preparation 
of the 146S antigen requires handling of live virus and is relatively labour intensive 
(205). To overcome some of these limitations a solid-phase blocking ELISA (SPBE) 
was developed (204) which offered several advantages over other tests; it is a more 
rapid test than the VNT, biological variability is minimised though the use of a mAb 
as the probe. However, infectious virus was still required for production of the 
inactivated antigen. In addition, when used to test different FMDV-susceptible species 
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and vaccinated populations, the specificity has been observed to vary considerably 
(204). 
Non-structural protein antibody tests 
Detection of antibodies against non-structural viral proteins can be used to determine 
past or present infection. Such tests can also be used to demonstrate the absence of 
infection in a given population, albeit indirectly, and may be used to differentiate 
infected from vaccinated animals (DIVA). These tests are not OIE prescribed tests for 
the purpose of international trade; rather they are to be used as confirmatory tests and 
are useful in circumstances where the serotype of FMDV is unknown.  
Enzyme immunotransfer blot assay 
Two screening methods described in the OIE manual have been developed by 
PANAFTOSA (Brazil) and include an enzyme immunotranfer blot assay (EITB) and 
I-ELISA. The EITB was developed to define antibody profiles of infected and 
vaccinated animals. Purified recombinant proteins 3A, 3B, 2C, 3D and 3ABC are 
separated by SDS-PAGE and electrophoretically transferred to nitrocellulose 
membrane strips. Strips are probed with test serum followed by an alkaline 
phosphatase-conjugated, species-specific secondary antibody. Interactions are 
detected by visualisation of the product of an alkaline phosphatase substrate. This 
method is utilised as a confirmatory test to the PANAFTOSA 3ABC I-ELISA (214) 
even though the requirement for five antigens makes it relatively difficult to produce. 
Indirect ELISA 
The PANAFTOSA 3ABC I-ELISA involves the immobilisation of 3ABC antigen to a 
microtiter plate. Antibodies present in test serum bind to the immobilised 3ABC 
antigen. Bound antibodies are detected using HRP-conjugated secondary antibodies. 
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Numerous alternative I-ELISAs have been commercialised or described in the 
literature. The most sensitive when compared to the PANAFTOSA I-ELISA (214) are 
a commercial kit developed by Cedi-Diagnostics BV (now Prionics) and an in-house 
assay from IZS-Brescia (215).  
1.4.3. Vaccination 
Although effective vaccines are available and despite animal welfare concerns, of the 
strategies recognised by the OIE to control the spread of FMDV infection following 
an outbreak, control by mass slaughter (stamping out) of infected or at-risk herds is 
the most commonly applied. When vaccination is used without subsequent slaughter, 
FMD-freedom status may be instated only after a period of six months from the last 
confirmed case and only with serological proof that the virus is no longer circulating 
(21). A declaration of FMD freedom may be granted after only 3 months following the 
last case if, following emergency vaccination, all vaccinated animals are slaughtered 
in addition to the culled animals (180). Countries wishing to be recognised as FMD-
free with vaccination must demonstrate the absence of circulating virus by showing 
vaccinated animals are free from antibodies against NSPs arising as a result of 
infection (180). Currently the most commonly used test is the 3ABC ELISA which is 
used as a herd test. Therefore a reliable method to provide evidence of infection or 
freedom from infection in vaccinated populations is essential. 
The practice of ‘aphtisation’ is the oldest known strategy of vaccination, where at the 
first sign of disease all animals in a herd were inoculated by rubbing virulent saliva 
taken from the lesions of FMD-infected animals on the muzzle or lips of healthy 
animals (216). Vallée and colleagues produced the first FMD-protective vaccine from 
ground mucosal FMD lesions inactivated in formaldehyde (100). Dutch researchers, 
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Waldmann and colleagues, semi-industrialised vaccine production by using fluids 
from infected tongues harvested at slaughter to inoculate tongues of healthy cattle 
destined for human consumption (217). The use of cell culture to produce virus for 
vaccine development was first introduced by Frenkel in 1947 using tongue epithelium 
cell culture (218). Later, cell culture of primary cell lines derived of calf or pig kidney 
were used. Finally, suspensions of the continuous baby hamster kidney cell line (BHK-
21) became the method of choice to propagate FMDV for vaccine production (219). 
These culture-based methods of vaccine production have taken decades to refine due 
to contaminating antigens derived from the cultured cells (220). In the 1970’s the 
introduction of oil-adjuvants provided longer lasting immunity (216) [for extensive 
reviews on the history of FMD vaccines see (216,221)]. 
The current vaccine production protocol requires the growth of large volumes of 
virulent virus, subsequent virus inactivation using a method described by Bahnemann 
(222), and antigen purification by chromatography [reviewed (221,223)]. Current 
vaccines do not provide broad cross-protection; that is, vaccination for one serotype 
does not provide protection against other serotypes. At greater cost and effort, many 
vaccines are prepared for multiple serotypes by including additional types as antigens 
(180). Additionally, current vaccines lack provision of long-term protection and 
require periodic inclusion of new viral strains into the vaccine formulation to protect 
animals from exposure to new viral subtypes. Therefore, multiple vaccinations are 
required to maintain an adequate level of herd immunity (223). The latest research 
aimed at developing novel vaccines focuses on vaccines composed of genetically 
engineered viral subunits, live viral vectors, synthetic peptides or nucleic acid based 
vaccines [reviewed by Zhang and colleagues (224)]. Subunit vaccines contain viral 
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antigens free of viral nucleic acid. These are structurally similar to empty virions, yet 
none have been as efficient in providing protection as traditional inactivated vaccines 
(224). Alternatively, recombinant empty capsid particles can be expressed that are 
antigenically and immunogenically similar to whole viruses [reviewed by Belsham 
and Bøtner (225)]. Live vector vaccines utilise viral vectors such as bovine enterovirus 
(226), adenovirus (227–229) or vaccinia virus (230,231) to deliver genetic material 
encoding FMDV antigens (224). Nucleic acid vaccines typically use a chemical system 
to deliver genetically engineered DNA encoding FMDV antigens to host cells for in 
vivo expression. Novel attenuated vaccines are engineered to knock out some regions 
of the virus critical to its viability; for example, Lpro-deficient serotype A virus. These 
novel attenuated vaccines are more stable and have reduced toxicity compared with 
traditional attenuated vaccines (224). They also have the potential for use as marker 
vaccines or to complement a DIVA testing strategy. Attempts to develop a live 
attenuated FMD vaccine have been unsuccessful because the viruses formed had 
unstable phenotypes, induced inconsistent protective immune responses or 
demonstrated differing degrees of pathogenesis between host species e.g. attenuated 
in cattle but not in pigs (223). Due to unpredictable changes in virulence in field strains 
and concern of reversion to virulent viable FMDV, live attenuated vaccines have not 
been pursued. Also, the use of live vaccines could complicate efforts to discriminate 
between naturally infected and vaccinated animals (216,221,223).   
1.4.4. Differentiating between FMDV-infected and vaccinated 
animals 
Differentiation of infected from vaccinated animals was first described in the context 
of the use of marker vaccines in conjunction with a differentiating diagnostic test 
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(232). Although vaccination is an acceptable control method, the fastest way to regain 
freedom from disease status is to slaughter all vaccinated and unvaccinated animals. 
This is due to the probability that FMD carriers remain amongst the herd, despite there 
being no experimental evidence of transmission of FMDV from carrier cattle to other 
animals (66). A major consideration remains as to whether vaccinated animals should 
be culled or allowed to live (233). After the 2001 outbreak in Europe there has been a 
growing demand to use vaccination as a means of reducing reliance on culling (234). 
The ‘vaccinate-to-live’ policy states that the spread of FMDV from future outbreaks 
could be controlled by a short period of “emergency” vaccination of surrounding 
herds, reducing the need for large-scale pre-emptive culling of at-risk animals. 
Therefore, differentiating infected from vaccinated animals would reduce the socio-
economic costs associated with slaughter of entire herds. DIVA testing is important 
for serological surveys designed to provide evidence of infection or freedom from 
infection in countries using vaccination as a control measure (235).  
It was not until the mid-1990’s that the roles of NSPs in the immune response were 
recognised and the potential to use these as a basis for the development of diagnostic 
reagents was realised. In infected animals, antibodies to both structural and non-
structural viral proteins are produced. In contrast, when NSP-free structural protein 
vaccines are used, antibody responses are directed towards structural proteins only. 
Thus, anti-NSP antibodies are only present in infected animals. Current inactivated 
vaccines consist of inactivated live virus and some are purified to remove NSPs. This 
benefits serological diagnosis by avoiding false-positives due to vaccinated animals 
and by allowing differentiation of infected from vaccinated animals.   
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Antibodies against FMDV proteins 2B, 2C, 3A, 3B, 3D and 3ABC have all been 
detected in infected animals (214,235). NSP 3D was first used as antigen in an agar 
gel immunodiffusion test (172,236). Villinger and colleagues (237) were first to use a 
recombinant 3D protein expressed in E. coli in an ELISA. NSP 3D-based ELISAs have 
been observed to be highly specific when testing non-vaccinated and non-infected 
animals, however, when testing vaccinated animals false positives are experienced 
(235,237–242). The presence of anti-3D antibodies in sera of repeat-vaccinated 
animals suggests 3D is present in vaccine preparations (175–177). Newman and 
colleagues (243) have suggested that the 3D protein could be incorporated into virus 
particles. The presence of this protein in vaccines prevents the use of 3D-based 
serodiagnostics as indicators of vaccinated animals’ exposure to infection (177). 
Antibodies against other NSPs were subsequently investigated and exploited as 
antigens for DIVA diagnostic tests.  
Protein 2C was assessed as a candidate DIVA diagnostic reagent (235,239). Protein 
2C associates with the cell membrane of infected cells and is easily removed during 
purification of viral structural proteins for vaccine preparation (244). ELISAs using 
NSP 2C produced as a synthetic peptide (245), expressed alone (246,247), or as part 
of a larger 2C3AB protein (248,249) have been established. These tests are typically 
used as companion tests to other NSP assays to improve detection efficiency (234). 
Bergmann and colleagues (214) identified 3A and 3B as promising candidates for 
development of DIVA tests, with each of 3A, 3B and 3AB having specific 
immunogenic activity in vivo (250). Protein 3A was commonly used in its intermediate 
forms as 3AB or 3ABC when used to develop DIVA assays (240,250–256). Sera of 
some uninfected vaccinated pigs and cattle produced false positive results in tests using 
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3A as antigen (235,257). However, DIVA tests using 3B alone correctly distinguished 
all samples from convalescent animals as demonstrated using an I-ELISA based on a 
synthetic 3B peptide (257). Others used an octamer of short (27aa) peptides containing 
three conserved linear B cell epitopes of 3B with similar results (258). Most recently, 
Mohapatra and colleagues (255,259) have developed an I-ELISA based on an E. coli-
expressed 3B protein which was used to complement a previously developed 3AB3 I-
ELISA.  
Many studies have used 3ABC as antigen for the development of diagnostic tests 
suitable for DIVA applications (see Table A-1 for review). However, it has been 
suggested that tests using 3B are more specific due to a reduction in the number of 
potential non-specific binding sites compared with the larger 3ABC protein (258). 
Regardless, several 3ABC ELISAs have been commercialised including the CHEKIT-
FMD-3ABC I-ELISA tests (IDEXX Laboratories/Bommeli Diagnostics) (176), 
PrioCHECK FMDV-NS blocking ELISA (Prionics Lelystad) (240,260), Ceditest 
FMDV-NS (Cedi-Diagnostics BV) and Svanovir FMDV 3ABC-Ab ELISA (Svanova 
Biotech). Other tests used in-house include: AAHL C-ELISA (CSIRO AAHL), 
NCPanaftosa-screening I-ELISA/EITB (PANAFTOSA) (261) and 3ABC trapping 
ELISA (IZS-Brescia) (176). Studies comparing some of these tests reveal the 
NCPanaftosa-screening test has the highest sensitivity, followed by the trapping 
ELISA from IZS-Brescia and the Ceditest ELISA (215). The highest specificities are 
provided by IZS-Brescia and Ceditest ELISAs. The specificity of the NCPanaftosa-
screening test was lower than these and this is likely due to the cut-off of this test being 
selected to optimise sensitivity (215). The NCPanaftosa test is used as an index 
screening test in combination with a highly specific and equally sensitive confirmatory 
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EITB test (215). None of the available commercial or published assays are able to 
discriminate FMDV-vaccinated from infected cattle with 100% diagnostic sensitivity 
and specificity (262). 
The consensus currently is that 3ABC is the most appropriate antigen for DIVA testing 
due to its high immunogenicity and relatively low concentration in FMDV-infected 
cell lysates used for vaccine production (178,263). However, reports of anti-3A 
antibodies in some sera of vaccinated animals exist (235,257). Most DIVA tests are 
ELISAs that incorporate viral antigens produced in either bacterial or baculovirus-
mediated expression systems in combination with polyclonal or monoclonal antibodies 
in an indirect or blocking format [reviewed by Ma and colleagues (32)]. NSP antibody 
based ELISAs are better suited to the differentiation of FMDV-infected from 
vaccinated animals during herd based serosurveillance, where reactivity aids the 
interpretation of the herd’s infectivity status in vaccinated populations. Of interest is 
the NSP 3B, a constituent of the widely used 3ABC, that has several potential 
advantages over 3ABC as a serodiagnostic. Shen and colleagues (257) have shown 3B 
alone in ELISA produces lower background than 3A alone or in combination with 3A; 
unlike 3C it has no peptidase activity and so does not need to be modified to remove 
catalytic activity; 3B consists of a triplet of highly similar amino acid sequences which 
may be shuffled between serotypes to produce a hybrid protein with cross-serotype 
specificity; and it is highly immunogenic and has a high density of linear B cell 
epitopes.  
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1.5. RESEARCH AIMS AND SIGNIFICANCE 
FMDV has been the focus of extensive research over many years; however, limitations 
still exist in current diagnostic capabilities. Of prime importance for both control and 
eradication is the accurate diagnosis of infection (4). Many NSP-based tests have been 
developed but these all use proteins derived from individual FMDV strains and may 
therefore be affected by strain-specific variations. The identification of an epitope 
shared between all of the seven serotypes could form the basis of a serotype-
independent for FMDV. It was hypothesised that a representative sequence of all 
serotypes exists and is suitable for use in the development of a pan-FMDV 
serodiagnostic test with DIVA capability.  
Aim 1: Identify the consensus sequence of FMDV non-structural protein 3B. 
Aim 2: Design and produce a recombinant 3B antigen capable of binding anti-3B 
antibodies from animals infected with any of the seven FMDV serotypes. 
Aim 3: Develop of an improved serotype independent test for FMDV.
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CHAPTER 2 
 MATERIALS AND METHODS 
2.1. BIOSAFETY AND BIOCONTAINMENT 
Genetic manipulations, molecular cloning and protein expression experiments were 
conducted within the Australian Animal Health Laboratory (AAHL) certified Physical 
Containment Level (PC) 2 laboratories. All enzyme-linked immunosorbent assay 
(ELISA) development experiments were undertaken within the AAHL biosecure PC3 
facility. All experiments were conducted in accordance with regulatory requirements; 
namely, Australia/New Zealand Standard™ 2243.3:2010 - Microbiological Safety and 
Containment (Standards Australia); Guidelines for the Transport, Storage and 
Disposal of GMOs (Version 1.1), 2011 (Office of the Gene Technology Regulator, 
Department of Health, Australian Government); Security Sensitive Biological Agents 
standards, 2013 (Department of Health, Australian Government) and Quarantine 
Approved Premises Class 5 (Department of Agriculture, Australian Government). 
Transfer of infectious material for gamma-irradiation was in accordance with 
Australian Standard 4834 – 2007 - Packaging for surface transport of biological 
material that may cause disease in humans, animals and plants (Standards Australia); 
gamma-irradiation was performed by Steritech (Australia). All appropriate 
Department of Agriculture and Office of the Gene Technology Regulator permits were 
in effect throughout the course of this study as determined and reviewed by the AAHL 
Biosafety Committee. All electronic data were stored and backed-up daily on secure 
servers at AAHL. All samples were stored in randomly allocated locations and sample 
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information was managed using a secure in-house database program, MicroStores 
version 1.2.26446 (CSIRO, Australia).  
2.2. CHEMICALS AND REAGENTS 
Dry chemicals were obtained from Sigma-Aldrich (Australia), solvents from Merck 
(Australia) and cell culture reagents from Thermo Fisher Scientific (Australia) unless 
otherwise stated. Ultra high purity water (resistivity of 18.2 MΩ.cm at 25oC) 
(Cascada™, Pall Corporation, Australia) was used as required. Oligonucleotide 
primers were from Sigma-Aldrich (Australia). 
Competent E. coli strain DH5α cells and the pcDNA3.1(+) plasmid were sourced from 
Thermo Fisher Scientific. Competent E. coli strain BL21 cells, pMAL-c5e plasmid, 
amylose-agarose resin, rabbit anti-maltose binding protein antibody and light chain 
recombinant enterokinase were sourced from New England Biolabs (NEB) via 
Genesearch (Australia). Serum samples were obtained from the national serum bank 
held at AAHL and include samples from at least one of each FMDV serotype (see 
Table A-6, Table A-7, and Table A-8) from the Canadian Food Inspection Agency 
(Winnipeg, Canada), field samples from Vietnam deposited by Mr Chris Morrissy; 
ovine sera from an experimental vaccination study deposited by Dr Jacquelyn 
Horsington; and sera from naïve cattle  deposited by Dr Mark Foord. All imported sera 
were gamma-irradiated (50 kGy).  
2.3. CONSUMABLES 
Plasticware was sourced from various suppliers and included: sterile filter-tip pipette 
tips (Axygen, USA or Rainin, USA); 10 and 25 ml serological pipettes (Axygen); 1.5 
ml microcentrifuge tubes (Eppendorf, USA or Axygen); 2 ml screw-capped 
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microtubes (Sarstedt, Germany); 15 and 50 ml screw-cap conical bottom and 15 ml 
polypropylene round bottom Falcon™ tubes (Becton, Dickinson & Company, USA); 
Nunc™ Cryotube vials, Nunc™ MaxiSorb® microtiter plates and microplate sealing 
tape (Thermo Fisher Scientific); 1 μl inoculation loops and 10 μl soft colony spreaders 
(Technical Service Consultants, United Kingdom); and 90 mm Petri dishes (Techno 
Plas, Australia). All reagents and materials used for sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) were from Thermo Fisher Scientific. 
2.4. CONSENSUS SEQUENCE IDENTIFICATION 
2.4.1. Sequence acquisition 
Full length amino acid sequences of the three tandem repeats of Foot-and-mouth 
disease virus (FMDV) non-structural protein (NSP) 3B, in series as a composite 
protein sequence, were extracted from translated whole virus genome entries in the 
National Center for Biotechnology Information (NCBI) GenBank database 
(http://www.ncbi.nlm.nih.gov). Sequences were grouped by serotype and origin 
genome sample accession numbers recorded. NCBI GenBank accession numbers 
corresponding to FMDV coding sequences are listed in Table A-2. 
2.4.2. Multiple sequence alignment 
Amino acid sequences were analysed by multiple sequence alignment (MSA) using 
MAFFT, MSAProbs, and Probalign MSA freeware programs. MAFFT, V6.864 
(264,265), and automatically selected L-INS-i as the most appropriate algorithm for 
the input dataset. This strategy used a weighted sum-of-pair score and consistency 
score from local alignments. MSAProbs (266) and Probalign (267) used algorithms 
based on the pair-hidden Markov model and partition function posterior probabilities.  
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Redundant FMDV 3B sequences (sequences demonstrating 100% identity) were 
removed using the Jalview applet (http://www.jalview.org/). A multiple sequence 
alignment of the remaining sequences (Table A-3) was generated using the L-INS-i 
algorithm of MAFFT (264,265). 
2.4.3. Relatedness of FMDV 3B protein sequences  
Evolutionary analyses of the FMDV 3B sequences dataset was conducted using 
MEGA5 (268). Evolutionary history was inferred using the Unweighted Pair Group 
Method with Arithmetic mean (UPGMA) method (269). Evolutionary distances were 
computed using the Poisson correction method (270) and expressed in units of the 
number of amino acid substitutions per site. 
2.4.4. Proportional representation of amino acid residues 
The FMDV 3B consensus sequence (c3B) was derived from the MAFFT MSA from 
the non-redundant set of all published 3B sequences using WebLogo freeware 
software V3.0 (271), where the residue with the highest probability of occurrence at 
each position was chosen as canonical. Consensus sequences were also produced for 
each serotype except the three Southern African Territories (SAT) serotypes’ 
sequences which were combined, and termed cSAT.   
2.4.5. Sequence analysis 
All differences in amino acid sequence between the consensus sequence c3B and 
sequences in the NCBI GenBank database were identified and considered for potential 
biological effect. Amino acids of wild type 3B sequences that differed from those in 
the equivalent position of c3B were categorised by their physical properties, including 
size, charge and polarity of the side chain (272). Changes specific to viral serotypes 
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were noted. Amino acid substitutions occurring in equal to or greater than 10% of 
sequences and having any change in property were considered to form an alternative 
consensus sequence.  
Post-translational modifications and biophysical characteristics of c3B and cSAT 
sequences were investigated using online tools. Phosphorylation was predicted using 
GPP prediction server (273); O-linked glycosylation was predicted using NetOGlyc 
3.1 server (274); N-linked glycosylation was predicted using NetNGlyc 1.0 
(http://www.cbs.dtu.dk/services/NetNGlyc/, (275)); hydrophobicity was predicted 
using ProtScale server (http://web.expasy.org/protscale/) by the method described by 
Welling and colleagues (276); continuous B cell epitopes were predicted using 
COBEPro (277); probability of sequence antigenicity was determined using 
ANTIGENpro (http://scratch.proteomics.ics.uci.edu/); and theoretical molecular 
weights and isoelectric points were determined using ExPASy Compute pI/MW tool 
(278). 
2.5. CONSTRUCTION OF EXPRESSION CLONES 
2.5.1. Synthetic coding sequences 
The coding sequence of a fusion of c3B and cSAT (c3B-cSAT) was codon-optimised 
using Gene-GPS™ expression optimisation technology (DNA2.0, USA) for 
expression in E. coli. The c3B-cSAT protein coding sequence was synthesised and 
provided in the plasmid vector pJ204 (DNA2.0, USA) on filter paper. Plasmids 
containing the c3B-cSAT coding sequence were eluted from filter paper in 10 mM 
Tris, 1 mM ethylenediaminetetraacetic acid (EDTA), pH 8.0 (TE) by centrifugation at 
15,000 x g for 1 min. 
Chapter 2 
 
50 
2.5.2. Bacterial culture conditions 
Bacterial cultures were established from individual colonies grown for 16 h at 37°C 
on agar plates containing Luria-Bertani (LB) medium with 100 μg/ml ampicillin (LB-
amp). LB-amp broth starter cultures (3 ml) were grown at 37°C with agitation at 250 
rpm for the times stated for broth cultures. Glycerol stocks were prepared for each 
clone by combining 500 μl of broth culture with 500 μl of sterile 80% (v/v) glycerol 
for storage at -80°C. 
2.5.3. Genetic manipulations and cloning 
Chemically competent E. coli strain DH5α cells were incubated on ice for 20 min with 
5 ng of pJ204-c3B-cSAT per 100 μl cells. Cells were transformed by heat shock at 
42°C for 45 s followed by incubation on ice for 2 min. For cell recovery, 900 μl Super 
Optimal broth with Catabolite repression (SOC) media was added to cells and 
incubated for 1 h at 37°C with agitation at 250 rpm. Transformed cells were streaked 
onto selective LB-amp agar plates at dilutions of 1:10 and 1:100 in SOC media, and 
grown for 16 h at 37°C. Individual clones were selected and used to prepare glycerol 
stocks and plasmid DNA for further processing. Plasmid DNA was purified from 3 ml 
cultures using the Wizard® Plus SV Miniprep DNA Purification System (Promega) 
and eluted in 50 μl of nuclease-free water (Promega) as per the manufacturer’s 
instructions.  
2.5.4. DNA sequence amplification 
Purified plasmid DNA from E. coli DH5α clones containing pJ204-c3B-cSAT was 
used as template DNA in PCR. PCR was used to amplify c3B and cSAT coding 
sequences separately using the following primers that introduced flanking KpnI and 
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NcoI (underlined) restriction sites: c3B forward 5’-
AAGGTACCGGGTCCGTACGCTGGTCCT-3’ and c3B reverse 5’-
CGTCCATGGCCTTATTCCGTGACGATCAGGTTCTT-3’; cSAT forward 5’- 
AAGGTACCGGGTCCATACGCGGGTCCACTG-3’ and cSAT reverse 5’- 
GCGTCCATGGCCTTACTCGGTAACAATCGGTGCTTT-3’. The c3B forward and 
cSAT reverse primers were used to amplify the c3B-cSAT coding sequence. 
PCR conditions for DNA sequence amplifications were: 94°C for 2 min then 30 cycles 
of 94°C for 30 s, 55°C or 68°C for 30 s and 72°C for 1 min followed by a final 
extension at 72°C for 7 min. PCR reactions were performed in 1x Expand High 
Fidelity Buffer (Roche), 1 μM forward and reverse primers, 10 ng template DNA, 200 
μM deoxinucleotides (dNTP), 1.5 mM MgCl2 and 2.6 units of Expand High Fidelity 
Enzyme (Roche) in a reaction volume of 50 μl. PCR products and 100 bp DNA ladder 
(Promega) were diluted in Blue/Orange Loading Dye (Promega) and subjected to 
electrophoresis at 100V for 1 h in 2% (w/v) agarose in 40 mM Tris, 20 mM acetic acid, 
1 mM EDTA, pH 8.0 (TAE) running buffer. GelRed® Nucleic Acid Gel stain 
(Biotium) was included in the gel to facilitate visualisation of DNA bands.  
2.5.5. PCR product purification 
PCR products of correct size were visualised on a SafeIlluminator Blue light box 
(Thermo Fisher Scientific) and excised using sterile scalpel blades. Amplicons were 
purified from agarose gel using a QIAquick Gel Extraction kit (Qiagen) according to 
the manufacturer’s instructions, except gel pieces were incubated at 50°C for 12 min 
and DNA was eluted with 30 μl Nuclease-free water. DNA concentration and purity 
were assessed by measuring the absorbance at 230, 260 and 280 nm using a NanoDrop 
1000 Spectrophotometer (Thermo Fisher Scientific).  
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2.5.6. Construction of pMAL fusion plasmid 
Purified PCR products and pMAL-c5e vector were digested with KpnI and NcoI 
(Promega) as per the manufacturer’s instructions. The plasmid vector pMAL-c5e 
contains the malE gene which encodes a maltose binding protein (MBP) 
solubility/affinity tag. MBP is followed by an enterokinase recognition motif for 
proteolytic cleavage of the MBP tag from expressed fusion proteins. Digested pMAL-
c5e was incubated with 1 unit of thermosensitive alkaline phosphatase (Promega) for 
15 min at 37°C. Digestion products were purified using a QIAquick PCR Purification 
Kit (Qiagen). Purified, digested pMAL-c5e (100 ng) and each amplicon insert (c3B, 
cSAT or c3B-cSAT) were ligated in frame with malE at a molar ratio of 1:3 with 0.5 
units of T4 DNA ligase (Promega) for 3 h at 20°C.  
Chemically competent E. coli strain DH5α cells were transformed with 10 ng of each 
ligated plasmid; pMAL-c5e, pMAL-c3B, pMAL-cSAT, and pMAL-c3B-cSAT, per 
100 μl cells. Individual clones were selected and used to prepare glycerol stocks and 
purify plasmid DNA as described above (section 2.5.3). Coding sequences of pMAL 
constructs were confirmed by sequencing (Micromon, Australia) using a malE gene-
specific forward primer and vector-specific reverse primer: 5’-
GGTCGTCAGACTGTCGATGAAGC-3’ and 5’-
TGTCCTACTCAGGAGAGCGTTCAC-3’. 
2.6. ELECTROPHORETIC SEPARATION OF PROTEINS 
Protein samples were prepared in 1x sample reducing buffer (SRB; 1x lithium dodecyl 
sulphate  (LDS), 50 mM dithiothreitol (DTT)) at a ratio of 6.5 parts protein sample: 
2.5 parts 4x LDS: 1 part DTT by volume. All samples were denatured at 100°C for 10 
min prior to SDS-PAGE. Samples were loaded onto pre-cast NuPAGE 4-12% Bis-Tris 
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polyacrylamide gels. Molecular weight markers used were SeeBlue Plus2 Pre-stained 
Standard, Mark12 Unstained Standard or BenchMark Protein Ladder. Electrophoresis 
was performed at 180 to 200 V for 35 to 50 min in MES (50 mM 2-[N-morpholino] 
ethane sulphonic acid, 50 mM Tris-HCl, 0.1% sodium dodecyl sulphate (SDS), 1 mM 
EDTA, pH 7.3) or MOPS (50 mM 3-[N-morpholino] propane sulphonic acid, 50 mM 
Tris, 0.1% SDS, 1 mM EDTA, pH 7.7) running buffers. 
2.7. PROTEIN VISUALISATION ON POLYACRYLAMIDE GELS 
2.7.1. Coomassie Brilliant blue (CBB) staining 
Proteins within gels were stained at 20°C on a rocking platform mixer for 10 min with 
0.25% (w/v) CBB R-250 dissolved in 45% (v/v) methanol, 10% (v/v) acetic acid. Gels 
were de-stained in 5% (v/v) acetic acid, 15% (v/v) methanol at 20°C on an orbital 
shaker. Digital images of stained gels created using a Syngene V750 PRO scanner and 
Epson Scan software, version 3.81EN (Seiko Epson Corporation, Japan). Images were 
saved as 600 dpi, 24-bit TIFF files.  
2.7.2. Silver nitrate staining 
All steps were performed at 20°C on an orbital shaker. Gels were submerged 
sequentially in 100 ml each of fixative (40% (v/v) ethanol, 10% (v/v) acetic acid) for 
1 h; sensitiser (30% (v/v) ethanol, 12.6 mM sodium thiosulphate, 0.83 M sodium 
acetate) for 30 min; silver solution (14.7 mM silver nitrate, 30 mM formaldehyde) for 
20 min; and developer (0.2 M sodium carbonate, 15 mM formaldehyde, 1.2 mM 
sodium thiosulphate) for approximately 6 min. Development was stopped by 
submersion of the gel in stopping solution (40 mM EDTA) for 10 min without shaking. 
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During this process, the gels were washed with ultrapure water prior to the addition of 
silver solution and developer. Digital images of stained gels were created as above. 
2.8. WESTERN TRANSFER AND IMMUNODETECTION 
2.8.1. Electro-transfer to polyvinylidene difluoride membrane 
Western transfer of recombinant proteins to BioTrace™ polyvinylidene difluoride 
(PVDF) membrane (Pall Corporation) was performed in 10 mM 3-(cyclohexylamino)-
1-propanesulphonic acid (CAPS) pH 11, 10% (v/v) methanol transfer buffer using a 
Bio-Rad Mini-trans blot cell. Transfers were performed at a constant current of 200 
mA for 1 h at 4°C. 
2.8.2. Immunodetection  
Following Western transfer of proteins, PVDF membranes were blocked with 50 ml 
5% (w/v) skim milk powder in 20 mM Tris, pH 7.4, 0.5 M NaCl (TBS), 0.05% (v/v) 
Tween 20 (TBST) for 1 h at 20°C. Blocked membranes were probed with either rabbit 
anti-MBP antibody or rabbit anti-3ABC polyclonal antibody (279) diluted 1:20,000 in 
10 ml TBST followed by incubation in goat anti-rabbit horseradish peroxidase (HRP)-
conjugated secondary antibody (Bio-Rad Laboratories, Inc.) diluted 1:40,000 in 10 ml 
TBST. Membranes were washed three times with TBST after incubations with 
blocking buffer and primary antibody. Membranes were washed twice with TBST 
followed by a single wash with TBS after incubation with HRP-conjugated secondary 
antibody. 
Immunoreactive bands were visualised using Pierce™ enhanced chemiluminescence 
(ECL) Plus Western Blotting (Thermo Fisher Scientific) HRP substrate that generates 
chemiluminescent and chemifluorescent products for detection using X-ray film, 
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charge-coupled or laser-based devices. Membranes were incubated in 3 ml of the 
substrate for 5 min then dried at 20°C.   
Membranes were scanned using a FLA9000 Typhoon fluorescence laser scanner (GE 
Healthcare) using FLA9000 Typhoon Control software V1.0 (GE Healthcare). 
Excitation was at 430 nm and fluorescence was measured at 503 nm. Images were 
saved as linear 16-bit TIFF files. 
2.9. EXPRESSION OF RECOMBINANT PROTEIN  
2.9.1. Establishment of expression clones 
Chemically competent E. coli strain BL21 cells were transformed with 10 ng per 50 μl 
cells of each purified plasmid, pMAL-c5e, pMAL-c3B, pMAL-c3B-cSAT or pMAL-
cSAT, for over-expression of recombinant MBP, MBP-c3B, MBP-c3B-cSAT or 
MBP-cSAT fusion proteins, respectively. Cells were transformed by incubation on ice 
for 30 min, followed by heat shocking at 42°C for 10 s and incubation on ice for 5 min. 
For cell recovery, 950 μl SOC media was added to cells and incubated for 1 h at 37°C 
with agitation at 250 rpm. Cultures were streaked onto selective LB-amp agar plates, 
3 ml cultures were grown and glycerol stocks prepared (section 2.5.3). 
2.9.2. Protein expression protocol 
Subcultures of each expression clone were inoculated to give an absorbance at 600 nm 
(A600) of 0.1 as determined over a 1 cm light path using a BioPhotometer Plus 
(Eppendorf). Cultures were grown until the A600 of the culture was between 0.5 and 
0.6. Protein expression was induced by treatment of cells with isopropyl-beta-D-
thiogalactoside (IPTG) to a final concentration of 1 mM. 
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2.9.3. Pilot expression of recombinant proteins  
Expression clones containing pMAL-c5e, pMAL-c3B, pMAL-cSAT, or pMAL-c3B-
cSAT plasmids were grown in 3 ml LB-amp broth and protein expression was induced. 
The A600 of 100 μl aliquots of culture was measured every hour post induction for 4 h. 
Aliquots were centrifuged at 17,000 x g for 5 min and the supernatant was discarded. 
Pellets were re-suspended in 100 μl 1x SRB and then further diluted with 1x SRB to 
normalise the cellular load per sample to that of a 100 μl pre-induction sample.  
2.9.4. Solubility of recombinant MBP-3B proteins 
Soluble and insoluble protein fractions were isolated from E. coli cell lysates prepared 
using BugBuster Master Mix (BBMM, Novagen). Cell pellets derived of 3 ml cultures 
were resuspended in 500 μl BBMM with gentle pipetting. The suspension was 
incubated at 20°C for 20 min with gentle rocking. Insoluble protein and cellular debris 
was removed by centrifugation at 16,000 x g at 4°C for 20 min. Supernatant, 
containing the soluble protein fraction, was diluted with an equal volume of 2x SRB 
for SDS-PAGE analysis.  
Inclusion bodies contained in insoluble fractions of the cell pellet were isolated using 
BBMM as per the manufacturer’s instructions. The pellet was resuspended to 
homogeneity in 500 μl 1x BBMM by vortexing. Three millilitres of BBMM diluted 
1:10 with de-ionised water was added to the suspension. The sample was mixed by 
vortexing, centrifuged at 5,000 x g at 4°C for 15 min and the supernatant was 
discarded. The pellet was resuspended to homogeneity by vortexing in 250 μl BBMM 
diluted 1:10, centrifuged at 5,000 x g at 4°C for 15 min and the supernatant was 
discarded. This was repeated twice and a final centrifugation performed at 16,000 x g 
at 4°C for 15 min. The pelleted insoluble protein fraction was resuspended in 500 μl 
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2x SRB. Samples were further diluted with 1x SRB to normalise protein loads to those 
of the pre-induction protein samples prior to SDS-PAGE, CBB staining or 
immunodetection (section 2.7.1 and 2.8). 
2.9.5. Large scale expression of recombinant MBP-3B proteins 
Ten millilitre cultures of E. coli strain BL21 clones containing pMAL-c5e, pMAL-
c3B, pMAL-cSAT, or pMAL-c3B-cSAT were used to inoculate 100 ml LB-amp broth 
containing 0.2% (w/v) glucose. Protein expression was induced by adding IPTG to the 
cultures. Cultures were incubated for 3 h then cell pellets were harvested by 
centrifugation at 4,000 x g for 10 min at 4°C. Cell pellets were re-suspended in 5 ml 
BBMM and lysed at 20°C for 20 min on a rocking platform mixer. The lysate was 
clarified by centrifugation at 16,000 x g at 4°C for 20 min and the supernatant 
containing soluble recombinant protein was aliquot and retained at -80°C indefinitely 
or 4°C for further processing. 
2.10. PURIFICATION OF RECOMBINANT PROTEINS 
2.10.1. Immobilised amylose affinity chromatography  
Recombinant MBP, MBP-c3B, MBP-cSAT and MBP-c3B-cSAT were purified from 
the soluble fraction of E. coli cell lysates by amylose resin affinity chromatography 
according to the manufacturer’s instructions. Econo-column® 1.5 x 10 cm glass 
chromatography columns (Bio-Rad) were packed with 20 ml of 50% slurry of amylose 
resin by gravity flow. Columns were equilibrated with 75 ml column buffer (20 mM 
Tris-HCl pH 7.4, 200 mM NaCl, 1 mM EDTA) at a flow rate of 2.5 ml/min using a 
peristaltic pump (Pharmacia). The soluble protein fraction was diluted 1:10 with 
column buffer, filtered through a 0.45 μm Minisart® high flow syringe filter 
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(Sartorius) then loaded onto the column at a flow rate of 1 ml/min. The column was 
washed with 180 ml of column buffer at 2.5 ml/min. MBP or MBP fusion proteins 
were eluted in 10-15 ml of column buffer containing 10 mM maltose at 1 ml/min. All 
material eluted from the column was passed through a 280 nm UV monitor 
(Pharmacia) and absorbance was recorded on a chart recorder (Pharmacia). Eluates 
were dialysed against two changes of 800 ml of 25 mM Tris-HCl pH 8.0 at 20°C for 8 
h and then at 4°C for 16 h. Dialysis was performed using Slide-A-Lyzer Dialysis 
Cassettes (Thermo Fisher Scientific) with a molecular weight cut off (MWCO) of 
≤10,000 Da. Dialysed recombinant proteins were mixed with glycerol at a final 
concentration of 50% (w/v) and stored at -20°C. 
Amylose resin was regenerated by washing sequentially with three column volumes 
each of water, 0.1% SDS, water and five column volumes of column buffer. 
Regenerated resin was removed from columns and stored in column buffer with 0.05% 
(w/v) sodium azide at 4°C. 
Samples from large scale expression and purification of recombinant MBP-3B 
proteins were collected for quality control purposes. Samples included pre-induction 
and 3 h post-induction cell pellets, soluble protein fractions, post-column (depleted) 
samples, column washes and eluted protein fractions. All samples were prepared in 1x 
SRB and normalized for protein load to the pre-induction cell lysate prior to analysis 
by SDS-PAGE. 
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2.11. PROTEIN CHARACTERISATION 
2.11.1. Quantitation of recombinant proteins 
Quantitation of proteins was performed using a Pierce Micro BCA™ Protein assay kit 
(Thermo Fisher Scientific) as per manufacturer’s instructions. In brief, purified MBP-
c3B, MBP-cSAT, MBP-c3B-cSAT and MBP were diluted 1:50, 1:100 and 1:500 with 
25 mM Tris-HCl pH 8.0, 50% (w/v) glycerol. Bovine serum albumin (BSA) protein 
standards were prepared by serial twofold dilution from 200 to 0.781 μg/μl in the same 
buffer. Internal BSA controls of 50 and 5 μg/μl were also prepared. All samples, 
standards and controls were prepared in triplicate. An aliquot of 150 μl per well of 
each protein sample was added in triplicate to a Nunc™ Nunclon delta 96-well 
microwell plate (Thermo Fisher Scientific) followed by incubation with 150 Pl of 
bicinchoninic acid reagent at 37°C for 2 h. Samples were cooled to 20°C and the 
absorbance at 450 nm (A450) of the product was measured using a MultiSkan PLUS 
MKII microplate reader (Titertek, Germany). Protein concentrations were determined 
by comparison of their A450 with a standard curve of A450 versus concentration 
generated from the BSA standards. A sample blank consisting of 25 mM Tris-HCl pH 
8.0 alone was included for background subtraction. 
2.11.2. Purity of recombinant proteins  
Purified recombinant 3B proteins were diluted with 1x SRB then resolved by SDS-
PAGE and visualised by CBB and silver nitrate staining, or immunodetection (sections 
2.6, 2.7, and 2.8). 
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2.11.3. Stability of recombinant proteins 
Aliquots of purified recombinant 3B proteins were prepared and stored at -20°C. 
Individual aliquots were analysed by SDS-PAGE and CBB staining at 1, 4, 20, 36 and 
60 week/s post-storage.  
2.11.4. Removal of MBP tag from c3B-cSAT using enterokinase  
According to the manufacturer’s instructions 1 U (0.16 ng) of recombinant 
enterokinase (EK) light chain (NEB) will cleave 25 μg of test substrate to 95% 
completion in 16 hours or less at 25°C. Cleavage reactions were prepared by 
combining EK with MBP-c3B-cSAT at enzyme to substrate molar ratios of 
approximately 1:50 and 1:500. Reactions were stopped by twofold dilution with 2x 
SRB followed by heating at 100°C for 10 min. Initially, 2.1 U or 0.21 U of EK was 
added to 33.6 μg of 0.56 mg/ml MBP-c3B-cSAT in 25 mM Tris-HCl pH 8.0, 50% 
(w/v) glycerol and was incubated at 20°C for 1, 2, 4 or 8 h.  
In a second experiment, MBP-c3B-cSAT was dialysed against two changes of 50 
volumes of EK cleavage buffer (25 mM Tris-HCl pH 7.4, 50 mM NaCl, 2 mM CaCl2) 
for 8 h at 20°C and 16 h at 4°C. Cleavage reactions involved 3.5 U or 0.35 U of EK 
added to 56 μg of 0.56 mg/ml MBP-c3B-cSAT in EK cleavage buffer. Reactions were 
performed at 20°C for 0.5, 1, 1.5 or 2 h. 
2.12. PROTEIN PREPARATION FOR MASS SPECTROMETRIC 
ANALYSIS  
The MBP-c3B-cSAT protein sequence was examined for trypsin and chymotrypsin 
cleavage sites using Protein Prospector: MS-Digest 
(www.prospector.ucsf.edu/prospector) to confirm cleavage would yield peptides of 
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mass amenable to MS identification in the range of 400 to 1,600 m/z. In-gel digests 
were performed on recombinant proteins based on the method by Shiell and colleagues 
(280). 
2.12.1. Excision and de-staining 
MBP, MBP-c3B, MBP-cSAT and MBP–c3B-cSAT proteins were loaded at 11.2 μg 
per well, resolved by SDS-PAGE and stained with CBB or silver nitrate. Gel slices 
containing recombinant proteins were excised from polyacrylamide gels and 
transferred to separate polypropylene microcentrifuge tubes then washed with 200 μl 
of 100 mM ammonium bicarbonate for 5 min. CBB stain was removed from gel slices 
by washing with 200 μl of 100 mM ammonium bicarbonate, 50% (v/v) acetonitrile for 
30 min in a ultrasonic water bath at 20°C. To remove silver stain, gel slices were 
incubated with 50 μl of a 1:1 solution of freshly prepared 30 mM potassium 
ferricyanide and 100 mM sodium thiosulphate for 15 min at 20°C with occasional 
vortexing. Following silver stain removal, gel pieces were washed twice with 200 μl 
100 mM ammonium bicarbonate. 
2.12.2. Reduction and alkylation 
Gel slices were incubated for 10 min in 200 μl of acetonitrile and dried for 10 min in 
a vacuum centrifuge (Speedi-Vac, Thermo Fisher Scientific). Proteins were reduced 
with 150 μl 10 mM DTT, 100 mM ammonium bicarbonate at 56°C for 1 h. Gel pieces 
were again washed with 200 μl acetonitrile for 10 min and the proteins alkylated by 
incubation in 150 μl 50 mM iodoacetamide, 100 mM ammonium bicarbonate for 20 
min in the dark. Alkylating agent was discarded and samples were washed with 200 μl 
of 100 mM ammonium bicarbonate for 10 min. Samples were again dehydrated with 
200 μl acetonitrile for 10 min and dried by vacuum centrifugation for 10 min.  
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2.12.3. Proteolytic digestion 
Protein containing gel slices were rehydrated in either 50 μl of fresh 10 μg/ml 
proteomics grade trypsin (Sigma-Aldrich) or proteomics grade chymotrypsin 
(Promega) in 1 mM HCl and then incubated for 16 h at 37°C or 25°C. Peptides were 
then extracted by addition of 150 μl protein extraction solution (0.2% (v/v) formic acid 
in 50% (v/v) acetonitrile) with sonication for 30 min. Gel pieces were spun down, the 
supernatant collected and then reduced in volume to 40 μl by vacuum centrifugation 
and stored at -20°C for subsequent LC-MS/MS analysis.  
2.13. LIQUID CHROMATOGRAPHY-TANDEM MASS 
SPECTROMETRY (LC-MS/MS) 
2.13.1. High resolution LC-MS analyses 
Maintenance and operation of the LC-MS instrumentation at the Bio21 Mass 
Spectrometry and Proteomics Core Facility, The University of Melbourne (Parkville, 
Australia), was performed by Dr Nick Williamson and Dr Ching-Seng Ang, Faculty 
of Science, The University of Melbourne. Data analysis was conducted by Brian Shiell 
of the Bioreagent Development and Protein Characterisation team, CSIRO, AAHL. 
Individual digests of gel-eluted proteins were subjected to LC-MS/MS analysis on a 
LTQ Orbitrap Elite mass spectrometer (Thermo Fisher Scientific) coupled to an 
Ultimate 3000 RSLC nanosystem (Dionex). The LC system was equipped with an 
Acclaim Pepmap nano-trap column (Dinoex-C18, 100 Å, 75 μm x 2 cm) and an 
Acclaim Pepmap RSLC analytical column (Dinoex-C18, 100 Å, 75 μm x 15 cm) 
running on a 3–80% acetonitrile-containing 0.1% formic acid gradient over 25 min. 
The mass spectrometer was operated in the data-dependent mode, whereby spectra 
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were acquired first in positive mode followed by MS/MS fragmentation using higher-
energy collisional dissociation. Ten of the most intense peptide ions with charge states 
≥2 were isolated and fragmented using normalized collision energy of 35 and 
activation time of 0.1 ms. The Orbitrap MS data was analysed using Proteome 
Discoverer program (Thermo Fisher Scientific version 2.0) with the Sequest search 
engine against a custom database containing the 3B fusion protein sequences in 
FASTA format. Search results were filtered by a single threshold where matches to 
proteins were reported only if the cross correlation factor (Xcorr) was >1.5 for a singly 
charged peptide ion, >2.0 for a doubly charged peptide ion or >2.5 for a triple charged 
peptide ion. 
2.13.2. Data acquisition and analysis 
A list of peptide masses was compiled and compared with theoretical values from the 
NCBI non-redundant protein database using the peptide mass fingerprinting (PMF) 
search program MS-Fit (http://prospector.ucsf.edu) using a peptide mass tolerance of 
+/- 200 parts per million. Protein identification was only confirmed if four or more 
peptides matching the above criteria were found in each sample digest. 
2.14. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 
DEVELOPMENT 
2.14.1. ELISA protocol 
Unless stated otherwise, all assays included a blank control that consisted of blocking 
buffer (Dulbecco’s phosphate buffered saline (PBS) pH 7.3, 0.05% (v/v) Tween-20, 
5% (w/v) skim milk powder), and an absorbance control that consisted of all test 
reagents except primary antibody (Amin) in an indirect ELISA or test serum (Amax) in a 
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competition ELISA. All samples were prepared in duplicate in 96-well microtiter 
plates and all incubations were conducted at 37°C on an orbital shaker. Wells of 96-
well plates were coated with 50 μl per well of antigen diluted in coating buffer (50 
mM carbonate-bicarbonate, pH 9.6) for 1 h. Blocking buffer was used at 200 μl per 
well for 30 min. All antibodies or sera were diluted in blocking buffer and used at 50 
μl per well for 30 min with the exception of HRP-conjugated secondary antibody 
which was incubated for 1 h. Washes were performed in triplicate with wash buffer 
(200 μl per well PBS pH 7.3, 0.5 mM MgCl2, 0.7 mM CaCl2) using either an automated 
plate washer (Select Deep Well Microplate washer ELx405, BioTek) or manual 
pipetting. Plates were washed after incubations with antigen, blocking buffer, chicken 
anti-3ABC antibody and HRP-conjugated rabbit anti-chicken polyclonal IgG (Pierce) 
diluted 1:4,000. Colour development was by incubation with 50 μl per well 3,3’,5,5’-
tetramethylbenzidine (TMB, Sigma-Aldrich) for 10 min at 20°C and the colourimetric 
reaction was stopped by addition of 50 μl per well 1 M sulphuric acid. Absorbance 
was measured at 450 nm (A450) using a microtiter plate reader (MultiSkan EX, Thermo 
Fisher Scientific). 
2.14.2. Determination of antigen coating concentration and 
absorbance maximum by Indirect ELISA  
Checkerboard titrations of MBP, MBP-c3B, MBP-cSAT or MBP-c3B-cSAT against 
chicken anti-3ABC polyclonal antibody (281) were performed in an indirect ELISA 
(I-ELISA) format to identify the optimal ratio of antibody and antigen, establishing 
the maximal absorbance, Amax. Rows of 96-well plates were coated with purified 
proteins serially diluted twofold from 70 to 1 ng per well. Plates were blocked with 
blocking buffer before incubation for 1 h with chicken anti-3ABC antibody serially 
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diluted twofold from 1:40 to 1:5,120. Plates were developed and the absorbance of 
each sample determined. Absorbance readings were plotted as mean ± standard 
deviation (SD) and fitted with a sigmoidal dose-response curve by non-linear 
regression analysis using GraphPad Prism V5.02 (USA).  
The optimal dilution of chicken anti-3ABC antibody at a constant concentration of 
protein was confirmed for use in a competition ELISA (C-ELISA). In brief, wells 
coated with MBP-c3B, MBP-cSAT or MBP-c3B-cSAT (50 ng per well) were 
incubated with 50 μl blocking buffer for 30 min. Dilutions of chicken anti-3ABC 
antibody resulting in an A450 of approximately 1.5 for each antigen were added directly 
to wells containing blocking buffer at a ratio of 1:1. Plates were developed and the A450 
of each well was measured. 
Chicken anti-3ABC immunoglobulin Y production 
Anti-3ABC immunoglobulin Y (IgY) was produced in chickens as described by 
Colling and colleagues (281). A second batch of chicken anti-3ABC antibody was 
produced by the AAHL Bioreagent Development and Protein Characterisation Group 
and was available for this project. Crude IgY extracts were prepared for screening. Egg 
yolks were separated from egg albumin, blotted with paper towel and transferred to 
sterile 50 ml tubes. The vitellin membranes (yolk sac) were removed using sterile 
wooden cotton buds and 100 μl aliquots of each yolk were diluted 1:1 with PBS. One 
volume of chloroform (200 μl) was added to each diluted yolk and the samples were 
mixed by vortexing then centrifuged at 15,000 x g at 20°C for 10 min. The aqueous 
supernatants were retained and tested for titre against 3ABC by immunodetection. Egg 
yolks corresponding to samples containing 3ABC-specific IgY were diluted sixfold 
with chilled acidified deionised water pH 5.0 and subjected to one freeze/thaw cycle. 
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Samples were centrifuged at 5,000 x g at 20°C for 30 min, and supernatants were 
pooled and filtered through sterile 0.8 μm cellulose nitrate rapid-flow membrane filters 
(Nalgene). Saturated ammonium sulphate was added (50 ml/min) to a final 
concentration of 50% with constant mixing at 20°C. The sample was mixed for a 
further 2 h then centrifuged as above before discarding the supernatant. Precipitated 
IgY was redissolved in one fifth of the original yolk volume of PBS and the sample 
was dialysed overnight against 2 x 50 volumes of PBSA at 20°C using Slide-A-Lyzer 
Dialysis Cassettes (Thermo Fisher Scientific) with a molecular weight cut off 
(MWCO) of ≤10,000 Da. 
Titration of chicken anti-3ABC antibody (batch 2) stock. Checkerboard titration of 
chicken anti-3ABC polyclonal antibody against MBP-c3B was performed by I-
ELISA. Wells were coated with MBP-c3B (50 ng per well) then, to replicate C-ELISA 
conditions, wells were incubated with 50 μl blocking buffer for 30 min. Chicken anti-
3ABC antibody was serially diluted twofold from 1:350 to 1:179,200 in blocking 
buffer was directly added to wells containing blocking buffer at a ratio of 1:1. Plates 
were developed and the A450 of each well was measured. The Amax was confirmed by 
C-ELISA using chicken anti-3ABC antibody diluted 1:8400 in blocking buffer. Plates 
were developed and the A450 of each well was measured. 
2.14.3. Development of C-ELISA 
Plates were coated with 50 ng purified MBP-c3B, MBP-cSAT or MBP-c3B-cSAT per 
well. Test sera and negative control serum (FMDV antibody-negative serum; C-) were 
used diluted 1:5 with blocking buffer. Positive control serum (28-day post-infection 
serum produced by sequential infection with C1 Detmold followed by Asia1 Shamir 
and A22 Iraq 8 and 12 weeks later, respectively) was diluted 1:5 and 1:50 and used to 
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represent high titre positive serum (C++) and low titre positive serum (C+). Competing 
chicken anti-3ABC antibody at its predetermined optimal dilution was added to each 
well. Results were expressed as percentage of inhibition (PI) using the following 
formula: PI = 100 – [(mean A450 of serum/mean Amax) x 100]. 
2.14.4. Preliminary control sample limits of C-ELISA 
Limits for the positive and negative control sera were determined by repeating the C-
ELISA method for each antigen three times. Limits were expressed as the mean and 
standard deviation. 
2.14.5. Detection of FMDV serotypes 
A panel of seven bovine sera collected from infected animals representing each of the 
FMDV serotypes (Asia1 Shamir, C1 Noville, SAT3 Zim 4/81, SAT2 Sau 1/2000, 
SAT1 Bot 1/68, O1 UKG 11/2001 and A24 Cruzeiro (Table A-6)) were used to 
evaluate the cross-serotype detection capability of the MBP-c3B C-ELISA. 
2.14.6. Control sample limits and repeatability of c3B C-ELISA 
Upper and lower limits for the Amax and positive and negative control sera were 
determined by repeating the c3B C-ELISA once per day for 10 days. Limits were 
expressed as the mean and range. 
2.14.7. Estimation of preliminary cut-off of c3B C-ELISA 
The presence of anti-FMDV NSP antibodies in test sera was confirmed using the 
AAHL C-ELISA (281). A total of 36 bovine samples (Table A-6) derived from 
naturally or experimentally FMDV-infected animals, including at least one 
representative of each FMDV serotype, and FMDV antibody-negative serum samples 
was used to estimate the preliminary cut-off of the c3B C-ELISA. Sample status was 
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indicated by dichotomised values with samples marked as ‘0’ for negative status and 
‘1’ for positive status as determined by the AAHL C-ELISA (281). Receiver operating 
characteristic (ROC) curve analysis using the method of DeLong and colleagues (282) 
was performed using MedCalc for Windows V13.2.2.0 (MedCalc Software, Belgium) 
to identify the optimum cut-off value for declaring positive and negative test results 
based on the maximal Youden index (283). The maximal Youden index identifies a 
cut-off value where equal weight is given to both diagnostic sensitivity (DSe) and 
diagnostic specificity (DSp), being that, false positives are as undesirable as false 
negatives (283). Serum sample dichotomised values from AAHL C-ELISA and PI 
values determined in the c3B C-ELISA were used for ROC analysis. 
2.14.8. Estimation of analytical sensitivity of c3B C-ELISA 
Analytical sensitivity (ASe) of the c3B C-ELISA was determined by endpoint dilution 
of the positive bovine control serum. Wells of a 96-well plate were coated with MBP-
c3B (50 ng per well) and blocked. Rows were incubated with positive and negative 
control sera serially diluted twofold from 1:5 to 1:320 in blocking buffer followed by 
incubation with chicken anti-3ABC antibody diluted 1:50, 1:100, 1:200, and 1:350 in 
blocking buffer. Plates were developed and the A450 of each sample was measured. 
Results were expressed as PI and used to construct dose-response curves using 
GraphPad Prism V5.02 (USA). 
2.14.9. Estimation of analytical specificity of c3B C-ELISA 
The analytical specificity (ASp) of the c3B C-ELISA was determined by testing bovine 
sera positive for Bluetongue virus (BTV) antibodies (n = 19) or Vesicular stomatitis 
virus (VSV) (n = 2, Table A-6); ovine sera that were positive for BTV antibodies (n = 
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17, Table A-7); and porcine sera that were positive for Swine vesicular disease virus 
(SVDV) antibodies (n = 6, Table A-8). 
2.14.10. Diagnostic sensitivity (DSe) and specificity (DSp) 
The presence of anti-FMDV NSP antibodies in test sera was confirmed by Dr Leanne 
McNabb (AAHL)using the AAHL C-ELISA (281). A total of 272 bovine serum 
samples (Table A-6) derived from animals that were naturally or experimentally 
FMDV-infected, including at least one representative of each FMDV serotype, 
vaccinated animals and FMDV antibody-negative serum samples were used to 
estimate the DSe and DSp of the c3B C-ELISA for cattle. A total of 249 ovine sera 
(Table A-7) derived from experimentally FMDV-infected animals and FMDV 
antibody-negative serum samples were used to estimate the DSe and DSp of the c3B 
C-ELISA for sheep. Sample status was indicated by dichotomised values with samples 
marked as ‘0’ for negative status and ‘1’ for positive status as determined by the AAHL 
C-ELISA (281). Results were summarised in 2 x 2 contingency tables partitioned into 
true positive (TP), false positive (FP), false negative (FN) and true negative (TN) to 
determine the DSe, DSp, positive predictive value (PPV), and negative predictive 
value (NPV). ROC curve analysis was performed as described in section 2.14.7. 
Estimations of DSe and DSp at fixed specificities and sensitivities of 80%, 90% and 
95% (284) with bootstrapped 95% confidence intervals as described by Efron (285) 
were also calculated using MedCalc. Serum samples dichotomised values from the 
AAHL C-ELISA and PI values determined in the c3B C-ELISA were used for ROC 
analysis. 
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2.14.11. Bayesian Latent Class analysis 
DSe and DSp of the c3B C-ELISA were compared with those of the AAHL C-ELISA 
using Bayesian modeling to corroborate results for two dependent tests, examining one 
population with no gold standard (281,286). Beta distribution parameters were derived 
using Beta Buster (http://www.epi.ucdavis.edu/diagnostictests/betabuster.html). 
Bayesian inferences were based on the joint posterior distribution, approximated using 
OpenBUGS V3.2.3 rev 1020 (287) (Figure A-1). The convergence estimates were 
derived using 2 x 106 iterations of simulation with sampling performed every 1 x 105 
iterations until the Monte Carlo (MC) error value was <5% of the standard deviation 
of the node estimate. Final inferences of DSe and DSp were given as the mean of their 
95% probability intervals. 
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CHAPTER 3 
 IN SILICO IDENTIFICATION OF 
FOOT-AND-MOUTH DISEASE VIRUS 
3B CONSENSUS SEQUENCE 
3.1. INTRODUCTION 
The NSP 3B protein is conserved across the FMDV serotypes, consists of multiple B 
cell epitopes, and is immunogenic (288). FMDV is the only picornavirus that encodes 
three similar repeats of 3B in series, essentially tripling the number of potential 
epitopes (140,179). Increasing the number of tandem repeats of 3B epitopes in order 
to multiply the number of antibody binding sites, has been successfully used to develop 
assays with DIVA capability (258). In addition, DIVA tests have been developed by 
expressing the entire 3B protein region (all three repeats) alone (250,259) or as part of 
a larger FMDV NSP - typically 3AB, 2C3AB or 3ABC (Table A-1). The majority of 
FMDV NSP assays are established using a coating antigen derived from a single virus 
isolate. In doing so, serotype-specific variations in sequence may affect antibody 
binding. Few assays have been assessed for their proficiency in detection of all FMDV 
serotypes. However, this is becoming increasingly important as some sequence 
differences indicative of serotype have been observed within NSP sequences 
(289,290). 
The study described in this chapter presents an alternative approach to FMDV antigen 
bioreagent development; that is, to identify a consensus antigen derived from all 
published sequences of the NSP 3B protein rather than from a single serotype isolate. 
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Identification of a stably conserved epitope that is present among all variants would 
overcome limitations associated with sequence variability observed between serotypes 
and strains. This canonical antigen will enable FMD diagnosis without knowledge of 
the virus serotype in circulation. In this study a 3B consensus sequence was derived 
from all available sequences to best represent all serotypes (c3B) (279). An alternative 
3B consensus sequence was also derived from the Southern African Territories (SAT) 
serotypes (cSAT) in isolation to account for identified sequence divergence. 
3.2. RESULTS 
3.2.1. FMDV 3B sequence acquisition 
A total of 374 full length amino acid sequences of the three tandem repeats of FMDV 
NSP 3B were translated from whole virus coding sequences retrieved from the NCBI 
GenBank database in March, 2012. The proportion of sequences representing each of 
the seven serotypes were: O, 47.6%; A, 27.1%; Asia1, 12.8%; C, 6.4%; SAT1, 2.7%; 
SAT2, 2.1%; and SAT3, 1.3%. Two sequences retrieved contained anomalies. These 
were sequences A_24 (accession no. AY593794.1) and A_50 (accession no. 
HM854021.1). A_24 contained a single amino acid insertion in the third repeat, and 
A_50 contained three unidentified amino acids within the second repeat of the 3B 
triplet, residues 29-31 (Table A-2). 
3.2.2. Multiple sequence alignment 
Three multiple sequence alignment (MSA) algorithm tools were assessed: MAFFT, 
MSAProbs and Probalign. MAFFT and MSAProbs, unlike Probalign, produced 
comparable alignments and both identified the majority of SAT sequences as being the 
most divergent. MAFFT and Probalign, unlike MSAProbs, aligned sequences A_24 
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and A_50 with like sequences regardless of the insertion and unidentified residues. 
MAFFT performed appropriately in both instances and was selected for subsequent 
analyses. Inspection of the resultant sequence alignment by MAFFT revealed multiple 
100% identical sequences. These redundant sequences were removed, as were A_24 
and A_50, leaving a single representation of each sequence. The total number of 
sequences was reduced from 374 to 125 sequences (Table A-3) and the proportion of 
sequences representing each of the seven serotypes after this reduction was: O, 35.2%; 
A, 28.0%; Asia1, 17.6%; C, 3.2%; SAT1, 8.0%; SAT2, 5.6%; and SAT3, 2.4%. 
3.2.3. 3B sequence relatedness 
Analysis of the evolutionary relatedness of 3B sequences using MEGA5 resulted in an 
optimal phylogenetic tree with a sum of branch length of 2.39 amino acid substitutions 
per site (Figure 3-1). Sequences were separated into two main branches: one contained 
16 of the 20 SAT serotype sequences, with a divergence of approximately 0.1125 
amino acid substitutions per site; and the other contained all of the remaining 
sequences, including four SAT serotype sequences. 
3.2.4. Proportional representation of amino acid residues 
Analysis of the MAFFT MSA using WebLogo revealed a 71 amino acid consensus 
sequence (c3B); the sequence that consisted of the most prevalent amino acid at a given 
position across all sequences (Figure 3-2). Consensus sequences for each of the 
serotypes O, A, C, and Asia1 individually, and for serotypes SAT1, 2, and 3 
collectively (cSAT) were also produced (Figure 3-3). When compared with the c3B 
sequence, consensus sequences for serotypes O, A, and Asia1 were identical; and the 
type C consensus sequence contained a single conservative residue substitution, K11R. 
The cSAT sequence contained 12 residue substitutions when compared with c3B: 
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K11Q, V15L, R16K, Q22A, M30L, R32K, K34Q, V38L, A42L, V45A, N66A, and 
L67P (Figure 3-4). Five of these substitutions (positions 15, 16, 30, 32 and 38) were 
conservative residue substitutions with similar physiochemical properties to the 
residue in the c3B sequence. The remaining seven were classified as non-conservative 
substitutions.  
3.2.5. Consensus sequence analysis 
Individual comparisons of each of the 125 3B amino acid sequences with the c3B 
sequence revealed 21 of the 71 residues were identical. Among the remaining 50 
residues a total of 97 different amino acid substitutions were observed (Table 3-1). 
Individual amino acid substitutions, relative to the c3B sequence, occurring in greater 
than 10% of non-redundant 3B sequences were assessed for possible impact on 
antibody binding. A total of 14 residue substitutions occurred in equal to or greater 
than 10% or more of all sequences. Of these, 10 originated mainly from sequences 
derived from SAT serotype viruses and, of those, seven resulted in non-conservative 
residue substitutions: K11Q, Q22A, K34Q, A42V, V45L, N66A and L67P. 
Substitutions resulting in addition of proline residues were examined as these residues 
introduce sharp turns in protein structure (Betts & Russell 2003). Five of the 97 
substitutions resulted in proline residues at positions 19, 36, 42, 66, and 67. This 
included substitution L67P, a non-conservative substitution which occurred in greater 
than 10% of sequences, exclusively in SAT serotype sequences: all SAT3 sequences 
(3/3), some SAT2 sequences (2/7) and the majority of SAT1 sequences (8/10).  
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Figure 3-1: Evolutionary relatedness of FMDV 3B amino acid sequences. 
The evolutionary relatedness of 3B amino acid sequences was inferred using the 
Unweighted Pair Group Method with Arithmetic Mean (UPGMA) method. The 
optimal tree with the sum of branch length = 2.39 is shown. The tree is drawn to scale, 
with branch lengths in the same units as those of the evolutionary distances used to 
infer the phylogenetic tree. The evolutionary distances were computed using the 
Poisson correction method and are in the units of the number of amino acid 
substitutions per site. The analysis involved 125 amino acid sequences. Evolutionary 
analyses were conducted in MEGA5. 
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Figure 3-2: FMDV 3B amino acid probability-based consensus sequence.  
Graphic depicting amino acid residue conservation of the 3B consensus protein sequence generated using WebLogo. Letter height 
indicates relative frequency (probability) of each amino acid appearing at that position within the sequence. Amino acid properties 
are indicated as follows: green, polar; purple, neutral; blue, basic; red, acidic; black, hydrophobic. The three tandem repeats of 
FMDV NSP 3B are indicated. 
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Figure 3-3: FMDV 3B serotype consensus sequences. 
Graphic depicting amino acid residue conservation of 3B consensus protein sequences generated using WebLogo. (A) All 3B 
sequences, c3B; (B) all Southern African Territory serotype sequences, cSAT; (C) serotype A sequences alone; (D) serotype Asia1 
sequences alone; (E) serotype C sequences alone; and (F) serotype O sequences alone. Letter height indicates relative frequency 
(probability) of each amino acid appearing at that position within the sequence. Amino acid properties shown are green, polar; 
purple, neutral; blue, basic; red, acidic; black, hydrophobic. 
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Figure 3-4: Comparison of FMDV 3B and SAT serotype consensus sequences. 
Graphic depicting amino acid conservation between (A) c3B and (B) cSAT generated using WebLogo. Amino acids that differ are 
indicated by arrows and include: K11Q, V15L, R16K, Q22A, M30L, R32K, K34Q, V38L, A42L, V45A, N66A, and L67P. Letter 
height indicates relative frequency (probability) of each amino acid appearing at that position within each sequence. 
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Table 3-1: FMDV 3B amino acid substitutions differing from the consensus 
sequence.   
Amino acids are noted using their single letter code. Physical properties of amino acids 
are indicated as follows: s, small side chain; b, bulky side chain; +, positively charged 
side chain; -, negatively charged side chain; p, polar side chain; h, hydrophobic side 
chain. Amino acid substitutions were graded in terms of the resultant change in 
physicochemical properties as ‘favourable’ for amino acids with similar properties, 
‘unfavourable’ for amino acids with opposing properties and ‘neutral’ for amino acids 
with property changes that do not detrimentally affect protein structure. Amino acid 
substitutions which result in an amino acid residue property change are shaded in 
yellow; substitutions to a proline residue are shaded in blue; amino acid substitutions 
present in more than 10% of all sequences are shaded in grey; candidate substitutions 
of dissimilar properties present in greater than or equal to 10% of all sequences are 
shaded in green; and candidate substitutions with conservative amino acid changes are 
shaded in purple. SAT serotype-specific residue substitutions are shown in italics. 
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Table 3-1 (continued) 
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Table 3-1 (continued) 
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3.2.6. Predictive protein characterisation 
In silico determination of the c3B sequence epitopic propensity scores predicted amino 
acid residues 9-15, 32-38 and 54-59 to be most antigenic, with epitopic propensity 
scores of 0.90, 0.90 and 0.81, respectively (Figure 3-5). For the cSAT sequence, two 
regions of antigenicity were predicted (paralleling those in c3B) that corresponded to 
residues 9-15 and 54-59 with epitopic propensity scores of 0.87 and 0.81, respectively 
(Figure 3-5). A third antigenic region located in the second repeat was shifted slightly 
upstream to residues 34-39 with an epitopic propensity score of 0.82. An additional 
antigenic region was predicted in the cSAT sequence at residues 65-71 with an epitopic 
propensity score of 0.71 (Figure 3-5). Whole protein probability of antigenicity scores 
were 0.6118 and 0.5398 for each of c3B and cSAT, respectively.  
Predicted post-translational modifications (PTM) included phosphorylation of all three 
tyrosine resides (positions 3, 26, and 50), consistent with known phosphorylation sites 
(144). Neither O-linked (Thr70) nor N-linked (Asn66) glycosylation were predicted. 
The theoretical molecular masses and isoelectric points of MBP, each 3B protein and 
each MBP-3B fusion protein are shown in Table 3-2.   
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Figure 3-5: Epitopic propensity predictions for individual amino acids within c3B 
and cSAT consensus sequences. 
Histograms generated by COBEpro to map predicted epitopic propensity scores of the 
top 5% (most likely) and bottom 5% (least likely) scoring fragments for (A) c3B and 
(B) cSAT sequences. Residues acquire a positive (+) ‘vote’ for each epitope fragment 
they are within or a negative (-) ‘vote’ for each non-epitope fragment. Amino acid 
substitutions compared with c3B are in bold font. Experimentally determined B cell 
epitopes of FMDV 3B protein are shaded.  
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Table 3-2: Theoretical molecular weight (kDa) and isoelectric point (pI) values 
calculated from amino acid sequences. 
Protein MW pI 
MBP-c3B 50.59 5.92 
c3B 7.97 10.11 
MBP-cSAT 50.44 5.60 
cSAT 7.82 9.89 
MBP-c3B-cSAT 58.19 8.70 
c3B-cSAT 15.57 10.05 
MBP 42.84 4.92 
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3.3. DISCUSSION 
Antigens used in immunoassays for the detection of FMDV NSP-positive antisera 
have all been derived from individual FMDV serotype strains. Antigens commonly 
used were either individual 3B peptide repeats, the entire 3B protein or larger FMDV 
NSPs that contain 3B, such as 3ABC (see Table A-1). With considerable sequence 
diversity being observed in NSPs (289,290), this approach to bioreagent design 
increases the possibility that sera from animals infected with other serotypes or strains 
may not be detected. In contrast, the approach to developing a 3B antigen presented 
here used all published 3B sequences, irrespective of serotype or strain, to create a 3B 
consensus sequence (c3B). In doing so, the effect of strain-specific variations in 
sequence on antibody binding may be ameliorated by providing conserved 3B epitopes 
which may be recognised across all serotypes. 
The high conservation of 3B sequences across serotypes provided a solid foundation 
for the derivation of a 3B consensus sequence. In the method presented, the c3B 
sequence was derived using proportional representation of each amino acid at each 
position for all non-redundant FMDV 3B sequences in the GenBank database. 
Analysis of amino acid conservation within related sequences is affected by the ratio 
of the number of similar sequences to the number of more distantly related sequences 
(291). The GenBank database contains significantly more sequence submissions for 
type O and A serotypes relative to the other serotypes. This may be due to type O and 
A being the most widely distributed serotypes of the virus, occurring in six of the seven 
pools shown in Figure 1-1. This dominance of O and A serotypes created a bias that 
was reflected in the amino acid composition of the c3B sequence. An alternative 
method might take individual consensus sequences derived from all sequences of a 
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particular serotype and combine them to derive a final 3B consensus sequence. This 
would remove the bias described above but would have the adverse effect of weighting 
the derived protein in favour of less represented serotypes. As a result, it was expected 
that the chosen method would produce an antigen best able to detect antibodies raised 
to 3B in the majority of infected animals, but would also have sufficient similarity to 
all serotypes for their detection.  
The high homology of 3B sequences was demonstrated within the non-redundant 
sequence dataset where 30% of the 71 amino acids comprising the 3B protein were 
found to be identical across all serotypes. Review of all amino acid substitutions, using 
c3B as the reference sequence, revealed 47% of the substitutions were conservative 
amino acid changes. Despite the high sequence homology of 3B proteins, non-
conservative differences were observed across the seven serotypes. Sequences of the 
3B protein originating from SAT serotype viruses showed the greatest variation by 
MSA and formed a distinct group upon phylogenetic analysis. It is worth noting, four 
sequences originating from SAT serotype viruses did not group with the majority of 
SAT sequences. These sequences, compared to other SAT sequences, contained a Leu 
at position 30 rather than Met. An Asp-Met rather than Ala-Pro or Pro-Ala was 
observed at residue positions 66-67. These findings are supported by data from 
Nsamba and colleagues (289) who observed the greatest 3B sequence variability 
between SAT and non-SAT serotypes (O, A, Asia1 and C). In order to better capture 
these SAT serotype-specific sequence differences, a second SAT consensus sequence 
(cSAT) was derived. Of the 12 residue substitutions within the cSAT sequence the 
non-conservative changes may affect antibody binding. In the event that the bias 
towards O and A serotype sequences in the c3B protein might lead to poor anti-3B 
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antibody binding in SAT-infected animal sera, this sequence would provide an 
alternative or additional antigen for capture of these antibodies.  
It was important to ensure the 3B consensus sequence contained epitopes that would 
be recognised by 3B-specific antibodies generated following infection with FMDV in 
a serotype-independent manner. Amino acids 11-15 and 34-38 corresponded to the 
known B cell epitope, QKPLK, found in the first and second repeats of the 3B triplet 
(288). Predicted antigenic regions of c3B and cSAT were consistent with previously 
experimentally-determined epitopes of 3B (179,257,288). Höhlich and colleagues 
(288) found the QKLPK epitope of strain SAT2 Kenya contained an amino acid 
substitution (QQPLK). In this study, the modified epitope was found to be common to 
17 of 21 SAT serotype sequences and was present in the cSAT sequence. An additional 
epitope (VKKPVA), not previously described, was predicted in the third repeat of both 
c3B and cSAT sequences. It remains to be determined whether this prediction 
translates into a biologically relevant immunogenic site.  
In summary, work described in this chapter demonstrates for the first time the 
derivation of an FMDV 3B protein consensus sequence for use in the design and 
development of a pan-FMDV serotype bioreagent. This technique may be applicable 
to other pathogens for the generation of type-independent diagnostic bioreagents or 
vaccines. 
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CHAPTER 4 
 PRODUCTION AND CHARACTERISATION OF 
RECOMBINANT FMDV 3B CONSENSUS 
PROTEINS 
4.1. INTRODUCTION 
Ideal antigen bioreagents for use in serodiagnostic tests are inexpensive to produce, 
are expressed in high yield as soluble proteins, retain antigenicity and can be purified. 
With these factors in mind, an important consideration prior to recombinant protein 
production is the method of expression. There are four major expression systems 
available for use; bacterial, yeast, insect, and mammalian. The repertoire of available 
post-translational modifications (PTMs) and the presence of cellular machinery 
required to produce proteins in their native form increases with host complexity, i.e. 
from bacteria through to mammalian systems. For protein yield per culture volume the 
reverse is true, where a greater quantity of recombinant protein is produced from 
bacteria when compared to other higher order hosts. Promoters, including T7 (pET 
derivatives; IPTG-inducible) used in this study, allow rapid production of large 
quantities of protein (292). This high rate expression of recombinant proteins in lower 
order host cells can often lead to protein accumulation in insoluble inclusion bodies 
(292). Proteins can be recovered from inclusion bodies by solubilisation using mild 
detergent and require re-folding to return to their native state. Alternatively, 
recombinant proteins can be expressed as fusions to protein tags possessing domains 
optimised for solubility and folding to encourage soluble protein expression. Thought 
should also be given to the overall purity of the antigen preparation which can vary 
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from crude lysate to highly purified proteins. These expressed proteins can be purified 
via affinity tags (maltose binding protein, 6x histidine, etc.), immunoprecipitation or 
chemical methods. Finally, appropriate methods to monitor recombinant protein 
production should also be considered and may include SDS-PAGE, immunodetection, 
mass spectrometry and protein function assays. Therefore to produce recombinant 
proteins that are fit for purpose, a number of physicochemical properties and 
modifications must be considered during initial bioreagent design. 
FMDV recombinant proteins have been produced using protein synthesis or 
expression in a heterologous host. The original FMDV 3B protein-based ELISA used 
a chemically synthesised 57-amino-acid peptide, containing amino acid sequences 
from each of the three 3B protein repeats derived from an FMDV A12 strain sequence 
(257,288). This synthetic peptide-based assay, although commercially available 
(United Biomedical Inc.), has not been routinely used in developing regions due to its 
high cost (258). Only two other assays have been developed based on synthetic 
peptides from NSPs 2B and 2C (245,246). In contrast, most FMDV nonstructural 
proteins produced for use as ELISA coating antigens have been expressed in bacterial 
or insect cells. These proteins were often insoluble and required purification under 
denaturing conditions using immobilised metal ion affinity chromatography (IMAC) 
(See Table A-1 for review) increasing processing time, production costs and reducing 
yield. In contrast, production of 3B proteins (250,259) or peptides (258) using E. coli 
expression systems is relatively inexpensive because bacterial cultures grow rapidly to 
high cell densities in simple growth media [reviewed in (293)]. A limitation of using 
bacteria instead of higher order hosts to express recombinant proteins is their inability 
to perform certain PTMs which may result in production of misfolded proteins that are 
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insoluble or inactive (294,295). The 3B consensus proteins identified in Chapter 3 are 
ideally suited to production using a bacterial expression system because they have few 
predicted PTMs and they contain known linear epitopes. Taking all of these factors 
into careful consideration, bacterial expression of the 3B consensus proteins was 
chosen. 
The non-structural protein 3B has several potential advantages over the widely used 
precursor protein, 3ABC, as a serodiagnostic. Non-specific reactions have been 
observed against 3A but not 3B in sera from vaccinated animals (235,257); and unlike 
3C, 3B does not possess peptidase activity and so does not require mutation to ensure 
expression of the full length protein. Further, 3ABC, whether expressed in bacterial or 
insect cells, has been seen to be inherently insoluble, requiring use of strong 
denaturants such as urea to extract and solubilise protein from inclusion bodies 
(176,178,235,296–300) (See Table A-1 for review). It should be noted that FMDV 3B 
has been expressed in E. coli in both soluble (258,259) and insoluble forms (250). To 
enhance recombinant protein solubility, protein fusion tags were considered. Maltose-
binding protein (MBP) (301), thioredoxin (TRX) (302) and glutathione S-transferase 
(GST) (303) proteins have been expressed as fusion proteins as a means of enhancing 
protein solubility, facilitating protein purification and reducing inclusion body 
formation (304). However, studies have shown that GST FMDV NSPs 2C, 3A, 3ABC 
and 3D fusion proteins (235) are insoluble and require purification under denaturing 
conditions. In contrast, TRX 3AB and 3A fusion proteins (179) and an MBP fusion 
with 2B (247) expressed in E. coli are predominantly soluble. A study comparing each 
of these solubility tags expressed in bacteria fused to six insoluble polypeptides 
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demonstrated that MBP is more effective at promoting solubility than GST or TRX 
(305). 
The pMAL-c5e bacterial expression vector allows subcloning of a protein coding 
sequence of interest downstream from the MBP-encoding malE gene allowing 
expression of high levels of soluble MPB-fusion protein (306–308) (Figure 4-1). 
Additionally, pMAL-c5e contains sequence encoding the recognition site of the 
protease, enterokinase (EK). EK cleaves the peptide bond located immediately after 
the sequence Asp-Asp-Asp-Asp-Lys which is encoded between MBP and a protein of 
interest (309) (Figure 4-1). In addition to enhancing solubility, MBP binds with high 
affinity to maltose and with lower affinity to amylose (310). This natural affinity has 
been exploited in the development of a single step affinity purification system in which 
MBP fusion proteins may be isolated on amylose-coupled resin and subsequently 
eluted in a buffered solution of maltose (304,311). Recombinant 3B consensus proteins 
were expressed and purified for use as coating antigens in a competition enzyme-
linked immunosorbent assay (C-ELISA).  
This study describes the bacterial expression, purification and characterisation of three 
recombinant 3B consensus proteins, namely MBP-c3B, MBP-cSAT and MBP-c3B-
cSAT.   
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Figure 4-1: Schematic illustration of expression and purification of recombinant 
3B proteins using the NEB pMAL™ Protein Fusion and Purification System. 
Sequence of events is: (1) 3B consensus protein coding sequences are inserted into the 
multiple cloning site of pMAL-c5e vector downstream of malE gene; (2) 3B consensus 
proteins are expressed with an N-terminal maltose binding protein (MBP) tag; (3) 
MBP fusion proteins are isolated by amylose-agarose affinity chromatography; (4) 
MBP fusion proteins are eluted from immobilised amylose by competition with 
maltose; (5) MBP and 3B consensus proteins are separated using enterokinase (EK) 
[adapted from https://www.neb.com/products/e8200-pmal-protein-fusion-and-
purification-system].  
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4.2. RESULTS 
4.2.1. Establishment of pMAL-3B expression clones  
The synthetic coding sequence of a fusion of c3B and cSAT (c3B-cSAT) was produced 
commercially. KpnI and NcoI-flanked c3B (213 bp), cSAT (213 bp) and c3B-cSAT 
(426 bp) coding sequences were successfully generated by PCR using pJ204:c3B-
cSAT as template (Figure 4-2). Specific amplification of cSAT and c3B-cSAT fusion 
coding sequences required an increased annealing temperature of 67°C (Figure 4-2). 
The 3B coding sequences were successfully digested with KpnI and NdeI and 
subcloned in-frame into pMAL-c5e as confirmed by sequencing (Figure 4-3 and 
Figure 4-4). 
4.2.2. Pilot expression of recombinant MBP-3B proteins 
The optical density of BL21 E. coli cultures expressing recombinant MBP-3B fusion 
proteins revealed similar growth curves for each clone (Figure 4-5). SDS-PAGE 
analysis of cell lysates revealed the presence of protein bands of molecular masses 
greater than the theoretical masses of MBP-c3B (50 kDa), MBP-cSAT (50 kDa) and 
MBP-c3B-cSAT (58 kDa) (Table 3-2, Figure 4-5). These bands were visible only in 
lysates from BL21 E. coli cultures that had been treated with IPTG. Maximal 
expression of IPTG-induced proteins was observed at least two hours after treatment 
with IPTG. 
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Figure 4-2: PCR amplification of 3B consensus coding sequences. 
 
(A) Diagram of amplicons expected to be produced by PCR using c3B-cSAT fusion 
coding sequence as template. (B) Agarose gel analysis of amplicons obtained from 
PCR amplification of pJ204 plasmid containing the commercially synthesised c3B-
cSAT gene. Amplification was performed at 55°C and 67°C as indicated. Lanes M, 
100 bp DNA molecular weight marker (Promega); Lane 1, c3B-cSAT amplicons; Lane 
2, c3B amplicon; Lane 3, cSAT amplicons; Lane 4, c3B-cSAT amplicon; and Lane 5, 
cSAT amplicon. Predicted amplicon sizes are ~400 bp for c3B-cSAT and ~200 bp for 
c3B and cSAT.  
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Figure 4-3: Plasmid vector construct pMAL-3B map. 
Vector map of pMAL-c5e (NEB) with 3B consensus protein coding sequences (green) 
shown inserted between restriction sites KpnI and NcoI. Map built using 
CloneManager, v9 (Sci-Ed software, USA). 
 
  
Chapter 4 
 
97 
 
Figure 4-4: Sequencing confirmation of 3B coding sequences’ in-frame insertion 
into pMAL-c5e. 
For each coding sequence (A) c3B (213 bp), (B) cSAT (213 bp) and (C) c3B-cSAT 
(426 bp) sequencing was performed by Micromon and confirmed coding sequences 
were subcloned in-frame into the pMAL-c5e vector. Sequence features are indicated 
as follows: the enterokinase recognition sequence is highlighted yellow; stop codons 
are highlighted red; inserted sequences are underlined; and restriction enzyme KpnI 
and NcoI sequences are in red text.  
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Figure 4-5: Growth curves for 3B expression clones and temporal expression of 
recombinant MBP-tagged 3B proteins. 
(A) Optical density (A600) versus time (h) growth curves for E. coli BL21 MBP-c3B, 
MBP-c3B-cSAT or MBP-cSAT expression clones. Induction of expression of each 3B 
protein was by addition of IPTG at A600 of approximately 0.6 (t = 0 h). (B) Coomassie 
Brilliant blue-stained SDS-PAGE profiles of total protein obtained from MBP-c3B, 
MBP-c3B-cSAT or MBP-cSAT expression clones. Samples are pre-induction of 3B 
protein expression (untreated, 0 h) and post-induction (treated with 1 mM IPTG and 
incubated for 1, 2, 3 and 4 h). Protein bands corresponding to MBP-c3B, MBP-c3B-
cSAT and MBP-cSAT are indicated by their respective molecular masses (arrows). 
Lane M, pre-stained protein molecular mass marker (SeeBlue Plus2). All sample loads 
were normalised to the cell density of the pre-induction, 0 h sample. 
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4.2.3. Solubility of recombinant MBP-3B proteins  
SDS-PAGE analysis of extracted soluble and insoluble protein fractions revealed 
protein bands that corresponded with the masses expected for MBP-c3B, MBP-cSAT 
and MBP-c3B-cSAT (Table 3-2). The majority of expressed protein was visible only 
in the soluble fractions of lysates when stained with CBB. Immunodetection using 
rabbit anti-3ABC antiserum also revealed protein bands of molecular masses similar 
to those observed by CBB staining. These bands were visible in the soluble fraction of 
lysates from all MBP-3B cultures treated with IPTG. Anti-3ABC reactive bands were 
also visible in the insoluble fraction from lysates of cultures treated with IPTG 
expressing MBP-c3B and lysate of the pre-induction culture for expression of MBP-
cSAT and, to a lesser extent, MBP-c3B-cSAT (Figure 4-6). 
4.2.4. Large-scale expression and purification of recombinant MBP-
3B proteins 
SDS-PAGE analysis of recombinant MBP-3B fusion proteins and MBP alone, purified 
from 100 ml cultures of BL21 E. coli by immobilised amylose affinity 
chromatography, revealed protein bands that corresponded to the expected molecular 
masses of MBP-c3B (50 kDa), MBP-cSAT (50 kDa), MPB-c3B-cSAT (58 kDa) and 
MBP (42 kDa) (Figure 4-7). Purified protein concentrations were determined by BCA 
assay to be 1.0 mg/ml MBP-c3B, 1.9 mg/ml MBP-cSAT, 1.1 mg/ml MBP-c3B-cSAT, 
and 2.1 mg/ml MBP. Yields of each expressed affinity-purified protein per 100 ml 
culture were approximately 14 mg, 19 mg, 17 mg and 24 mg of MBP-c3B, MBP-
cSAT, MBP-c3B-cSAT and MBP, respectively.  
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Figure 4-6: Solubility of recombinant MBP-3B proteins derived of lysed E. coli 
BL21 MBP-c3B, MBP-c3B-cSAT or MBP-cSAT expression clones. 
(A) Coomassie Brilliant blue-stained SDS polyacrylamide gel and (B) immunoblot 
using rabbit anti-3ABC antiserum diluted 1:10,000. Lanes 1 and 2, total protein from 
lysates of each 3B clone before and 3 h after induction of protein expression, 
respectively; lanes 3 and 4, soluble and insoluble proteins from lysates of each 3B 
clone prepared 3 h after induction of protein expression, respectively; lanes M, 
unstained protein molecular mass markers (A) Mark12 and (B) SeeBlue Plus2. MBP-
c3B and MBP-cSAT are indicated (arrows) at approximately 50 kDa and MBP-c3B-
cSAT is indicated (arrows) at approximately 58 kDa. All sample loads were 
normalised to the cell density of the pre-induction samples (lanes 1). 
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Figure 4-7: Expression of soluble recombinant 3B proteins and purification by affinity chromatography.  
Coomassie Brilliant blue-stained gels of proteins present during expression and purification of (A) MBP-c3B, (B) MBP-cSAT, 
(C) MBP-c3B-cSAT and (D) MBP protein. Lanes 1 and 2, total protein from lysates of each 3B clone before and after induction 
of protein expression, respectively; lanes 3 and 4, soluble protein fraction of cell lysates before and after filtration, respectively; 
lanes 5, unbound proteins in post-column flow-through; lanes i and ii, proteins present in the first and second column volumes 
of column buffer, respectively; lanes 6, eluted MBP-3B proteins; lanes M, unstained protein molecular mass marker (Mark12). 
Bands corresponding to MBP-c3B, MBP-cSAT, MBP-c3B-cSAT, and MBP are indicated (arrows) at approximately 50, 50, 58 
and 42 kDa, respectively. All sample loads were normalised to the pre-induction sample (lane 1).  
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4.2.5. Purity of recombinant proteins  
Analysis of each affinity purified MBP-3B fusion protein by SDS-PAGE, CBB and 
silver nitrate staining revealed protein bands of molecular masses at approximately 50, 
50, 58 and 42 kDa for MBP-c3B, MBP-cSAT, MPB-c3B-cSAT and MBP, 
respectively (Figure 4-8). Silver nitrate staining also revealed multiple protein bands 
ranging in size from each protein’s expected mass down to approximately 40 kDa. A 
protein band at 75 kDa was also observed across all samples and is likely to be a co-
purified E. coli protein contaminant. The additional protein bands that were visible 
only on silver-stained gels could not be identified by mass spectrometric analysis 
because the quantity of each protein isolated from gel slices was below the sensitivity 
of the instrument used. 
Analysis of purified recombinant MBP, MBP-c3B, MBP-cSAT and MBP-c3B-cSAT 
proteins by immunodetection with rabbit anti-MBP antibodies revealed bands 
consistent in molecular mass with those observed by CBB and silver nitrate staining. 
Additional minor bands of lower molecular mass similar to those on silver-stained gels 
were also observed. Immunodetection using rabbit anti-3ABC or anti-MBP antibodies 
detected all recombinant MBP-3B proteins (Figure 4-8). No reaction was observed 
where MBP alone was probed with rabbit anti-3ABC antiserum. 
4.2.6. Confirmation of protein identities by mass spectrometry 
Mass spectrometry was used for confirmation of protein identities and for quality 
control to assess consistent antigen production from batch to batch. Lists of possible 
peptide products of MBP-c3B-cSAT treated with trypsin or chymotrypsin were 
generated in silico (Figure 4-9). Mass spectrometric analysis of proteins digested with 
trypsin generated peptide matches covering 56.3%, 78.9% and 50.0% of the c3B, 
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cSAT and c3B-cSAT sequences, respectively. Peptide matches to the MBP component 
of MBP-c3B, MBP-cSAT and MBP-c3B-cSAT covered 67.7%, 82.4% and 46.7%, 
respectively. Proteins digested with chymotrypsin generated peptide matches covering 
95.8%, 95.8%, and 90.85% of c3B, cSAT and c3B-cSAT sequences, respectively. 
Peptide matches to the MBP component of MBP-c3B, MBP-cSAT and MBP-c3B-
cSAT covered 48.5%, 47.3%, and 40.8% of the MBP sequence. LC-MS/MS peptide-
spectrum matches from trypsin and chymotrypsin digestions are given in Table A-4 
and Table A-5, respectively. Combination of peptide matches from trypsin and 
chymotrypsin digestions of recombinant 3B proteins are shown in Figure 4-10 and 
confirm the identity of each recombinant 3B protein. A minor percentage of protein 
sequences were not identified as their nature prevented them from being detected by 
the mass spectrometer. 
4.2.7. Stability of purified recombinant proteins 
All purified recombinant proteins were stable when stored at -20°C for up to 60 weeks. 
SDS-PAGE analysis of each recombinant 3B fusion protein stored for a prolonged 
period revealed bands of masses that corresponded only with MBP (42 kDa), MBP-
c3B (50 kDa), MBP-cSAT (50 kDa) and MBP-c3B-cSAT (58 kDa) (Figure 4-11). 
Over the course of the analysis (1 to 60 weeks) no other protein bands of smaller 
molecular mass were observed. 
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Figure 4-8: Purity of affinity isolated MBP-3B proteins.  
Affinity purified recombinant MBP, MBP-c3B, MBP-c3B-cSAT, and MBP-cSAT were resolved by SDS-PAGE and visualised by 
(A) Coomassie Brilliant blue or by immunodetection with (B) rabbit anti-MBP antiserum or (C) rabbit anti-3ABC antisera, each 
diluted 1:20,000 or (D) silver nitrate staining. Lanes 1, MBP; lanes 2, MBP-c3B; lanes 3, MBP-c3B-cSAT; lanes 4, MBP-cSAT; lanes 
M, unstained protein molecular mass markers, diluted (A) 1:4 and (D) 1:8 (BenchMark); and lanes M2, pre-stained protein molecular 
mass markers (SeeBlue Plus2). MBP, MBP-c3B, MBP-c3B-cSAT, and MBP-cSAT are indicated (arrows) at approximately 42, 50, 
58 and 50 kDa, respectively. Additional protein indicated (arrow) at approximately 75 kDa. Samples were loaded at (A; D, lanes a) 
560 ng, or (D, lanes b) 280 ng, or (B, C) 140 ng per well. 
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A 
1  MKIEEGKLVI WINGDKGYNG LAEVGKKFEK DTGIKVTVEH PDKLEEKFPQ VAATGDGPDI IFWAHDRFGG YAQSGLLAEI 
81  TPDKAFQDKL YPFTWDAVRY NGKLIAYPIA VEALSLIYNK DLLPNPPKTW EEIPALDKEL KAKGKSALMF NLQEPYFTWP 
161 LIAADGGYAF KYENGKYDIK DVGVDNAGAK AGLTFLVDLI KNKHMNADTD YSIAEAAFNK GETAMTINGP WAWSNIDTSK 
241 VNYGVTVLPT FKGQPSKPFV GVLSAGINAA SPNKELAKEF LENYLLTDEG LEAVNKDKPL GAVALKSYEE ELVKDPRIAA 
321 TMENAQKGEI MPNIPQMSAF WYAVRTAVIN AASGRQTVDE ALKDAQTNSS SNNNNNNNNN NLGDDDDKVP GPYAGPLERQ 
401 KPLKVRAKLP QQEGPYAGPM ERQKPLKVKA KAPVVKEGPY EGPVKKPVAL KVKAKNLIVT EGPYAGPLER QQPLKLKAKL 
481 PQAEGPYAGP LEKQQPLKLK AKLPVAKEGP YEGPVKKPVA LKVKAKAPIV TE    
 
B 
1  MKIEEGKLVI WINGDKGYNG LAEVGKKFEK DTGIKVTVEH PDKLEEKFPQ VAATGDGPDI IFWAHDRFGG YAQSGLLAEI 
81  TPDKAFQDKL YPFTWDAVRY NGKLIAYPIA VEALSLIYNK DLLPNPPKTW EEIPALDKEL KAKGKSALMF NLQEPYFTWP 
161 LIAADGGYAF KYENGKYDIK DVGVDNAGAK AGLTFLVDLI KNKHMNADTD YSIAEAAFNK GETAMTINGP WAWSNIDTSK 
241 VNYGVTVLPT FKGQPSKPFV GVLSAGINAA SPNKELAKEF LENYLLTDEG LEAVNKDKPL GAVALKSYEE ELVKDPRIAA 
321 TMENAQKGEI MPNIPQMSAF WYAVRTAVIN AASGRQTVDE ALKDAQTNSS SNNNNNNNNN NLGDDDDKVP GPYAGPLERQ 
401 KPLKVRAKLP QQEGPYAGPM ERQKPLKVKA KAPVVKEGPY EGPVKKPVAL KVKAKNLIVT EGPYAGPLER QQPLKLKAKL 
481 PQAEGPYAGP LEKQQPLKLK AKLPVAKEGP YEGPVKKPVA LKVKAKAPIV TE    
 
 
Figure 4-9: In silico enzymatic cleavage of MBP-c3B-cSAT protein. 
MBP-c3B-cSAT enzymatic cleavage profile generated by Protein Prospector: MS-
Digest using (A) trypsin or (B) chymotrypsin. Trypsin cleaves at the C-terminal side 
of lysine (K) or arginine (R) residues. Chymotrypsin cleaves at the C-terminal side 
of tyrosine (Y), phenylalanine (F), tryptophan (W) or leucine (L) residues. Residues 
at which cleavage may occur are underlined.   
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A 
GPYAGPLERQKPLKVRAKLPQQEGPYAGPMERQKPLKVKAKAPVVKEGPYEGPVKKPVALKVKAKNLIVTE 
 
B 
GPYAGPLERQQPLKLKAKLPQAEGPYAGPLEKQQPLKLKAKLPVAKEGPYEGPVKKPVALKVKAKAPIVTE 
 
C  
GPYAGPLERQKPLKVRAKLPQQEGPYAGPMERQKPLKVKAKAPVVKEGPYEGPVKKPVALKVKAKNLIVTEG
PYAGPLERQQPLKLKAKLPQAEGPYAGPLEKQQPLKLKAKLPVAKEGPYEGPVKKPVALKVKAKAPIVTE 
 
D 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYA
QSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKG
KSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEA
AFNKGETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTD
EGLEAVNKDKPLGAVALKSYEEELVKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDE
ALKDAQTNSSSNNNNNNNNNNLGDDDDKVP 
 
Figure 4-10: Sequence coverage by LC-MS/MS analysis of in-gel tryptic and 
chymotryptic digests of MBP-3B proteins. 
(A) c3B (71/71 amino acids = 100% coverage); (B) cSAT (71/71 amino acids = 100% 
coverage); C) c3B-cSAT (138/142 amino acids = 97.2% coverage); and D) MBP 
(352/390 amino acids = 90.3% coverage). Tryptic peptides identified with 95% 
certainty are italicized; chymotryptic peptides identified with 95% certainty are 
underlined; identified sequences are highlighted. 
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Figure 4-11: Stability of purified recombinant MBP-3B proteins stored at -20°C 
in 50% glycerol. 
Purified (1) MBP; (2) MBP-c3B; (3) MBP-c3B-cSAT; (4) MBP-cSAT were sampled 
after storage for (A) 1 week, and (B) 4, (C) 20, (D) 36, and (E) 60 weeks. Proteins 
were resolved by SDS-PAGE and stained with Coomassie Brilliant blue. MBP, MBP-
c3B, MBP-c3B-cSAT, and MBP-cSAT proteins are indicated (arrows) at 
approximately 42, 50, 58 and 50 kDa, respectively. Lane M, protein molecular mass 
standard (BenchMark); lanes M2-4, BenchMark standard serially two-fold diluted. 
Samples were loaded at (a) 560 ng or (b) 280 ng per well.   
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4.2.8. Cleavage of MBP tag from c3B-cSAT 
Enterokinase (EK) digestion of MBP-c3B-cSAT resulted in approximately 90% of the 
substrate cleaved within two hours of incubation using a 1:50 molar ratio of enzyme 
to substrate (Figure 4-12). A reduced rate of substrate cleavage occurred using an 
enzyme to substrate ratio of 1:500. A similar banding profile was observed at 1 and 8 
h for the 1:500 and 1:50 enzyme to substrate ratios, respectively. Several additional 
bands that did not correspond to the expected masses of cleaved MBP (FMBP, 42 kDa) 
and c3B-cSAT (F3B, 15 kDa) alone were observed by CBB staining and 
immunodetection. At least three bands appeared incrementally between MBP-c3B-
cSAT (substrate, S, 58 kDa) and FMBP over the course of the reaction. In the same way, 
at least five bands appeared incrementally over the course of the reaction in the 8 to 3 
kDa region, each one decreasing in molecular weight by approximately 1 kDa (FC). 
The fragment pattern also included a doublet band between 17 and 19 kDa (FA). 
Membranes probed with anti-3ABC antiserum showed a similar band pattern to CBB 
staining. As expected, band FMBP was not detected by anti-3ABC antiserum. 
Immunodetection analysis also revealed a band at approximately 100 kDa (band P, 
Figure 4-12). Using 1:50 enzyme to substrate, the intensity of band FA gradually faded 
over the incubation period indicating fragment FA was further cleaved by EK until the 
substrate was exhausted.  
SDS-PAGE and CBB analysis of MBP-c3B-cSAT protein digested with enterokinase 
in EK buffer revealed cleavage of approximately 30% of the substrate within 30 
minutes using a 1:50 ratio of enzyme to substrate (Figure 4-13). Fewer fragments were 
observed from cleavage in EK buffer, containing enzyme co-factor (Ca2+), than in a 
buffer of 25 mM Tris-HCl pH 8.0 at parallel time points (1 and 2 h), where bands P 
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and FC were not detected at any time point within the 2 h incubation period. Similar to 
the first experiment, yet at a reduced rate, at least three bands appeared incrementally 
between MBP-c3B-cSAT and FMBP over the course of the reaction. Cleavage products 
FA and F3B were barely detectable by CBB staining. Fragment patterns derived from 
reactions using the 1:500 ratio of enzyme to substrate could not be distinguished from 
the profile of control wells for all time points up to 2 h. Immunodetection with anti-
3ABC antiserum showed a similar band pattern to CBB staining, bands FA and F3B 
were also detected in the higher ratio of enzyme to substrate when probed with anti-
3ABC antibodies. However, when probed with anti-MBP antiserum only bands of the 
substrate (MBP-c3B-cSAT), FMBP and the bands in-between these bands were 
detected. No proteins smaller than 42 kDa were detected by immunodetection with the 
anti-MBP antibody. A list of observed fragments is given in Table 4-1.  
4.3. DISCUSSION 
This chapter described the expression, purification and characterisation of each of the 
three recombinant 3B consensus proteins (c3B, cSAT and c3B-cSAT). The c3B and 
cSAT coding sequences were commercially synthesised as a single fusion sequence, 
c3B-cSAT. This was the first use of a synthetic coding sequence as starting material 
for the expression of a recombinant FMDV NSP protein. A synthetic FMDV coding 
sequence is ideal for use in countries free of FMD and laboratories that are not capable 
or permitted to handle infectious material. Additionally, the use of synthetic coding 
sequences derived from gene design algorithms afford the ability to optimise codon 
usage of the sequence of interest for a heterologous expression host to significantly 
improve gene expression (312).   
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Figure 4-12: Cleavage of MBP-c3B-cSAT by enterokinase. 
Cleavage products produced from the treatment of 33.6 μg purified MBP-c3B-cSAT 
without or with enterokinase at an enzyme to substrate molar ratios of 1:50 or 1:500. 
Samples were taken at the times indicated (h) and resolved by SDS-PAGE. Proteins 
were detected by (A) Coomassie Brilliant blue staining and (B) immunodetection with 
rabbit anti-3ABC antiserum diluted 1:20,000. The major bands are as follows: P, 
unknown protein (100 kDa); S, substrate (58 kDa); FMBP, fragment corresponding to 
theoretical molecular mass of MBP (42 kDa); FA, doublet fragment of molecular 
masses between 17 and 19 kDa; F3B, fragment corresponding to theoretical molecular 
mass of c3B-cSAT (15 kDa); and FC, incremental fragments of molecular masses 
between 3 and 8 kDa. Lane M, pre-stained protein molecular mass marker (SeeBlue 
Plus2). Samples were loaded at (A) 3.5 μg or (B) 1 μg per well. 
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Figure 4-13: Cleavage of MBP-c3B-cSAT by enterokinase in EK buffer. 
Cleavage products produced from the treatment of 56 μg purified MBP-c3B-cSAT with enterokinase at an enzyme to substrate molar 
ratios of 1:50 and 1:500. Proteins were sampled at the times indicated (h) and resolved by SDS-PAGE. Proteins were detected by (A) 
Coomassie Brilliant blue staining or immunodetection with (B) rabbit anti-MBP or (C) rabbit anti-3ABC antisera, each diluted 
1:20,000. The major bands are as follows: S, substrate (58 kDa); FMBP, fragment corresponding to theoretical molecular mass of MBP 
(42 kDa); FA, doublet fragment of molecular masses between 17 and 19 kDa; and F3B, fragment corresponding to theoretical molecular 
mass of c3B-cSAT (15 kDa). Lane M, pre-stained protein molecular mass marker (SeeBlue Plus2). Samples were loaded at (A) 3.5 
μg or (B, C) 1 μg per well. 
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Table 4-1: Cleavage products from MBP-c3B-cSAT digested with enterokinase. 
Fragment 
Apparent 
molecular 
mass (kDa) 
Description 
P 100  Protein of unknown identity 
S 58  Substrate, purified MBP-c3B-cSAT protein 
FMBP 42 Cleavage product corresponding to molecular mass of MBP 
FA 17  Cleavage product detected by anti-3ABC antibodies 
F3B 15  Cleavage product corresponds to molecular mass of c3B-cSAT 
FC 8 - 3  Cleavage products detected by anti-3ABC antibodies 
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The c3B-cSAT sequence uniquely presents six tandem repeats of 3B including 
representation of the SAT type sequences, providing multiple epitopes for binding and 
cross-serotype specificity. Use of repeated peptides containing the epitope motif 
(QKPLK) of the FMDV 3B protein has been demonstrated to improve the sensitivity 
of a diagnostic immunoassays (258). Subsequent studies will explore which of the c3B, 
cSAT or c3B-cSAT sequences is the optimum pan-FMDV antigen in a given 
application. For instance, it could be expected that the use of c3B-cSAT would be ideal 
for use in an indirect ELISA but provide less sensitivity, compared with c3B or cSAT, 
in a competitive format.   
The pMAL-c5e vector enabled over-expression of soluble 3B proteins that were 
readily purified using the MBP tag. Purified recombinant MBP-3B fusion proteins had 
molecular masses consistent with sequence-based predictions and each of the fusion 
proteins reacted with anti-3ABC and anti-MBP antibodies by immunoblotting. These 
findings confirmed that each 3B protein was expressed with the MBP tag thereby 
confirming the identity of the MBP-c3B, MBP-cSAT and MBP-c3B-cSAT. Others 
have had similar success in recent studies that expressed MBP FMDV 2B or poliovirus 
2C fusions using pMAL vectors (136,247).    
SDS-PAGE and immunoblotting demonstrated expected molecular mass and the 
presence of MBP and 3B epitopes which is highly suggestive of correct, full-length 
expression of the target recombinant proteins. However, this study went one step 
further by using mass spectroscopy to try to identify the entire amino acid sequence of 
each protein. Trypsin cleaved proteins after basic residues, lysine and arginine 
residues, which are abundant the 3B sequences. This resulted in the generation of 
numerous small peptide fragments which gave masses below the reliable limit of 
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detection for identification of a unique peptide. Chymotrypsin was used to complement 
the data derived from trypsin-digested proteins as it produced a greater number of 
identifiable peptides. Data obtained for trypsin and chymotrypsin digests were 
combined to give protein coverage of greater than 90% for each of the three MBP-3B 
proteins.   
Additional low molecular mass protein bands were present in each purified MBP-3B 
preparation. These proteins reacted with anti-3ABC, but not with anti-MBP antibodies. 
This indicated truncation of the 3B components of the fusion proteins, but not the MBP 
component, had occurred. This is likely due to proteolytic cleavage or premature 
translation termination (313,314). However, the observed pattern of protein banding 
was similar to that shown in a study of a 6×His-tagged 3B protein purified from 
bacteria (259) suggesting 3B proteins are susceptible to partial degradation in this 
system. The chymotrypsin-like serine protease, FMDV 3Cpro, is responsible for 
secondary cleavage of the viral polyprotein into its constituent proteins during virus 
replication. This results in cleavage of 3B into 3B1, 3B2 and 3B3 (see Figure 1-3) 
(122,125,315). The masses of these smaller protein bands were consistent with the 
incremental cleavage of the individual 3B repeats. It is therefore likely that a bacterial 
serine protease similar to 3Cpro has cleaved each of the 3B proteins. Despite this 
degradation, the vast majority of each purified protein remained intact. Protein 
integrity may be improved by the use of protease inhibitors or rapid processing of 
cultures at 4°C. Cryopreservation of proteins in solutions of glycerol is an established 
long-term storage method (316). This study chose to store proteins in glycerol at -20°C 
with a future view that this reagent may be stored in laboratories with rudimentary 
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capabilities. By this method, the purified MBP-3B proteins were shown to be stable 
for up to 15 months.  
The pMAL-3B constructs encoded enterokinase (EK)-specific recognition sites to 
facilitate removal of MBP from the recombinant 3B proteins. Successful time and 
concentration dependent enzymatic cleavage of MBP from c3B-cSAT using EK was 
observed. However, under all conditions tested, additional non-specific cleavages of 
the 3B protein occurred. Immunodetection with anti-3ABC and anti-MBP antibodies 
indicated that these fragments were predominantly due to cleavage of the 3B portion 
of MBP-c3B-cSAT and not MBP. These findings indicated that EK does not 
demonstrate high cleavage site specificity and this is consistent with other studies that 
describe off-target cleavage by EK (317–319). The published EK recognition site is 
Asp-Asp-Asp-Asp-Lys (320). However, there are reports that showed cleavage where 
one (321) or two (317) basic residues (Lys or Arg) are preceded by an acidic residue 
(Glu or Asp). Cleavage at these additional sites would generate proteins with 
molecular masses that correspond with those of bands observed by staining and 
immunodetection. Thus MBP could not be removed using EK without coincident 
fragmentation of c3B-cSAT under the conditions tested.  
In summary, work described in this chapter demonstrated successful bacterial 
expression and affinity purification of recombinant MBP-3B fusion proteins. All 
proteins were generated in soluble form at high yield and purity, and were 
demonstrated to be highly stable when stored. The following chapter assesses the 
potential of the MBP-c3B fusion protein as a bioreagent with pan-FMDV serotype 
diagnostic potential. 
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CHAPTER 5 
 DEVELOPMENT OF COMPETITION ELISA 
BASED ON C3B ANTIGEN 
5.1. INTRODUCTION 
Immunoassays based on Foot-and-mouth disease virus (FMDV) non-structural 
proteins (NSPs) have two main advantages compared to assays based on structural 
proteins: they allow detection of multiple serotypes due to their high sequence 
similarity, and they allow differentiation of infected from vaccinated animals (DIVA) 
where FMDV structural proteins are used in vaccines (214,215,240). The proposed 
competition enzyme-linked immunosorbent assay (C-ELISA) was developed using a 
3B consensus (c3B) antigen designed in Chapter 3 that will allow the binding of anti-
3B antibodies in test sera and/or binding by competing antibody. The ELISA system 
can be widely used in both rudimentary and modern laboratories because it is relatively 
simple to perform, sensitive and cost-effective (322). In regions where FMD is 
endemic the pan-serodiagnostic assay developed here would provide an affordable 
system for detection of FMD infection and aid in progression towards FMD-free 
status. For FMD-free regions, this assay could be applied in surveillance or provide 
evidence of FMD-freedom in post-outbreak situations including those where 
vaccination was implemented as part of FMD control measures. 
The World Organisation for Animal Health (OIE) have described principles and 
methods for development and subsequent validation of a diagnostic assay for 
infectious diseases (323). Development of the prototype 3B FMDV pan-diagnostic 
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assay was guided by the criteria outlined in Figure 5-1. In brief, the process begins 
with optimisation of antigen and antibody ratios. The second phase of the OIE 
guidelines establishes the assay’s performance characteristics by estimating the test’s 
analytical sensitivity (ASe), analytical specificity (ASp) and repeatability. The next 
phase characterises diagnostic performance by establishing diagnostic sensitivity 
(DSe, measure of the proportion of samples from known infected reference animals 
that test positive in the assay), diagnostic specificity (DSp, proportion of samples from 
uninfected animals that test negative in the assay) and threshold (cut-off) values (324). 
The optimal cut-off value is determined by Receiver Operating Characteristic (ROC) 
analysis of diagnostic sensitivity and specificity at different cut-off values. 
Determination of the optimal cut-off is determined empirically but may then be 
modified to complement the intended purpose of the assay.   
No test demonstrates perfect performance characteristics (325,326), so to evaluate the 
performance of a new diagnostic test it should be compared with a ‘recommended’ or 
‘reference’ tests. The reference test for FMDV non-structural protein antibodies (the 
3ABC ELISA produced by Prionics) is not available in Australia so the assay was 
evaluated by direct comparison with a validated in-house FMDV NSP C-ELISA 
(AAHL C-ELISA). This test used 3ABC as antigen, where the majority of antigenicity 
is derived from B cell epitopes within NSP 3B. Bayesian analysis, a form of Latent 
Class analysis, was then used to determine the relative diagnostic performance of the 
new assay compared with the existing assay. The final phase of test development 
characterises the assay’s precision and reproducibility by distribution and assessment 
of the c3B C-ELISA by other laboratories in Australia or abroad. This phase and 
subsequent validation was not performed here due to a lack of appropriate samples, 
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especially FMDV-antibody positive serum samples and due to resource and time 
restraints.  
This chapter describes the use of a NSP antigen for serotype-independent identification 
of FMDV infection in the development of a C-ELISA for detection of anti-FMDV 
NSP antibodies. The majority of FMDV NSP assays are established using a coating 
antigen derived from a single virus isolate. However, the new assay is based on a 
coating antigen produced using a novel approach to FMDV antigen bioreagent 
development. Furthermore, the new assay’s performance in testing anti-FMDV 
antibody positive sera representing the seven FMDV serotypes will demonstrate the 
pan-diagnostic capacity of this unique approach to reagent development. FMDV NSP 
3B was selected and produced for development of the pan-serodiagnostic assay. Herein 
the consensus antigen (MBP-c3B protein) based C-ELISA is described as a candidate 
pan-serotype diagnostic test for FMDV infection.   
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Figure 5-1: Assay development and validation pathway.  
Pathway as described by the World Organisation for Animal Health (OIE) (adapted 
from OIE Terrestrial Manual (324)).  
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5.2. RESULTS 
5.2.1. Assay formulation 
The ELISA developed here used a 3B consensus antigen coated directly onto a 96-
well ELISA plate that allowed binding of anti-NSP 3B antibodies in test serum and 
chicken anti-NSP 3B immunoglobulin Y (IgY) generated against FMDV NSP 3ABC. 
Unlabelled chicken anti-3ABC antibody was then bound by an anti-chicken antibody 
conjugated to horseradish peroxidase for generation of a colour product upon 
incubation with the substrate, 3,3’,5,5’-tetramethylbenzidine (TMB, Figure 5-2). A 
positive result was indicated by an established degree of inhibition of binding of the 
unlabelled chicken anti-3ABC antibodies to antibodies present in the test serum, and 
subsequent loss of chromogenic signal development from the secondary antibody.  
5.2.2. Titration of 3B consensus antigens and anti-3ABC antibody 
The indirect ELISA (I-ELISA) used for titration of the 3B fusion protein antigens and 
chicken anti-3ABC antibody was similar to the C-ELISA, however no test serum was 
added in order to establish conditions for the maximum absorbance (Amax) of the test. 
Checkerboard titrations by I-ELISA (section 2.14.2) of MBP-3B consensus antigens 
with chicken anti-3ABC antibody produced absorbance values at 450 nm (A450) up to 
3.2 which was above the useful limit of detection of approximately 1.5. Dilutions of 
antibody that gave A450 values around 1.5 were 1:640, 1:320 and 1:1,280 at protein 
concentrations of 35, 35, and 50 ng per well for MBP-c3B, MBP-cSAT, and MBP-
c3B-cSAT, respectively (Figure 5-3). At these conditions non-specific binding of 
chicken anti-3ABC antibody with the MBP alone negative control gave A450 ˂0.1 
(Figure 5-3). To translate these findings to a C-ELISA, the chicken anti-3ABC 
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antibody dilutions established by I-ELISA were adjusted by performing titrations in a 
C-ELISA format. Using antigen coated at 50 ng per well for MBP-c3B, MBP-cSAT 
and MBP-c3B-cSAT, the optimal dilutions of chicken anti-3ABC antibody were 
determined to be 1:350, 1:200 and 1:400, respectively. These conditions produced A450 
values of 1.42 (95% confidence interval (CI): 1.33 – 1.50), 1.04 au (95% CI: 0.92 – 
1.18) and 1.31 au (95% CI: 1.20 – 1.43) (n = 28) for MBP-c3B, MBP-cSAT, and MBP-
c3B-cSAT, respectively. 
5.2.3. Establishment of control values for C-ELISA 
Absorbance values for control sera were determined using the C-ELISA and were 
expressed in terms of percent inhibition (PI) defined as: 100 – [(mean A450 of 
serum/mean Amax) x 100] (section 2.14.3). Preliminary average PI values for the high 
titre positive (C++), low titre positive (C+) and negative (C-) control sera were 
estimated for each of MBP-c3B, MBP-cSAT, and MBP-c3B-cSAT by C-ELISA 
(Table 5-1).  
5.2.4. Detection of seven FMDV serotypes 
The seven FMDV antibody-positive bovine serum samples, containing antibodies 
raised against the seven distinct serotypes of FMDV, resulted in PI values well above 
the negative control values in each of the three 3B consensus antigen C-ELISAs (Table 
5-2). Bovine serum samples representing each of the seven serotypes that recorded the 
highest PI values for MBP-c3B, MBP-cSAT, and MBP-c3B-cSAT were types O, 
SAT1, and SAT3, respectively. All serum samples tested in the MBP-c3B antigen 
based C-ELISA recorded PI values between the high and low titre positive controls. 
The c3B C-ELISA was selected for further assay development because it produced the 
highest PI values across the majority of serotypes.  
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Figure 5-2: Schematic of a competition ELISA. 
Wells of a 96-well plate were coated with (A) antigen followed by incubation with (B) 
test serum; (C) competing antibody was added directly to wells containing test serum; 
competing antibody was bound by an (D) anti-species antibody conjugated to 
horseradish peroxidase. Detection was through the addition of (E) TMB substrate 
followed by (F) sodium hydroxide which stopped the reaction and formed a 
quantifiable yellow product from the substrate (adapted from 
www.leinco.com/indirect_elisa).  
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Figure 5-3: Checkerboard titration of MBP and MBP-3B recombinant protein 
antigens with chicken anti-3ABC polyclonal antibody.  
Sigmoidal dose response curves of absorbance readings generated by titration of (A) 
MBP, (B) MBP-c3B-cSAT, (C) MBP-c3B, and (D) MBP-cSAT with chicken anti-
3ABC antibody by indirect ELISA. Antigens were serially diluted twofold from 70 to 
1 ng/well and chicken anti-3ABC antibody was diluted as indicated (A, inset). Values 
shown are mean absorbance at 450 nm (A450) ± one standard deviation for each 
concentration of protein tested (n = 3).  
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Table 5-1: Preliminary control sample percent inhibition limits for each 3B 
consensus antigen C-ELISA. 
Antigen and 
parameter 
Mean 
PI 
Standard 
deviation 
MBP-c3B   
 C++  84.92 ±2.71 
 C+ 51.88 ±1.00 
 C- 7.20 ±5.10 
MBP-cSAT   
 C++  78.15 ±1.39 
 C+ 46.52 ±1.35 
 C- 4.30 ±2.26 
MBP-c3B-cSAT   
 C++  81.90 ±1.39 
 C+ 47.96 ±3.22 
 C- 6.83 ±2.53 
PI, percent inhibition (n = 3); C++, high positive 
control; C+ low positive control; C-, negative control.  
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Table 5-2: Comparison of percent inhibition values for bovine sera representing 
the seven FMDV serotypes assessed using each 3B consensus antigen C-ELISA. 
 C-ELISA Antigen 
Serotype c3B cSAT c3B-cSAT 
O 71 30 50 
A 69 23 53 
Asia1 68 26 49 
C 56 30 45 
SAT1 56 61 58 
SAT2 63 48 55 
SAT3 57 61 67 
            Values are mean percent inhibition.  
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5.2.5. Control sample limits and repeatability of c3B C-ELISA 
Control sample limits of the c3B C-ELISA were established to monitor the assay’s 
performance within and between tests. The average PI and range for the high-positive-
control (C++), low-positive-control (C+), and negative-control (C-) sera were 
determined by repeated testing to be: C++, 87.8% (85.0 to 90.8%); C+, 66.0% (60.0 
to 72.8%); C-, 23.2% (15.0 to 35.0%) (n = 10). The mean absorbance limit for Amax 
was 1.081 (0.85 to 1.71) (n = 10). The Amin control wells, containing all test reagents 
except primary antibody, produced background absorbance readings of ˂0.06. 
5.2.6. Estimation of preliminary cut-off 
ROC analysis (section 2.14.7) using 36 bovine sera (8 positive and 28 negative, as 
determined using the AAHL C-ELISA test (samples 1-36, Table A-6)), estimated a 
preliminary PI cut-off value (95% CI) for a positive sample of >47% (CI >41 to >49%) 
(Figure 5-4). 
5.2.7. Evaluation of the analytical sensitivity and specificity of the c3B 
C-ELISA 
The analytical sensitivity of the c3B C-ELISA was evaluated by determining the 
highest dilution of antibody-positive sample where a positive result (>47%) was 
recorded. The positive control serum yielded high PI values of approximately 80% at 
a dilution of 1:5 when diluted with negative control serum or blocking buffer. The 
limit of detection of the stock positive control serum was identified at a dilution of 
approximately 1:120 in either diluent (Figure 5-5, A). Choice of diluents had no effect 
on PI at the optimal dilution of chicken anti-3ABC antibody (Figure 5-5, B). Negative 
control serum PI values were all below the preliminary cut-off PI value, even at the 
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highest dilution (1:350) of chicken anti-3ABC antibody tested (Figure 5-5, C). At a 
dilution of 1:320 the PI (30%) of the positive control serum was indistinguishable from 
that recorded at a dilution of 1:5 of negative control serum. The c3B C-ELISA was 
shown to distinguish the target analyte, anti-FMDV NSP 3B antibodies, from non-
target analytes with 100% specificity. Bovine, ovine and porcine sera from animals 
infected with bluetongue virus (BTV), vesicular stomatitis virus (VSV) or swine 
vesicular disease virus (SVDV) all produced PI values below the cut-off limit using 
the c3B C-ELISA (Table A-6, Table A-7, and Table A-8).  
5.2.8. Determination of diagnostic sensitivity (DSe) and specificity 
(DSp) of the c3B C-ELISA across species  
Determination of DSe and DSp using bovine sera. 
DSe and DSp of the c3B C-ELISA were determined by testing 272 bovine sera (105 
positive and 167 negative, as determined using the AAHL C-ELISA) (Table A-6). The 
cross-classified data of the 2 x 2 contingency table showed 91 true positives, 12 false 
positives, 14 false negatives and 155 true negatives (Table 5-3). The positive predictive 
value, based on prevalence of FMD in the tested population, indicated with high 
probability samples that tested positive in the c3B C-ELISA were infected with FMDV 
(Table 5-3). The negative predictive value was also high and indicated negative results 
obtained in the c3B C-ELISA were reliable. ROC analysis of these data gave an area 
under the curve (AUC) of 0.932, a maximal Youden index (283) value of 0.795 (Figure 
5-6, A) and a PI cut-off value (95% CI) for a positive sample of >47% (>46 to >51%) 
(Figure 5-6, B). At PI >47%, DSe and DSp (95% CI) were 86.67% (78.60 - 92.50%) 
and 92.81% (87.80 - 96.20%), respectively. To explore the effect of adjusting 
parameters to increase either sensitivity or specificity estimations of DSe at specific 
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DSp values (80, 90 and 95%), and corresponding cut-off values are given in Table 5-4. 
Likewise, DSp and cut-off values are given for specific DSe values of 80, 90 and 95% 
(Table 5-4). Bayesian analysis showed the c3B C-ELISA had a DSe = 86.70% (95% 
probability interval: 79.20 – 93.41%) and DSp = 91.97% (95% probability interval: 
86.95 – 96.30%) (Table 5-5). 
Determination of DSe and DSp using ovine sera.  
DSe and DSp of the c3B C-ELISA were determined by testing 249 ovine sera (27 
positive and 222 negative, as determined with the AAHL C-ELISA) (Table A-7). The 
cross-classified data showed 26 true positives, 9 false positives, 1 false negative and 
213 true negatives. The negative predictive value indicated, with high probability, that 
negative results obtained in the c3B C-ELISA were reliable (Table 5-3). The positive 
predictive value indicated approximately 75% of positive results for samples tested in 
the c3B C-ELISA were true positives, based on disease prevalence of the sample 
population (Table 5-3). ROC analysis of these data gave an AUC of 0.987, a maximal 
Youden index (283) value of 0.922 (Figure 5-7, A) and a PI cut-off value (95% CI) for 
a positive sample of >34% (>26 to >37%) (Figure 5-7, B). At PI >34%, DSe and DSp 
(95% CI) were 96.30% (81.00 – 99.90%) and 95.95% (92.40 – 98.10%), respectively. 
Estimations of DSe at specific DSp values (80, 90 and 95%) and corresponding cut-
off values are given in Table 5-6. Likewise, DSp and cut-off values are given for 
specific DSe values of 80, 90 and 95% (Table 5-6). Bayesian analysis showed the c3B 
C-ELISA had DSe = 91.72% (95% probability interval: 76.73 – 99.21%) and DSp = 
91.62% (95% probability interval: 88.60 – 94.21%) (Table 5-6).  
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Figure 5-4: Preliminary Receiver Operator Characteristic (ROC) analysis of 
results from c3B C-ELISA testing of bovine sera. 
Diagnostic performance of the c3B C-ELISA was assessed by comparison with the 
AAHL C-ELISA. A panel of thirty six cattle sera containing eight FMDV antibody-
positive samples were tested. (A) ROC curve analysis plot of true positive results 
(sensitivity) as a function of the false positive results (100-specificity). Thin blue lines 
represent the 95% confidence interval. Circle (upper left corner) indicates the 
maximum Youden index, the maximum vertical distance between the ROC curve and 
the diagonal line, 0.9304. AUC, area under the curve. Diagonal red line represents 
values where positive and negative results cannot be discriminated. (B) Plot of 
sensitivity (blue continuous line) and specificity (red dashed line) versus different 
percent inhibition cut-off values. The optimum PI cut-off is indicated where sensitivity 
and specificity intersect, >47%. Thin blue and red lines represent the 95% confidence 
intervals for sensitivity and specificity, respectively.    
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Figure 5-5: Analytical sensitivity of the c3B C-ELISA. 
Percent inhibition (PI) values for positive and negative control sera serially diluted 
twofold from 1:5 to 1:320 in the diluents indicated. (A) Limit of detection analysis of 
the positive control serum diluted in blocking buffer (left) or negative control bovine 
serum (right) performed using chicken anti-3ABC antibody diluted in blocking buffer 
as indicated (inset). (B) Comparison of percent inhibition values for positive control 
serum diluted twofold in blocking buffer (●) or negative control bovine serum (■) 
using chicken anti-3ABC antibody diluted 1:350. (C) Percent inhibition of negative 
control bovine serum twofold serially diluted with blocking buffer using chicken anti-
3ABC antibody diluted as indicated (inset).  
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Table 5-3: Cross-classified data summarised in a 2 x 2 contingency table.  
Diagnostic performance assessed by comparison of results derived from the c3B C-
ELISA compared with the AAHL C-ELISA. Results were partitioned into true 
positive, false positive, false negative and true negative. Derived values for diagnostic 
sensitivity (DSe), diagnostic specificity (DSp), positive predictive value (PPV), and 
negative predictive value (NPV) are indicated for bovine or ovine sera.  
 
Example 
 Test 2  
Test 1 
A (true positive) C (false negative) A/(A+C) = DSe 
B (false positive) D (true negative) D/(B+D) = DSp 
 A/(A+B) = PPV D/(C+D) = NPV  
 
Bovine samples 
 c3B C-ELISA  
AAHL  
C-ELISA 
91 14 0.8667 
12 155 0.9281 
 0.8835 0.9172  
 
Ovine samples 
 c3B C-ELISA  
AAHL  
C-ELISA 
26 1 0.9630 
9 213 0.9595 
 0.7429 0.9953  
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Figure 5-6: Receiver Operator Characteristic (ROC) analysis of results from c3B 
C-ELISA testing of bovine sera. 
Diagnostic performance of the c3B C-ELISA was assessed using results generated 
from testing 272 cattle sera using the c3B C-ELISA and AAHL C-ELISA. (A) ROC 
curve analysis plot of true positive results (sensitivity) as a function of false positive 
results (100-specifiity). Thin blue lines represent the 95% confidence interval. Circle 
(upper left corner) indicates the maximum Youden index, the maximum vertical 
distance between the ROC curve and the diagonal line, 0.7948. AUC, area under the 
curve. Diagonal red line represents values where positive and negative results cannot 
be discriminated. (B) Plot of sensitivity (blue continuous line) and specificity (red 
dashed line) versus different cut-off values. The optimum PI cut-off is indicated where 
sensitivity and specificity intersect, >47%. Thin blue and red lines represent the 95% 
confidence intervals for sensitivity and specificity, respectively.   
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Table 5-4: Effect of varying sensitivity or specificity on specificity or sensitivity, 
respectively, for bovine sera tested using the c3B C-ELISA. 
DSp was estimated for a range of fixed diagnostic sensitivities, and conversely, DSe 
was estimated for a range of fixed diagnostic specificities. 
 
Specificity Sensitivity 95% confidence intervala PI cut-off value 
80 95.21 86.13 to 98.80 >50.50 
90 78.59 55.11 to 95.21 >40.75 
95 58.83   9.17 to 80.76 >33.25 
 
Sensitivity Specificity 95% confidence intervala PI cut-off value 
80 89.02 80.03 to 94.25 >41.53 
90 87.62 79.05 to 93.33 >45.66 
95 80.33 65.51 to 88.90 >50.33 
aBias-corrected and accelerated bootstrap confidence interval (1,000 iterations; random number seed: 978) 
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Table 5-5: Bayesian Latent Class analysis of C-ELISA results for bovine serum samples analysed using the c3B 
or AAHL C-ELISAs. 
ELISA and 
parametera Mean (%) 
Standard 
deviation 
Monte 
Carlo error 
Minimum 
(%) Median (%) 
Maximum 
(%) 
c3B       
 DSe  86.70 ±0.04 4.20E-05 79.20 86.84 93.41 
 DSp 91.97 ±0.02 2.91E-05 86.95 92.09 96.30 
AAHL       
 DSe 90.74 ±0.03 3.56E-05 84.62 90.97 95.58 
 DSp 95.50 ±0.02 3.45E-05 90.73 95.76 98.80 
aDSe, diagnostic sensitivity; DSp, diagnostic specificity 
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Figure 5-7: Receiver Operator Characteristic (ROC) analysis of c3B C-ELISA 
evaluating ovine sera. 
Diagnostic performance of the c3B C-ELISA was assessed using results generated 
from testing 249 ovine sera using the c3B C-ELISA and AAHL C-ELISA. (A) ROC 
curve analysis plot of true positive results (sensitivity) as a function of false positive 
results (100-specifiity). Thin blue lines represent the 95% confidence interval. Circle 
(upper left corner) indicates the maximum Youden index, the maximum vertical 
distance between the ROC curve and the diagonal line, 0.9224. AUC, area under the 
curve. Diagonal red line represents values where positive and negative results cannot 
be discriminated. (B) Plot of sensitivity (blue continuous line) and specificity (red 
dashed line) versus different cut-off values. The optimum PI cut-off is indicated where 
sensitivity and specificity intersect, >34%. Thin blue and red lines represent the 95% 
confidence intervals for sensitivity and specificity, respectively.   
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Table 5-6: Effect of varying sensitivity or specificity on specificity or sensitivity, 
respectively, for ovine sera tested using the c3B C-ELISA. 
DSp was estimated for a range of fixed diagnostic sensitivities, and conversely, DSe 
was estimated for a range of fixed diagnostic specificities.  
 
Sensitivity Specificity 95% confidence intervala PI cut-off value 
80 98.74 94.43 to 100.00 >40.2 
90 98.65 80.29 to 100.00 >38.4 
95 96.58      73.38 to  99.10 >34.35 
 
Specificity Sensitivity 95% confidence intervala PI cut-off value 
80 96.94 85.19 to 100.00 >26.83 
90 96.30 77.78 to 100.00 >29.98 
95 96.30 78.23 to 100.00 >32.95 
a Bias-corrected and accelerated bootstrap confidence interval (1000 iterations; random number seed: 978) 
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Table 5-7: Bayesian Latent Class analysis of C-ELISA results for ovine serum samples analysed using the c3B 
or AAHL C-ELISAs. 
ELISA and 
parametera Mean (%) 
Standard 
deviation 
Monte 
Carlo error 
Minimum 
(%) Median (%) 
Maximum 
(%) 
c3B       
 DSe  91.72 ±0.06 9.20E-05 76.73 93.08 99.21 
 DSp 91.62 ±0.01 5.07E-05 88.60 91.69 94.21 
AAHL       
 DSe 90.56 ±0.03 2.84E-05 83.70 90.87 95.70 
 DSp 88.87 ±0.02 4.67E-05 85.41 88.94 91.91 
 αDSe, diagnostic sensitivity; DSp, diagnostic specificity. 
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Determination of DSe and DSp using ovine sera.  
DSe and DSp of the c3B C-ELISA were determined by testing 249 ovine sera (27 
positive and 222 negative, as determined with the AAHL C-ELISA) (Table A-7). The 
cross-classified data showed 26 true positives, 9 false positives, 1 false negative and 
213 true negatives. The negative predictive value indicated, with high probability, that 
negative results obtained in the c3B C-ELISA were reliable (Table 5-3). The positive 
predictive value indicated approximately 75% of positive results for samples tested in 
the c3B C-ELISA were true positives, based on disease prevalence of the sample 
population (Table 5-3). ROC analysis of these data gave an AUC of 0.987, a maximal 
Youden index (283) value of 0.922 (Figure 5-7, A) and a PI cut-off value (95% CI) for 
a positive sample of >34% (>26 to >37%) (Figure 5-7, B). At PI >34%, DSe and DSp 
(95% CI) were 96.30% (81.00 – 99.90%) and 95.95% (92.40 – 98.10%), respectively. 
Estimations of DSe at specific DSp values (80, 90 and 95%) and corresponding cut-
off values are given in Table 5-6. Likewise, DSp and cut-off values are given for 
specific DSe values of 80, 90 and 95% (Table 5-6). Bayesian analysis showed the c3B 
C-ELISA had DSe = 91.72% (95% probability interval: 76.73 – 99.21%) and DSp = 
91.62% (95% probability interval: 88.60 – 94.21%) (Table 5-6). 
5.2.9. Differentiation of infected from vaccinated animals 
Eleven bovine sera derived from vaccinated animals (three type A, four type O, two 
type Asia1, and two type SAT2) (Table A-6) all returned negative results when tested 
by the c3B C-ELISA using a cut-off value of >47%. In addition, 33 out of 34 ovine 
sera samples obtained from a vaccine efficacy experiment returned negative results 
when tested using a cut-off value of >34% (Table A-6). 
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5.2.10. Reproducibility of chicken anti-3ABC antibody 
Prior to depletion of the first batch of chicken anti-3ABC antibody, a second, 
independently prepared, batch of antibody was titrated against MBP-c3B protein. The 
optimal dilution of this batch of chicken anti-3ABC antibody was between 1:5,600 and 
1:11,200 (Figure 5-8). Further titrations refined the optimal dilution to 1:8,400. These 
conditions produced an average A450 value of 1.28 au (95% CI 1.24 – 1.33 au) (n = 
22). The new batch of anti-3ABC antibody recorded similar PI values when used at a 
dilution of 1:8,400 in the c3B C-ELISA when examining the seven bovine serum 
samples representing each of the serotypes of FMDV (Table 5-8). PI values of the 
control samples, acquired using the second batch of chicken anti-3ABC antibody at a 
dilution of 1:8,400, were within the range observed using the previous batch as 
described above.  
  
Chapter 5 
 
140 
 
 
 
 
 
 
 
 
Figure 5-8: Titration of chicken anti-3ABC polyclonal antibody by I-ELISA. 
Plot of absorbance values derived from titration of the second batch of chicken anti-
3ABC antibody against 50 ng MBP-c3B protein by I-ELISA. Values shown are mean 
absorbance at 450 nm (A450) ± one standard deviation for each dilution of antibody (n = 
3). Optimal dilution of chicken anti-3ABC antibody batch 2 corresponding to the 
equivalent absorbance generated using batch 1 is indicated (blue line) between 1:5,600 
and 1:11,200. 
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Table 5-8: Comparison of PI values for each serotype serum sample assessed by 
the c3B C-ELISA using different batches of chicken anti-3ABC antibody. 
Serotype Batch 1  Batch 2 
O 71 70 
A 69 69 
Asia1 68 67 
C 56 55 
SAT1 56 49 
SAT2 63 67 
SAT3 57 66 
Batch 1 diluted 1:350 in blocking buffer; Batch 2 
diluted 1:8,400 in blocking buffer; values are 
percent inhibition.  
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5.3. DISCUSSION 
Limitations still exist in diagnostic capability for FMD. Affordable, readily available 
assays with high diagnostic sensitivity and specificity that are suitable for routine 
diagnosis and DIVA surveillance of FMDV are lacking. The OIE recommended 
screening method for anti-FMDV NSP antibodies is difficult to obtain in quantities 
required for an outbreak situation and alternative commercial FMDV NSP ELISAs 
cost upwards of US $2 per sample. In addition, evidence of NSP sequence divergence, 
particularly between SAT and non-SAT serotypes, is increasing (289,290,327). As 
such, current assays that depend on assumed sequence homology of NSPs may become 
less reliable for detection of all serotypes. Development of the 3B C-ELISA addressed 
many of these issues by producing a sensitive, specific, serotype-independent test 
capable of differentiating infected and vaccinated animals by using an antigen most 
representative of the 3B protein of all serotypes. 
Diagnostic assays based on ELISA systems for either detection of antibodies or 
circulating antigens have become the most widely used in both rudimentary and 
modern laboratories because they are relatively simple to perform, sensitive and cost-
effective (322). A number of assays based on the FMDV 3B protein as coating antigen 
have been developed (250,258,259) and commercialised (257). These assays use an I-
ELISA format requiring multiple species-specific conjugated antibodies for direct 
detection of anti-3B antibodies present in infected animals of different species. In 
contrast, a C-ELISA has the advantage of providing a system that does not require 
multiple species-specific reagents. C-ELISAs have also been utilised in the 
development of assays using non-structural FMDV proteins as coating antigen 
(240,260,281,297,300,328,329) (see Table A-1). Irrespective of the format used, the 
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test described here is the first demonstration of a competition ELISA using a consensus 
FMDV 3B protein as coating antigen (279). 
Previously developed FMDV NSP-based C-ELISAs have utilised competing 
antibodies generated in guinea pigs or chickens against 3ABC protein (281,297) or in 
mice against 3B1 (300,330) and 3B2 proteins (249). Chicken antibodies were used in 
the development of the c3B C-ELISA because, compared with polyclonal mammalian 
antibodies, they can be produced and purified in large quantities and do not 
demonstrate cross-reactivity with mammalian antibodies [reviewed in (331,332)]. 
Anti-3ABC chicken antibodies used in the c3B C-ELISA did not cross-react with the 
MBP tag by I-ELISA, consistent with reactions observed by immunodetection (Figure 
5-3 and Figure 4-8).  
The 3B consensus C-ELISAs required between two- and four-fold lower 
concentrations of competing chicken anti-3ABC antibody compared with the AAHL 
C-ELISA. All 3B consensus antigens were highly purified by affinity isolation 
allowing thorough characterisation of the antigens and enhancing reproducibility. By 
comparison, the AAHL C-ELISA uses a crude 3ABC protein preparation as coating 
antigen. The observed difference in the amount of competing antibody required by the 
AAHL C-ELISA may be due to these differences. However, this is difficult to assess 
because the protein concentration of the crude antigen preparation is not indicative of 
the 3ABC antigen concentration thus preventing direct antibody-antigen binding 
comparisons. The 3ABC protein also presents additional binding sites within proteins 
3A and 3C compared with 3B alone.  
When a constant amount of coating antigen was used, the dilution of chicken anti-
3ABC antibody required to achieve an optimal signal of 1.5 for the Amax control in a 
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C-ELISA varied for each of the 3B consensus proteins. MBP-cSAT required a higher 
concentration of antibody compared to MBP-c3B and this may be due to the affinity 
of antibodies towards the modified epitopes of the cSAT sequence (QQPLKLK and 
APIVTE) compared with (QKPLKVR and NLIVTE) in c3B (section 3.2.6). MBP-
c3B-cSAT antigen required only a slightly lower concentration of antibody than MBP-
c3B, but two-fold lower concentration than MBP-cSAT. This is most likely due to the 
fact that this antigen presents twice the number of repeats of 3B.  
It was important to select the most appropriate serotype-independent antigen from the 
three 3B proteins. That is, the one that showed the highest reactivity with test serum 
from all seven FMDV serotypes. Each of the 3B consensus proteins were recognised 
by sera from cattle infected with each of the seven FMDV serotypes. This 
demonstrated the pan-serotype diagnostic potential of this approach to antigen design 
and development. Serum samples from SAT1 and SAT3 serotype-infected cattle 
showed a clear bias for MBP-cSAT and MBP-c3B-cSAT proteins in the C-ELISA. 
However, all serum samples collected from cattle infected with one each of the seven 
FMDV serotypes showed similar PI values when tested with the MBP-c3B as coating 
antigen. Therefore, consistent with the hypothesis that a pan-serotype consensus 
antigen could be derived, MBP-c3B was selected as the best all-round serotype-
independent antigen candidate for further development of a diagnostic ELISA.  
The c3B C-ELISA effectively detected test serum antibodies diluted 1:5 with blocking 
buffer which is consistent with previously developed FMDV NSP C-ELISAs 
(281,297,300). Analytical sensitivity was demonstrated by dilution of the positive 
control serum to the limit of detection of anti-3B antibodies using the c3B C-ELISA. 
The highest dilution to produce a positive result was similar to that reported for cattle 
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serum samples tested using a recombinant 3B protein-based I-ELISA (259), but twice 
that of the AAHL C-ELISA (281). This difference may be due to the higher number 
of potential epitopes available for binding test sera antibodies in the AAHL test which 
use 3ABC as antigen. In C-ELISAs the PI is affected by the relative affinity and titre 
of test serum and competing antibodies.  
PI values of sera from different species (cattle, sheep and pigs) infected with clinically 
relevant diseases but not FMDV were all below the cut-off value for a positive result, 
demonstrating that the analytical specificity of the c3B C-ELISA was 100%. 
The c3B C-ELISA successfully differentiated sera from FMDV-infected and un-
infected cattle with high discriminatory power (333) using a PI cut-off value of >47%. 
Using this cut-off value, the DSe and DSp of the c3B C-ELISA were marginally lower 
than those of the AAHL C-ELISA. To estimate the accuracy of the c3B C-ELISA and 
AAHL C-ELISA, Bayesian Latent Class analysis in the absence of a gold standard test 
revealed that the DSe and DSp of the c3B C-ELISA was not significantly different 
from those derived by ROC analysis. Furthermore, the DSe and DSp of the AAHL C-
ELISA were each reduced by less than 1%. These minor adjustments in the diagnostic 
performance measures of both assays indicated that the estimated values were 
accurate. 
When analysing sheep serum samples using the c3B C-ELISA with a cut-off value of 
>34%, the DSe of the test was greater than for the AAHL C-ELISA, whereas DSp was 
similar between the assays. The positive predictive value indicated positive results 
recorded for sheep had a moderate probability of being true positives, and that these 
results should be subsequently tested in a confirmatory test. As this predictive value is 
based on disease prevalence within the sample population, where all positive samples 
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were derived from experimental infections, it does not reflect disease prevalence in the 
native population and should be viewed with caution. Bayesian Latent Class analysis 
revealed DSe and DSp of the c3B C-ELISA were reduced by approximately 4% and 
DSp was reduced by more than 7%. DSe of the AAHL C-ELISA was only slightly 
reduced. This indicates that the ROC estimates of diagnostic performance for the c3B 
C-ELISA assay was less accurate when examining sheep sera compared with cattle 
sera samples. It is worth noting, that the final estimates of DSe and DSp of c3B C-
ELISA for sheep samples were better than those of the AAHL C-ELISA. The 
differences in diagnostic characteristics of the c3B and AAHL C-ELISAs may be 
explained, in part, by the fact that the c3B C-ELISA DSe and DSp were determined 
for individual species (cattle and sheep), whereas the AAHL C-ELISA was not. This 
species-related effect is highlighted by the different cut-off values determined to give 
optimal diagnostic characteristics in the c3B C-ELISA for cattle and sheep. The 
reduced cut-off value of the c3B C-ELISA when examining sheep serum samples is 
most likely due to the fact these animals frequently develop subclinical infections and, 
as a result, may fail to produce similar antibody titres against FMDV NSPs as other 
host species (297). Furthermore, the AAHL C-ELISA was validated by testing 2,500 
samples, whereas the prototype c3B C-ELISA described here has been assessed by 
testing almost five-fold fewer samples. The estimates of diagnostic sensitivity and 
specificity of the c3B C-ELISA are anticipated to improve with the evaluation of more 
samples during full test validation (324).  
Depending on the FMD status of a country or region, cut-off values and intermediate 
ranges favouring either higher DSe and/or DSp would need to be selected. For a FMD-
free region, where the c3B C-ELISA would fulfil the purpose of surveillance and 
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exclusion testing, preference would be given to greater specificity rather than 
sensitivity in order to reduce the occurrence of false positive results. Conversely, in a 
region where FMD is endemic or post outbreak, where the c3B C-ELISA would 
provide proof-of-freedom, preference would be given to greater sensitivity rather than 
specificity in order to reduce the occurrence of false negative results. If, for example, 
DSe and DSp were set to 95% an intermediate range (IR) would be established. PI 
values falling within the IR would be considered neither positive nor negative (334) 
and would need to be assessed using a secondary test before a definitive diagnosis 
could be made. Using current data, the majority of false negative results (9/14) and 
some false positive results (3/12) for bovine samples determined using a cut-off of 
>47% would fall within this region.  
The c3B C-ELISA uses a NSP antigen giving it the capability to differentiate between 
vaccinated and infected animals (DIVA) if pure vaccines consisting solely of structural 
proteins are used. To assess the DIVA capability of the c3B C-ELISA, a small panel 
of vaccinated bovine and ovine samples were tested. The c3B C-ELISA correctly 
identified the majority of vaccinated animals as negative for FMDV infection. One 
ovine sample (sheep 4), collected 1 day post-exposure in a vaccine efficacy trial, was 
recorded as positive using the cut-off of >34% in the c3B C-ELISA. It is difficult to 
explain this result because it is unlikely this animal had generated anti-NSP antibodies 
at this time-point. It is equally unlikely that the vaccine contained NSPs since no other 
sample produced a false positive result. In addition, all previous and subsequent 
samples from sheep 4 tested negative for anti-3B antibodies in the c3B C-ELISA. 
While the bulk of these data are promising, a larger well-characterised population of 
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samples from vaccinated, vaccinated and challenged, and infected animals will be 
required to extensively examine the c3B C-ELISA as a DIVA test. 
Diagnostic assay validation is used to determine an assay’s fitness-for-purpose. 
Development of the prototype c3B C-ELISA describe here has been guided by the OIE 
validation pathway (324). For the assay as it currently stands to be validated, an 
increased number of defined samples of known history and infection status, 
particularly positive for FMDV antibodies need to be tested (324). This will increase 
confidence in resultant DSe and DSp values. Furthermore, there is a need for testing 
more samples representing different host species with well-characterised vaccination 
and/or infection statuses to increase confidence in the host-independent application of 
the assay. Finally, to confirm that the novel approach taken to create a 3B antigen that 
is most representative of the 3B protein in all FMDV serotypes translates to a serotype-
independent diagnostic test, many more sera from animals infected with each of the 
different serotypes will need to be assessed.  
A major obstacle to this work will be accessing appropriate samples. Australia is free 
from FMD and has developed strict quarantine regulations to minimise the threat of 
an outbreak. This means samples available for testing in Australia are limited to 
irradiated sera held at the AAHL serum bank. To facilitate the transition of the c3B C-
ELISA from promising prototype assay to fully validated assay, much of the future 
work will need to be conducted offshore.  
The final stage of validation requires assessment of the assay’s precision and 
reproducibility (324). To do this the c3B C-ELISA will need to be distributed to other 
laboratories in Australia or abroad for assessment. Proposals for this to occur are 
currently under consideration. In due course, it seems likely that the c3B C-ELISA 
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will replace the current AAHL C-ELISA for diagnostic surveillance in Australia due 
to its comparable performance and relative ease of production. It may also be 
distributed for use in countries and regions, where FMD is endemic, through aid 
programs or a commercial partner. 
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CHAPTER 6 
 GENERAL DISCUSSION 
Foot-and-mouth disease is a viral vesicular disease that affects livestock (19,28). FMD 
remains endemic in regions of lower economic capacity and a high biosecurity risk to 
countries that are free of the disease. FMD outbreaks result in severe socioeconomic 
loss due to trade restrictions and reduced livestock productivity. The loss to the 
Australian economy from an outbreak has been estimated at AUD >$50 billion. Thus, 
vigilance is required to prevent future outbreaks, to minimise the impact of new 
outbreaks and to control existing outbreaks. Critical to all of these aims is the ability 
to rapidly diagnose FMD wherever it appears and to demonstrate freedom from 
infection as soon as possible. This thesis described the development and 
characterisation of a prototype test that will improve the tools available to do this.  
Global control of FMD is therefore a priority. It is encouraging that strategies designed 
to bring this to fruition have been established. These include the FAO and OIE 
Progressive Control Pathway for Foot-and-Mouth Disease (PCP-FMD) (335,336), the 
South-East Asia and China FMD Campaign (SEACFMD) (337) and the Hemispheric 
eradication program of South America (338). However, even the best plans will 
struggle to be effective in countries with insufficient resources to mount and maintain 
an effective response resulting in areas that remain trapped in a cycle of persistent 
FMD infection (339). An added complication exists where current commercial NSP-
based ELISA tests may not be used broadly enough in endemic regions due to the high 
cost per test. Similarly, the OIE prescribed tests are unlikely to be used at the scale 
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required as they are difficult to source. For these reasons, the number of in-house 
assays being developed continues to grow. 
After a program of culling and/or vaccination, it is necessary to achieve and 
demonstrate FMD-freedom before trade sanctions are lifted. This is possible through 
the use of serological tests designed to detect FMDV NSPs because of their ability to 
differentiate vaccinated from infected animals. If strategies for global control are to be 
effective, they must allow for the different economic capacities of affected nations. 
Providing access to a simple low-cost NSP ELISA, such as the c3B C-ELISA, would 
go some way to assisting in establishing freedom from disease status wherever the 
disease occurs. A future development that would further reduce the economic burden 
of response plans would be the incorporation into the c3B C-ELISA of a recombinant 
anti-3B scFv expressed in bacteria as a fusion to alkaline phosphatase which has been 
developed at AAHL (340). This would remove the need for a secondary HRP-
conjugated antibody, further reduce the cost of production of the test and significantly 
reduce the time required to perform the test. It would also make the test more robust 
by reducing the number of components and steps required to perform the assay. If 
global control of FMD is a genuine goal then this unique fully recombinant test would 
provide a real advancement, particularly in regions where cost is a constraining factor 
in disease control, in the response aimed at rapidly establishing freedom from disease 
through DIVA diagnostics after an outbreak. 
Clinical symptoms of FMD are synonymous with other vesicular diseases meaning a 
definitive diagnosis is possible only by laboratory-based testing (180). Further 
complicating the diagnosis of FMD are the antigenic differences in FMDV structural 
proteins that distinguish the seven serotypes and vary between strains (4). Identifying 
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the circulating serotype requires multiple SP-based tests but is critical for vaccination 
strategies because previous infection or vaccination by one serotype does not provide 
cross-serotype protection (105,106). The process typically involves diagnosis of an 
FMD outbreak using PCR or antigen-based tests followed by serotyping in order to 
guide vaccine selection. NSP-based tests are then used to monitor the eradication 
process. Despite pools of FMDV serotypes being shown to circulate in defined regions, 
FMD is a transboundary disease. As recently as 2012 an incursion of FMDV SAT2 
into Egypt occurred for the first time (341). In order to detect incursions of serotypes 
previously unseen in a region, front line tests must be capable of detecting all 
serotypes. NSP-based tests used for monitoring outbreaks are not subject to the same 
limitation as they are considered serotype-independent. Given the consensus sequence 
approach used in development of the c3B C-ELISA is expected to ameliorate the effect 
of epitopic differences due to serotype and strain on antibody binding, with further 
validation, the c3B C-ELISA is likely to provide an improved method for monitoring 
of FMD outbreaks be they endemic or exotic to a region. 
The PCP-FMD provides a detailed plan for FMD control and eradication (335,336). 
The plan encompasses everything from outbreak epidemiology and distribution to 
appropriate control measures and reporting. A typical response to an outbreak begins 
with clinical and definitive laboratory diagnoses followed by implementation of a 
containment and control strategy that may involve restrictions on animal movement, 
quarantine of infected premises, stamping out and protection of uninfected animals by 
vaccination. The overwhelming motivation for the outbreak response plan to be 
successful in a previously free country, is the resumption of normal trade that comes 
only when a disease-free status is achieved. An alternative status, recognised by the 
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OIE, is FMD-free with vaccination (342). Evidence of FMD-freedom is only possible 
through the extensive use of serological surveillance testing of post-outbreak, 
vaccinated herds (234,235). Moreover, the serodiagnostics used must utilise FMDV 
NSPs in order to differentiate infected from vaccinated animals (DIVA) (259). 
A range of responses to outbreaks exist with the most commonly applied being a 
combination of slaughter and vaccination. A slaughter policy with strict movement 
controls was applied in the UK in 2001 with success, but the scale of slaughter at times 
overwhelmed both financial and organisational capacity and had severe social effects 
(11). FMD in Western Europe was eradicated in the 1980s through a combination of 
slaughter, preventive vaccination and sanitary measures (343). While in parts of South 
America and southern Africa, vaccination and quarantine with limited culling have 
been applied with moderate success (344). The Australian Veterinary Emergency Plan 
recommends stamping out and emergency vaccination as part of an outbreak response 
(345). Regardless of the approach taken, herd surveillance following control is 
essential for freedom-from-FMD status to be achieved. Whether vaccination forms 
part of the response or not, the use of NSP-based tests provides an ideal mechanism 
for demonstrating proof of freedom (342). The c3B C-ELISA offers DIVA testing 
capability and could be utilised to the benefit surveillance programs. However, within 
a vaccinated herd it is important to bear in mind that the performance of an NSP-based 
assay is directly dependent upon the quality of the vaccine in use. That is, where an SP 
vaccine contains the NSP used in the detection system as a contaminant, it is not 
possible to differentiate vaccinated from infected animals as has been observed in sub-
Saharan Africa (346–348).   
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For certifying bodies to be satisfied that a country is free of FMD they must have 
confidence in the reliability of the tests used to demonstrate freedom. Validation 
establishes a test as being fit-for-purpose. A defined process for test validation is 
available through the OIE Assay Development and Validation Pathway (324). An 
essential requirement of the validation process is access to a sufficient number of well-
characterised serum samples. The theoretical number of sera used to assess the 
diagnostic capacity of an assay ranges from tens to thousands, depending on the 
desired level of confidence. The OIE recommended NSP I-ELISA has cumulatively 
tested 6000 negative and 250 positive sera, and is considered validated for cattle 
samples (349).  
FMDV is able to infect multiple livestock and wildlife species. Evidence exists that 
shows wildlife are able to act as a reservoir of disease and that spill-over in to livestock 
is possible. The African buffalo (350) provides an example of this as it is a natural host 
of SAT serotypes of FMDV and can be infected with serotypes O and A (49,53,92). 
Cases of both natural and experimental transmission of FMD from buffalo to cattle 
have been clearly documented (56,96,351). It will be important, therefore, not only to 
test sufficient numbers of sera, but also sera of sufficient diversity. This means that for 
a comprehensive validation of a test to occur, populations of sera derived from 
vaccinated, infected or vaccinated and exposed/infected animals; sera from different 
species encompassing livestock and relevant wildlife; and sera from animals infected 
with different FMDV serotypes and strains will be required. This daunting task must 
be viewed as an achievable challenge if FMD eradication is to be tackled in an effective 
manner. One benefit that the c3B C-ELISA provides in this arena is its competitive 
format. Being a competitive ELISA means that there is no requirement for the use of 
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a different anti-species antibody conjugate for each species tested, as is the case for I-
ELISAs. This will make future validation of the test across all relevant species more 
achievable.  
FMD is a heavily politicised disease due to its effect on international trade. FMD status 
is of great significance for both FMD-free and endemic countries as it either allows or 
prevents free trade. Clearly there is a tremendous need for readily available vaccine-
matched diagnostics that are effective across species and FMDV serotypes if regions 
are ever to be recognised by the OIE as free from FMD. Unfortunately, the prescribed 
tests are often too expensive or unobtainable. The vast array of in-house tests makes a 
uniform approach to surveillance difficult and validation even harder on a global level. 
The pan-serotype FMD diagnostic assay described herein provides another potential 
tool to help meet these needs. It is simple and can be performed in all but the most 
rudimentary of laboratories; it uses recombinant antigen expressed in bacteria making 
manufacture cost-effective; it detects antibodies to FMDV of all serotypes and it has 
the potential to be used as a DIVA test. It is hoped future work will at least move this 
assay towards full validation for important livestock species. Implementing 
modifications making the test fully recombinant and the associated cost benefits would 
be welcomed. Ultimately, the final validated test should be distributed to wherever 
FMD is a concern. Whether through commercial partners or aid organisations, the use 
of the described affordable recombinant antigen production method should facilitate 
this.   
In closing, it seems incumbent on those whom are able to develop an affordable, robust 
and validated test capable of serotype-independent DIVA detection of FMD, and to 
Chapter 6 
 
156 
make it available globally, if FMD control is to be taken as a serious aim. The c3B C-
ELISA lays the groundwork for this to occur. 
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CONCLUSION 
 
In this thesis it has been clearly demonstrated that a consensus sequence in FMDV 
exists and a FMDV serotype-independent assay based on a derived consensus 
sequence antigen has been described for the first time. The 3B consensus sequence 
formed a reagent encompassing all sequences for pan-diagnosis of FMDV. The use of 
a synthetic coding sequence and expression of recombinant proteins in E. coli has 
provided a more economical and safer reagent without the requirement for infectious 
material. MBP proved an ideal fusion protein not only influencing the fusion partner’s 
solubility but an exceedingly effective purification strategy for production of a highly 
pure antigen for assay development. Recombinant c3B antigen provided the basis for 
a pan-serodiagnostic DIVA C-ELISA with high diagnostic power that is affordable 
and practical for use in regions where FMD is present. The c3B antigen effectively 
detected all seven bovine sera collected from infected animals representing each of the 
FMDV serotypes, thus demonstrating this antigen to be the most appropriate for pan-
serodiagnosis of FMDV. This advanced method could be applied to the generation of 
pan-reagents for other diseases with many serotypes or strains, or for production of a 
pan-vaccine for all seven serotypes of FMDV. 
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APPENDICES 
 APPENDIX A 
The following tables comprise the large datasets that were obtained throughout the 
project. 
Table A-1 refers to reviewed literature on FMDV NSP ELISAs. 
Table A-2 and Table A-3 refer to material presented and discussed in Chapter 3. 
Table A-4 and Table A-5 refer to material presented and discussed in Chapter 4. 
Table A-6 to Table A-9 refer to material presented and discussed in Chapter 5. 
Figure A-1 refers to material presented and discussed in Chapter 5. 
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Table A-1: Comparison of recombinant FMDV NSP based enzyme-linked immunosorbent assays. 
Anti-FMDV NSP antibody enzyme-linked immunosorbent assays (ELISA) were categorised based on the antigen used. Tags used for purification or 
protein production monitoring are indicated as follows: GST, glutathione S-transferase; MBP, maltose-binding protein; MS2, bacteriophage coat protein; 
TRX, thioredoxin; His-tag, multiple histidine residue tag; and S-tag, oligopeptide derived from pancreatic ribonuclease A. Species tested are indicated as 
follows: B, bovine; O, ovine; P, porcine; C, caprine; and Bf, buffalo. Commercialised assays are noted as follows: ~, 3ABC trapping-ELISA (IZSLER, 
Brescia, Italy); *, NCPanaftosa-screening ELISA (Panaftosa, PAHO, Rio de Janeiro, Brazil); ^, UBI® FMDV NS ELISA (United Biomedical Inc., New 
York, USA); +, CHEKIT-FMD-3ABC ELISA (Bommeli Diagnostics/Idexx, Bern, Switzerland); #, Ceditest FMDV-NS (Cedi Diagnostics/Prionics, B.V. 
Lelystad, The Netherlands). A ‘-’ indicates not applicable or not defined.  
Antigen 
Sequence Expression 
system Tag Solubilisation Test format (specifications) Species Reference Type Isolate Format 
Lb O O1 Kaufbeuren Inactive Lb E. coli GST  Urea Indirect ELISA (antigen coated) B Mackay DKJ, et al. 1998 (235)  
2B 
O O1 Kaufbeuren Peptide #7, 13-mer Synthesised - - Indirect ELISA (antigen coated) B Inoue T, et al. 2006 (246) 
O O IND R2/1975 Mutated (lack transmembrane region) E. coli MBP  (soluble) Indirect ELISA (antigen coated) B Biswal JK, et al. 2014 (247) 
2C 
A A12 See Meyer RF, et al. 1991 (352) Baculovirus - - Indirect ELISA (antigen coated) B Meyer RF, et al. 1997 (239) 
O O1 Kaufbeuren Complete sequence E. coli GST  Urea Indirect ELISA (antigen coated) B Mackay DKJ, et al. 1998 (235) 
O O/SKR/2000 Antigenic sites, peptide #13 Synthesised - - Indirect ELISA (antigen coated) B, O, P Oem J-K, et al. 2005 (245) 
Asia1 IND/491/1997 N-terminus truncated, 2Ct E. coli His (soluble) Indirect ELISA (antigen coated) B Mahajan S, et al. 2013 (353) 
2C3AB 
O O/China/99 B cell epitopes of 2C and complete sequence of 3AB (see Lu Z, et al 2007 (178)) E. coli His & S 
IB solubilisation 
buffer Indirect ELISA (antigen coated) B, P Lu Z, et al. 2010 (248) 
O O/China/99 
B cell epitopes of 2C and complete sequence of 
3AB (see Lu Z, et al. 2010 (248) and Fu Y, et 
al. 2011 (354)) 
E. coli His & S IB solubilisation buffer Blocking ELISA (antigen-capture) B, O, P Fu Y, et al. 2014 (249) 
3A 
O O1 Kaufbeuren Complete sequence E. coli GST  Urea Indirect ELISA (antigen coated) B Mackay DKJ, et al. 1998 (235) 
A A22 550 Complete sequence E. coli His Urea Indirect ELISA (antigen coated) B Yakovleva AS, et al 2006 (250) 
3AB 
C C-Turup Complete sequence Baculovirus - - Blocking ELISA (antigen-capture) B, O, P 
#Sørensen K-J, et al. 1998 (240) 
Chung W, et al. 2002 (253) 
A A22 550 Complete sequence E. coli His Urea Indirect ELISA (antigen coated) B Yakovleva AS, et al 2006 (250)  
- - B cell epitopes (see Sun T, et al. 2004 (179) and Höhlich B, et al. (288)) E. coli 
Tymovirus-like 
particle - Indirect ELISA (antigen coated) 
B, Bf, O, 
P Hema M, et al. 2007 (355) 
O O/SKR/2002 Complete sequence E. coli TRX & His - Blocking ELISA (antigen coated) B, P Oem, J-K, et al. 2007 (330) 
Asia1 Jiangsu/China/2005 Complete (3AB) and truncated 3A (3aB) E. coli His Urea/(soluble) Indirect ELISA (antigen coated) B He C, et al 2010 (254) 
Asia1 IND491/1997 r3AB3  E. coli His - Indirect ELISA (antigen coated) B Mohapatra JK et al. 2011 (255) 
O O/China/99 Complete sequence E. coli His Insoluble Indirect ELISA (antigen coated) B, O, P Shao J, et al. 2011 (356) 
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Table A-1 (continued) 
Antigen 
Sequence Expression 
system Tag Solubilisation Test format (specifications) Species Reference Type Isolate Format 
3AB1 
O O1 Caseros Complete sequence E. coli/ baculovirus GST /- - Indirect ELISA (antigen coated) B Silberstein E, et al. 1997 (251) 
O O1 Kaufbeuren Complete sequence E. coli Ig - Indirect ELISA (antigen-capture) B López A, et al. 2005 (357) 
Unk Unknown Unknown E. coli His Electroelution Indirect ELISA (antigen coated) B Nanni M, et al. 2005 (358) 
- - See Nanni M, et al, 2005 (358) E. coli His Electroelution Indirect ELISA (antigen coated) B Jaworski JP, et al. 2011 (256)  
3ABC 
O O1 Kaufbeuren Complete sequence E. coli MS2 - Indirect ELISA (antigen coated) P Rodriguez A, et al. 1994 (359) 
O O1 Kaufbeuren See Strebel K, et al. 1986 (360) E. coli MS2  Urea Indirect ELISA (antigen-capture) B ~De Diego MI, et al. 1997 (176) 
O O1 Kaufbeuren Inactive 3C E. coli GST  Urea Indirect ELISA (antigen coated) B Mackay DKJ, et al. 1998 (235) 
- - See Neitzert E, et al. 1991 (361) E. coli - Electrophoretic homogeneity Indirect ELISA (antigen coated) B *Malirat V, et al. 1998 (261) 
C C-Turup Complete sequence Baculovirus - - Blocking ELISA (antigen-capture) B, O Sørensen K-J, et al. 1998(240) 
- - See Neitzert E, et al 1991 (361) E. coli - Electrophoretic homogeneity Indirect ELISA (antigen-coated)  B *Bergmann IE, et al. 2000 (214) 
O O/SKR/2000  Baculovirus - - Indirect ELISA (antigen-capture) B Kweon CH, et al. 2003 (362) 
O O1 Kaufbeuren See Strebel K, et al. 1986 (360); De Diego M, et al. 1997(176) E. coli MS2  Urea Indirect ELISA (antigen coated) B, O, P 
+Bruderer U, et al. 2004 (263) 
O O1/Campos/ Brazil/58 Complete sequence, mutated (3C) E. coli His 
IB solubilisation 
buffer Competition ELISA (antigen-capture) B, O, P Clavijo A, et al. 2004 (297) 
O O/HKN/14/82 6 repeats of Fragment F5, aa 141-190 3ABC E. coli TRX & His - Indirect ELISA (antigen coated) P Sun T, Lu P, Wang X. 2004 (179) 
C C-Turup See Sørensen K-J, et al. 1998 (240) Baculovirus - - Blocking ELISA (antigen-capture) B, O, P Sørensen K-J, et al. 2005 (260) 
- - See De Diego MI, et al. 1997 (176) E. coli MS2  Urea Indirect ELISA (antigen-capture) O, C Armstrong R, et al. 2005 (363) 
O O1 Kaufbeuren -  E. coli - Urea Competition ELISA (antigen coated) B, O, P Foord et al. 2007 (329) 
O O/China/99 Complete sequence E. coli His & S Urea Indirect ELISA (antigen coated) B, O, P Lu Z-J, et al 2007 (178) 
O O/TAW/2/99 BOV Partial sequence (see Chen T-H, et al., 2009 (364)) E. coli His (soluble) Indirect ELISA (antigen-capture) P Chen T-H, et al. 2011 (365) 
Asia1 IND 491/1997 Full length, mutated (3C) E. coli His Denaturing conditions Competition ELISA (antigen coated) 
B, Bf, C, 
P  Sharma GK, et al 2012 (328) 
O O/Thailand/02 Complete sequence, mutated (3C) Baculovirus His Urea Indirect ELISA (antigen coated) B 
Srisombundit V, et al. 2013 
(299)  
Sariya, L, et al., 2011 (366) 
C C Turup Complete sequence, mutated (3C) Baculovirus - - Competition ELISA (antigen coated) B, O, P, C Colling A, et al. 2014 (281) 
Asia1 IND 491/1997 Full length, mutated (3C) E. coli His Denaturing conditions 
Competition ELISA (antigen coated)/ 
Sandwich ELISA (antigen captured) B Sharma G, et al. 2014 (298)  
A IND/40/2000 Complete sequence, mutated (3C) Baculovirus - Urea Indirect ELISA (antigen coated) B, O,C, Bf Hosamani M, et al. 2015 (296) 
O O1/Campos/ Brazil/58 See Clavijo A, et al., 2004 (297) E. coli His Urea Competition ELISA (antigen coated) B, O, P Yang M, et al. 2015 (300) 
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Table A-1 (continued) 
Antigen 
Sequence Expression 
system Tag Solubilisation Test format (specifications) Species Reference Type Isolate Format 
3B 
A A12 Peptide Synthesised - - Indirect ELISA (antigen coated) B, O, P ^Shen F, et al. 1999 (257) 
A A22 550 Complete sequence E. coli His Urea Indirect ELISA (antigen coated) B Yakovleva AS, et al 2006 (250) 
- - 27-mer of linear epitopes of 3B proteins (see Höhlich B, et al. 2003 (288)) E. coli His (soluble) Indirect ELISA (antigen coated) B Gao M, et al 2012 (258) 
Asia1 IND/491/1997 Complete sequence E. coli His (soluble) Indirect ELISA (antigen coated) B Mohapatra AK, et al. 2014 (259) 
- - Consensus sequence E. coli MBP  (soluble) Competition ELISA (antigen coated) B, O, P Van Dreumel AK, et al. 2015 (279) 
3D 
O O1 Lausanne Complete sequence E. coli MS2  Urea Indirect ELISA (antigen coated) B Villinger F, et al. 1989(237) 
A A12 Complete sequence  E. coli GST  (soluble) Blocking ELISA (antigen-capture) B, O, P O’Donnell VK, et al. 1996 (238) 
A A12 See Meyer RF, et al. 1991 (352) Baculovirus - - Indirect ELISA (antigen coated) B Meyer RF, et al. 1997 (239) 
C C-Turup Complete sequence Baculovirus - - Blocking ELISA (antigen-capture) B, O Sørensen K-J, et al. 1998(240) 
O O1 Kaufbeuren Complete sequence E. coli GST  Urea Indirect ELISA (antigen coated) B Mackay DKJ, et al. 1998 (235) 
Asia1 IND/63/72 Complete sequence Baculovirus His - Indirect ELISA (antigen coated) B Kumar R, et al. 2012 (241) 
Asia1 IND/491/1997 Complete sequence E. coli His (soluble) Indirect ELISA (antigen coated) B Mahajan S, et al. 2015 (242) 
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Table A-2: FMDV coding sequences used to derive NSP 3B amino acid sequences. 
Serotype Accession number Total  
O 
JN998085.1; JN998085.1; HQ632771.1; HQ632769.1; HQ632772.1; HQ632770.1; HQ632768.1; 
GU582115.1; GU582116.1; HQ113232.1; HM008917.1; HQ412603.1; HQ009509.1; HM191257.1; 
GU384682.1; FJ175665.1; FJ175663.1; FJ175661.1; GU384683.1; FJ175666.1; FJ175664.1; 
FJ175662.1; GU125649.1; GU125647.1; GU125650.1; GU125648.1; HM229661.1; AY686687.1; 
HM055510.1; AF377945.1; AF189157.1; FJ542372.1; FJ542370.1; FJ542368.1; FJ542366.1; 
FJ542371.1; FJ542369.1; FJ542367.1; FJ542365.1; FJ461344.1; FJ461345.1; EU214601.1; EU140964.1; 
EF614457.1; EF552696.1; EF552694.1; EF552692.1; EF552690.1; EF552688.1; EF552697.1; 
EF552695.1; EF552693.1; EF552691.1; EF552689.1; AY593837.1; AY593835.1; AY593833.1; 
AY593831.1; AY593829.1; AY593827.1; AY593825.1; AY593823.1; AY593821.1; AY593819.1; 
AY593817.1; AY593815.1; AY593813.1; AY593811.1; AY593834.1; AY593836.1; AY593832.1; 
AY593830.1; AY593828.1; AY593826.1; AY593824.1; AY593822.1; AY593820.1; AY593818.1; 
AY593816.1; AY593814.1; AY593812.1; AF511039.1; EF175732.1; DQ404179.1; DQ404177.1; 
DQ404175.1; DQ404173.1; DQ404171.1; DQ404170.1; DQ404167.1; DQ404165.1; DQ404163.1; 
DQ404161.1; DQ404159.1; DQ404180.1; DQ404178.1; DQ404176.1; DQ404174.1; DQ404172.1; 
DQ404169.1; DQ404168.1; DQ404166.1; DQ404164.1; DQ404162.1; DQ404160.1; DQ404158.1; 
DQ478936.1; DQ478937.1; DQ248888.1; AY312587.1; AY333431.1; AY359854.1; AY312589.1; 
AF026168.2; AF506822.2; AF308157.1; DQ119643.2; AY317098.1; AB079061.1; EU448381.1; 
EU448379.1; EU448377.1; EU448375.1; EU448373.1; EU448371.1; EU448369.1; EU448380.1; 
EU448378.1; EU448376.1; EU448374.1; EU448372.1; EU448370.1; EU448368.1; EF611987.1; 
AJ539141.1; AJ539139.1; AJ539137.1; AJ539140.1; AJ539138.1; AJ539136.1; AJ320488.1; 
AJ633821.1; EU400597.1; HM625677.1; HM625675.1; HM625673.1; HM625674.1; AY614501.1; 
AJ295002.1; AJ295000.1; AJ294998.1; AJ294996.1; AJ294994.1; AJ294992.1; AJ294990.1; 
AJ294988.1; AJ294986.1; AJ294984.1; AJ294982.1; AJ294980.1; AJ294978.1; AJ295003.1; 
AJ295001.1; AJ294999.1; AJ294997.1; AJ294995.1; AJ294993.1; AJ294991.1; AJ294989.1; 
AJ294987.1; AJ294985.1; AJ294983.1; AJ294981.1; AJ294979.1; AJ294977.1; NP740465.1; 
JN652665.1; JN998086.1; HM625676.1 
179 
A 
AY593751.1; EF117837.1; AY593752.1; AY593754.1; AY593758.1; AY593756.1; AY593760.1; 
AY593762.1; AY593764.1; AY593766.1; AY593768.1; AY593770.1; AY593772.1; AY593774.1; 
AY593776.1; AY593778.1; AY593780.1; AY593782.1; AY593784.1; AY593786.1; AY593788.1; 
AY593790.1; AY593792.1; AY593802.1; AY593751.1; AY593753.1; AY593755.1; AY593757.1; 
AY593759.1; AY593761.1; AY593763.1; AY593765.1; AY593767.1; AY593769.1; AY593771.1; 
AY593773.1; AY593775.1; AY593777.1; AY593779.1; AY593781.1; AY593783.1; AY593785.1; 
AY593787.1; AY593789.1; AY593791.1; AY593793.1; AY593801.1; AY593803.1; HM854023.1; 
M854025.1; HM854022.1; HM854024.1; GQ406248.1; GQ406250.1; GQ406252.1; GQ406247.1; 
GQ406249.1; GQ406251.1; HQ632773.1; HQ832577.1; HQ832579.1; HQ832581.1; HQ832583.1; 
HQ832585.1; HQ832587.1; HQ832589.1; HQ832591.1; HQ832576.1; HQ832578.1; HQ832580.1; 
HQ832582.1; HQ832584.1; HQ832586.1; HQ832588.1; HQ832590.1; EF494488.1; JN099696.1; 
JN099693.1; JN099691.1; JN099703.1; JN006722.1; JN099700.1; JN099697.1; JN099692.1; 
JN099690.1; JN099689.1; JN099702.1; JN099694.1; JN099698.1; JN099695.1; JN099701.1; 
JN099699.1; JN099688.1; EF494486.1; EF494487.1; HQ832592.1; FJ623456.1; UniProtKB/Swiss-Prot: 
P03308.1; UniProtKB/Swiss-Prot: P03306.2; UniProtKB/Swiss-Prot: P49303.1 
102 
C 
AY593810.1; FJ824812.1; DQ409190.1; DQ409188.1; DQ409186.1; DQ409184.1; DQ409191.1; 
DQ409187.1; DQ409185.1; DQ409183.1; AF274010.1; AM409325.1; DQ409189.1; J133358.1; 
AJ133359.1; AJ133357.1; AY593805.1; AY593804.1; AY593807.1; AY593806.1; AY593808.1; 
AY593809.1; AJ007347.1; AJ007572.1 
24 
Asia1 
DQ533483.1; AY593799.1; AY593797.1; AY593795.1; AY593800.1; AY593798.1; AY593796.1; 
EF149010.1; GU931682.1; AY687334.1; AY687333.1; GQ452295.1; AY304994.1; DQ989303.1; 
DQ989306.1; DQ989304.1; AF207526.1; AJ295004.1; DQ989310.1; DQ989315.1; DQ989309.1; 
EF614458.1; HQ631363.1; GU125645.1; DQ989305.1; DQ989319.1; JN006719.1; DQ989313.1; 
JN006720.1; HQ113233.1; GU125646.1; FJ906802.1; DQ989317.1; DQ989322.1; DQ989318.1; 
DQ989316.1; DQ989314.1; DQ989308.1; DQ989321.1; DQ989311.1; DQ989312.1; DQ989307.1; 
JF739177.1; DQ989323.1; DQ989320.1; EF149009.1; AY390432.1; HQ632774.1 
48 
SAT1 AY593838.1; HM067706.1; AY593845.1; AY593843.1; AY593841.1; AY593846.1; AY593839.1; AY593844.1; AY593842.1; AY593840.1 10 
SAT2 HM067705.1; HM067704.1; AF540910.1; FJ461346.1; AY593849.1; AY593847.1; AY593848.1; AJ251473.1 8 
SAT3 AF540910.1; AY593853.1; AY593852.1; AY593850.1; AY593851.1 5 
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Table A-3: FMDV coding sequences used to derive NSP 3B amino acid sequences 
for alignment. 
Serotype 
and 
sequence 
number 
Strain Isolate Country and                      year of isolation 
Accession 
number 
A_1 A10 Holland a10holland iso82 Netherlands, 1942 AY593751.1 
A_2 - Lindholm 1.3,PAK3/2006 Pakistan, 2006 EF117837.1 
A_3 A12-119 a12valle 119 iso20 United Kingdom, 1932, vaccine AY593752.1 
A_4 A14 Spain a14 Spain iso39 Spain, 1959 AY593754.1 
A_5 A18 Zulia a18zulia iso40 Venezuela: Zulia, 1967 AY593758.1 
A_6 A16 Belem a16belem iso80 Brazil: Belem, 1959 AY593756.1 
A_7 A20 USSR a20ussr iso10 Russia,1964 AY593760.1 
A_12 A26 Argentina a26arg iso74 Argentina, 1966 AY593770.1 
A_15 A3 Mecklenburg a3mecklenburg iso81 Germany, 1968 AY593776.1 
A_17 A5 Allier a5allier iso45 France, 1960 AY593780.1 
A_18 Aarg2000 a Argentina 2000 iso104 Argentina, 2000 AY593782.1 
A_21 A Brazil abrazil iso67 Brazil, 1958 AY593788.1 
A_22 Aarg2001 a general lopez iso102 Argentina, 2001 AY593790.1 
A_30 A1 Bayern a1bayern iso41 Germany, 1951 AY593759.1 
A_31 A21 Kenya a21kenya iso77 Kenya, 1964 AY593761.1 
A_35 A25 Argentina a25 Argentina iso38 Argentina, 1959 AY593769.1 
A_41 A5 Westerwald a5westerwald iso73 Germany: West, 1951 AY593781.1 
A_50 IND81/00 - India, 2000 HM854021.1 
A_51 IND258/99 - India, 1999 HM854023.1 
A_53 IND17/77 - India, 1997 HM854022.1 
A_57 A/VN/20/2009 - Viet Nam, 2009 GQ406252.1 
A_62 IND 110/1999 - India: Haryana, 1999 HQ832577.1 
A_64 - IND 64/2004 India: Andhra Pradesh, 2004 HQ832581.1 
A_65 - IND 447/2005 India: Gujarat, 2005 HQ832583.1 
A_67 - IND 50/2006 India: Karnataka, 2005 HQ832587.1 
A_69 - IND 437/2008 India: Karnataka, 2008 HQ832591.1 
A_72 - IND 818/2003 India: Assam, 2003 HQ832580.1 
A_73 - IND 249/2004 India: Haryana, 2004 HQ832582.1 
A_74 - IND 22/2006 India: Assam, 2006 HQ832584.1 
A_75 - IND 43/2006 India: J&K, 2006 HQ832586.1 
A_77 - IND 245/2007 India: Tamilnadu, 2007 HQ832590.1 
A_95 A/IRQ/09 4235 Iraq: Altenia, Hilla, Babil, 2009 JN099688.1 
A_98 - IND 17/2009 India: Kerala, 2009 HQ832592.1 
A_99 Talasskiy - Kazakhstan, 1999 FJ623456.1 
A_101 A10-61 - - P03306.2 
Asia1_1 ZB/CHA/58(att Unknown China, 1958 DQ533483.1 
Asia1_2 Asia1Leb83 asia1leb4 iso4 Lebanon, 1983 AY593799.1 
Asia1_3 Asia1-3 asia1-3kimron iso61 Israel, 1963 AY593797.1 
Asia1_7 Asia1-2 asia1-2isrl3-63 iso6 Israel, 1963 AY593796.1 
Asia1_8 Asia 1/HNK/CHA/05 Unknown China: Hong Kong, unknown (2005?) EF149010.1 
Asia1_9 Unknown Asia1/YS/CHA/05 China, 2005 GU931682.1 
Asia1_11 Unknown IND 321/01 India: Madhya Pradesh, 2001 AY687333.1 
Asia1_13 vaccine IND 63/72 - - AY304994.1 
Asia1_17 Asia/IRN/05 - - AF207526.1 
Asia1_28 - IND 52-87 India, 1986 DQ989313.1 
Asia1_29 - As/SIN/PAK/L2810/2009 - JN006720.1 
Asia1_33 - IND 148-01 India, 2000 DQ989317.1 
Asia1_34 - IND 139-02 India, 2002 DQ989322.1 
Asia1_36 - IND 21-89 India, 1989 DQ989316.1 
Asia1_38 - IND 397-97 India, 1994 DQ989308.1 
Asia1_40 - IND 37-02 India, 2002 DQ989311.1 
Asia1_41 - IND 13-91 India, 1990 DQ989312.1 
Asia1_42 - IND 247-92 India, 1992 DQ989307.1 
Asia1_44 - IND 97-03 India, 2002 DQ989323.1 
Asia1_45 - IND 182-02 India, 2002 DQ989320.1 
Asia1_46 Asia 1/Jiangsu/China/2005 - China: Jiangsu, Wuxi, 2005 EF149009.1 
Asia1_48 - MAY/9/99 Malaysia: Kawasan, Masjid Tanah, 1999 HQ632774.1 
C_2 C-S8p200 Unknown Spain, unknown FJ824812.1 
C_17 C1 Oberbayern c1ober iso88 Germany, 1960 AY593805.1 
C_21 C4 Argentina C4 Tierra del Fuego iso2 Argentina, 1966 AY593808.1 
C_22 C5 Argentina c5arg iso60 Argentina, 1969 AY593809.1 
O_5 Unknown MAY/7/2007 Malaysia: Jasin, Melaka, 2007 HQ632772.1 
O_7 - MAY/3/2000 Malaysia: Gombak, Selangor HQ632768.1 
O_8 - O/VN/QB88/2009 Viet Nam, Oct-2009 GU582115.1 
O_9 - O/VN/YB105/2009 Viet Nam, Sept-2009 GU582116.1 
O_10 Panasia III O/ISL/PAK/L1573/2009 Pakistan, 30-Jan-2009 HQ113232.1 
O_11 - O/YS/CHA/05 China, Oct-2005 HM008917.1 
O_12 - O/YM/YN/2000 China, 18-Dec-2000 HQ412603.1 
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Table A-3 (continued)  
Serotype 
and 
sequence 
number 
Strain Isolate Country and                       year of isolation 
Accession 
number 
O_15 - PAK/44/2008 Pakistan, 2008 GU384682.1 
O_16 - Israel 07-6391 Israel, 2007 FJ175665.1 
O_23 - O/VN/SL21/2006 Viet Nam: Son La Province, Oct-2006 GU125649.1 
O_25 - O/VN/GL13/2006 Viet Nam: Gia Lai Province, Apr-2006 GU125650.1 
O_27 - HKN/20/2010 Hong Kong, 03-Mar-2010 HM229661.1 
O_28 - O/ES/2001 China, unknown (2001?) AY686687.1 
O_30 - O/SKR/2000 Korea, unknown (2000?) AF377945.1 
O_40 - Kumi District Uganda, Jul-2002 FJ461344.1 
O_42 - UKG/8098/2001 United Kingdom, (2001?) EU214601.1 
O_56 O PanAsia otaiwan97 iso106/112 Taiwan, 1997 AY593835.1 
O_59 O6 o6pirbright iso58 United Kingdom, 1965 AY593829.1 
O_60 O3 Venezuela o3venezuela iso15 Venezuela, 1971 AY593827.1 
O_61 O1 Valle o1valle iso64 Argentina, 1939 AY593825.1 
O_62 O1 Manisa o1manisa iso87 Turkey, 1969 AY593823.1 
O_67 O11 Indonesia o11indonesia iso52 Indonesia, 1962 AY593813.1 
O_68 O10 Philippines o10phil54 iso54 Philippines, 1958 AY593811.1 
O_73 O5 India o5india iso34 India, 1962 AY593828.1 
O_74 O2 Brescia o2brescia iso17 Italy, 1947 AY593826.1 
O_92 UKG/14339/2001 - United Kingdom, (2001?) DQ404163.1 
O_104 UKG/14476/2001 - United Kingdom, (2001?) DQ404162.1 
O_111 - - China, unknown AY333431.1 
O_118 HKN/2002 - China, (2002?) AY317098.1 
O_119 O/JPN/2000 - Japan: Miyazaki, 2000 AB079061.1 
O_138 - SAR/19/2000 South Africa, (2000?) AJ539140.1 
O_145 - O/K/109/2000 Kenya: Uasin Gishu, 2000 HM625675.1 
O_149 - O/VIT/2/97 Viet Nam, (1997?) AJ295002.1 
O_151 - O/HKN/1/99 Hong Kong, (1998?) AJ294998.1 
O_152 - O/HKN/16/96 Hong Kong, (1996?) AJ294996.1 
O_153 - O/HKN/12/91 Hong Kong, (1991?) AJ294994.1 
O_155 - O/HKN/14/82 Hong Kong, (1982?) AJ294990.1 
O_156 - O/HKN/3/75 Hong Kong, (1975?) AJ294988.1 
O_159 - O/CAM/2/98 Cambodia, (1998?) AJ294982.1 
O_162 - O/VIT/3/97 Vietnam, (1997?) AJ295003.1 
O_164 - O/PHI/7/96 Philippines, (1996?) AJ294999.1 
O_165 - O/HKN/20/96 Hong Kong, (1996?) AJ294997.1 
O_168 - O/HKN/17/82 Hong Kong, (1982?) AJ294991.1 
O_177 - O/IRN/1/2010 Iran, (2010?) JN652665.1 
SAT1_1 SAT1bot1/68 sat1-1bech iso30 Botswana, 1970 AY593838.1 
SAT1_2 SAT 1 Uga 1/07 Buffalo 17 QE Uganda, 2007 HM067706.1 
SAT1_3 SAT1bot1/68 sat1bot iso47 Botswana, 1968 AY593845.1 
SAT1_4 SAT1-6swa40/61 sat1-6swa iso16 Namibia, 1940 AY593843.1 
SAT1_5 SAT1-4sr2/58 sat1-4srhod iso24 Zimbabwe: Rhodesia, 1958 AY593841.1 
SAT1_6 SAT1rhod5/66 sat1rhod iso33 Zimbabwe: Rhodesia, 1966 AY593846.1 
SAT1_7 SAT1-20 RV 11/37 sat1-20 iso11 Unknown AY593839.1 
SAT1_8 SAT1-7isrl4/62 sat1-7isrl iso12 Israel, 1962 AY593844.1 
SAT1_9 SAT1/5sa/61 sat1-5sa iso13 South Africa, 1961 AY593842.1 
SAT1_10 SAT1-3swa1/49 sat1-3swa iso14 Namibia, 1949 AY593840.1 
SAT2_1 SAT 2 Uga 1/07 Buffalo 10 QE Uganda, 2007 HM067705.1 
SAT2_2 SAT 2 Uga 2/07 Buffalo 6 QE Uganda, 2007 HM067704.1 
SAT2_4 Unknown Murchison Falls National Park Uganda, 2002 FJ461346.1 
SAT2_5 SAT2-3kenya 11/60 sat2-3kenya-21 Kenya, 1960 AY593849.1 
SAT2_6 SAT2-1rhod/48 sat2-1rhod iso26 Zimbabwe: Rhodesia, 1948 AY593847.1 
SAT2_7 SAT2-2 106/67 sat2-2 iso25 Unknown, 1967 AY593848.1 
SAT2_8 KEN/3/57 Unknown Kenya, unknown  AJ251473.1 
SAT3_2 SAT3-4bech 1/65 sat3-4bech iso23 Botswana, 1965 AY593853.1 
SAT3_3 SAT3-3kenya 11/60 sat3-3kenya iso22 Kenya, 1960 AY593852.1 
SAT3_4 SAT3-2sa57/59 sat3-2sa iso27 South Africa, 1959 AY593850.1 
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Table A-4: Target peptide spectrum matches from LC-MS/MS of MBP-3B fusion 
proteins digested with trypsin. 
Peptide fragment properties are indicated as follows: DeltaScore, relative difference 
between the match and the next best match XCorr scores; m/z, mass to charge ratio; MH+, 
protonated molecule ion size; DeltaM, Delta mass given as the deviation of the measured 
mass from the theoretical mass of a peptide in parts per million (ppm); XCorr, cross 
correlation, a measure of the goodness of fit of experimental fragments to the theoretical 
spectra. 
Protein Annotated Sequence Modifications 
No. of 
Missed 
Cleavages 
Charge Delta Score 
m/z  
[Da] 
MH+  
[Da] 
DeltaM  
[ppm] XCorr 
MBP-c3B 
 SAGINAASPNKELAKEF  1 2 0.515 873.954 1746.901 -0.526 5.83 
 DIKDVGVDNAGAKAGLTF  1 2 0.550 895.968 1790.929 0.118 5.29 
 LTDEGLEAVNKDKPL  2 2 0.526 821.438 1641.868 -0.793 4.92 
 DIKDVGVDNAGAKAGL  0 2 0.567 771.909 1542.812 -0.336 4.90 
 AQSGLLAEITPDKAF  2 2 0.594 780.917 1560.827 0.176 4.28 
 SAGINAASPNKELAKEF  1 3 0.521 582.972 1746.902 -0.079 4.07 
 NKDLLPNPPKTW  2 2 0.585 711.890 1422.773 -0.688 3.88 
 VGVLSAGINAASPNKEL  1 2 0.652 820.454 1639.901 -0.488 3.85 
 EAVNKDKPLGAVAL  1 2 0.392 712.909 1424.81 -0.370 3.83 
 TDEGLEAVNKDKPL  1 2 0.577 764.896 1528.785 -0.321 3.45 
 SAGINAASPNKEL  0 2 0.431 636.334 1271.66 0.750 3.32 
 DIKDVGVDNAGAKAGL  0 3 0.310 514.942 1542.811 -0.463 3.32 
 AHDRFGGY  1 2 0.414 461.712 922.4173 0.752 3.26 
 NGLAEVGKKF  1 2 0.526 531.801 1062.595 0.521 3.25 
 NGLAEVGKKF  1 2 0.554 531.801 1062.594 -0.168 3.16 
 TDEGLEAVNKDKPL  1 3 0.484 510.266 1528.785 -0.469 3.10 
 QRRSTEIVAIDALHF  1 3 0.243 585.985 1755.94 -5.698 3.09 
 QRRSTEIVAIDALHF  1 2 0.129 878.471 1755.935 -8.506 3.02 
 LTDEGLEAVNKDKPL  2 3 0.087 547.961 1641.869 -0.355 2.99 
 mKIEEGKLVIW M1(Oxidation) 1 2 0.505 681.378 1361.75 -0.129 2.97 
 NKGETAmTINGPW M7(Oxidation) 0 2 0.538 717.838 1434.668 -0.206 2.92 
 mKIEEGKLVIW M1(Oxidation) 1 3 0.544 454.588 1361.75 -0.049 2.85 
 qRRSTEIVAIDALHF N-Terminal (Gln->pyro-Glu) 1 3 0.304 580.308 1738.91 -7.896 2.80 
 DIKDVGVDNAGAKAGLTF  1 3 0.257 597.647 1790.927 -0.674 2.76 
 NGKLIAYPIAVEAL  2 2 0.574 736.430 1471.852 -0.108 2.70 
 KGQPSKPF  0 2 0.544 444.750 888.4936 -0.157 2.70 
 DIKDVGVDNAGAKAGL  0 2 0.340 771.909 1542.812 -0.415 2.62 
 LVDLIKNKHmNADTDY M10(Oxidation) 2 2 0.425 953.472 1905.937 -0.353 2.61 
 INGDKGYNGL  1 2 0.058 525.765 1050.522 0.427 2.58 
 LDVGSIPGRFSDNGF  2 3 0.118 527.591 1580.758 -7.753 2.55 
 
mNPmVmMMVLPL 
M1(Oxidation) 
M4(Oxidation) 
M6(Oxidation) 
1 3 0.369 485.561 1454.669 7.028 2.55 
 QQEGIANITALKDQLL  2 2 0.008 877.980 1754.953 -6.562 2.53 
 KIAKVF  0 2 0.146 353.237 705.4662 0.654 2.53 
 MPRGGLETVLQTSGPVL  2 2  877.980 1754.953 3.557 2.51 
 KKLmNQIHDHLEmTEL M4(Oxidation); M13(Oxidation) 2 3 0.142 671.338 2011.999 2.656 2.47 
 KATLDKQEVPDTTPVL  1 3 0.020 585.655 1754.952 -1.038 2.47 
 RVNGEKILEDF  1 2 0.237 660.351 1319.695 0.069 2.45 
 KVINKDQWcNVLEF C9(Carbamidomethyl) 2 3 0.012 598.304 1792.899 -3.610 2.45 
 KATLDKQEVPDTTPVL  1 2  877.980 1754.953 -0.161 2.43 
 GKQGFQcQEL C7(Carbamidomethyl) 1 3 0.046 398.857 1194.556 -0.707 2.42 
 KEQQEVAAAVIQRcY C14(Carbamidomethyl) 0 3  598.304 1792.899 -1.366 2.42 
 MPRGGLETVLQTSGPVL  2 3  585.655 1754.952 2.680 2.42 
 mKIEEGKL M1(Oxidation) 0 2 0.402 482.262 963.5174 -0.521 2.39 
 AEITPDKAF  0 2 0.395 496.258 991.5095 0.020 2.38 
 SNIDTSKVNY  0 2 0.432 570.781 1140.554 0.860 2.36 
 NKDLLPNPPKTW  2 3 0.496 474.930 1422.775 0.439 2.36 
 PDDSKDTWKKRGNVDY  1 3 0.346 641.975 1923.91 -4.950 2.34 
 LERRASSGARVEDLPL  2 3 0.254 590.328 1768.97 2.130 2.32 
 qPEPQKNEEL N-Terminal (Gln->pyro-Glu) 0 3  398.857 1194.556 -6.169 2.31 
 RPmGLPTASSINPAPL M3(Oxidation) 1 2 0.162 819.434 1637.861 -4.463 2.28 
 RRTQSLPSGGPGQNGLL  2 2 0.036 869.467 1737.927 -4.696 2.24 
 cTVISQQIQY C1(Carbamidomethyl) 0 2 0.081 620.309 1239.61 5.127 2.22 
 KKNGAGLMVNSRFGF  2 2 0.131 813.428 1625.849 -5.617 2.21 
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Table A-4 (continued)  
Protein Annotated Sequence Modifications 
No. of 
Missed 
Cleavages 
Charge Delta Score 
m/z  
[Da] 
MH+  
[Da] 
DeltaM  
[ppm] XCorr 
          
 KIAKVF  0 2 0.177 353.237 705.4657 -0.038 2.21 
 RmFDPSGKGVVNKDEFKQL M2(Oxidation) 2 2 0.158 1106.056 2211.104 -8.307 2.21 
 KYLNSGAGGL  2 2 0.124 490.260 979.5133 -7.584 2.18 
 RREERNWEQKL  1 2 0.051 772.402 1543.797 -7.613 2.18 
 LRSDKANSVDSLPEL  2 2 0.000 822.433 1643.859 -0.433 2.17 
 TSRAPSPSGLMSPSRL  1 2  822.433 1643.859 3.537 2.17 
 SVNHTSGKVAAGLQGAAGL  1 2  869.467 1737.927 1.768 2.16 
 PcAWVVESSGILNVL C2(Carbamidomethyl) 2 2  822.433 1643.859 7.923 2.15 
 DIKDVGVDNAGAKAGLTF  1 2 0.330 895.967 1790.928 -0.428 2.12 
 EEIPALDKEL  1 2 0.431 578.809 1156.611 1.117 2.11 
 TTQDDLDKAVELL  2 2 0.005 730.871 1460.735 -8.962 2.11 
 QDGYILVGVENL  2 2 0.124 660.344 1319.681 -2.611 2.10 
 cDLWAVGITAIEL C1(Carbamidomethyl) 2 2  730.871 1460.735 -7.249 2.10 
 cDIWAVGITAIEL C1(Carbamidomethyl) 1 2  730.871 1460.735 -7.249 2.10 
 LDKDEKDLRSTPNL  2 2  822.433 1643.859 -0.433 2.08 
 QLREGGSKETAAVF  1 2 0.183 746.886 1492.764 -7.683 2.08 
 LAEITPDKAF  1 2 0.406 552.800 1104.594 0.112 2.07 
 mGTVLSLSPSY N-Terminal (Prot)(Acetyl) 2 2 0.314 598.801 1196.594 5.888 2.07 
 KAENSAAAQTNL  0 2 0.015 609.309 1217.611 -0.458 2.06 
 GGNELSEPTATLL  2 2 0.034 651.339 1301.67 9.218 2.05 
 VNNVSSPLPGEGKSISY  1 2 0.049 874.447 1747.886 -0.040 2.05 
 EEEmKGVADITGIPL M4(Oxidation) 0 2 0.153 809.411 1617.815 7.085 2.03 
 SDEDKPLFGPL  2 2  609.309 1217.611 5.464 2.03 
 EIDQTEDFRPW  1 2 0.050 718.330 1435.652 2.307 2.01 
 EVDEMKETKL  0 2 0.185 611.303 1221.599 -3.043 2.00 
 VLDELKRGDNF  2 2 0.060 653.338 1305.669 -8.325 1.99 
 KGTNASAPDQLSL  1 2  651.339 1301.67 0.588 1.98 
 SLGVVKEF  1 2 0.136 439.753 878.4984 0.233 1.98 
 GVVLAPDGSTVAVEPLL  2 2 0.306 818.954 1636.901 -8.973 1.96 
 EHRPSEMVPVNRSPL  0 2  874.447 1747.886 -2.734 1.95 
 AKEFLENY  2 2 0.185 507.251 1013.494 0.045 1.95 
 LAEITPDKAF  1 2 0.469 552.800 1104.593 -0.551 1.94 
 VFRAcmLPML C5(Carbamidomethyl)M6(Oxidation) 2 2 0.042 627.317 1253.627 5.428 1.93 
 AGTDGETTTQGLDGL  1 2  718.330 1435.652 -1.783 1.91 
MBP-c3B-cSAT 
 AKLPQAEGPYAGPLEK  1 2 0.512 834.951 1668.895 -0.507 4.90 
 VTVEHPDKLEEK  1 2 0.447 712.375 1423.743 -0.008 4.88 
 HmNADTDYSIAEAAFNK M2(Oxidation) 0 2 0.650 957.421 1913.835 0.640 4.60 
 EGPYEGPVKKPVALK  1 3 0.555 537.974 1611.909 -1.195 4.52 
 LPQAEGPYAGPLEK  0 2 0.526 735.385 1469.763 -0.080 4.39 
 DKVPGPYAGPLER  1 3 0.482 466.917 1398.737 -0.180 4.15 
 YDIKDVGVDNAGAK  1 2 0.478 732.870 1464.733 -0.210 4.12 
 HmNADTDYSIAEAAFNK M2(Oxidation) 0 3 0.604 638.616 1913.834 0.155 4.04 
 FLEQQNQVLQTK  0 2 0.267 738.396 1475.786 0.204 4.01 
 NKYEDEINKR  2 3 0.390 436.890 1308.654 -0.105 3.72 
 VTVEHPDKLEEK  1 3 0.276 475.252 1423.743 -0.103 3.66 
 TVEHPDKLEEK  1 2 0.525 662.841 1324.674 0.032 3.66 
 LPQAEGPYAGPLEK  0 2 0.548 735.385 1469.764 0.169 3.58 
 GFSSGSAVVSGGSR  0 2 0.551 627.807 1254.607 -0.257 3.54 
 AKLPQQEGPYAGPmER M14(Oxidation) 1 3 0.384 596.629 1787.874 -0.381 3.52 
 TNAENEFVTIK  0 2 0.489 633.322 1265.637 -0.059 3.50 
 KPLGAVALK  0 2 0.159 448.800 896.593 0.268 3.46 
 ALEESNYELEGK  0 2 0.420 691.328 1381.648 -0.211 3.43 
 EFLENYLLTDEGLEAVNK  0 2 0.566 1049.023 2097.038 -0.126 3.34 
 EITYmHSEGILAGELKHGPL M5(Oxidation) 1 2 0.066 1106.056 2211.106 -2.675 3.32 
 SYEEELVKDPR  1 2 0.533 682.838 1364.668 -0.983 3.30 
 AKLPQAEGPYAGPLEK  1 3 0.349 556.970 1668.896 0.216 3.27 
 AVFVDLEPTVIDEVR  0 2 0.461 851.457 1701.906 0.091 3.19 
 TDYSIAEAAFNK  0 2 0.576 665.320 1329.633 0.372 3.18 
 YDIKDVGVDNAGAK  1 3 0.540 488.916 1464.734 0.969 3.15 
 SYEEELVKDPR  1 2 0.506 682.838 1364.669 0.090 3.12 
 VGVLSAGINAASPNK  0 2 0.362 699.391 1397.775 -0.086 3.07 
 ADTDYSIAEAAFNK  0 2 0.434 758.352 1515.697 0.265 3.02 
 DKVPGPYAGPLER  1 2 0.447 699.872 1398.737 -0.344 3.02 
 TAAENDFVTLK  0 2 0.444 604.811 1208.616 -0.079 3.02 
 AQSGLLAEITPDK  0 2 0.512 671.864 1342.721 0.067 2.99 
 EEIPALDKELK  1 2 0.331 642.856 1284.704 -0.129 2.99 
 LLTDEGLEAVNK  0 2 0.368 651.351 1301.695 0.115 2.99 
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Table A-4 (continued) 
Protein Annotated Sequence Modifications 
No. of 
Missed 
Cleavages 
Charge Delta Score 
m/z  
[Da] 
MH+  
[Da] 
DeltaM  
[ppm] XCorr 
          
 ALEEANADLEVK  0 2 0.343 651.333 1301.658 0.028 2.97 
 LENEIQTYR  0 2 0.347 583.295 1165.583 -1.373 2.97 
 AKLPQAEGPYAGPLEK  1 2 0.557 834.951 1668.895 -0.068 2.96 
 PLIAADGGYAFK  0 2 0.449 611.827 1222.647 0.203 2.96 
 EGPYEGPVK  0 2 0.120 488.243 975.478 -0.241 2.92 
 TAVINAASGR  0 2 0.377 480.267 959.5261 -0.792 2.92 
 KYEDEINKR  2 3 0.352 398.875 1194.611 -0.430 2.87 
 YEELQLTAGR  0 2 0.331 590.304 1179.6 -0.136 2.87 
 VTVEHPDKLEEK  1 3 0.248 475.253 1423.744 0.540 2.86 
 YEEELVKDPR  1 2 0.468 639.322 1277.636 -0.823 2.82 
 VTVEHPDKLEEK  1 4 0.083 356.691 1423.743 0.059 2.78 
 DDDKVPGPYAGPLER  1 3 0.486 543.602 1628.792 0.525 2.78 
 VEHPDKLEEK  1 2 0.447 612.317 1223.627 -0.106 2.75 
 DDKVPGPYAGPLER  1 2 0.382 757.386 1513.764 -0.054 2.72 
 VTMQNLNDR  0 2 0.432 545.769 1090.53 -0.593 2.71 
 TWEEIPALDK  0 2 0.208 601.309 1201.61 0.390 2.65 
 LTDEGLEAVNK  0 2 0.254 594.808 1188.61 -0.937 2.64 
 LPQAEGPYAGPLEK  0 2 0.413 735.385 1469.763 -0.495 2.64 
 KLFDSTIADEGTWTLEDRK  2 3 0.015 742.378 2225.119 4.764 2.61 
 SYEEELVKD  1 2 0.450 556.261 1111.515 -0.049 2.60 
 LFSLSSVEQLDQVYGSNEIP  0 3  742.378 2225.119 9.812 2.57 
 YLLTDEGLEAVNK  0 2 0.469 732.883 1464.76 1.037 2.56 
 SYELPDGQVITIGNER  0 2 0.484 895.950 1790.893 0.395 2.54 
 GYNGLAEVGK  0 2 0.343 504.261 1007.515 -0.266 2.54 
 VNYGVTVLPTFK  0 2 0.472 669.377 1337.747 0.290 2.54 
 qTVDEALKD N-Term(Gln->pyro-Glu) 1 2 0.425 501.243 1001.479 0.347 2.52 
 KFEKDTGIK  2 2 0.215 533.301 1065.594 0.146 2.51 
 VAAAFPGDVDR  0 2 0.394 559.286 1117.564 0.216 2.49 
 DDDKVPGPYAGPLER  1 2 0.198 814.899 1628.791 -0.178 2.47 
 DQGYSEVVLATSmLQVSALAL M13(Oxidation) 0 3 0.037 737.707 2211.105 -7.349 2.43 
 WTLLQEQGTK  0 2 0.360 602.322 1203.637 0.164 2.42 
 AQVEmKAVHENLA M5(Oxidation) 1 3 0.227 485.916 1455.732 4.177 2.42 
 GYNGLAEVGKK  1 2 0.413 568.309 1135.611 -0.068 2.40 
 ASLEAAIADAEQR  0 2 0.329 672.841 1344.676 0.150 2.37 
 VPGPYAGPLER  0 2 0.387 578.311 1155.616 -0.137 2.35 
 KGKNSDEEAPK  2 2 0.179 601.804 1202.6 -0.739 2.35 
 DKPLGAVALK  0 2 0.264 506.314 1011.62 0.272 2.35 
 EPLTKFPDDVNPV  1 2 0.009 735.878 1470.749 1.327 2.35 
 EITYmHSEGILAGELKHGPL M5(Oxidation) 1 3  737.707 2211.105 -2.874 2.34 
 GVVDSEDIPLNLSR  0 2 0.382 757.397 1513.786 0.342 2.33 
 GVVDSEDLPLNISR  0 2 0.382 757.397 1513.786 0.342 2.33 
 qDALWGMKGKPEK N-Term(Gln->pyro-Glu) 1 2  735.878 1470.749 5.763 2.33 
 DAEAWFNEK  0 2 0.191 555.249 1109.49 0.421 2.30 
 AQYEEIAQR  0 2 0.249 554.275 1107.543 -0.017 2.21 
 SYEEELVK  0 2 0.333 498.749 996.4901 1.687 2.19 
 EYLEETRPTPR  0 2 0.138 695.846 1390.685 -7.919 2.18 
 EELRKEEER  2 2 0.107 609.306 1217.604 -6.473 2.16 
 SGLLAEITPDK  0 2 0.433 572.316 1143.626 0.068 2.15 
 KPAIEPScPmKPL C8(Carbamidomethyl) M10(Oxidation) 0 2 0.047 742.393 1483.779 9.765 2.13 
 SLDLDSIIAEVK  0 2 0.395 651.861 1302.716 0.384 2.10 
 GATTPTLEK  0 2 0.010 459.251 917.4942 0.382 2.10 
 DIKDVGVDNAGAK  1 2 0.257 651.338 1301.669 -0.443 2.10 
 QGVGEERAVGR  1 2 0.171 579.299 1157.591 -9.649 2.10 
 LASYLDK  0 2 0.096 405.224 809.4404 0.087 2.09 
 QAEGPYAGPLEK  0 2 0.397 630.316 1259.625 -1.072 2.09 
 AGLQFPVGR  0 2 0.316 472.769 944.5311 -0.183 2.09 
 LLAEITPDK  0 2 0.359 500.290 999.5726 0.470 2.09 
 VAVSTLPR  0 2 0.062 421.758 842.5094 0.022 2.09 
 LAADDFR  0 2 0.244 404.203 807.3992 -0.404 2.09 
 EAQLESLK  0 2  459.251 917.4942 0.382 2.08 
 EAKISEIQ  1 2  459.251 917.4942 0.382 2.08 
 ISELDRQIR  1 2 0.208 565.314 1129.621 -9.964 2.07 
 KGAVAEDGVEPKTE  2 2 0.063 715.362 1429.717 0.207 2.07 
 QSVEADINGLR  0 2 0.354 601.312 1201.617 -0.226 2.06 
 NVELDPEIQK  0 2 0.073 592.812 1184.616 0.229 2.05 
 NLPFVARQmALHA M9(Oxidation) 1 2  742.393 1483.779 -3.105 2.03 
 QNGLISKDEFIR  1 2 0.261 710.378 1419.748 -7.891 2.03 
 QGVASEHmKR M8(Oxidation) 1 2 0.187 579.791 1158.574 4.944 2.03 
 ALFLDALGP  0 2 0.197 458.759 916.5099 -4.332 2.03 
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Table A-4 (continued) 
Protein Annotated Sequence Modifications 
No. of 
Missed 
Cleavages 
Charge Delta Score 
m/z  
[Da] 
MH+  
[Da] 
DeltaM  
[ppm] XCorr 
          
 ADLINNLGTIAK  0 2 0.361 621.856 1242.704 -0.966 2.02 
 QTLTGLLEQmQVHR M10(Oxidation) 0 2 0.099 835.444 1669.88 6.610 2.02 
 EAEKAELK  1 2  459.251 917.4942 0.382 2.01 
 YSIAEAAFNK  0 2 0.422 557.282 1113.556 -1.387 1.99 
 
qSTcPGNKEKFK 
N-Term(Gln->pyro-
Glu) 
C4(Carbamidomethyl) 
2 2 0.196 703.844 1406.68 5.113 1.99 
 EGALEREHSR  1 2 0.147 592.296 1183.584 2.101 1.97 
 YGVTVLPTFK  0 2 0.452 562.821 1124.635 -0.078 1.97 
 VLDELTLAR  0 2 0.367 515.301 1029.594 0.270 1.96 
 LATVVTPR  0 2 0.072 428.766 856.5248 -0.364 1.95 
 GVDEVTIVNILTNR  0 2 0.272 771.928 1542.848 -0.104 1.95 
 AKLPVAK  1 2 0.232 363.747 726.4872 -0.092 1.94 
 VLDELTLTK  0 2 0.140 516.303 1031.598 0.129 1.93 
 AQYEEIALK  0 2 0.259 532.785 1064.563 0.393 1.93 
 GNPTVEVDLYTAK  0 2 0.579 703.862 1406.716 -0.052 1.90 
 LVIWINGDK  0 2 0.168 529.306 1057.604 0.226 1.90 
MBP-cSAT 
 HmNADTDYSIAEAAFNK M2(Oxidation) 0 2 0.670 957.420 1913.834 0.066 5.76 
 VTVEHPDKLEEK  1 2 0.400 712.375 1423.743 0.335 5.25 
 EGPYEGPVKKPVALK  1 2 0.514 806.458 1611.908 -1.225 5.10 
 EGPYEGPVKKPVALK  1 3 0.555 537.975 1611.911 0.168 4.90 
 DDDKVPGPYAGPLER  1 3 0.448 543.602 1628.792 0.300 4.87 
 AKLPQQEGPYAGPmER M14(Oxidation) 1 3 0.568 596.630 1787.875 0.029 4.86 
 DKVPGPYAGPLER  1 3 0.487 466.918 1398.738 0.410 4.66 
 LPQAEGPYAGPLEK  0 2 0.498 735.385 1469.763 -0.163 4.56 
 EGPYEGPVKKPVALK  1 4 0.575 403.733 1611.909 -0.863 4.38 
 YDIKDVGVDNAGAK  1 2 0.499 732.870 1464.732 -0.793 4.35 
 DDKVPGPYAGPLER  1 3 0.515 505.260 1513.765 0.260 4.29 
 LPQAEGPYAGPLEK  0 2 0.517 735.385 1469.763 -0.080 4.12 
 HmNADTDYSIAEAAFNK M2(Oxidation) 0 3 0.652 638.616 1913.834 0.250 4.08 
 NKHmNADTDYSIAEAAFNK M4(Oxidation) 1 4 0.524 539.748 2155.97 -0.780 3.99 
 NKYEDEINKR  2 3 0.425 436.890 1308.654 0.175 3.98 
 LGDDDDKVPGPYAGPLER  1 3 0.467 638.646 1913.924 -0.076 3.96 
 FLEQQNQVLQTK  0 2 0.262 738.396 1475.784 -0.540 3.93 
 AKLPQQEGPYAGPmER M14(Oxidation) 1 3 0.454 596.630 1787.874 -0.278 3.92 
 PQAEGPYAGPLEK  0 2 0.587 678.843 1356.679 -0.298 3.87 
 LPQQEGPYAGPmER M12(Oxidation) 0 3 0.424 530.253 1588.743 0.338 3.87 
 AKLPQAEGPYAGPLEK  1 3 0.390 556.970 1668.896 -0.003 3.80 
 AKLPQAEGPYAGPLEK  1 2 0.515 834.951 1668.895 -0.361 3.79 
 NLIVTEGPYAGPLER  0 2 0.544 814.936 1628.864 -0.189 3.77 
 DDDKVPGPYAGPLER  1 3 0.440 543.602 1628.791 -0.037 3.73 
 DDDDKVPGPYAGPLER  1 3 0.373 581.944 1743.819 0.125 3.70 
 AKLPQAEGPYAGPLEK  1 3 0.416 556.970 1668.896 0.326 3.70 
 GDDDDKVPGPYAGPLER  1 3 0.360 600.951 1800.84 -0.206 3.69 
 VTVEHPDKLEEK  1 3 0.181 475.252 1423.743 0.025 3.64 
 VGVLSAGINAASPNK  0 2 0.486 699.391 1397.775 0.089 3.58 
 AQSGLLAEITPDK  0 2 0.532 671.865 1342.722 0.340 3.57 
 PLIAADGGYAFK  0 2 0.511 611.827 1222.647 0.103 3.54 
 SYEEELVKDPR  1 2 0.499 682.838 1364.669 0.090 3.53 
 LPQAEGPYAGPLEK  0 2 0.512 735.385 1469.763 -0.163 3.48 
 AKLPQAEGPYAGPLEK  1 2 0.465 834.951 1668.895 -0.361 3.44 
 AKLPQQEGPYAGPmER M14(Oxidation) 1 2 0.317 894.441 1787.874 -0.100 3.44 
 AKLPQQEGPYAGPmER M14(Oxidation) 1 3 0.465 596.630 1787.876 1.053 3.42 
 NLIVTEGPYAGPLER  0 2 0.551 814.936 1628.865 0.261 3.41 
 DKVPGPYAGPLER  1 2 0.425 699.872 1398.737 -0.170 3.41 
 NKHmNADTDYSIAEAAFNK M4(Oxidation) 1 3 0.555 719.329 2155.971 -0.010 3.39 
 VEHPDKLEEK  1 2 0.361 612.317 1223.627 -0.106 3.38 
 AKLPQQEGPYAGPmER M14(Oxidation) 1 3 0.413 596.629 1787.873 -0.893 3.37 
 NNLGDDDDKVPGPYAGPLER  1 3 0.557 714.675 2142.011 0.455 3.36 
 AKLPQAEGPYAGPLEK  1 3 0.491 556.970 1668.896 0.107 3.36 
 SYEEELVKDPR  1 2 0.515 682.838 1364.669 -0.267 3.30 
 DKPLGAVALK  0 3 0.255 337.878 1011.62 -0.104 3.29 
 LPQQEGPYAGPmER M12(Oxidation) 0 2 0.431 794.875 1588.742 -0.269 3.27 
 VKEGPYEGPVK  1 3 0.419 401.552 1202.643 1.049 3.22 
 TNAENEFVTIK  0 2 0.430 633.322 1265.637 0.230 3.21 
 YEEELVKDPR  1 2 0.425 639.322 1277.637 -0.345 3.20 
 NLGDDDDKVPGPYAGPLER  1 3 0.478 676.661 2027.967 0.069 3.20 
 AKLPQQEGPYAGPmER M14(Oxidation) 1 3 0.544 596.630 1787.875 0.234 3.20 
 EGPYEGPVK  0 2 0.091 488.243 975.4779 -0.303 3.18 
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Table A-4 (continued) 
Protein Annotated Sequence Modifications 
No. of 
Missed 
Cleavages 
Charge Delta Score 
m/z  
[Da] 
MH+  
[Da] 
DeltaM  
[ppm] XCorr 
          
 AKLPQQEGPYAGPmER M14(Oxidation) 1 3 0.492 596.630 1787.875 0.029 3.17 
 KVPGPYAGPLER  1 3 0.546 428.575 1283.711 0.015 3.17 
 DDDKVPGPYAGPLER  1 2 0.350 814.899 1628.791 -0.029 3.14 
 TDYSIAEAAFNK  0 2 0.535 665.320 1329.633 0.372 3.12 
 LPQAEGPYAGPLEK  0 2 0.537 735.385 1469.763 -0.246 3.11 
 KPLGAVALK  0 2 0.071 448.800 896.5928 -0.004 3.11 
 NLIVTEGPYAGPLER  0 2 0.433 814.936 1628.864 -0.039 3.07 
 KFEKDTGIK  2 2 0.410 533.301 1065.594 0.032 3.05 
 ADTDYSIAEAAFNK  0 2 0.456 758.351 1515.695 -0.862 3.05 
 LPQQEGPYAGPmER M12(Oxidation) 0 2 0.446 794.875 1588.742 -0.269 3.03 
 YDIKDVGVDNAGAK  1 3 0.480 488.916 1464.734 0.781 3.00 
 NNNNLGDDDDKVPGPYAGPLE
R  1 3 0.383 790.703 2370.094 -0.893 2.98 
 DDKVPGPYAGPLER  1 2 0.403 757.386 1513.765 0.027 2.95 
 LLTDEGLEAVNK  0 2 0.393 651.350 1301.694 -0.823 2.93 
 LIVTEGPYAGPLER  0 2 0.543 757.914 1514.821 -0.150 2.93 
 EEIPALDKELK  1 3 0.309 428.906 1284.705 0.003 2.91 
 AVQRGDPEMEQKmNR M13(Oxidation) 2 3 0.197 602.290 1804.854 6.421 2.90 
 LPQAEGPYAGPLEK  0 2 0.517 735.385 1469.764 0.086 2.90 
 AVFVDLEPTVIDEVR  0 2 0.416 851.457 1701.906 0.091 2.84 
 NKHmNADTDYSIAEAAFNK M4(Oxidation) 1 3 0.525 719.328 2155.971 -0.349 2.84 
 EEIPALDKELK  1 2 0.234 642.856 1284.704 -0.224 2.82 
 KFEKDTGIK  2 3 0.223 355.869 1065.594 -0.182 2.82 
 VTVEHPDKLEEK  1 4 0.093 356.691 1423.743 0.144 2.81 
 AKLPQAEGPYAGPLEK  1 3 0.335 556.970 1668.895 -0.332 2.81 
 NNNLGDDDDKVPGPYAGPLER  1 3 0.464 752.688 2256.049 -1.795 2.80 
 VNYGVTVLPTFK  0 2 0.488 669.377 1337.747 0.381 2.79 
 GPDIIFWAHDR  0 3 0.500 442.891 1326.659 0.087 2.78 
 NRAGSPSPQPSGELP  1 3 0.126 498.579 1493.723 -7.851 2.77 
 VTVEHPDKLEEK  1 3 0.163 475.252 1423.743 0.090 2.76 
 DQGYSEVVLATSmLQVSALAL M13(Oxidation) 0 3 0.106 737.706 2211.105 -7.598 2.75 
 NNNNNNLGDDDDKVPGPYAGP
LER  1 3 0.558 866.732 2598.181 -0.101 2.74 
 VNPDLLKKEIENcI C13(Carbamidomethyl) 2 3 0.102 562.301 1684.889 -2.608 2.74 
 TWEEIPALDKELK  1 3 0.320 524.615 1571.83 -1.186 2.72 
 KVPGPYAGPLER  1 2 0.471 642.358 1283.71 -0.878 2.72 
 QAEGPYAGPLEK  0 2 0.348 630.316 1259.626 -0.782 2.70 
 SSSNNNNNNNNNNLGDDDDKV
PGPYAGPLER  1 3 0.532 1105.822 3315.45 0.224 2.69 
 TVEHPDKLEEK  1 3 0.306 442.230 1324.674 0.045 2.68 
 AAVEQLTEEQKNEFK  1 3 0.431 588.632 1763.88 -0.556 2.67 
 AQQPAGKDNGTSQQHVR  1 3 0.157 607.965 1821.881 -7.768 2.67 
 VLDELTLAR  0 2 0.365 515.300 1029.593 -0.560 2.66 
 ALEESNYELEGK  0 2 0.411 691.328 1381.648 0.231 2.63 
 EPQTEAVAQLAQELYN  0 2 0.164 902.437 1803.866 -5.634 2.63 
 mAGQRPHWLLIDSFSLPQT N-Term(Prot)(Acetyl) 0 3 0.050 747.050 2239.135 0.905 2.62 
 AKLPQQEGPYAGPmER M14(Oxidation) 1 3 0.477 596.630 1787.874 -0.278 2.60 
 EYLEETRPTPR  0 2 0.250 695.846 1390.685 -7.919 2.60 
 GVDEVTIVNILTNR  0 2 0.469 771.928 1542.848 -0.104 2.60 
 LPQAEGPYAGPLEK  0 2 0.510 735.385 1469.763 -0.329 2.55 
 SYEEELVKDPR  1 2 0.471 682.837 1364.667 -1.430 2.55 
 SGLLAEITPDK  0 2 0.347 572.317 1143.626 0.282 2.54 
 DPFGEESPMFLKHA  1 2 0.008 802.872 1604.736 -3.255 2.54 
 AKLPQAEGPYAGPLEK  1 3 0.304 556.970 1668.896 0.216 2.53 
 LLQQLAmTGSEEGDP M7(Oxidation) 0 2  802.8717 1604.736 -6.915 2.52 
 LPQAEGPYAGPLEK  0 3 0.4325 490.5932 1469.765 1.012 2.52 
 QQEVHQLQEKLSVMESGLR  1 3  747.0498 2239.135 -6.734 2.49 
 NLIVTEGPYAGPLER  0 3 0.5772 543.6271 1628.867 1.489 2.46 
 YEELQLTAGR  0 2 0.302 590.3038 1179.6 -0.033 2.45 
 GPDIIFWAHDR  0 2 0.5164 663.833 1326.659 -0.156 2.44 
 EPLEKDmNEVEEK M7(Oxidation) 1 2 0.2181 803.3638 1605.72 -6.763 2.43 
 NNNNNLGDDDDKVPGPYAGPL
ER  1 3 0.2963 828.7169 2484.136 -1.032 2.43 
 NLIVTEGPYAGPLER  0 2 0.2562 814.9356 1628.864 -0.189 2.42 
 AmGImNSFVNDIFER M2(Oxidation); M5(Oxidation) 0 2 0.6198 888.4077 1775.808 -0.612 2.42 
 GHYTEGAELVDSVLDVVR  0 3 0.4647 653.6651 1958.981 -0.535 2.41 
 AKLPQAEGPYAGPLEK  1 2 0.5602 834.9516 1668.896 0.224 2.41 
 QPKVQGSSDIGKMAHK  2 2 0.0583 855.9562 1710.905 5.560 2.40 
 AKLPQAEGPYAGPLEK  1 3 0.3625 556.9697 1668.895 -0.552 2.40 
 ASLEAAIADAEQR  0 2 0.3598 672.8411 1344.675 -0.304 2.39 
 VTMQNLNDR  0 2 0.1506 545.7685 1090.53 -1.153 2.39 
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Table A-4 (continued) 
Protein Annotated Sequence Modifications 
No. of 
Missed 
Cleavages 
Charge Delta Score 
m/z  
[Da] 
MH+  
[Da] 
DeltaM  
[ppm] XCorr 
          
 NLIVTEGPYAGPLER  0 2 0.3305 814.9358 1628.864 0.036 2.39 
 QTVDEALKDAQTN  1 2 0.3487 716.8495 1432.692 0.189 2.38 
 GYNGLAEVGKK  1 2 0.4449 568.3091 1135.611 0.254 2.36 
 AKLPQQEGPYAGPmER M14(Oxidation) 1 3 0.5127 596.6298 1787.875 0.234 2.36 
 VTVEHPDKLEEK  1 3 0.2 475.2526 1423.743 0.411 2.35 
 VEHPDKLEEK  1 3 0.2723 408.5469 1223.626 -0.317 2.35 
 WWmQGMLRSLALGVYSRTK M3(Oxidation) 2 3 0.0342 767.0632 2299.175 -3.855 2.34 
 VTVQSFGWSDRAK  1 3 0.03 494.2594 1480.764 6.371 2.33 
 YGVTVLPTFK  0 2 0.5193 562.8212 1124.635 0.139 2.33 
 QALFQQEMARLARE  2 2 0.133 845.9416 1690.876 3.876 2.33 
 GPWAWSNIDTSK  0 2 0.4675 681.3281 1361.649 0.302 2.31 
 LPQAEGPYAGPLEK  0 2 0.443 735.3851 1469.763 -0.329 2.28 
 VPGPYAGPLER  0 2 0.3947 578.3113 1155.615 -0.242 2.28 
 LPSIEQmLAANPGK M7(Oxidation) 0 2 0.0796 742.8852 1484.763 -9.854 2.26 
 qLDPEASVLDTLREK N-Term(Gln->pyro-Glu) 1 2 0.0664 848.9487 1696.89 8.755 2.26 
 TWEEIPALDK  0 2 0.1549 601.3085 1201.61 -0.219 2.26 
 DKPLGAVALK  0 2 0.1964 506.3129 1011.619 -1.116 2.24 
 EELRKEEER  2 2 0.1518 609.3061 1217.605 -5.871 2.24 
 LVAIVDVIDQNR  0 2 0.4505 677.8877 1354.768 -0.573 2.22 
 YLLTDEGLEAVNK  0 2 0.4661 732.8829 1464.758 0.287 2.21 
 EIMLGVcASGLLIYR C7(Carbamidomethyl) 0 2 0.1041 847.9581 1694.909 7.110 2.21 
 GEImPNIPQmSAF M4(Oxidation); M10(Oxidation) 0 2 0.3182 733.8368 1466.666 0.610 2.20 
 FGGYAQSGLLAEITPDK  0 2 0.4364 883.952 1766.897 0.473 2.20 
 qTVDEALKD N-Term(Gln->pyro-Glu) 1 2 0.3699 501.2432 1001.479 0.591 2.19 
 HmNADTDYSIAEAAF M2(Oxidation) 0 2 0.5509 836.3513 1671.695 -0.100 2.16 
 IAATmENAQK M5(Oxidation) 0 2 0.4491 546.7713 1092.535 -0.054 2.16 
 IEKmVDLTQLME M4(Oxidation) 1 2 0.1435 733.3628 1465.718 -6.392 2.16 
 qVQAEVPGSPIFVM N-Term(Gln->pyro-Glu) 0 2 0.107 742.8752 1484.743 -1.541 2.15 
 ARSGEcGVLQEETGP C6(Carbamidomethyl) 1 2 0.1963 795.3694 1589.731 5.713 2.14 
 SYELPDGQVITIGNER  0 2 0.615 895.9495 1790.892 -0.150 2.13 
 AKLPVAK  1 2 0.2019 363.7472 726.4872 -0.092 2.13 
 GLLAEITPDK  0 2 0.1745 528.7999 1056.592 -1.038 2.12 
 SNmDNmFESYINNLR M3(Oxidation); M6(Oxidation) 0 2 0.5519 940.4012 1879.795 0.089 2.12 
 SGSPPIcRQAQTK C7(Carbamidomethyl) 1 2 0.0758 715.3619 1429.716 -3.598 2.11 
 NGLAEVGKK  1 2 1 458.2666 915.526 0.198 2.10 
 KPIPLGK  0 2 0.2201 376.7553 752.5034 0.689 2.09 
 
qSTcPGNKEKFK 
N-Term(Gln->pyro-
Glu); 
C4(Carbamidomethyl) 
2 2 0.0817 703.8437 1406.68 4.852 2.08 
 RRPmANGLAAAGSPV M4(Oxidation) 1 2 0.0096 742.3932 1483.779 -0.394 2.08 
 EPLTKFPDDVNPV  1 2 0.0097 735.8787 1470.75 1.742 2.06 
 NLPFVARQmALHA M9(Oxidation) 1 2  742.3932 1483.779 -3.105 2.06 
 PPEQQmLQKPDK M6(Oxidation) 0 2 0.039 727.874 1454.741 6.860 2.05 
 DKPLGAVALK  0 2 0.122 506.3137 1011.62 0.332 2.05 
 RSYScPVcEKSFS C5(Carbamidomethyl); C8(Carbamidomethyl) 2 2 0.0686 803.861 1606.715 9.915 2.04 
 qDALWGMKGKPEK N-Term(Gln->pyro-Glu) 1 2  735.8787 1470.75 6.178 2.04 
 
qNIAERLLRVMc 
N-Term(Gln->pyro-
Glu); 
C12(Carbamidomethyl) 
2 2 0.0637 743.3826 1485.758 -5.709 2.04 
 DKPLGAVALK  0 2 0.2157 506.3134 1011.619 -0.211 2.04 
 DKPLGAVALK  0 2 0.1373 506.3131 1011.619 -0.754 2.04 
 SYEEELVKD  1 2 0.3842 556.2614 1111.516 0.171 2.03 
 EHPDKLEEK  1 2 0.2836 562.7829 1124.559 0.258 2.01 
 KPAIEPScPmKPL C8(Carbamidomethyl); M10(Oxidation) 0 2  742.3932 1483.779 9.765 2.01 
 LVIWINGDK  0 2 0.1741 529.3057 1057.604 0.110 2.01 
 LLAEITPDK  0 2 0.29 500.29 999.5727 0.592 2.00 
 DAEAWFNEK  0 2 0.1357 555.2487 1109.49 0.311 1.99 
 PGPYAGPLER  0 2 0.0505 528.7764 1056.546 -1.600 1.98 
 LPQQEGPYAGPMER  0 2 0.4772 786.8777 1572.748 0.454 1.97 
 QPFIQPEGPSLGGQ  0 2  727.874 1454.741 9.178 1.97 
 IPYKYEHNKAHA  2 2  735.8787 1470.75 0.832 1.97 
 EEIPALDK  0 2 0.2995 457.7453 914.4833 0.421 1.97 
 VVRASTmLGDIYNKK M7(Oxidation) 2 2 0.0964 855.957 1710.907 -8.142 1.97 
 EREALmLKHLQE M6(Oxidation) 2 2 0.198 756.8927 1512.778 -3.811 1.97 
 VNYGVTVLPTFK  0 2 0.4541 669.3768 1337.746 0.016 1.96 
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Table A-4 (continued) 
Protein Annotated Sequence Modifications 
No. of 
Missed 
Cleavages 
Charge Delta Score 
m/z  
[Da] 
MH+  
[Da] 
DeltaM  
[ppm] XCorr 
          
 LLQQLAmTGSEEGDP M7(Oxidation) 0 2 0.0612 802.8719 1604.737 -6.611 1.96 
 AKAPIVTE  1 2 0.4184 414.7449 828.4825 -0.017 1.96 
 VLDELTLTK  0 2 0.1813 516.3029 1031.598 0.129 1.93 
 DEIVQEFVTSVQTR  0 2 0.0417 825.9247 1650.842 5.299 1.92 
 QGVASEHmKR M8(Oxidation) 1 2 0.1623 579.7905 1158.574 4.628 1.91 
 AGLQFPVGR  0 2 0.2158 472.7695 944.5317 0.463 1.90 
MBP 
 HmNADTDYSIAEAAFNK M2(Oxidation) 0 2 0.714 957.420 1913.834 0.066 5.84 
 VTVEHPDKLEEK  1 2 0.455 712.375 1423.744 0.592 4.88 
 TNAENEFVTIKK  1 2 0.404 697.369 1393.732 -0.398 4.46 
 TNAENEFVTIKK  1 3 0.448 465.249 1393.733 0.249 4.17 
 TVEHPDKLEEK  1 2 0.500 662.841 1324.675 0.585 3.94 
 FLEQQNQVLQTK  0 2 0.239 738.396 1475.785 0.039 3.89 
 YDIKDVGVDNAGAK  1 2 0.461 732.870 1464.732 -0.793 3.88 
 TNAENEFVTIK  0 2 0.389 633.323 1265.638 0.423 3.81 
 AVFVDLEPTVIDEVR  0 2 0.488 851.457 1701.906 0.019 3.79 
 HmNADTDYSIAEAAFNK M2(Oxidation) 0 3 0.629 638.616 1913.834 0.155 3.75 
 NKHmNADTDYSIAEAAFNK M4(Oxidation) 1 3 0.584 719.328 2155.97 -0.519 3.75 
 YDIKDVGVDNAGAK  1 3 0.574 488.916 1464.734 0.656 3.73 
 VTVEHPDKLEEK  1 3 0.260 475.253 1423.743 0.411 3.65 
 NKHmNADTDYSIAEAAFNK M4(Oxidation) 1 3 0.529 719.328 2155.97 -0.689 3.61 
 SLNNQFASFIDK  0 2 0.479 692.349 1383.69 -0.140 3.61 
 KPLGAVALK  0 2 0.122 448.800 896.5937 1.017 3.36 
 NKYEDEINKR  2 3 0.485 436.890 1308.656 1.504 3.36 
 ADTDYSIAEAAFNK  0 2 0.486 758.352 1515.696 -0.298 3.25 
 ALEESNYELEGK  0 2 0.486 691.328 1381.648 -0.034 3.25 
 SYEEELVKDPR  1 2 0.495 682.838 1364.668 -0.625 3.23 
 AQSGLLAEITPDK  0 2 0.530 671.864 1342.721 -0.024 3.21 
 VGVLSAGINAASPNK  0 2 0.408 699.390 1397.774 -0.785 3.11 
 EEIPALDKELK  1 2 0.294 642.856 1284.704 -0.509 3.10 
 TDYSIAEAAFNK  0 2 0.520 665.320 1329.632 0.096 3.04 
 TWEEIPALDKELK  1 2 0.307 786.419 1571.83 -0.673 3.03 
 SYEEELVKDPR  1 2 0.497 682.838 1364.669 -0.357 3.02 
 PLIAADGGYAFK  0 2 0.449 611.827 1222.647 0.203 3.01 
 ALEEANADLEVK  0 2 0.337 651.333 1301.659 0.403 3.00 
 WTLLQEQGTK  0 2 0.358 602.322 1203.636 -0.343 2.99 
 NVELDPEIQK  0 2 0.201 592.812 1184.616 0.538 2.99 
 VTVEHPDKLEEK  1 3 0.340 475.253 1423.744 1.054 2.97 
 SLDLDSIIAEVK  0 2 0.416 651.861 1302.715 0.103 2.96 
 QSVEADINGLR  0 2 0.362 601.312 1201.616 -1.039 2.96 
 ASLEAAIADAEQR  0 2 0.490 672.841 1344.676 0.240 2.94 
 YLLTDEGLEAVNK  0 2 0.440 732.883 1464.758 -0.130 2.91 
 YEELQLTAGR  0 2 0.293 590.304 1179.601 0.071 2.87 
 VTVEHPDKLEEK  1 4 0.115 356.691 1423.744 0.830 2.86 
 TAAENEFVTLKK  1 3 0.329 450.914 1350.727 0.539 2.86 
 NKYEDEINKR  2 2 0.374 654.832 1308.656 1.468 2.86 
 VNYGVTVLPTFK  0 2 0.493 669.377 1337.747 0.290 2.86 
 GPDIIFWAHDR  0 2 0.489 663.833 1326.659 -0.248 2.84 
 KFEKDTGIK  2 2 0.449 533.300 1065.593 -0.541 2.83 
 TWEEIPALDKELK  1 3 0.291 524.615 1571.831 -0.487 2.82 
 HmNADTDYSIAEAAFNK M2(Oxidation) 0 3 0.591 638.616 1913.834 0.250 2.81 
 GVDEVTIVNILTNR  0 2 0.500 771.928 1542.848 -0.262 2.78 
 EYLEETRPTPR  0 2 0.264 695.846 1390.685 -8.182 2.77 
 VLDELTLAR  0 2 0.323 515.301 1029.594 0.151 2.76 
 GPWAWSNIDTSK  0 2 0.500 681.328 1361.648 -0.326 2.70 
 ISRMSDNTMRVIcDP C13(Carbamidomethyl) 2 2 0.004 897.911 1794.815 -8.104 2.69 
 NIAKVERcDmDGTNR C8(Carbamidomethyl); M10(Oxidation) 2 2  897.9111 1794.815 -3.985 2.68 
 GPDIIFWAHDR  0 3 0.5448 442.8911 1326.659 -0.051 2.68 
 GSPGVPSFAAGPPISEGK  0 2 0.5955 827.9254 1654.843 -0.048 2.67 
 VNYGVTVLPTFK  0 2 0.4887 669.377 1337.747 0.199 2.66 
 VEHPDKLEEK  1 2 0.3523 612.3173 1223.627 0.592 2.64 
 SGLLAEITPDK  0 2 0.4093 572.3173 1143.627 1.562 2.59 
 GYAQSGLLAEITPDK  0 2 0.4806 781.907 1562.807 0.478 2.58 
 QDDLSEQMASLEGLMK  0 2  897.9111 1794.815 -5.481 2.57 
 cAMESRRLGEAEETR C1(Carbamidomethyl) 2 2  897.9111 1794.815 -3.985 2.57 
 AmGImNSFVNDIFER M2(Oxidation); M5(Oxidation) 0 2 0.6094 888.4083 1775.809 0.144 2.56 
 SYELPDGQVITIGNER  0 2 0.5137 895.9495 1790.892 -0.082 2.55 
 DKPLGAVALK  0 3 0.2609 337.878 1011.62 -0.194 2.53 
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Table A-4 (continued) 
Protein Annotated Sequence Modifications 
No. of 
Missed 
Cleavages 
Charge Delta Score 
m/z  
[Da] 
MH+  
[Da] 
DeltaM  
[ppm] XCorr 
          
 EITYmHSEGILAGELKHGPL M5(Oxidation) 1 3 0.0553 737.7063 2211.104 -3.205 2.53 
 GHYTEGAELVDSVLDVVR  0 3 0.4427 653.6644 1958.979 -1.563 2.53 
 TWEEIPALDK  0 2 0.2 601.3088 1201.61 0.390 2.50 
 FGGYAQSGLLAEITPDK  0 2 0.6064 883.9517 1766.896 0.058 2.49 
 QGVASEHmKR M8(Oxidation) 1 2 0.0769 579.7911 1158.575 5.576 2.47 
 EELRKEEER  2 2 0.0776 609.3059 1217.605 -6.172 2.45 
 GYNGLAEVGK  0 2 0.3389 504.2614 1007.515 -0.145 2.39 
 LVIWINGDK  0 2 0.2343 529.3057 1057.604 -0.005 2.39 
 HmNADTDYSIAEAAF M2(Oxidation) 0 2 0.5966 836.3508 1671.694 -0.684 2.38 
 GYNGLAEVGKK  1 2 0.4202 568.3088 1135.61 -0.283 2.38 
 ESLTELRR  1 2 0.1345 502.2802 1003.553 0.125 2.38 
 VTVEHPDKLEEK  1 3 0.3136 475.2524 1423.743 -0.103 2.36 
 GVVDSEDIPLNLSR  0 2 0.4 757.3962 1513.785 -0.303 2.35 
 GVVDSEDLPLNISR  0 2 0.4 757.3962 1513.785 -0.303 2.35 
 TVEHPDKLEEK  1 3 0.3489 442.2299 1324.675 0.667 2.35 
 YGVTVLPTFK  0 2 0.5787 562.8212 1124.635 0.031 2.35 
 KFEKDTGIK  2 3 0.1702 355.8695 1065.594 -0.010 2.35 
 NHEEEMNALR  0 2 0.3419 621.7803 1242.553 0.187 2.34 
 NADTDYSIAEAAFNK  0 2 0.5983 815.3729 1629.739 -0.327 2.34 
 VAPEEHPVLLTEAPLNPK  0 3 0.0558 652.0265 1954.065 0.262 2.33 
 VTMQNLNDR  0 2 0.3391 545.769 1090.531 -0.258 2.33 
 TAVINAASGR  0 2 0.3734 480.2668 959.5264 -0.537 2.33 
 
qSTcPGNKEKFK 
N-Term(Gln->pyro-
Glu); 
C4(Carbamidomethyl) 
2 2 0.1466 703.8435 1406.68 4.592 2.32 
 mAGQRPHWLLIDSFSLPQT N-Term(Prot)(Acetyl) 0 3 0.0519 747.0486 2239.131 -0.730 2.31 
 TFLPSAVLQSMK  0 2 0.0519 661.3659 1321.725 4.615 2.31 
 TAAENEFVTLK  0 2 0.4069 611.8184 1222.63 -1.496 2.31 
 TVmGQLDASR M3(Oxidation) 0 2 0.1053 547.2674 1093.528 -2.854 2.28 
 NKHmNADTDYSIAEAAFNK M4(Oxidation) 1 2 0.5242 1078.489 2155.971 -0.145 2.27 
 SYEEELVKD  1 2 0.36 556.261 1111.515 -0.488 2.25 
 LASYLDK  0 2 0.0987 405.2239 809.4405 0.238 2.23 
 YEELQQTAGR  0 2 0.1493 597.7908 1194.574 -0.463 2.21 
 LLTDEGLEAVNK  0 2 0.2579 651.3501 1301.693 -1.385 2.21 
 IAATmENAQK M5(Oxidation) 0 2 0.4747 546.7712 1092.535 -0.278 2.17 
 VSISSSPGLAR  0 2 0.0888 537.3007 1073.594 -0.845 2.14 
 MPSQPSTGQYPPPTV  0 2 0.0657 793.8859 1586.764 7.898 2.13 
 IEKmVDLTQLME M4(Oxidation) 1 2 0.1557 733.363 1465.719 -6.143 2.12 
 LAADDFR  0 2 0.2275 404.2034 807.3995 -0.101 2.11 
 DLADELALVDVIEDK  0 2 0.4455 829.4294 1657.851 -0.956 2.11 
 SYEEELVK  0 2 0.3333 498.7485 996.4898 1.381 2.10 
 PLGAVALK  0 2 0.0571 384.7523 768.4974 -0.492 2.10 
 VAVSTLPR  0 2 0.0714 421.7582 842.5091 -0.340 2.10 
 DLLPNPPK  0 2 0.2762 447.2582 893.5091 0.054 2.10 
 QGVASEHmKR M8(Oxidation) 1 2 0.0478 579.7903 1158.573 4.311 2.09 
 QASLDTLSGYGTK  0 2 0.2057 670.8384 1340.67 0.274 2.09 
 TSTVASSVTMLSSSQTA  0 2 0.0817 829.3992 1657.791 -2.245 2.08 
 ALEEANTELEVK  0 2 0.2452 673.346 1345.685 0.140 2.08 
 EELRKEEER  2 2 0.1202 609.3062 1217.605 -5.771 2.08 
 RGDDGGFFPRTLEIH  2 2 0.0097 858.929 1716.851 3.140 2.07 
 GLLAEITPDK  0 2 0.1602 528.8004 1056.593 -0.114 2.06 
 LKSIEQSIEQEEGLN  1 2  858.929 1716.851 -8.388 2.05 
 VPMMNRLGMFDLHR  1 2  858.929 1716.851 0.671 2.04 
 DKPLGAVALK  0 2 0.2353 506.3134 1011.62 -0.090 2.04 
 qLDPEDMDEIE N-Term(Gln->pyro-Glu) 0 2 0.3202 658.7654 1316.524 2.851 2.03 
 YSIAEAAFNK  0 2 0.495 557.2818 1113.556 -1.058 2.02 
 QGVGEERAVGR  1 2 0.0697 579.2991 1157.591 -9.649 2.01 
 EQAIEIKEEGVELTE  1 2  858.929 1716.851 -1.845 2.00 
 DAEAWFNEK  0 2 0.1307 555.2485 1109.49 -0.019 1.99 
 VQDLGHGcIFLV C8(Carbamidomethyl) 0 2 0.0201 679.3517 1357.696 2.159 1.99 
 PFTWDAVR  0 2 0.2814 496.2535 991.4997 0.090 1.99 
 KRDEGIQESP  2 2  579.7903 1158.573 -1.320 1.99 
 LVAIVDVIDQNR  0 2 0.3518 677.8877 1354.768 -0.573 1.99 
 TRLEQEIATYR  1 2 0.2576 690.3677 1379.728 0.233 1.98 
 VNPEITTLQTML  0 2 0.1162 680.3663 1359.725 4.735 1.98 
 EGALEREHSR  1 2 0.1523 592.2955 1183.584 1.997 1.97 
 LLAEITPDK  0 2 0.269 500.2898 999.5723 0.164 1.97 
 SISISVAR  0 2 0.1066 416.7489 832.4905 2.129 1.97 
 DKPLGAVALK  0 2 0.1929 506.3127 1011.618 -1.599 1.97 
 LDIIDLTcLM C8(Carbamidomethyl) 0 2 0.132 603.8057 1206.604 -5.641 1.97 
 EELRKEEER  2 2 0.1071 609.3058 1217.604 -6.272 1.96 
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Table A-4 (continued) 
Protein Annotated Sequence Modifications 
No. of 
Missed 
Cleavages 
Charge Delta Score 
m/z  
[Da] 
MH+  
[Da] 
DeltaM  
[ppm] XCorr 
          
 EIIDLVLDR  0 2 0.2704 543.3139 1085.621 0.396 1.96 
 ELIDLVLDR  0 2 0.2704 543.3139 1085.621 0.396 1.96 
 
qSTcPGNKEKFK 
N-Term(Gln->pyro-
Glu); 
C4(Carbamidomethyl) 
2 2 0.1888 703.843 1406.679 3.811 1.96 
 SLADELALVDVLEDK  0 2 0.3949 815.4327 1629.858 -0.048 1.95 
 AQYEEIAQR  0 2 0.3077 554.2753 1107.543 0.314 1.95 
 QDVISNLEVNQV  0 2  679.3517 1357.696 0.317 1.95 
 RAIDNQYTPL  1 2 0.0619 595.8074 1190.607 -7.511 1.94 
 AASLMPSGAARTPQ  1 2  679.3517 1357.696 5.123 1.94 
 ESQDKPLWQ  0 2 0.0258 565.7821 1130.557 8.198 1.94 
 qTVDEALKD N-Term(Gln->pyro-Glu) 1 2 0.3679 501.2429 1001.478 -0.140 1.93 
 NIAATYIHMIPN  0 2  679.3517 1357.696 2.160 1.92 
 TWEEIPALDK  0 2 0.2042 601.3088 1201.61 0.390 1.91 
 EPVAAGSGIPQIK  0 2 0.1728 633.8503 1266.693 -9.428 1.91 
 VLDELTLTK  0 2 0.1474 516.3027 1031.598 -0.226 1.90 
 LSSSSPISNESTK  0 2 0.1947 668.8365 1336.666 5.053 1.90 
 EEIPALDK  0 2 0.3 457.7453 914.4833 0.355 1.90 
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Table A-5: Target peptide spectrum matches from LC-MS/MS of MBP-3B fusion 
proteins digested with chymotrypsin. 
Peptide fragment properties are indicated as follows: DeltaScore, relative difference 
between the match and the next best match XCorr scores; m/z, mass to charge ratio; MH+, 
protonated molecule ion size; DeltaM, Delta mass, deviation of the measured mass from 
the theoretical mass of peptide in parts per million (ppm); XCorr, cross correlation, a 
measure of the goodness of fit of experimental fragments to the theoretical spectra. 
Protein Annotated Sequence Modifications 
No. of 
Missed 
Cleavages 
Charge Delta Score 
m/z  
[Da] 
MH+  
[Da] 
DeltaM  
[ppm] XCorr 
MBP-c3B 
 KVKAKAPVVKEGPY  0 2 0.650 757.459 1513.91 0.811 5.23 
 DIKDVGVDNAGAKAGL  0 2 0.558 771.910 1542.81 -0.019 5.04 
 KVKAKAPVVKEGPY  0 3 0.669 505.308 1513.91 0.520 5.04 
 KVKAKAPVVKEGPY  0 3 0.551 505.308 1513.91 -0.327 4.41 
 SAGINAASPNKELAKEF  1 2 0.529 873.955 1746.90 0.033 4.37 
 SAGINAASPNKELAKEF  1 3 0.537 582.972 1746.90 0.130 4.28 
 KVKAKAPVVKEGPY  0 4 0.532 379.233 1513.91 0.551 4.10 
 KVKAKAPVVKEGPY  0 3 0.673 505.308 1513.91 -0.327 4.00 
 KVKAKAPVVKEGPY  0 3 0.732 505.308 1513.91 -0.629 3.65 
 LTDEGLEAVNKDKPL  2 2 0.388 821.438 1641.87 -0.273 3.51 
 KVRAKLPQQEGPY  1 2 0.507 757.428 1513.85 -0.147 3.47 
 KVKAKNLIVTE  1 3 0.564 414.931 1242.78 -0.818 3.46 
 KVKAKAPVVKEGPY  0 4 0.580 379.233 1513.91 0.148 3.45 
 DIKDVGVDNAGAKAGL  0 3 0.299 514.942 1542.81 -0.107 3.38 
 KVKAKAPVVKEGPY  0 3 0.694 505.308 1513.91 -0.508 3.33 
 NGLAEVGKKF  1 2 0.523 531.801 1062.59 0.406 3.33 
 KKTDPSVMKDREmNY M13(Oxidation) 0 2 0.103 929.450 1857.89 4.996 3.29 
 AGPLERQKPL  1 3 0.524 370.221 1108.65 1.453 3.28 
 KVRAKLPQQEGPY  1 3 0.460 505.288 1513.85 0.771 3.22 
 DIKDVGVDNAGAKAGLTF  1 2 0.415 895.967 1790.93 -0.632 3.18 
 EGPVKKPVAL  0 2 0.470 519.321 1037.63 -1.465 3.17 
 KVKAKNLIVTE  1 3 0.547 414.931 1242.78 -0.008 3.07 
 KVKAKNLIVTE  1 2 0.615 621.893 1242.78 0.003 2.99 
 AGPLERQKPL  1 2 0.432 554.828 1108.65 0.722 2.92 
 EAVNKDKPLGAVAL  1 2 0.319 712.909 1424.81 0.144 2.85 
 KVKAKAPVVKEGPY  0 3 0.695 505.308 1513.91 0.036 2.82 
 QDGYILVGVENL  2 2 0.395 660.344 1319.68 -1.871 2.76 
 KVKAKAPVVKEGPY  0 4 0.611 379.233 1513.91 0.148 2.75 
 LDVGSIPGRFSDNGF  2 3 0.233 527.591 1580.76 -7.869 2.66 
 mKIEEGKL M1(Oxidation) 0 2 0.441 482.262 963.52 -0.901 2.63 
 KQGHSVVVSSLNIF  1 3 0.252 505.616 1514.83 1.068 2.62 
 DIKDVGVDNAGAKAGLTF  1 3 0.341 597.648 1790.93 0.042 2.61 
 KVKAKAPVVKEGPY  0 3 0.625 505.308 1513.91 -0.206 2.61 
 NKGETAmTINGPW M7(Oxidation) 0 2 0.562 717.837 1434.67 -0.376 2.58 
 SAGINAASPNKEL  0 2 0.539 636.333 1271.66 0.079 2.58 
 DIKDVGVDNAGAKAGL  0 2 0.375 771.909 1542.81 -0.415 2.56 
 DPTQTSFLKmADSGGQPQL M10(Oxidation) 2 2 0.098 1018.974 2036.94 -8.904 2.54 
 
tISVGGcAVQmYVFTAL 
N-Term(Prot)(Acetyl) 
C7(Carbamidomethyl) 
M11(Oxidation) 
2 3 0.261 625.645 1874.92 9.603 2.53 
 SNIDTSKVNY  0 2 0.420 570.779 1140.55 -1.601 2.50 
 EGLKSQAEmDPVL M9(Oxidation) 1 2 0.157 716.850 1432.69 -4.376 2.49 
 KVKAKNL  0 2 0.407 400.771 800.54 -0.209 2.46 
 NKDLLPNPPKTW  2 3 0.586 474.930 1422.77 0.118 2.44 
 KHKGGGRGSGKGELF  1 2 0.107 757.920 1514.83 9.681 2.44 
 AKELEKF  1 2 0.017 432.745 864.48 -0.087 2.42 
 EGPVKKPVAL  0 2 0.504 519.321 1037.64 -0.171 2.42 
 EKALSVAF  1 2  432.745 864.48 -0.087 2.38 
 NLAAKEVDPQVNWAAL  2 2 0.000 869.958 1738.91 -2.516 2.37 
 KLQKAISVLEmENGY M11(Oxidation) 2 2  869.958 1738.91 2.005 2.37 
 QRGENLTAENQPRLL  2 2  869.958 1738.91 -6.663 2.35 
 AEITPDKAF  0 2 0.407 496.259 991.51 0.390 2.31 
 
mNPmVmMMVLPL 
M1(Oxidation) 
M4(Oxidation) 
M6(Oxidation) 
1 3 0.268 485.561 1454.67 6.966 2.31 
 AELKEKF  1 2  432.745 864.48 -0.087 2.31 
 RREERNWEQKL  1 2 0.088 772.402 1543.80 -8.167 2.28 
 NGKLIAYPIAVEAL  2 2 0.603 736.430 1471.85 0.306 2.24 
 VPATNSPELRW  1 2 0.527 635.333 1269.66 -0.284 2.22 
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Table A-5 (continued) 
Protein Annotated Sequence Modifications 
No. of 
Missed 
Cleavages 
Charge Delta Score 
m/z  
[Da] 
MH+  
[Da] 
DeltaM  
[ppm] XCorr 
          
 EEEmKGVADITGIPL M4(Oxidation) 0 2 0.184 809.411 1617.82 7.161 2.17 
 EQPGGEALVEYL  2 2 0.019 652.820 1304.63 -3.169 2.16 
 VPTPVQRGAL  0 2 0.111 519.309 1037.61 0.070 2.16 
 EAGADGTIVNNVL  0 2 0.223 636.826 1272.64 0.649 2.15 
 VRPLEEGmL M8(Oxidation) 1 2 0.257 530.277 1059.55 -4.001 2.14 
 GVVLAPDGSTVAVEPL  1 2 0.132 762.412 1523.82 -9.506 2.13 
 KTQHSSAVcTVS C9(Carbamidomethyl) 0 2  652.820 1304.63 4.915 2.12 
 KIAKVF  0 2 0.166 353.237 705.47 -0.038 2.11 
 MGHRTEGLEKF  1 2  652.820 1304.63 -6.778 2.11 
 QTKHSSNFDQL  1 2  652.820 1304.63 7.499 2.09 
 KIAKVF  0 2 0.192 353.237 705.47 0.395 2.08 
 KKGDVAAAHTcF C11(Carbamidomethyl) 0 2  652.820 1304.63 -6.778 2.06 
 QVPLADSmKL M8(Oxidation) 1 2 0.152 559.305 1117.60 9.428 2.04 
 EGPVKKPVAL  0 2 0.542 519.321 1037.63 -0.877 2.03 
 RPmGLPTASSINPAPL M3(Oxidation) 1 2 0.129 819.434 1637.86 -4.761 2.01 
 KDARDTSKDSLYW  2 2 0.289 792.888 1584.77 2.339 2.01 
 LVDLIKNKHmNADTDY M10(Oxidation) 2 2 0.392 953.472 1905.94 -0.161 1.99 
 GPASNLPQSFL  2 2 0.424 565.796 1130.58 0.416 1.96 
 cTVISQQIQY C1(Carbamidomethyl) 0 2 0.246 620.309 1239.61 5.521 1.95 
 LAEITPDKAF  1 2 0.433 552.800 1104.59 -0.109 1.94 
MBP-c3B-cSAT 
 KVKAKAPVVKEGPY  0 2 0.707 757.459 1513.91 0.166 5.36 
 KVKAKAPVVKEGPY  0 3 0.629 505.308 1513.91 0.157 5.28 
 DIKDVGVDNAGAKAGL  0 2 0.564 771.910 1542.812 0.060 5.11 
 KLKAKLPQAEGPY  2 2 0.521 721.922 1442.836 -0.071 5.07 
 KVKAKAPVVKEGPY  0 3 0.625 505.308 1513.911 0.459 5.01 
 KVKAKAPVVKEGPY  0 3 0.678 505.308 1513.91 -0.146 4.38 
 KVKAKAPVVKEGPY  0 4 0.532 379.233 1513.912 1.277 4.38 
 KAKLPQAEGPY  1 2 0.527 601.333 1201.658 0.787 4.38 
 KAKLPVAKEGPY  1 2 0.499 650.885 1300.763 0.679 4.19 
 KLKAKLPVAKEGPY  2 3 0.668 514.652 1541.941 -0.354 4.07 
 KVKAKAPVVKEGPY  0 2 0.612 757.458 1513.908 -1.044 4.02 
 KLKAKLPVAKEGPY  2 4 0.668 386.241 1541.942 0.113 4.00 
 KVRAKLPQQEGPY  1 2 0.479 757.428 1513.848 -0.067 3.95 
 KVKAKAPVVKEGPY  0 4 0.602 379.233 1513.91 0.067 3.94 
 SAGINAASPNKELAKEF  1 2 0.508 873.955 1746.902 0.173 3.86 
 KAKLPVAKEGPY  1 3 0.561 434.259 1300.764 0.927 3.83 
 EGPVKKPVAL  0 2 0.455 519.321 1037.635 0.064 3.80 
 KLKAKLPQAEGPY  2 3 0.395 481.617 1442.837 0.237 3.70 
 KVRAKLPQQEGPY  1 2 0.549 757.428 1513.849 0.578 3.66 
 AGPLEKQQPL  1 2 0.283 540.806 1080.605 0.338 3.64 
 KAKLPVAKEGPY  1 3 0.587 434.259 1300.762 -0.340 3.44 
 KVKAKNLIVTEGPY  1 3 0.592 520.643 1559.915 -0.230 3.43 
 EAVNKDKPLGAVAL  1 2 0.383 712.908 1424.809 -0.884 3.42 
 KAKLPVAKEGPY  1 3 0.565 434.259 1300.762 -0.411 3.38 
 LTDEGLEAVNKDKPL  2 2 0.507 821.438 1641.868 -0.942 3.37 
 AGPLEKQQPL  1 2 0.257 540.806 1080.604 -0.566 3.35 
 KVKAKAPIVTE  0 2 0.600 592.374 1183.741 -0.200 3.35 
 KLKAKLPVAKEGPY  2 4 0.743 386.241 1541.941 -0.046 3.31 
 KLKAKLPVAKEGPY  2 3 0.603 514.652 1541.942 0.240 3.30 
 SNIDTSKVNY  0 2 0.429 570.780 1140.552 -0.852 3.29 
 NGLAEVGKKF  1 2 0.532 531.801 1062.595 0.291 3.29 
 AGPLERQQPL  1 2 0.473 554.809 1108.611 -0.371 3.28 
 KVRAKLPQQEGPY  1 3 0.412 505.288 1513.85 1.255 3.28 
 KLKAKLPVAKEGPY  2 2 0.659 771.474 1541.941 -0.503 3.23 
 KVKAKAPVVKEGPY  0 3 0.654 505.308 1513.91 -0.146 3.18 
 KAKLPVAKEGPY  1 3 0.601 434.259 1300.762 -0.059 3.06 
 KLKAKLPVAKEGPY  2 2 0.712 771.474 1541.94 -0.820 3.05 
 DIKDVGVDNAGAKAGL  0 3 0.386 514.942 1542.812 0.011 3.03 
 AGPLERQQPL  1 2 0.427 554.809 1108.61 -0.592 2.95 
 KLKAKLPQAEGPY  2 2 0.500 721.922 1442.836 -0.409 2.90 
 AGPLEKQQPL  1 2 0.398 540.806 1080.604 -0.340 2.89 
 mKIEEGKL M1(Oxidation) 0 2 0.408 482.262 963.5177 -0.267 2.82 
 KVKAKAPIVTE  0 3 0.380 395.252 1183.741 0.279 2.79 
 KAKLPVAKEGPY  1 3 0.541 434.259 1300.762 -0.129 2.79 
 KVKAKAPIVTE  0 3 0.708 395.252 1183.742 1.362 2.74 
 KVKAKAPVVKEGPY  0 3 0.632 505.308 1513.908 -1.174 2.72 
 KVKAKAPVVKEGPY  0 3 0.683 505.308 1513.909 -0.871 2.68 
 NKGETAmTINGPW M7(Oxidation) 0 2 0.577 717.838 1434.668 -0.036 2.67 
 KVKAKAPIVTE  0 3 0.338 395.252 1183.741 0.047 2.66 
 KVKAKAPVVKEGPY  0 3 0.717 505.308 1513.91 -0.025 2.65 
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Table A-5 (continued) 
Protein Annotated Sequence Modifications 
No. of 
Missed 
Cleavages 
Charge Delta Score 
m/z  
[Da] 
MH+  
[Da] 
DeltaM  
[ppm] XCorr 
          
 KLKAKLPQAEGPY  2 3 0.345 481.617 1442.837 0.110 2.64 
 KVRAKLPQQEGPY  1 3 0.386 505.288 1513.849 0.287 2.62 
 EGPVKKPVAL  0 2 0.441 519.321 1037.635 -0.759 2.61 
 QLLNSAPEPL  2 2 0.161 541.299 1081.591 1.573 2.61 
 SAGINAASPNKEL  0 2 0.525 636.333 1271.659 0.079 2.61 
 KLKAKLPVAKEGPY  2 3 0.521 514.652 1541.94 -0.591 2.59 
 KAKLPQAEGPY  1 3 0.372 401.224 1201.659 0.903 2.58 
 KIAKVF  0 2 0.164 353.237 705.4662 0.568 2.56 
 SAGINAASPNKELAKEF  1 3 0.410 582.972 1746.902 -0.079 2.51 
 EEEmKGVADITGIPL M4(Oxidation) 0 2 0.248 809.411 1617.815 6.557 2.34 
 RREERNWEQKL  1 2 0.073 772.402 1543.797 -7.771 2.34 
 DIKDVGVDNAGAKAGL  0 2 0.502 771.909 1542.811 -0.890 2.31 
 KVKAKAPIVTE  0 3 0.370 395.252 1183.74 -0.417 2.30 
 AGPLERQKPL  1 2 0.290 554.828 1108.648 0.392 2.28 
 AGPLEKQQPL  1 2 0.456 540.806 1080.604 -0.679 2.28 
 KLKAKLPQAEGPY  2 2 0.531 721.921 1442.835 -1.171 2.28 
 KAKLPQAEGPY  1 2 0.606 601.332 1201.656 -1.041 2.26 
 AKELEKF  1 2 0.122 432.745 864.4828 0.336 2.22 
 AGPLEKQQPL  1 2 0.518 540.806 1080.604 -0.340 2.18 
 PDNQVKLLKEIF  2 2 0.213 722.414 1443.821 0.093 2.11 
 cTVISQQIQY C1(Carbamidomethyl) 0 2 0.214 620.309 1239.61 5.127 2.10 
 KIAKVF  0 2 0.213 353.237 705.466 0.308 2.07 
 AQGKPQQGFL  1 2 0.029 537.286 1073.564 -9.249 2.07 
 QMPPVSLQPL  1 2 0.215 555.301 1109.595 -6.931 2.05 
 LAEITPDKAF  1 2 0.302 552.800 1104.593 -0.440 2.02 
 mGTVLSLSPSY N-Term(Prot)(Acetyl) 2 2 0.383 598.801 1196.595 6.806 2.01 
 qNLAKASPVY N-Term(Gln->pyro-Glu) 1 2  537.286 1073.564 1.215 2.01 
 EAGADGTIVNNVL  0 2 0.055 636.825 1272.643 -0.023 2.00 
 SREAPEELKQQPL  1 2 0.200 762.904 1524.801 -0.376 2.00 
 AGPLERQQPL  1 2 0.523 554.809 1108.61 -0.482 1.99 
 DDARIQILQSF  1 2 0.106 653.338 1305.668 -8.793 1.99 
 GPASNLPQSFL  2 2 0.396 565.796 1130.585 0.416 1.97 
 RmFDPSGKGVVNKDEFKQL M2(Oxidation) 2 2 0.097 1106.056 2211.104 -8.417 1.95 
 AKEFLENY  2 2 0.197 507.251 1013.494 -0.015 1.93 
 QIPVKAL  0 2 0.197 384.753 768.4981 0.382 1.93 
 GSVAGAVGATAVY  0 2 0.016 561.793 1122.579 -0.270 1.93 
 KDARDTSKDSLYW  2 2 0.063 792.888 1584.768 1.877 1.92 
 AEKVKNAESF  0 2  561.793 1122.579 -0.270 1.90 
 IQSFLEDY  2 2 0.321 507.742 1014.478 -0.203 1.90 
 AEITPDKAF  0 2 0.416 496.259 991.5101 0.636 1.90 
MBP-cSAT 
 DIKDVGVDNAGAKAGL  0 2 0.551 771.910 1542.812 -0.257 5.57 
 SAGINAASPNKELAKEF  1 3 0.488 582.972 1746.902 -0.184 5.47 
 KLKAKLPQAEGPY  2 2 0.506 721.922 1442.836 -0.494 5.26 
 SAGINAASPNKELAKEF  1 2 0.576 873.955 1746.902 -0.037 5.00 
 KAKLPVAKEGPY  1 3 0.514 434.258 1300.761 -1.115 4.24 
 KVKAKAPIVTE  0 2 0.601 592.374 1183.742 0.625 4.14 
 KAKLPVAKEGPY  1 2 0.510 650.885 1300.762 -0.166 4.10 
 KLKAKLPVAKEGPY  2 2 0.694 771.474 1541.941 -0.266 3.69 
 KAKLPVAKEGPY  1 3 0.574 434.259 1300.762 -0.059 3.66 
 KLKAKLPVAKEGPY  2 4 0.753 386.241 1541.941 -0.046 3.60 
 AGPLEKQQPL  1 2 0.264 540.806 1080.604 -0.905 3.56 
 DIKDVGVDNAGAKAGL  0 3 0.385 514.942 1542.812 0.011 3.48 
 KLKAKLPVAKEGPY  2 3 0.645 514.652 1541.941 -0.235 3.46 
 KLKAKLPVAKEGPY  2 4 0.736 386.241 1541.941 0.034 3.41 
 EGPVKKPVAL  0 2 0.471 519.321 1037.635 -0.406 3.40 
 NGLAEVGKKF  1 2 0.513 531.801 1062.595 0.406 3.39 
 KAKLPQAEGPY  1 2 0.569 601.333 1201.658 0.279 3.32 
 SNIDTSKVNY  0 2 0.455 570.781 1140.554 0.539 3.32 
 NKGETAmTINGPW M7(Oxidation) 0 2 0.547 717.838 1434.668 -0.036 3.22 
 EAVNKDKPLGAVAL  1 2 0.318 712.909 1424.811 0.059 3.21 
 AGPLERQQPL  1 2 0.422 554.809 1108.611 0.069 3.08 
 AGPLEKQQPL  1 2 0.344 540.806 1080.604 -0.340 3.08 
 KAKLPVAKEGPY  1 3 0.524 434.259 1300.762 0.012 3.07 
 KLKAKLPQAEGPY  2 3 0.430 481.617 1442.837 0.174 2.98 
 LTDEGLEAVNKDKPL  2 2 0.406 821.438 1641.868 -0.719 2.98 
 KVKAKAPIVTE  0 3 0.512 395.252 1183.742 0.665 2.97 
 KLKAKLPVAKEGPY  2 3 0.549 514.652 1541.941 -0.116 2.97 
 VSAGIQTSFRTGNPTGTY  1 2 0.266 928.958 1856.909 -2.417 2.78 
 mKIEEGKL M1(Oxidation) 0 2 0.457 482.262 963.5173 -0.647 2.78 
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Table A-5 (continued) 
Protein Annotated Sequence Modifications 
No. of 
Missed 
Cleavages 
Charge Delta Score 
m/z  
[Da] 
MH+  
[Da] 
DeltaM  
[ppm] XCorr 
          
 SAGINAASPNKEL  0 2 0.469 636.333 1271.659 0.367 2.77 
 SNLSDSAGNAVLEAL  2 3 0.181 487.583 1460.735 8.352 2.66 
 KAKLPQAEGPY  1 3 0.254 401.224 1201.658 0.598 2.56 
 KVKAKAPIVTE  0 3 0.402 395.252 1183.741 0.279 2.54 
 PDNQVKLLKEIF  2 3 0.398 481.946 1443.823 1.437 2.51 
 QDGYILVGVENL  2 2 0.171 660.344 1319.681 -2.704 2.46 
 AGPLERQQPL  1 2 0.388 554.809 1108.611 0.289 2.45 
 RREERNWEQKL  1 2 0.120 772.402 1543.797 -7.929 2.42 
 LAEITPDKAF  1 2 0.463 552.800 1104.594 0.002 2.42 
 AEITPDKAF  0 2 0.382 496.258 991.5095 0.020 2.38 
 QMPPVSLQPL  1 2 0.251 555.301 1109.595 -6.270 2.35 
 DSEELPLRmL M9(Oxidation) 2 2 0.186 609.802 1218.597 -5.529 2.31 
 EEEmKGVADITGIPL M4(Oxidation) 0 2 0.183 809.411 1617.815 6.859 2.30 
 RmFDPSGKGVVNKDEFKQL M2(Oxidation) 2 2 0.276 1106.056 2211.104 -8.307 2.25 
 KYLNSGAGGL  2 2 0.142 490.260 979.5132 -7.709 2.25 
 SDVITDTMQEL  0 2 0.202 626.298 1251.588 8.785 2.23 
 KIAKVF  0 2 0.210 353.237 705.4662 0.568 2.19 
 GGNELSEPTATLL  2 2 0.073 651.339 1301.671 9.406 2.19 
 TDEGLEAVNKDKPL  1 2 0.491 764.896 1528.785 -0.001 2.16 
 GLDFPNVPEGL  2 2 0.061 579.299 1157.591 6.390 2.15 
 AKELEKF  1 2 0.038 432.745 864.4828 0.266 2.13 
 GVVLAPDGSTVAVEPL  1 2 0.169 762.412 1523.817 -9.746 2.13 
 KIAKVF  0 2 0.223 353.236 705.4655 -0.384 2.11 
 LQIDNARL  1 2 0.163 471.772 942.5373 0.608 2.09 
 AELKEKF  1 2  432.745 864.4828 0.266 2.05 
 VENSVGSIRY  0 2 0.1225 562.2855 1123.564 -9.296 2.04 
 mPEGAGGLSLSKPSPRL N-Term(Prot)(Acetyl) 2 2 0.1034 869.9575 1738.908 -4.595 2.03 
 mGTVLSLSPSY N-Term(Prot)(Acetyl) 2 2 0.401 598.8009 1196.595 6.500 2.02 
 NGKLIAYPIAVEAL  2 2 0.4545 736.4294 1471.851 -0.274 1.98 
 AHDRFGGY  1 2 0.3112 461.7122 922.4172 0.619 1.96 
 EEIPALDKEL  1 2 0.4359 578.8085 1156.61 0.062 1.95 
 QIPVKAL  0 2 0.1959 384.7525 768.4978 -0.015 1.94 
 QLLNSAPEPL  2 2 0.0829 541.2981 1081.589 0.106 1.93 
 cTVISQQIQY C1(Carbamidomethyl) 0 2 0.2656 620.3085 1239.61 4.832 1.92 
 QKAIIEL  0 2 0.0421 407.7554 814.5035 0.302 1.90 
MBP 
 SAGINAASPNKELAKEF  1 2 0.515 873.954 1746.901 -0.526 5.83 
 DIKDVGVDNAGAKAGLTF  1 2 0.550 895.968 1790.929 0.118 5.29 
 LTDEGLEAVNKDKPL  2 2 0.526 821.438 1641.868 -0.793 4.92 
 DIKDVGVDNAGAKAGL  0 2 0.567 771.909 1542.812 -0.336 4.90 
 AQSGLLAEITPDKAF  2 2 0.594 780.917 1560.827 0.176 4.28 
 SAGINAASPNKELAKEF  1 3 0.521 582.972 1746.902 -0.079 4.07 
 NKDLLPNPPKTW  2 2 0.585 711.890 1422.773 -0.688 3.88 
 VGVLSAGINAASPNKEL  1 2 0.652 820.454 1639.901 -0.488 3.85 
 EAVNKDKPLGAVAL  1 2 0.392 712.909 1424.81 -0.370 3.83 
 TDEGLEAVNKDKPL  1 2 0.577 764.896 1528.785 -0.321 3.45 
 SAGINAASPNKEL  0 2 0.431 636.334 1271.66 0.750 3.32 
 DIKDVGVDNAGAKAGL  0 3 0.310 514.942 1542.811 -0.463 3.32 
 AHDRFGGY  1 2 0.414 461.712 922.4173 0.752 3.26 
 NGLAEVGKKF  1 2 0.526 531.801 1062.595 0.521 3.25 
 NGLAEVGKKF  1 2 0.554 531.801 1062.594 -0.168 3.16 
 TDEGLEAVNKDKPL  1 3 0.484 510.266 1528.785 -0.469 3.10 
 QRRSTEIVAIDALHF  1 3 0.243 585.985 1755.94 -5.698 3.09 
 QRRSTEIVAIDALHF  1 2 0.129 878.471 1755.935 -8.506 3.02 
 LTDEGLEAVNKDKPL  2 3 0.087 547.961 1641.869 -0.355 2.99 
 mKIEEGKLVIW M1(Oxidation) 1 2 0.505 681.378 1361.75 -0.129 2.97 
 NKGETAmTINGPW M7(Oxidation) 0 2 0.538 717.838 1434.668 -0.206 2.92 
 mKIEEGKLVIW M1(Oxidation) 1 3 0.544 454.588 1361.75 -0.049 2.85 
 qRRSTEIVAIDALHF N-Terminal (Gln->pyro-Glu) 1 3 0.304 580.308 1738.91 -7.896 2.80 
 DIKDVGVDNAGAKAGLTF  1 3 0.257 597.647 1790.927 -0.674 2.76 
 NGKLIAYPIAVEAL  2 2 0.574 736.430 1471.852 -0.108 2.70 
 KGQPSKPF  0 2 0.544 444.750 888.4936 -0.157 2.70 
 DIKDVGVDNAGAKAGL  0 2 0.340 771.909 1542.812 -0.415 2.62 
 LVDLIKNKHmNADTDY M10(Oxidation) 2 2 0.425 953.472 1905.937 -0.353 2.61 
 INGDKGYNGL  1 2 0.058 525.765 1050.522 0.427 2.58 
 LDVGSIPGRFSDNGF  2 3 0.118 527.591 1580.758 -7.753 2.55 
 
mNPmVmMMVLPL 
M1(Oxidation); 
M4(Oxidation); 
M6(Oxidation) 
1 3 0.369 485.561 1454.669 7.028 2.55 
 QQEGIANITALKDQLL  2 2 0.008 877.980 1754.953 -6.562 2.53 
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Table A-5 (continued) 
Protein Annotated Sequence Modifications 
No. of 
Missed 
Cleavages 
Charge Delta Score 
m/z  
[Da] 
MH+  
[Da] 
DeltaM  
[ppm] XCorr 
          
 KIAKVF  0 2 0.146 353.237 705.4662 0.654 2.53 
 MPRGGLETVLQTSGPVL  2 2  877.980 1754.953 3.557 2.51 
 KKLmNQIHDHLEmTEL M4(Oxidation); M13(Oxidation) 2 3 0.142 671.338 2011.999 2.656 2.47 
 KATLDKQEVPDTTPVL  1 3 0.020 585.655 1754.952 -1.038 2.47 
 RVNGEKILEDF  1 2 0.237 660.351 1319.695 0.069 2.45 
 KVINKDQWcNVLEF C9(Carbamidomethyl) 2 3 0.012 598.304 1792.899 -3.610 2.45 
 KATLDKQEVPDTTPVL  1 2  877.980 1754.953 -0.161 2.43 
 GKQGFQcQEL C7(Carbamidomethyl) 1 3 0.046 398.857 1194.556 -0.707 2.42 
 KEQQEVAAAVIQRcY C14(Carbamidomethyl) 0 3  598.304 1792.899 -1.366 2.42 
 MPRGGLETVLQTSGPVL  2 3  585.655 1754.952 2.680 2.42 
 mKIEEGKL M1(Oxidation) 0 2 0.402 482.262 963.5174 -0.521 2.39 
 AEITPDKAF  0 2 0.395 496.258 991.5095 0.020 2.38 
 SNIDTSKVNY  0 2 0.432 570.781 1140.554 0.860 2.36 
 NKDLLPNPPKTW  2 3 0.496 474.930 1422.775 0.439 2.36 
 PDDSKDTWKKRGNVDY  1 3 0.346 641.975 1923.91 -4.950 2.34 
 LERRASSGARVEDLPL  2 3 0.254 590.328 1768.97 2.130 2.32 
 qPEPQKNEEL N-Terminal (Gln->pyro-Glu) 0 3  398.857 1194.556 -6.169 2.31 
 RPmGLPTASSINPAPL M3(Oxidation) 1 2 0.162 819.434 1637.861 -4.463 2.28 
 RRTQSLPSGGPGQNGLL  2 2 0.036 869.467 1737.927 -4.696 2.24 
 cTVISQQIQY C1(Carbamidomethyl) 0 2 0.081 620.309 1239.61 5.127 2.22 
 KKNGAGLMVNSRFGF  2 2 0.131 813.428 1625.849 -5.617 2.21 
 KIAKVF  0 2 0.177 353.237 705.4657 -0.038 2.21 
 RmFDPSGKGVVNKDEFKQL M2(Oxidation) 2 2 0.158 1106.056 2211.104 -8.307 2.21 
 KYLNSGAGGL  2 2 0.124 490.260 979.5133 -7.584 2.18 
 RREERNWEQKL  1 2 0.051 772.402 1543.797 -7.613 2.18 
 LRSDKANSVDSLPEL  2 2 0.000 822.433 1643.859 -0.433 2.17 
 TSRAPSPSGLMSPSRL  1 2  822.433 1643.859 3.537 2.17 
 SVNHTSGKVAAGLQGAAGL  1 2  869.467 1737.927 1.768 2.16 
 PcAWVVESSGILNVL C2(Carbamidomethyl) 2 2  822.433 1643.859 7.923 2.15 
 DIKDVGVDNAGAKAGLTF  1 2 0.330 895.967 1790.928 -0.428 2.12 
 EEIPALDKEL  1 2 0.431 578.809 1156.611 1.117 2.11 
 TTQDDLDKAVELL  2 2 0.005 730.871 1460.735 -8.962 2.11 
 QDGYILVGVENL  2 2 0.124 660.344 1319.681 -2.611 2.10 
 cDLWAVGITAIEL C1(Carbamidomethyl) 2 2  730.871 1460.735 -7.249 2.10 
 cDIWAVGITAIEL C1(Carbamidomethyl) 1 2  730.871 1460.735 -7.249 2.10 
 LDKDEKDLRSTPNL  2 2  822.433 1643.859 -0.433 2.08 
 QLREGGSKETAAVF  1 2 0.183 746.886 1492.764 -7.683 2.08 
 LAEITPDKAF  1 2 0.406 552.800 1104.594 0.112 2.07 
 mGTVLSLSPSY N-Terminal (Prot)(Acetyl) 2 2 0.314 598.801 1196.594 5.888 2.07 
 KAENSAAAQTNL  0 2 0.015 609.309 1217.611 -0.458 2.06 
 GGNELSEPTATLL  2 2 0.034 651.339 1301.67 9.218 2.05 
 VNNVSSPLPGEGKSISY  1 2 0.049 874.447 1747.886 -0.040 2.05 
 EEEmKGVADITGIPL M4(Oxidation) 0 2 0.153 809.411 1617.815 7.085 2.03 
 SDEDKPLFGPL  2 2  609.309 1217.611 5.464 2.03 
 EIDQTEDFRPW  1 2 0.050 718.330 1435.652 2.307 2.01 
 EVDEMKETKL  0 2 0.185 611.303 1221.599 -3.043 2.00 
 VLDELKRGDNF  2 2 0.060 653.338 1305.669 -8.325 1.99 
 KGTNASAPDQLSL  1 2  651.339 1301.67 0.588 1.98 
 SLGVVKEF  1 2 0.136 439.753 878.4984 0.233 1.98 
 GVVLAPDGSTVAVEPLL  2 2 0.306 818.954 1636.901 -8.973 1.96 
 EHRPSEMVPVNRSPL  0 2  874.447 1747.886 -2.734 1.95 
 AKEFLENY  2 2 0.185 507.251 1013.494 0.045 1.95 
 LAEITPDKAF  1 2 0.469 552.800 1104.593 -0.551 1.94 
 VFRAcmLPML C5(Carbamidomethyl) M6(Oxidation) 2 2 0.042 627.317 1253.627 5.428 1.93 
 AGTDGETTTQGLDGL  1 2  718.330 1435.652 -1.783 1.91 
  
Appendix A 
205 
Table A-6: Bovine serum samples used to evaluate the c3B C-ELISA’s diagnostic 
performance. 
Serum sample properties are described as follows: (+) positive or (-) negative result using 
cut-off of >35% in the AAHL C-ELISA or >47% in the c3B C-ELISA; PI, percent 
inhibition; PT, proficiency test; FMDV, foot-and-mouth disease virus; BTV, Bluetongue 
virus; VSV; Vesicular stomatitis virus; DPI, days post infection; DPP, days post-partum. 
Diagnoses of the c3B C-ELISA that oppose the AAHL C-ELISA result are highlight.  
No. Sample details Species Infection serotype 
Vaccination 
serotype 
Percent 
inhibition score 
Result at cut-
off  
AAHL c3B  AAHL c3B  
1 Winnipeg, Canada, experimental infection, C-145, 28 DPI bovine Asia1 Shamir  NONE 70 79 + + 
2 Australian origin field serum bovine NONE NONE 12 25 - - 
3 Winnipeg, Canada, experimental infection, C-146, 28 DPI bovine C1 Noville  NONE 77 71 + + 
4 Australian origin field serum bovine NONE NONE 0 31 - - 
5 Australian origin field serum bovine NONE NONE 22 54 - + 
6 Australian origin field serum bovine NONE NONE 11 37 - - 
7 PT Panel 3 FMD - sample 539 (2013) bovine NONE Asia1 9 38 - - 
8 Australian origin field serum bovine NONE NONE 26 29 - - 
9 Winnipeg, Canada, experimental infection, C-424, 28 DPI bovine SAT3 Zim 4/81  NONE 73 77 + + 
10 PT Panel 3 FMD - sample 368 (2012) bovine NONE O 30 46 - - 
11 PT Panel 3 FMD - sample 265 (2013) bovine NONE SAT2 24 36 - - 
12 Australian origin field serum bovine NONE NONE 17 32 - - 
13 PT Panel 3 FMD - sample 554 (2013) bovine 
O, A, Asia1, 
SAT1, SAT2, 
SAT3 
Undetermined 69 76 + + 
14 PT Panel 3 FMD - sample 436 (2012) bovine NONE NONE 15 26 - - 
15 Winnipeg, Canada, experimental infection, C-237, 28 DPI bovine SAT2 Sau 1/2000  NONE 71 81 + + 
16 Australian origin field serum bovine NONE NONE 16 37 - - 
17 PT Panel 3 FMD - sample 333 (2013) bovine NONE NONE 9 30 - - 
18 PT Panel 3 FMD - sample 96 (2013) bovine NONE NONE 11 33 - - 
19 Winnipeg, Canada, experimental infection, C-137, 28 DPI bovine SAT1 Bot 1/68  NONE 63 72 + + 
20 Australian origin field serum bovine NONE NONE -5 44 - - 
21 Australian origin field serum bovine NONE NONE 4 32 - - 
22 Australian origin field serum bovine NONE NONE -6 24 - - 
23 Australian origin field serum bovine NONE NONE -1 45 - - 
24 Australian origin field serum bovine NONE NONE 17 32 - - 
25 PT Panel 3 FMD - sample 195 (2012) bovine NONE Asia1 17 28 - - 
26 PT Panel 3 FMD - sample 25 (2013) bovine NONE SAT2 -1 28 - - 
27 Australian origin field serum bovine NONE NONE 2 35 - - 
28 Australian origin field serum bovine NONE NONE 3 37 - - 
29 PT Panel 3 FMD - sample 116 (2013) bovine NONE O 11 36 - - 
30 Australian origin field serum bovine NONE NONE -2 43 - - 
31 Australian origin field serum bovine NONE NONE 13 38 - - 
32 Winnipeg, Canada, experimental infection, C-138, 28 DPI bovine O 1 UKG 11/2001  NONE 61 83 + + 
33 Winnipeg, Canada, experimental infection, C-140, 28 DPI bovine A24 Cruzeiro  NONE 71 79 + + 
34 Australian origin field serum bovine NONE NONE -2 32 - - 
35 PT Panel 3 FMD - sample 175 (2012) bovine NONE NONE 18 33 - - 
36 Australian origin field serum bovine NONE NONE 0 44 - - 
37 Australian origin field serum bovine NONE NONE 9 36 - - 
38 Australian origin field serum bovine NONE NONE 26 29 - - 
39 Australian origin field serum bovine NONE NONE 26 43 - - 
40 Australian origin field serum bovine NONE NONE 19 45 - - 
41 Australian origin field serum bovine NONE NONE 11 39 - - 
42 Australian origin field serum bovine NONE NONE 26 36 - - 
43 Australian origin field serum bovine NONE NONE 13 13 - - 
44 Australian origin field serum bovine NONE NONE 21 29 - - 
45 Australian origin field serum bovine NONE NONE 15 22 - - 
46 Australian origin field serum bovine NONE NONE 31 36 - - 
47 Australian origin field serum bovine NONE NONE 20 45 - - 
48 Australian origin field serum bovine NONE NONE 28 41 - - 
49 Australian origin field serum bovine NONE NONE 34 35 - - 
50 Australian origin field serum bovine NONE NONE 30 47 - - 
51 Australian origin field serum bovine NONE NONE 24 41 - - 
52 Australian origin field serum bovine NONE NONE 28 27 - - 
53 Australian origin field serum bovine NONE NONE 15 51 - + 
54 Australian origin field serum bovine NONE NONE 14 54 - + 
55 Australian origin field serum bovine NONE NONE 13 33 - - 
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Table A-6 (continued) 
No. Sample details Species Infection serotype 
Vaccination 
serotype 
Percent 
inhibition score 
Result at cut-
off  
AAHL c3B  AAHL c3B  
56 Australian origin field serum bovine NONE NONE -3 30 - - 
57 Australian origin field serum bovine NONE NONE 15 35 - - 
58 Australian origin field serum bovine NONE NONE 3 36 - - 
59 Australian origin field serum bovine NONE NONE 6 30 - - 
60 Australian origin field serum bovine NONE NONE 10 34 - - 
61 Australian origin field serum bovine NONE NONE 25 36 - - 
62 Australian origin field serum bovine NONE NONE 18 28 - - 
63 Australian origin field serum bovine NONE NONE 23 35 - - 
64 Australian origin field serum bovine NONE NONE 23 32 - - 
65 Australian origin field serum bovine NONE NONE 21 24 - - 
66 Australian origin field serum bovine NONE NONE 21 36 - - 
67 Australian origin field serum bovine NONE NONE 9 28 - - 
68 Australian origin field serum bovine NONE NONE 4 27 - - 
69 Australian origin field serum bovine NONE NONE 17 32 - - 
70 Australian origin field serum bovine NONE NONE 24 40 - - 
71 Australian origin field serum bovine NONE NONE 16 26 - - 
72 Australian origin field serum bovine NONE NONE 23 37 - - 
73 Australian origin field serum bovine NONE NONE -11 25 - - 
74 Australian origin field serum bovine NONE NONE 29 35 - - 
75 Australian origin field serum bovine NONE NONE 18 32 - - 
76 Australian origin field serum bovine NONE NONE 3 27 - - 
77 Australian origin field serum bovine NONE NONE 10 31 - - 
78 Australian origin field serum bovine NONE NONE 12 23 - - 
79 Australian origin field serum bovine NONE NONE 15 28 - - 
80 Australian origin field serum bovine NONE NONE 14 24 - - 
81 Australian origin field serum bovine NONE NONE -1 24 - - 
82 Australian origin field serum bovine NONE NONE 0 21 - - 
83 Australian origin field serum bovine NONE NONE 3 32 - - 
84 Australian origin field serum bovine NONE NONE 7 20 - - 
85 Australian origin field serum bovine NONE NONE 6 16 - - 
86 Australian origin field serum bovine NONE NONE 21 24 - - 
87 Australian origin field serum bovine NONE NONE 10 23 - - 
88 Australian origin field serum bovine NONE NONE 11 16 - - 
89 Australian origin field serum bovine NONE NONE -4 27 - - 
90 Australian origin field serum bovine NONE NONE 12 23 - - 
91 Australian origin field serum bovine NONE NONE -21 18 - - 
92 Australian origin field serum bovine NONE NONE 29 17 - - 
93 Australian origin field serum bovine NONE NONE 19 31 - - 
94 Vietnam origin field serum bovine Unknown Unknown 79 74 + + 
95 Vietnam origin field serum bovine Unknown Unknown 75 74 + + 
96 Vietnam origin field serum bovine Unknown Unknown 76 69 + + 
97 Vietnam origin field serum bovine Unknown Unknown 74 58 + + 
98 Vietnam origin field serum bovine Unknown Unknown 65 55 + + 
99 Vietnam origin field serum bovine Unknown Unknown 71 68 + + 
100 Vietnam origin field serum bovine Unknown Unknown 77 72 + + 
101 Vietnam origin field serum bovine Unknown Unknown 76 67 + + 
102 Vietnam origin field serum bovine Unknown Unknown 76 54 + + 
103 Vietnam origin field serum bovine Unknown Unknown 73 42 + - 
104 Vietnam origin field serum bovine Unknown Unknown 75 53 + + 
105 Vietnam origin field serum bovine Unknown Unknown 76 51 + + 
106 Vietnam origin field serum bovine Unknown Unknown 74 62 + + 
107 Vietnam origin field serum bovine Unknown Unknown 74 66 + + 
108 Vietnam origin field serum bovine Unknown Unknown 75 72 + + 
109 Vietnam origin field serum bovine Unknown Unknown 78 67 + + 
110 Vietnam origin field serum bovine Unknown Unknown 78 71 + + 
111 Vietnam origin field serum bovine Unknown Unknown 75 69 + + 
112 Vietnam origin field serum bovine Unknown Unknown 77 62 + + 
113 Vietnam origin field serum bovine Unknown Unknown 72 69 + + 
114 Vietnam origin field serum bovine Unknown Unknown 77 69 + + 
115 Vietnam origin field serum bovine Unknown Unknown 74 58 + + 
116 Vietnam origin field serum bovine Unknown Unknown 78 60 + + 
117 Vietnam origin field serum bovine Unknown Unknown 71 57 + + 
118 Vietnam origin field serum bovine Unknown Unknown 76 69 + + 
119 Vietnam origin field serum bovine Unknown Unknown 62 59 + + 
120 Vietnam origin field serum bovine Unknown Unknown 72 66 + + 
121 Vietnam origin field serum bovine Unknown Unknown 74 73 + + 
122 Vietnam origin field serum bovine Unknown Unknown 79 55 + + 
123 Vietnam origin field serum bovine Unknown Unknown 73 72 + + 
124 Vietnam origin field serum bovine Unknown Unknown 77 49 + + 
125 Vietnam origin field serum bovine Unknown Unknown 71 71 + + 
126 Vietnam origin field serum bovine Unknown Unknown 75 66 + + 
127 Vietnam origin field serum bovine Unknown Unknown 70 73 + + 
128 Vietnam origin field serum bovine Unknown Unknown 79 48 + + 
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Table A-6 (continued) 
No. Sample details Species Infection serotype 
Vaccination 
serotype 
Percent 
inhibition score 
Result at cut-
off  
AAHL c3B  AAHL c3B  
129 Vietnam origin field serum bovine Unknown Unknown 70 52 + + 
130 Vietnam origin field serum bovine Unknown Unknown 84 90 + + 
131 Vietnam origin field serum bovine Unknown Unknown 70 41 + - 
132 Vietnam origin field serum bovine Unknown Unknown 72 54 + + 
133 Vietnam origin field serum bovine Unknown Unknown 52 59 + + 
134 Vietnam origin field serum bovine Unknown Unknown 88 88 + + 
135 Vietnam origin field serum bovine Unknown Unknown 76 72 + + 
136 Vietnam origin field serum bovine Unknown Unknown 25 47 - + 
137 Vietnam origin field serum bovine Unknown Unknown 65 78 + + 
138 Vietnam origin field serum bovine Unknown Unknown 76 58 + + 
139 Vietnam origin field serum bovine Unknown Unknown 72 77 + + 
140 Vietnam origin field serum bovine Unknown Unknown 77 70 + + 
141 Vietnam origin field serum bovine Unknown Unknown 80 56 + + 
142 Vietnam origin field serum bovine Unknown Unknown 77 69 + + 
143 Vietnam origin field serum bovine Unknown Unknown 75 58 + + 
144 Vietnam origin field serum bovine Unknown Unknown 76 63 + + 
145 Vietnam origin field serum bovine Unknown Unknown 77 56 + + 
146 Vietnam origin field serum bovine Unknown Unknown 67 63 + + 
147 Vietnam origin field serum bovine Unknown Unknown 76 61 + + 
148 Vietnam origin field serum bovine Unknown Unknown 77 95 + + 
149 Vietnam origin field serum bovine Unknown Unknown 50 55 + + 
150 Vietnam origin field serum bovine Unknown Unknown 48 50 + + 
151 Vietnam origin field serum bovine Unknown Unknown 52 73 + + 
152 Vietnam origin field serum bovine Unknown Unknown 63 50 + + 
153 Vietnam origin field serum bovine Unknown Unknown 62 52 + + 
154 Vietnam origin field serum bovine Unknown Unknown 82 82 + + 
155 Vietnam origin field serum bovine Unknown Unknown 68 62 + + 
156 Vietnam origin field serum bovine Unknown Unknown 72 51 + + 
157 Vietnam origin field serum bovine Unknown Unknown 71 64 + + 
158 Vietnam origin field serum bovine Unknown Unknown 80 74 + + 
159 Vietnam origin field serum bovine Unknown Unknown 34 37 - - 
160 Vietnam origin field serum bovine Unknown Unknown 79 72 + + 
161 Vietnam origin field serum bovine Unknown Unknown 33 42 - - 
162 Vietnam origin field serum bovine Unknown Unknown 49 37 + - 
163 Vietnam origin field serum bovine Unknown Unknown 65 52 + + 
164 Vietnam origin field serum bovine Unknown Unknown 11 22 - - 
165 Vietnam origin field serum bovine Unknown Unknown 11 46 - - 
166 Vietnam origin field serum bovine Unknown Unknown 12 10 - - 
167 Vietnam origin field serum bovine Unknown Unknown 48 58 + + 
168 Vietnam origin field serum bovine Unknown Unknown 41 31 + - 
169 Vietnam origin field serum bovine Unknown Unknown 47 60 + + 
170 Vietnam origin field serum bovine Unknown Unknown 8 47 - - 
171 Vietnam origin field serum bovine Unknown Unknown 13 23 - - 
172 Vietnam origin field serum bovine Unknown Unknown 9 29 - - 
173 Vietnam origin field serum bovine Unknown Unknown 9 23 - - 
174 Vietnam origin field serum bovine Unknown Unknown 14 45 - - 
175 Vietnam origin field serum bovine Unknown Unknown 13 38 - - 
176 Vietnam origin field serum bovine Unknown Unknown 25 13 - - 
177 Vietnam origin field serum bovine Unknown Unknown 10 1 - - 
178 Vietnam origin field serum bovine Unknown Unknown 0 31 - - 
179 Vietnam origin field serum bovine Unknown Unknown 8 11 - - 
180 Vietnam origin field serum bovine Unknown Unknown 84 83 + + 
181 Vietnam origin field serum bovine Unknown Unknown 17 55 - + 
182 Vietnam origin field serum bovine Unknown Unknown 18 52 - + 
183 Vietnam origin field serum bovine Unknown Unknown 9 41 - - 
184 Vietnam origin field serum bovine Unknown Unknown 9 36 - - 
185 Vietnam origin field serum bovine Unknown Unknown 8 38 - - 
186 Vietnam origin field serum bovine Unknown Unknown 6 27 - - 
187 Vietnam origin field serum bovine Unknown Unknown 6 6 - - 
188 Vietnam origin field serum bovine Unknown Unknown 2 33 - - 
189 Vietnam origin field serum bovine Unknown Unknown 74 73 + + 
190 Vietnam origin field serum bovine Unknown Unknown 7 53 - - 
191 Vietnam origin field serum bovine Unknown Unknown 9 30 - - 
192 Vietnam origin field serum bovine Unknown Unknown 12 46 - - 
193 Vietnam origin field serum bovine Unknown Unknown -6 40 - - 
194 Vietnam origin field serum bovine Unknown Unknown 5 13 - - 
195 Vietnam origin field serum bovine Unknown Unknown 18 46 - - 
196 Vietnam origin field serum bovine Unknown Unknown 9 7 - - 
197 Vietnam origin field serum bovine Unknown Unknown 27 43 - - 
198 Vietnam origin field serum bovine Unknown Unknown 19 4 - - 
199 Vietnam origin field serum bovine Unknown Unknown 33 23 - - 
200 Positive control 16 weeks post challenge (23/6/1998) bovine Asia1 NONE 71 74 - - 
201 Australian origin field serum bovine NONE NONE 9 36 - - 
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Table A-6 (continued) 
No. Sample details Species Infection serotype 
Vaccination 
serotype 
Percent 
inhibition score 
Result at cut-
off 
AAHL c3B  AAHL c3B  
202 Australian origin field serum bovine NONE NONE 10 42 - - 
203 Australian origin field serum bovine NONE NONE 7 42 - - 
204 Australian origin field serum bovine NONE NONE 17 44 - - 
205 Australian origin field serum bovine NONE NONE 16 50 - + 
206 Australian origin field serum bovine NONE NONE 3 51 - + 
207 Australian origin field serum bovine NONE NONE 4 45 - - 
208 Australian origin field serum bovine NONE NONE 9 33 - - 
209 Vietnam origin field serum bovine Unknown Unknown 47 54 + + 
210 Vietnam origin field serum bovine Unknown Unknown 72 45 + - 
211 Vietnam origin field serum bovine Unknown Unknown 65 48 + + 
212 Vietnam origin field serum bovine Unknown Unknown 26 35 - - 
213 Vietnam origin field serum bovine Unknown Unknown 24 48 - + 
214 Vietnam origin field serum bovine Unknown Unknown 80 88 + + 
215 Vietnam origin field serum bovine Unknown Unknown 56 55 + + 
216 Vietnam origin field serum bovine Unknown Unknown 57 50 + + 
217 Vietnam origin field serum bovine Unknown Unknown 29 24 - - 
218 Vietnam origin field serum bovine Unknown Unknown 22 45 - - 
219 Vietnam origin field serum bovine Unknown Unknown 50 68 + + 
220 Vietnam origin field serum bovine Unknown Unknown 57 37 + - 
221 Vietnam origin field serum bovine Unknown Unknown 60 47 + - 
222 Vietnam origin field serum bovine Unknown Unknown 52 34 + - 
223 Vietnam origin field serum bovine Unknown Unknown 62 77 + + 
224 Vietnam origin field serum bovine Unknown Unknown 56 28 + - 
225 Vietnam origin field serum bovine Unknown Unknown 39 14 + - 
226 Vietnam origin field serum bovine Unknown Unknown 42 12 + - 
227 Vietnam origin field serum bovine Unknown Unknown 44 36 + - 
228 Vietnam origin field serum bovine Unknown Unknown 9 13 - - 
229 Vietnam origin field serum bovine Unknown Unknown 54 22 + - 
230 Vietnam origin field serum bovine Unknown Unknown 55 74 + + 
231 Vietnam origin field serum bovine Unknown Unknown 80 95 + + 
232 Vietnam origin field serum bovine Unknown Unknown 85 94 + + 
233 Vietnam origin field serum bovine Unknown Unknown 84 96 + + 
234 Vietnam origin field serum bovine Unknown Unknown 87 88 + + 
235 Vietnam origin field serum bovine Unknown Unknown 84 78 + + 
236 Vietnam origin field serum bovine Unknown Unknown 65 70 + + 
237 Vietnam origin field serum bovine Unknown Unknown 72 64 + + 
238 Vietnam origin field serum bovine Unknown Unknown 19 7 - - 
239 Vietnam origin field serum bovine Unknown Unknown 28 28 - - 
240 Vietnam origin field serum bovine Unknown Unknown 32 59 - + 
241 Vietnam origin field serum bovine Unknown Unknown 21 39 - - 
242 Vietnam origin field serum bovine Unknown Unknown 29 23 - - 
243 Vietnam origin field serum bovine Unknown Unknown 12 49 - + 
244 PT panel 3 FMD, sample 4 (2014) bovine NONE NONE 13 19 - - 
245 PT panel 3 FMD, sample 57 (2014) bovine NONE Type A 24 22 - - 
246 PT panel 3 FMD, sample 85 (2014) bovine NONE Type O 25 28 - - 
247 PT panel 3 FMD, sample 121 (2014) bovine NONE Type O 13 26 - - 
248 PT panel 3 FMD, sample 151 (2014) bovine NONE Type A 10 23 - - 
249 PT panel 3 FMD, sample 264 (2014) bovine NONE Type A 19 26 - - 
250 PT panel 3 FMD, sample 549 (2014) bovine NONE NONE 10 23 - - 
251 PT panel 3 FMD, sample 593 (2014) bovine Type O Type SAT 3 62 41 + - 
252 VSV control sample bovine New Jersey NONE -1 15 - - 
253 VSV control sample bovine Indiana NONE 30 25 - - 
254 BTV - V41 bovine 23 NONE 13 31 - - 
255 BTV, Australian origin, animal #6, DPP 0 bovine 3 NONE 27 26 - - 
256 BTV, Australian origin, animal #5, DPP 9 bovine 3 NONE 29 29 - - 
257 BTV, Australian origin, animal #6, DPP 9 bovine 3 NONE 24 27 - - 
258 BTV, Australian origin, animal #5, DPP 14 bovine 3 NONE 21 25 - - 
259 BTV, Australian origin, animal #6, DPP 14 bovine 3 NONE 22 31 - - 
260 BTV, Cow #5, DPP 28, final bleed bovine 3 NONE 30 33 - - 
261 BTV. Animal #V29 bovine 20 NONE 13 46 - - 
262 BTV, Animal #B62 bovine 15 NONE 13 38 - - 
263 BTV, Animal #V33 bovine 1 NONE 9 27 - - 
264 BTV, Animal #B71 bovine 15 NONE 12 16 - - 
265 BTV, Animal #V41 bovine 23 NONE 9 20 - - 
266 BTV, Animal #V45 bovine 21 NONE 11 21 - - 
267 BTV, Animal #V40 bovine 21 NONE 14 25 - - 
268 BTV, Animal #V35 bovine 1 NONE 15 28 - - 
269 BTV, Animal #V45 bovine 21 NONE 16 24 - - 
270 BTV, Animal #B62 bovine 15 NONE 13 26 - - 
271 BTV, Animal #R1377 bovine 20 NONE 14 29 - - 
272 BTV, Animal #D22 bovine 20 NONE 16 23 - - 
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Table A-7: Ovine serum samples used to evaluate the c3B C-ELISA’s diagnostic 
performance. 
Serum sample properties are described as follows: (+) positive or (-) negative result using 
cut-off of >35% in the AAHL C-ELISA or >34% in the c3B C-ELISA; FMDV, foot-and-
mouth disease virus; BTV, Bluetongue virus; VSV; Vesicular stomatitis virus; DPI, days 
post infection. Sera samples obtained from a vaccine efficacy experiment where animals 
were vaccinated against FMDV strain O1 Manisa eight days prior to exposure to animals 
infected with FMDV strain O SKR 2012 (Dr J. Horsington, personal communication). 
Serum sample properties are described as follows: UI, unvaccinated and infected (donor 
animal); VC, vaccinated and challenged; UV, unvaccinated and challenged. Diagnoses of 
the c3B C-ELISA that oppose the AAHL C-ELISA result are shaded in grey.  
No. Sample details Species Infection serotype 
Vaccination 
serotype 
Percent 
inhibition score 
Result at cut-
off  
AAHL c3B  AAHL c3B  
1 BTV, Animal #CS154 ovine 21 NONE 3 14 - - 
2 BTV, SA sheep 4225, #44, DPI 13 ovine 7 NONE 19 19 - - 
3 BTV, DPP559, animal #77, DPI 9 ovine 1 NONE 16 17 - - 
4 BTV, SA sheep 4226, animal #45, DPI 13 ovine 8 NONE 27 26 - - 
5 BTV, SA sheep 4269, animal #63, DPI 13 ovine 18 NONE 12 18 - - 
6 BTV, Animal #1 ovine SA BTV 1 NONE 2 12 - - 
7 BTV, Animal #4 ovine SA BTV 2 NONE 2 11 - - 
8 BTV, Animal #5 ovine SA BTV 3 NONE 0 9 - - 
9 BTV, Animal #7 ovine SA BTV 4 NONE 12 6 - - 
10 BTV, Animal #10 ovine SA BTV 5 NONE 2 8 - - 
11 BTV, Animal #13 ovine SA BTV 6 NONE 18 12 - - 
12 BTV, Animal #16 ovine SA BTV 7 NONE 7 8 - - 
13 BTV, Animal #17 ovine SA BTV 8 NONE 5 6 - - 
14 BTV, Animal #20 ovine SA BTV 9 NONE -6 7 - - 
15 BTV ovine SA BTV 10 NONE 27 18 - - 
16 BTV ovine SA BTV 11 NONE 2 16 - - 
17 BTV ovine SA BTV 12 NONE 8 2 - - 
18 Australian origin field serum ovine NONE NONE -4 30 - - 
19 Australian origin field serum ovine NONE NONE 3 34 - - 
20 Australian origin field serum ovine NONE NONE 7 28 - - 
21 Australian origin field serum ovine NONE NONE 11 34 - - 
22 Australian origin field serum ovine NONE NONE 5 22 - - 
23 Australian origin field serum ovine NONE NONE 16 21 - - 
24 Australian origin field serum ovine NONE NONE -6 19 - - 
25 Australian origin field serum ovine NONE NONE 5 21 - - 
26 Australian origin field serum ovine NONE NONE -1 24 - - 
27 Australian origin field serum ovine NONE NONE 9 19 - - 
28 Australian origin field serum ovine NONE NONE 14 20 - - 
29 Australian origin field serum ovine NONE NONE 14 19 - - 
30 Australian origin field serum ovine NONE NONE 12 24 - - 
31 Australian origin field serum ovine NONE NONE 21 36 - + 
32 Australian origin field serum ovine NONE NONE 18 6 - - 
33 Australian origin field serum ovine NONE NONE 14 20 - - 
34 Australian origin field serum ovine NONE NONE 20 24 - - 
35 Australian origin field serum ovine NONE NONE 14 30 - - 
36 Australian origin field serum ovine NONE NONE 20 26 - - 
37 Australian origin field serum ovine NONE NONE 28 31 - - 
38 Australian origin field serum ovine NONE NONE 21 24 - - 
39 Australian origin field serum ovine NONE NONE 27 15 - - 
40 Australian origin field serum ovine NONE NONE 16 15 - - 
41 Australian origin field serum ovine NONE NONE 13 26 - - 
42 Australian origin field serum ovine NONE NONE 3 28 - - 
43 Australian origin field serum ovine NONE NONE 9 26 - - 
44 Australian origin field serum ovine NONE NONE 20 21 - - 
45 Australian origin field serum ovine NONE NONE 18 25 - - 
46 Australian origin field serum ovine NONE NONE 16 21 - - 
47 Australian origin field serum ovine NONE NONE 20 20 - - 
48 Australian origin field serum ovine NONE NONE -18 15 - - 
49 Australian origin field serum ovine NONE NONE -5 31 - - 
50 Australian origin field serum ovine NONE NONE -30 30 - - 
51 Australian origin field serum ovine NONE NONE -15 22 - - 
52 Australian origin field serum ovine NONE NONE -14 20 - - 
53 Australian origin field serum ovine NONE NONE -21 19 - - 
54 Australian origin field serum ovine NONE NONE 34 16 - - 
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Table A-7 (continued) 
No. Sample details Species Infection serotype 
Vaccination 
serotype 
Percent 
inhibition score 
Result at cut-
off 
AAHL c3B  AAHL c3B  
55 Australian origin field serum ovine NONE NONE -13 24 - - 
56 Australian origin field serum ovine NONE NONE 23 31 - - 
57 Australian origin field serum ovine NONE NONE 24 31 - - 
58 Australian origin field serum ovine NONE NONE 22 32 - - 
59 Australian origin field serum ovine NONE NONE 21 35 - + 
60 Australian origin field serum ovine NONE NONE 22 29 - - 
61 Australian origin field serum ovine NONE NONE 8 24 - - 
62 Australian origin field serum ovine NONE NONE 5 18 - - 
63 Australian origin field serum ovine NONE NONE 15 24 - - 
64 Australian origin field serum ovine NONE NONE 19 30 - - 
65 Australian origin field serum ovine NONE NONE 10 29 - - 
66 Australian origin field serum ovine NONE NONE 0 27 - - 
67 Australian origin field serum ovine NONE NONE 12 24 - - 
68 Australian origin field serum ovine NONE NONE 25 26 - - 
69 Australian origin field serum ovine NONE NONE 22 18 - - 
70 Australian origin field serum ovine NONE NONE 17 9 - - 
71 Australian origin field serum ovine NONE NONE 22 12 - - 
72 Australian origin field serum ovine NONE NONE 10 14 - - 
73 Australian origin field serum ovine NONE NONE 21 25 - - 
74 Australian origin field serum ovine NONE NONE 8 31 - - 
75 Australian origin field serum ovine NONE NONE 20 19 - - 
76 Australian origin field serum ovine NONE NONE 15 21 - - 
77 Australian origin field serum ovine NONE NONE 20 16 - - 
78 Australian origin field serum ovine NONE NONE 27 10 - - 
79 Australian origin field serum ovine NONE NONE 34 18 - - 
80 Australian origin field serum ovine NONE NONE 26 26 - - 
81 Australian origin field serum ovine NONE NONE 29 30 - - 
82 Australian origin field serum ovine NONE NONE 30 33 - - 
83 Australian origin field serum ovine NONE NONE 20 26 - - 
84 Australian origin field serum ovine NONE NONE 17 19 - - 
85 Australian origin field serum ovine NONE NONE 28 16 - - 
86 Australian origin field serum ovine NONE NONE 34 16 - - 
87 Australian origin field serum ovine NONE NONE 24 29 - - 
88 Australian origin field serum ovine NONE NONE 16 28 - - 
89 Australian origin field serum ovine NONE NONE 13 27 - - 
90 Australian origin field serum ovine NONE NONE 15 28 - - 
91 Australian origin field serum ovine NONE NONE 14 19 - - 
92 Australian origin field serum ovine NONE NONE 25 17 - - 
93 Australian origin field serum ovine NONE NONE 18 7 - - 
94 Australian origin field serum ovine NONE NONE 16 14 - - 
95 Australian origin field serum ovine NONE NONE 18 25 - - 
96 Australian origin field serum ovine NONE NONE 20 35 - + 
97 Australian origin field serum ovine NONE NONE 19 27 - - 
98 Australian origin field serum ovine NONE NONE 11 25 - - 
99 Australian origin field serum ovine NONE NONE 21 27 - - 
100 Australian origin field serum ovine NONE NONE 20 25 - - 
101 Australian origin field serum ovine NONE NONE 19 14 - - 
102 Australian origin field serum ovine NONE NONE 21 24 - - 
103 Australian origin field serum ovine NONE NONE 16 31 - - 
104 Australian origin field serum ovine NONE NONE 15 26 - - 
105 Australian origin field serum ovine NONE NONE 14 29 - - 
106 Australian origin field serum ovine NONE NONE 20 21 - - 
107 Australian origin field serum ovine NONE NONE 18 24 - - 
108 Australian origin field serum ovine NONE NONE 19 18 - - 
109 Australian origin field serum ovine NONE NONE 19 17 - - 
110 Australian origin field serum ovine NONE NONE 12 16 - - 
111 Australian origin field serum ovine NONE NONE 16 23 - - 
112 Australian origin field serum ovine NONE NONE 16 23 - - 
113 Australian origin field serum ovine NONE NONE 22 24 - - 
114 Australian origin field serum ovine NONE NONE 13 25 - - 
115 Australian origin field serum ovine NONE NONE 19 20 - - 
116 Australian origin field serum ovine NONE NONE 8 9 - - 
117 Australian origin field serum ovine NONE NONE 12 9 - - 
118 Australian origin field serum ovine NONE NONE 19 16 - - 
119 Canadian experiment, Sheep 8, VC, Day -8 ovine NONE O1 Manisa -6 7 - - 
120 Canadian experiment, Sheep 9, UI, Day -8 ovine O SKR 2012 NONE 23 8 - - 
121 Canadian experiment, Sheep 10, UI, Day -8 ovine O SKR 2012 NONE 7 7 - - 
122 Canadian experiment, Sheep 11, UI, Day -8 ovine O SKR 2012 NONE 6 10 - - 
123 Canadian experiment, Sheep 12, UI, Day -8 ovine O SKR 2012 NONE 9 6 - - 
124 Canadian experiment, Sheep 13, UI, Day -8 ovine O SKR 2012 NONE 1 14 - - 
125 Canadian experiment, Sheep 14, UI, Day -8 ovine O SKR 2012 NONE 6 5 - - 
126 Canadian experiment, Sheep 15, UI, Day -8 ovine O SKR 2012 NONE 7 4 - - 
127 Canadian experiment, Sheep 24, UI, Day -8 ovine O SKR 2012 NONE -1 10 - - 
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Table A-7 (continued) 
No. Sample details Species Infection serotype 
Vaccination 
serotype 
Percent 
inhibition score 
Result at cut-
off 
AAHL c3B  AAHL c3B  
128 Canadian experiment, Sheep 10, UI, Day -1 ovine O SKR 2012 NONE 7 11 - - 
129 Canadian experiment, Sheep 11, UI, Day -1 ovine O SKR 2012 NONE 4 12 - - 
130 Canadian experiment, Sheep 12, UI, Day -1 ovine O SKR 2012 NONE 11 37 - + 
131 Canadian experiment, Sheep 13, UI, Day -1 ovine O SKR 2012 NONE 2 5 - - 
132 Canadian experiment, Sheep 14, UI, Day -1 ovine O SKR 2012 NONE 2 6 - - 
133 Canadian experiment, Sheep 15, UI, Day -1 ovine O SKR 2012 NONE 5 4 - - 
134 Canadian experiment, Sheep 16, UI, Day -1 ovine O SKR 2012 NONE -4 8 - - 
135 Canadian experiment, Sheep 21, UI, Day -1 ovine O SKR 2012 NONE 2 16 - - 
136 Canadian experiment, Sheep 22, UI, Day -1 ovine O SKR 2012 NONE 8 11 - - 
137 Canadian experiment, Sheep 23, UI, Day -1 ovine O SKR 2012 NONE 12 16 - - 
138 Canadian experiment, Sheep 24, UI, Day -1 ovine O SKR 2012 NONE 4 13 - - 
139 Canadian experiment, Sheep 1, VC, Day 0 ovine Unknown O1 Manisa 2 9 - - 
140 Canadian experiment, Sheep 2, VC, Day 0 ovine Unknown O1 Manisa 1 8 - - 
141 Canadian experiment, Sheep 3, VC, Day 0 ovine Unknown O1 Manisa 6 5 - - 
142 Canadian experiment, Sheep 4, VC, Day 0 ovine Unknown O1 Manisa -6 6 - - 
143 Canadian experiment, Sheep 5, VC, Day 0 ovine Unknown O1 Manisa 12 9 - - 
144 Canadian experiment, Sheep 6, VC, Day 0 ovine Unknown O1 Manisa 11 10 - - 
145 Canadian experiment, Sheep 7, VC, Day 0 ovine Unknown O1 Manisa 14 17 - - 
146 Canadian experiment, Sheep 8, VC, Day 0 ovine Unknown O1 Manisa 12 9 - - 
147 Canadian experiment, Sheep 9, UI, Day 0 ovine O SKR 2012 NONE 31 15 - - 
148 Canadian experiment, Sheep 10, UI, Day 0 ovine O SKR 2012 NONE 12 13 - - 
149 Canadian experiment, Sheep 11, UI, Day 0 ovine O SKR 2012 NONE 9 10 - - 
150 Canadian experiment, Sheep 12, UI, Day 0 ovine O SKR 2012 NONE 7 12 - - 
151 Canadian experiment, Sheep 13, UI, Day 0 ovine O SKR 2012 NONE -2 6 - - 
152 Canadian experiment, Sheep 14, UI, Day 0 ovine O SKR 2012 NONE 11 7 - - 
153 Canadian experiment, Sheep 15, UI, Day 0 ovine O SKR 2012 NONE 12 9 - - 
154 Canadian experiment, Sheep 16, UI, Day 0 ovine O SKR 2012 NONE 8 33 - - 
155 Canadian experiment, Sheep 17, UV, Day 0 ovine Unknown NONE 7 9 - - 
156 Canadian experiment, Sheep 18, UV, Day 0 ovine Unknown NONE 7 5 - - 
157 Canadian experiment, Sheep 19, UV, Day 0 ovine Unknown NONE 11 9 - - 
158 Canadian experiment, Sheep 20, UV, Day 0 ovine Unknown NONE 3 41 - + 
159 Canadian experiment, Sheep 21, UI, Day 0 ovine O SKR 2012 NONE 1 22 - - 
160 Canadian experiment, Sheep 22, UI, Day 0 ovine O SKR 2012 NONE 3 22 - - 
161 Canadian experiment, Sheep 23, UI, Day 0 ovine O SKR 2012 NONE 17 24 - - 
162 Canadian experiment, Sheep 24, UI, Day 0 ovine O SKR 2012 NONE 12 16 - - 
163 Canadian experiment, Sheep 1, VC, Day 1 ovine Unknown O1 Manisa 13 21 - - 
164 Canadian experiment, Sheep 2, VC, Day 1 ovine Unknown O1 Manisa 11 11 - - 
165 Canadian experiment, Sheep 3, VC, Day 1 ovine Unknown O1 Manisa 11 9 - - 
166 Canadian experiment, Sheep 4, VC, Day 1 ovine Unknown O1 Manisa 10 49 - + 
167 Canadian experiment, Sheep 5, VC, Day 1 ovine Unknown O1 Manisa 7 30 - - 
168 Canadian experiment, Sheep 6, VC, Day 1 ovine Unknown O1 Manisa 13 29 - - 
169 Canadian experiment, Sheep 7, VC, Day 1 ovine Unknown O1 Manisa 12 22 - - 
170 Canadian experiment, Sheep 8, VC, Day 1 ovine Unknown O1 Manisa 10 22 - - 
171 Canadian experiment, Sheep 9, UI, Day 1 ovine O SKR 2012 O1 Manisa 31 20 - - 
172 Canadian experiment, Sheep 10, UI, Day 1 ovine O SKR 2012 O1 Manisa 12 17 - - 
173 Canadian experiment, Sheep 11, UI, Day 1 ovine O SKR 2012 O1 Manisa 10 20 - - 
174 Canadian experiment, Sheep 12, UI, Day 1 ovine O SKR 2012 O1 Manisa 11 26 - - 
175 Canadian experiment, Sheep 13, UI, Day 1 ovine O SKR 2012 O1 Manisa 10 28 - - 
176 Canadian experiment, Sheep 14, UI, Day 1 ovine O SKR 2012 O1 Manisa 15 30 - - 
177 Canadian experiment, Sheep 15, UI, Day 1 ovine O SKR 2012 O1 Manisa 19 29 - - 
178 Canadian experiment, Sheep 16, UI, Day 1 ovine O SKR 2012 O1 Manisa 14 19 - - 
179 Canadian experiment, Sheep 17, UV, Day 1 ovine Unknown NONE 9 35 - + 
180 Canadian experiment, Sheep 18, UV, Day 1 ovine Unknown NONE 12 18 - - 
181 Canadian experiment, Sheep 19, UV, Day 1 ovine Unknown NONE 13 15 - - 
182 Canadian experiment, Sheep 20, UV, Day 1 ovine Unknown NONE 8 35 - + 
183 Canadian experiment, Sheep 21, UI, Day 1 ovine O SKR 2012 NONE 16 31 - - 
184 Canadian experiment, Sheep 22, UI, Day 1 ovine O SKR 2012 NONE 2 29 - - 
185 Canadian experiment, Sheep 23, UI, Day 1 ovine O SKR 2012 NONE 8 23 - - 
186 Canadian experiment, Sheep 24, UI, Day 1 ovine O SKR 2012 NONE 5 42 - + 
187 Canadian experiment, Sheep 1, VC, Day 2 ovine Unknown O1 Manisa 2 16 - - 
188 Canadian experiment, Sheep 2, VC, Day 2 ovine Unknown O1 Manisa 0 19 - - 
189 Canadian experiment, Sheep 3, VC, Day 2 ovine Unknown O1 Manisa 8 16 - - 
190 Canadian experiment, Sheep 4, VC, Day 2 ovine Unknown O1 Manisa -5 27 - - 
191 Canadian experiment, Sheep 5, VC, Day 2 ovine Unknown O1 Manisa -9 31 - - 
192 Canadian experiment, Sheep 6, VC, Day 2 ovine Unknown O1 Manisa 7 27 - - 
193 Canadian experiment, Sheep 7, VC, Day 2 ovine Unknown O1 Manisa 9 27 - - 
194 Canadian experiment, Sheep 8, VC, Day 2 ovine Unknown O1 Manisa 5 24 - - 
195 Canadian experiment, Sheep 9, UI, Day 2 ovine O SKR 2012 NONE 19 20 - - 
196 Canadian experiment, Sheep 10, UI, Day 2 ovine O SKR 2012 NONE 6 25 - - 
197 Canadian experiment, Sheep 11, UI, Day 2 ovine O SKR 2012 NONE -3 17 - - 
198 Canadian experiment, Sheep 13, UI, Day 2 ovine O SKR 2012 O1 Manisa -9 13 - - 
199 Canadian experiment, Sheep 14, UI, Day 2 ovine O SKR 2012 O1 Manisa 1 19 - - 
200 Canadian experiment, Sheep 15, UI, Day 2 ovine O SKR 2012 O1 Manisa 3 19 - - 
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Table A-7 (continued) 
No. Sample details Species Infection serotype 
Vaccination 
serotype 
Percent 
inhibition score 
Result at cut-
off 
AAHL c3B  AAHL c3B  
201 Canadian experiment, Sheep 16, UI, Day 2 ovine O SKR 2012 O1 Manisa 4 23 - - 
202 Canadian experiment, Sheep 17, UV, Day 2 ovine Unknown NONE -5 17 - - 
203 Canadian experiment, Sheep 18, UV, Day 2 ovine Unknown NONE 1 15 - - 
204 Canadian experiment, Sheep 19, UV, Day 2 ovine Unknown NONE -3 17 - - 
205 Canadian experiment, Sheep 20, UV, Day 2 ovine Unknown NONE -5 12 - - 
206 Canadian experiment, Sheep 21, UI, Day 2 ovine O SKR 2012 NONE 9 12 - - 
207 Canadian experiment, Sheep 22, UI, Day 2 ovine O SKR 2012 NONE 3 12 - - 
208 Canadian experiment, Sheep 23, UI, Day 2 ovine O SKR 2012 NONE 11 18 - - 
209 Canadian experiment, Sheep 24, UI, Day 2 ovine O SKR 2012 NONE 6 22 - - 
210 Canadian experiment, Sheep 2, VC, Day 7 ovine Unknown O1 Manisa 4 27 - - 
211 Canadian experiment, Sheep 4, VC, Day 7 ovine Unknown O1 Manisa -1 28 - - 
212 Canadian experiment, Sheep 6, VC, Day 7 ovine Unknown O1 Manisa 11 20 - - 
213 Canadian experiment, Sheep 10, UI, Day 7 ovine O SKR 2012 NONE 65 52 + + 
214 Canadian experiment, Sheep 12, UI, Day 7 ovine O SKR 2012 NONE 44 41 + + 
215 Canadian experiment, Sheep 15, UI, Day 7 ovine O SKR 2012 NONE 69 48 + + 
216 Canadian experiment, Sheep 16, UI, Day 7 ovine O SKR 2012 NONE 73 56 + + 
217 Canadian experiment, Sheep 19, UV, Day 7 ovine Unknown NONE 2 6 - - 
218 Canadian experiment, Sheep 22, UI, Day 7 ovine O SKR 2012 NONE 62 44 + - 
219 Canadian experiment, Sheep 24, UI, Day 7 ovine O SKR 2012 NONE 58 47 + + 
220 Canadian experiment, Sheep 2, VC, Day 10 ovine Unknown O1 Manisa 8 30 - - 
221 Canadian experiment, Sheep 4, VC, Day 10 ovine Unknown O1 Manisa 3 20 - - 
222 Canadian experiment, Sheep 6, VC, Day 10 ovine Unknown O1 Manisa 9 26 - - 
223 Canadian experiment, Sheep 10, UI, Day 10 ovine O SKR 2012 NONE 79 63 + + 
224 Canadian experiment, Sheep 12, UI, Day 10 ovine O SKR 2012 NONE 68 43 + + 
225 Canadian experiment, Sheep 15, UI, Day 10 ovine O SKR 2012 NONE 87 35 + + 
226 Canadian experiment, Sheep 16, UI, Day 10 ovine O SKR 2012 NONE 82 64 + + 
227 Canadian experiment, Sheep 19, UV, Day 10 ovine Unknown NONE 36 27 + + 
228 Canadian experiment, Sheep 22, UI, Day 10 ovine O SKR 2012 NONE 76 61 + + 
229 Canadian experiment, Sheep 24, UI, Day 10 ovine O SKR 2012 NONE 75 65 + + 
230 Canadian experiment, Sheep 2, VC, Day 14 ovine Unknown O1 Manisa 5 22 - - 
231 Canadian experiment, Sheep 4, VC, Day 14 ovine Unknown O1 Manisa 8 21 - - 
232 Canadian experiment, Sheep 6, VC, Day 14 ovine Unknown O1 Manisa 10 13 - - 
233 Canadian experiment, Sheep 10, UI, Day 14 ovine O SKR 2012 NONE 82 67 + + 
234 Canadian experiment, Sheep 12, UI, Day 14 ovine O SKR 2012 NONE 74 44 + + 
235 Canadian experiment, Sheep 15, UI, Day 14 ovine O SKR 2012 NONE 86 48 + + 
236 Canadian experiment, Sheep 16, UI, Day 14 ovine O SKR 2012 NONE 83 61 + + 
237 Canadian experiment, Sheep 19, UV, Day 14 ovine Unknown NONE 72 57 + + 
238 Canadian experiment, Sheep 22, UI, Day 14 ovine O SKR 2012 NONE 72 56 + + 
239 Canadian experiment, Sheep 24, UI, Day 14 ovine O SKR 2012 NONE 69 54 + + 
240 Canadian experiment, Sheep 2, VC, Day 35 ovine Unknown O1 Manisa 8 24 - - 
241 Canadian experiment, Sheep 4, VC, Day 35 ovine Unknown O1 Manisa -5 11 - - 
242 Canadian experiment, Sheep 6, VC, Day 35 ovine Unknown O1 Manisa 10 5 - - 
243 Canadian experiment, Sheep 10, UI, Day 35 ovine O SKR 2012 NONE 75 54 + + 
244 Canadian experiment, Sheep 12, UI, Day 35 ovine O SKR 2012 NONE 71 40 + + 
245 Canadian experiment, Sheep 15, UI, Day 35 ovine O SKR 2012 NONE 77 41 + + 
246 Canadian experiment, Sheep 16, UI, Day 35 ovine O SKR 2012 NONE 66 40 + + 
247 Canadian experiment, Sheep 19, UV, Day 35 ovine Unknown NONE 73 56 + + 
248 Canadian experiment, Sheep 22, UI, Day 35 ovine O SKR 2012 NONE 69 44 + + 
249 Canadian experiment, Sheep 24, UI, Day 35 ovine O SKR 2012 NONE 66 39 + + 
  
Appendix A 
213 
 
 
 
 
 
 
 
 
 
Table A-8: Porcine serum samples used to evaluate the c3B C-ELISA’s diagnostic 
performance. 
Serum sample properties are described as follows: (+) positive or (-) negative result using 
a cut-off value of >35% in the AAHL C-ELISA or >47% in the c3B C-ELISA; PT, 
proficiency test; SVD, swine vesicular disease. 
No. Sample details Species Infection serotype 
Vaccinati
on 
serotype 
Percent 
inhibition score Result at cut-off   
AAHL  c3B  AAHL c3B  
1 SVD positive control sample porcine UKG72 NONE 23 23 - - 
2 SVD positive control sample porcine Italy NONE 8 11 - - 
3 PT panel 4 SVD, sample 321 (2014) negative porcine NONE NONE 8 5 - - 
4 PT panel 4 SVD, sample 303 (2014) positive porcine Unknown NONE -6 4 - - 
5 PT panel 4 SVD, sample 295 (2014) positive porcine Unknown NONE 8 4 - - 
6 PT panel 4 SVD, sample 205 (2014) positive porcine Unknown NONE -3 14 - - 
7 PT panel 4 SVD, sample 133 (2014) positive porcine Unknown NONE -5 13 - - 
8 PT panel 4 SVD, sample 77 (2014) negative porcine NONE NONE -7 15 - - 
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model{ 
  x[1:4] ~ dmulti(p[1:4], n) 
  p[1] <- pi*(SeAAHL*Sec3B+covDp) + (1-pi)*((1-SpAAHL)*(1-Spc3B)+covDn) 
  p[2] <- pi*(SeAAHL*(1-Sec3B)-covDp) + (1-pi)*((1-SpAAHL)*Spc3B-covDn) 
  p[3] <- pi*((1-SeAAHL)*Sec3B-covDp) + (1-pi)*(SpAAHL*(1-Spc3B)-covDn) 
  p[4] <- pi*((1-SeAAHL)*(1-Sec3B)+covDp) + (1-pi)*(SpAAHL*Spc3B+covDn) 
  ls <- (SeAAHL-1)*(1-Sec3B) 
  us <- min(SeAAHL,Sec3B) - SeAAHL*Sec3B 
  lc <- (SpAAHL-1)*(1-Spc3B) 
  uc <- min(SpAAHL,Spc3B) - SpAAHL*Spc3B 
  pi ~ dbeta(183.1928,290.8093) ### Mode=0.386, 95% sure > 0.35 
  SeAAHL ~ dbeta(80.0343,8.342) ### Mode=0.915, 95% sure > 0.85 
  SpAAHL ~ dbeta(63.1043,3.3192) ### Mode=0.964, 95% sure > 0.90 
  Sec3B ~ dbeta(35.2821,6.2726) ### Mode=0.8667, 95% sure > 0.75 
  Spc3B ~ dbeta(57.146,5.3496) ### Mode=0.9281, 95% sure > 0.85 
  covDn ~ dunif(lc, uc) 
  covDp ~ dunif(ls, us) 
  rhoD <- covDp / sqrt(SeAAHL*(1-SeAAHL)*Sec3B*(1-Sec3B)) 
  rhoDc <- covDn / sqrt(SpAAHL*(1-SpAAHL)*Spc3B*(1-Spc3B)) 
} 
list(n=272, x=c(91, 12, 14, 155) 
list(pi=0.38, SeAAHL=0.915, SpAAHL=0.964, Sec3B=0.867, Spc3B=0.928) 
 
Figure A-1: Model used for Bayesian Latent Class analysis in OpenBUGS.  
Model modified for two dependent tests, one population with no gold. Data input for 
evaluation of bovine serum samples are in boldface.  
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Table A-9: Bayesian Latent Class analysis control value results for bovine and ovine 
serum samples analysed by c3B and AAHL C-ELISA tests. 
Species and 
parametera Mean  
Standard 
deviation 
Monte 
Carlo 
error 
Minimum  Median  Maximum  
Bovine 
 rhoDc 0.3287 0.22 3.03E-04 -0.02962 0.3199 0.7695 
 rhoD 0.3394 0.24 2.95E-04 -0.07267 0.3427 0.7779 
Ovine 
 rhoDc 0.7777 0.05773 1.02E-04 0.6535 0.7818 0.8784 
 rhoD 0.3042 0.254 2.27E-04 -0.08019 0.276 0.8284 
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Pan-Serotype Diagnostic for Foot-and-Mouth Disease Using the
Consensus Antigen of Nonstructural Protein 3B
Alyssa K. Van Dreumel,a,b Wojtek P. Michalski,a Leanne M. McNabb,a Brian J. Shiell,a Nagendrakumar B. Singanallur,a
Grantley R. Pecka
CSIRO Australian Animal Health Laboratory, Geelong, Victoria, Australiaa; School of Medicine, Faculty of Health, Deakin University, Geelong, Victoria, Australiab
An amino acid consensus sequence for the seven serotypes of foot-and-mouth disease virus (FMDV) nonstructural protein 3B,
including all three contiguous repeats, and its use in the development of a pan-serotype diagnostic test for all seven FMDV sero-
types are described. The amino acid consensus sequence of the 3B protein was determined from a multiple-sequence alignment
of 125 sequences of 3B. The consensus 3B (c3B) protein was expressed as a soluble recombinant fusion protein with maltose-
binding protein (MBP) using a bacterial expression system and was affinity purified using amylose resin. The MBP-c3B protein
was used as the antigen in the development of a competition enzyme-linked immunosorbent assay (cELISA) for detection of an-
ti-3B antibodies in bovine sera. The comparative diagnostic sensitivity and specificity at 47% inhibition were estimated to be
87.22% and 93.15%, respectively. Reactivity of c3B with bovine sera representing the seven FMDV serotypes demonstrated the
pan-serotype diagnostic capability of this bioreagent. The consensus antigen and competition ELISA are described here as candi-
dates for a pan-serotype diagnostic test for FMDV infection.
Foot-and-mouth disease (FMD) is the most contagious viralvesicular disease that affects cloven-hoofed livestock species.
FMD has significant global socioeconomic consequences, from
national livestock industries suffering because of international
trade restrictions to subsistence farmers suffering because of losses
of stock productivity and livelihoods. Western European, North
American, and Far East Asian/Pacific regions and most South
American countries have official recognition of freedom-from-
FMD status, with or without vaccination, by theWorld Organiza-
tion for Animal Health (OIE). Regions in which FMD remains
endemic tend to be those of lesser economic capacity, and this
limits their ability to control or to eradicate the disease (1, 2). As a
result, FMD remains an ongoing problem in regions in which it is
endemic, and it is a persistent threat to regions that are free of the
disease.
Seven serotypes have been described for foot-and-mouth dis-
ease virus (FMDV), i.e., O, A, C, Asia 1, and South African Terri-
tories 1 (SAT1), SAT2, and SAT3. The disease forms produced by
each serotype are clinically indistinguishable (3); similarly, FMD
is clinically indistinguishable from other vesicular lesion-causing
diseases, such as vesicular stomatitis, swine vesicular exanthema,
and swine vesicular disease, and laboratory-based clinical diagno-
sis is required (4, 5). FMD infectionsmay bemild or subclinical in
ovine or caprine species, further complicating clinical diagnosis
(6, 7). Exposure to one serotype does not confer cross-serotype
immunity, potentially complicating diagnosis when multiple se-
rotypes are circulating during an outbreak (8). A definitive diag-
nosis of FMD is possible only with laboratory testing.
Conventional serological assays for FMD, including the virus
neutralization test, liquid-phase blocking enzyme-linked immu-
nosorbent assay (ELISA), and solid-phase competition ELISA
(cELISA), detect antibodies to structural proteins and are serotype
specific (9–11). However, immunoassays based on FMDV non-
structural proteins (NSPs) have two advantages over these con-
ventional assays, namely, (i) detection ofmultiple serotypes due to
their high sequence homology and (ii) differentiation of infected
from vaccinated animals (DIVA) when FMDV structural proteins
are used in vaccines (12–14). DIVA tests are important for sero-
logical surveys, providing evidence of FMDor freedom fromFMD
in vaccinated herds (15, 16). Most serodiagnostic DIVA tests for
FMD are enzyme-linked immunosorbent assays that use NSP an-
tigens produced in either bacterial or baculovirus-mediated ex-
pression systems, in an indirect or competitive format. The NSP
intermediate 3ABC is commonly used as an antigen for FMDV
DIVA testing because of its high immunogenicity and relatively
low abundance in vaccine preparations generated from FMDV-
infected cells (4).
The NSP 3B, a constituent of the 3ABC protein, is highly con-
served across FMDV serotypes, contains a high density of linear
B-cell epitopes, is highly immunogenic, and lacks the autocatalytic
activity associated with the 3C component (17). FMDV is the only
picornavirus that encodes three similar repeats of 3B in series,
essentially tripling the number of potential epitopes (18, 19).
These innate characteristics set 3B apart as a prime target for the
development of a pan-serotype diagnostic bioreagent. We hy-
pothesized that, through alteration of the amino acid sequence of
each triplet to better mimic the sequences present across all
FMDV serotypes, an antigenic consensus sequence for 3B suitable
for use as a pan-serotype diagnostic reagent for FMDV could be
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developed. This study takes a novel approach to pan-serotype an-
tigen design and applies it to the development of a low-cost sero-
diagnostic ELISA with potential DIVA application. We describe
the in silico identification of a consensus 3B (c3B) sequence, the
purification and characterization of recombinant c3B, and its use
in the development of a cELISA diagnostic test.
MATERIALS AND METHODS
Sources of materials. The NCBI GenBank accession numbers used to
derive FMDV 3B amino acid sequences are listed in Table S1 in the sup-
plementalmaterial. Competent BL21 Escherichia coli, pMAL-c5e plasmid,
amylose resin, and rabbit anti-maltose-binding protein (MBP) antibody
were fromNew England BioLabs (Genesearch, Australia). Serum samples
were obtained from the national serum bank at the CSIRO Australian
Animal Health Laboratory and included at least one sample of each
FMDV serotype (see Table S2 in the supplementalmaterial). All imported
sera were gamma irradiated (50 Gy). Oligonucleotide primers were from
Sigma-Aldrich (Australia).
Identification and analysis of FMDV 3B protein consensus se-
quence. Full-length amino acid sequences were translated from 374
FMDV nonstructural protein 3B gene entries in the NCBI GenBank da-
tabase, and redundant sequences were removed. A multiple-sequence
alignment of the remaining 125 sequences was generated using the L-
INS-i algorithm of MAFFT v6.864 (20, 21). The consensus 3B (c3B) se-
quence was derived from the aligned sequences using WebLogo software
v3.0 (22), with the residue with the greatest probability of occurrence at
each position being chosen as canonical. Posttranslational modifications
and biophysical characteristics of c3B were investigated using a variety of
online tools, i.e., phosphorylation by the GPP prediction server (23), O-
linked glycosylation by the NetOGlyc 3.1 server (24), N-linked glycosyla-
tion by NetNGlyc 1.0 (http://www.cbs.dtu.dk/services/NetNGlyc), hy-
drophobicity by the method described by Welling et al. (25), available on
the ProtScale server (http://web.expasy.org/protscale), and continuous
B-cell epitopes by COBEPro (26); the theoretical molecular mass was
calculated using the ExPASy Compute pI/MW tool (27).
Plasmids and cloning. A gene encoding c3B was codon optimized
using Gene-GPS expression optimization technology (DNA2.0), for ex-
pression in E. coli. The c3B gene was synthesized and provided in pJ204
(DNA2.0). PCR was used to amplify the c3B gene using the primers 5=-A
AGGTACCGGGTCCGTACGCTGGTCCT-3= and 5=-CGTCCATGGCC
TTATTCCGTGACGATCAGGTTCTT-3= (enzyme restriction sites are
underlined). PCR conditions for amplification of c3B were 94°C for 2
min; 30 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 1 min; and 1
cycle of 72°C for 7 min. PCR products were purified from agarose gels
using a QIAquick gel extraction kit (Qiagen). The c3B PCR product and
pMAL-c5e were digested with KpnI and NcoI (Promega). Digested plas-
mid was incubated for 15 min at 37°C with 1 U thermosensitive alkaline
phosphatase (Promega). Digested products were purified using a
QIAquick PCR purification kit (Qiagen) and ligated using T4 DNA ligase
(Promega). Chemically competent DH5 E. coli (Invitrogen) was trans-
formed and pMAL-c5e containing c3B (pMAL-c3B) was purified from
individual colonies using a Wizard Plus SV miniprep DNA purification
kit (Promega). DNA sequence integrity of all constructs was confirmed by
sequencing (Micromon, Australia) using the vector-specific primers 5=-G
GTCGTCAGACTGTCGATGAAGC-3= and 5=-TGTCCTACTCAGGAG
AGCGTTCAC-3=.
Expression and purification of recombinant proteins. Chemically
competent BL21 E. coli (NEB) was transformed with 10 ng pMAL-c5e or
pMAL-c3B for overexpression of recombinant MBP or MBP-c3B fusion
protein, according to the manufacturer’s instructions. Cultures of each
clone were expanded to 100 ml in Luria-Bertani broth containing 100
g/ml ampicillin and 0.2% (wt/vol) glucose by incubation at 37°C, with
shaking at 225 rpm in an orbital shaking incubator, until the optical den-
sity at 600 nm (OD600) reached 0.5 to 0.6 units. Protein expression was
induced by the addition of isopropyl--D-thiogalactoside (IPTG) to a
final concentration of 1mM, and cells were incubated for 3 h at 37°C with
shaking at 225 rpm in an orbital shaking incubator. Cells were harvested
by centrifugation at 4,000 g for 10min. Cell pellets were resuspended in
5ml BugBustermastermix (MerckMillipore) and allowed to lyse at room
temperature (RT) for 20 min on a rocking platform mixer. The lysate was
clarified by centrifugation at 16,000 g for 20 min at 4°C, and the super-
natant containing soluble recombinant protein was retained.
Recombinant MBP and MBP-c3B were purified by affinity chroma-
tography on amylose resin, according to the manufacturer’s instructions.
Clarified lysate was diluted 1:18 in binding buffer (20 mM Tris [pH 7.4],
200mMNaCl, 1mMEDTA), and then recombinant proteins were bound
to the resin, washedwith 10 column volumes of binding buffer, and eluted
with binding buffer containing 10 mM maltose. Eluted proteins were
dialyzed against 25 mM Tris (pH 8.0), and protein concentrations were
determined using a Pierce bicinchoninic acid protein assay kit (Thermo
Scientific). Purified protein was diluted to 0.56 mg/ml or 0.05 mg/ml in
50% (wt/vol) glycerol and stored at20°C.
Recombinant FMDV 3ABCwas produced as described above with the
following exceptions: chemically competent BL21(DE3) E. coli (C6000-
03; Invitrogen) was transformed with 10 ng purified pRSETb-3ABC (28).
3ABC inclusion bodies were partially purified using BugBuster master
mix (Novagen) containing protease inhibitors (P8849; Sigma), according
to the manufacturers’ instructions. Inclusion bodies were resuspended
and solubilized by being heated to 100°C for 10min in SDS-PAGE sample
reducing buffer (Invitrogen).
3ABC was resolved by SDS-PAGE on NuPAGE Novex 4 to 12% Bis-
Tris gels (1 mm; two-dimensional well format), in morpholinepropane-
sulfonic acid (MOPS) running buffer (Invitrogen), at 200 V for 50 min.
Gel segments containing 3ABC were visualized with ice-cold 0.3 M KCl
and excised. The protein was passively eluted into phosphate-buffered
saline (PBS) with 0.1% (wt/vol) SDS and was dialyzed against PBS.
Immunogen preparation and antiserumproduction.All procedures
involving animals were approved by the Australian Animal Health Labo-
ratory Animal Ethics Committee. Immunogen was prepared as a water-
in-oil emulsion of purified 3ABCprotein and triple adjuvant, as described
previously (29). New Zealand White rabbits were immunized by intra-
muscular injection on three occasions approximately 3 weeks apart. Each
immunization used a total of 75 g 3ABC in two 0.25-ml doses, with one
dose in each hind leg. Sera were obtained by exsanguination and were
assessed for immunoreactivity with 3ABC by immunoblotting.
SDS-PAGE and immunodetection. Protein samples were analyzed by
SDS-PAGE under reducing conditions, in precast NuPAGE Novex 4 to
12% Bis-Tris gels, in MOPS or morpholineethanesulfonic acid (MES)
running buffer (Invitrogen). Protein bands were visualized by staining
with Coomassie brilliant blue R-250 (CBB) or silver nitrate. Proteins were
transferred to polyvinylidene fluoride (PVDF) membranes by Western
blotting, in 10 mM N-cyclohexyl-3-aminopropanesulfonic acid (CAPS)
buffer (pH 11) containing 10% (vol/vol) methanol, for immunodetec-
tion. Membranes were blocked for 1 h at RT with 5% (wt/vol) skim milk
powder in Tris-buffered saline (pH 7.3) containing 0.05% (vol/vol)
Tween 20 and then were probed with either rabbit anti-MBP antibody or
rabbit anti-3ABC antiserum (prepared in-house) diluted 1:20,000, fol-
lowed by goat anti-rabbit IgG-horseradish peroxidase (HRP) conjugate
(170-6515; Bio-Rad) diluted 1:40,000. Immunoreactive bands were visu-
alized using ECL Plus substrate (Pierce) and a Typhoon FLA9000 fluores-
cence laser scanner (GE Healthcare).
Mass spectrometry. Purified proteins were separated by SDS-PAGE
and stained with CBB. Protein bands were excised and subjected to in-gel
digestion with trypsin or chymotrypsin (30). Extracted peptides were an-
alyzed by liquid chromatography-tandem mass spectrometry (LC-MS/
MS) using a Dionex UltiMate 3000 nano-high-performance liquid chro-
matography (HPLC) system connected directly to the nanospray ion
source of a Thermo Orbitrap Velos Pro hybrid ion trap-Orbitrap mass
spectrometer (Thermo Scientific). Proteins were identified using the Se-
quest algorithm within the Proteome Discoverer 1.4 platform (Thermo
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Scientific). Briefly, mass spectra of HPLC-separated peptides were
matched with theoretical mass spectra produced by in silico tryptic or
chymotryptic digestion of protein sequences from a custom database.
Search results were filtered with a single threshold; matches to peptides
were reported only if the Sequest cross-correlation factor (Xcorr) was
1.5 for a singly charged peptide ion,2.0 for a doubly charged peptide
ion, or2.5 for a triply charged peptide ion.
Enzyme-linked immunosorbent assays. Unless stated otherwise, all
assays included a blank control that consisted of blocking buffer (PBS [pH
7.3] with 0.05% [vol/vol] Tween 20 [PBST] plus 5% [wt/vol] skim milk
powder) only and aminimumabsorbance (Amin) control that consisted of
all test reagents except primary antibody. All samples were prepared in
duplicate in 96-well Nunc MaxiSorb microtiter plates (Thermo Scien-
tific), and all incubations were performed at 37°C on an orbital shaker.
Plates were coated for 1 h with 50 l/well of antigen diluted in coating
buffer (50mM carbonate-bicarbonate [pH 9.6]), and blocking buffer was
applied at 200 l/well for 30 min; all antibodies or sera were diluted in
blocking buffer and used at 50 l/well for 30 min except for HRP-conju-
gated secondary antibody, which was incubated for 1 h. Signal color de-
velopment was performed by incubation with 50 l/well of the HRP sub-
strate 3,3=,5,5=-tetramethylbenzidine (TMB) (Sigma) for 10 min at RT,
and the colorimetric reaction was stopped by the addition of 50l/well of
1 M sulfuric acid. Absorbance was measured at 450 nm using a microtiter
plate reader (MultiSkan EX; Thermo Scientific). Washes were performed
in triplicate with wash buffer (200l/well Dulbecco’s phosphate-buffered
saline [DPBS] with 0.5 mM MgCl2 and 0.7 mM CaCl2), using an auto-
mated plate washer (ELx405 select deep well microplate washer; BioTek);
plates were washed after incubations with antigen, blocking buffer, anti-
serum or antibody, and HRP-conjugated polyclonal rabbit anti-chicken
IgG antibody (Pierce) diluted 1:4,000.
Determination of c3B antigen coating concentration and absor-
bancemaximumbyELISA.Checkerboard titrations ofMBPorMBP-c3B
against chicken anti-3ABCpolyclonal antibody (31)were performed in an
indirect ELISA format. Rows of 96-well plates were coated with purified
MBP-c3B fusion protein or MBP, serially diluted 2-fold from 70 ng/well
to 1 ng/well and incubated for 1 h with chicken anti-3ABC antibody,
FIG 1 FMDV 3B amino acid consensus sequence and B-cell epitope predictions. (A) WebLogo graphic depicting amino acid residue conservation of the 3B
protein consensus sequence. Letter heights indicate the relative frequency (probability) of each amino acid appearing at that position within the sequence (22).
Amino acid properties shown are as follows: green, polar; purple, neutral; blue, basic; red, acidic; black, hydrophobic. (B)Histogramgenerated byCOBEPro (26),
mapping predicted antigenic propensity scores (/). Published B-cell epitopes of FMDV protein 3B are shown boxed in gray.
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serially diluted 2-fold from 1:40 to 1:5,120. Plates were developed, and the
absorbance at 450 nm (A450) of each sample was determined. A450 read-
ings were plotted as mean	 standard deviation (SD) and were fitted with
a sigmoidal dose-response curve by nonlinear regression analysis using
GraphPad Prism (v5.02). The absorbance maximum was confirmed by
cELISA, in which titration of chicken anti-3ABC antibody was performed
by incubating wells coated with MBP-c3B (50 ng/well) with chicken anti-
3ABC antibody diluted 1:300, 1:350, or 1:400 in blocking buffer. Plates
were developed, and the A450 of each sample was measured.
Development of c3B cELISA. Plates were coated with 50 ng purified
MBP-c3B fusion protein per well. Test sera and negative-control serum
(C) (naive FMDV antibody-negative serum) were used at a dilution of
1:5. Positive control serum (28-day postinfection positive-control serum,
produced by sequential infection with C1 Detmold, 8WPI Asia 1 Shamir,
and 12WPI A22 Iraq) was used diluted 1:5 and 1:50, to represent high-
positive controls (C) and low-positive controls (C), respectively.
Competing chicken anti-3ABC antibody diluted 1:350 was added to each
well (31). All assays included duplicate blank control wells and controls
(quadruplicate) that contained all test reagents except test serum, for cal-
culation of the absorbance maximum (Amax) of the test matrix. Results
were expressed as percent inhibition (PI) using the following formula:
PI
 100 [(mean A450 of serum/mean Amax) 100].
Preliminary control sample repeatability.Upper and lower limits for
the Amax values and positive and negative control sera were determined by
repeating the cELISA method once per day for 10 days. Limits were ex-
pressed as the mean and range.
Analytical sensitivity and specificity of c3B cELISA.Analytical sensi-
tivity (ASe) was determined by endpoint dilution of the positive bovine
control serum against chicken anti-3ABC antibody. Positive and negative
control sera were serially 2-fold diluted, added to a 96-well plate coated
with MBP-c3B, and then titrated against dilutions of chicken anti-3ABC
antibody. Results were expressed as PI and were used to construct dose-
response curves. Analytical specificity (ASp) was assessed using bovine
sera that were positive for bluetongue virus (BTV) antibodies (n
 19) or
vesicular stomatitis virus (VSV) (n
 2), ovine sera that were positive for
BTV antibodies (n 
 17), and porcine sera that were positive for swine
vesicular disease virus (SVDV) antibodies (n
 7).
Diagnostic sensitivity and specificity. Sera derived from 105 natu-
rally or experimentally infected cattle, including at least one representa-
tive of each FMDV serotype, were used to estimate the diagnostic sensi-
tivity (DSe). Seroconversions were confirmed using the AAHL 3ABC
cELISA (31). Sera from 184 FMDV antibody-negative bovine samples
were used to estimate the diagnostic specificity (DSp). Receiver operating
characteristic (ROC) curve analysis using the method of DeLong et al.
(32) was performed using MedCalc for Windows v13.2.2.0 (MedCalc
Software, Belgium), to identify the optimal cutoff value for declaring pos-
itive and negative test results.
Bayesian latent class analysis. The DSe and DSp of the c3B cELISA
were compared with those of the AAHL 3ABC cELISA by using Bayesian
modeling for two dependent tests for one population with no gold stan-
dard (31, 33). Beta distribution parameters were derived using Beta
Buster. Bayesian inferences were based on the joint posterior distribution,
approximated using OpenBUGS (34) (see Table S3 in the supplemental
material). The convergence estimates were derived using 2  106 itera-
tions of simulation, with sampling performed every 1  105 iterations
until theMonte Carlo (MC) error value, defined as the standard deviation
divided by the square root of the number of iterations, was 5% of the
standard deviation of the node estimate. Final inferences of DSe and DSp
were given as the means of their 95% probability intervals.
RESULTS
Identification and analysis of 3B protein consensus sequence.
WebLogo analysis of a multiple-sequence alignment of translated
gene sequences of FMDV 3B revealed a 71-amino-acid consensus
sequence (c3B); the sequence consisted of the most prevalent
amino acids at the given positions within all sequences (Fig. 1A).
The regions of c3B that were predicted to be most antigenic were
residues 9 to 15, 32 to 38, and 54 to 59, with epitopic propensity
scores of 0.90, 0.81, and 0.81, respectively (Fig. 1B). Amino acids
11 to 15 and 34 to 38 correspond to the known B-cell epitope
QKPLK, which was found in the first and second repeats of the 3B
triplet (17). Residues 54 to 59 (VKKPVA) are present in the third
repeat and correspond to a predicted B-cell epitope. The entire
FIG 2 Recombinant c3B protein expression, purification, and detection. (A) Coomassie blue-stained polyacrylamide gel of recombinant MBP-c3B protein
expressed in BL21 E. coli and affinity purified using amylose resin. Lane M, molecular mass markers (Mark 12; Invitrogen); lane 1, preinduction whole-cell
extract; lane 2, 2-h postinduction whole-cell extract; lane 3, soluble protein fraction; lane 4, soluble protein fraction after 0.45-m filtration; lane 5, unbound
protein fraction; lanes 6 and 7, consecutive column wash samples; lane 8, eluted purified protein. Arrow, MBP-c3B at 52 kDa. (B) Coomassie blue-stained
polyacrylamide gel (left) and immunoblots (center and right) of purified recombinantMBP (lanes 1, 3, and 5) orMBP-c3B (lanes 2, 4, and 6). LanesM,molecular
mass markers (See Blue Plus 2; Invitrogen). The center panel was probed with rabbit anti-MBP antibody (NEB). The right panel was probed with rabbit
anti-3ABC antiserum. The primary antibody and antiserum were diluted 1:20,000, and the secondary HRP-conjugated anti-rabbit IgG antibody was diluted
1:40,000. MBP and MBP-c3B are indicated (arrows) at approximately 42 and 52 kDa, respectively.
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c3B sequence produced a probability of antigenicity score of
0.6118. Analysis of posttranslational modification predictions for
the 3B protein indicated that neither O-linked (Thr70) nor N-
linked (Asn66) glycosylation was likely, scoring below threshold
values. Phosphorylation was predicted for all three tyrosine resi-
dues, consistent with known phosphorylation sites (35). The the-
oretical molecular mass of MBP-c3B was 52.89 kDa.
Expression and characterization of c3B protein. Recombi-
nant MBP and MBP-c3B were expressed in BL21 E. coli. SDS-
PAGE analysis revealed protein bands corresponding toMBP and
MBP-c3B at approximately 42 and 52 kDa, respectively (Fig. 2A).
These bands were visible only in the soluble protein fractions of
lysates fromBL21 E. coli cultures that had been treated with IPTG.
A total of 24 mg MBP and 14 mg MBP-c3B protein were affinity
purified from 100 ml of culture. The identities of purified MBP
and MBP-c3B were confirmed by immunodetection with anti-
3ABC antibody (Fig. 2B) and LC-MS/MS analysis. Mass spectro-
metric analysis of MBP-c3B resulted in peptide matches to MBP
and c3B. Peptide matches to c3B provided 94% coverage of the
protein.
Titration of c3B and anti-3ABC antibody by ELISA. Check-
erboard titrations by indirect ELISA of c3B and chicken anti-
3ABC antibody gave A450 values of approximately 1.5 after devel-
opment for 10 min using 50 ng/well c3B and antibody diluted
1:640 (Fig. 3A). Titrations by cELISA confirmed that the optimal
concentration of MBP-c3B antigen was 50 ng/well and the opti-
mal dilution of chicken anti-3ABC antibody was 1:350. These
conditions produced an A450 value of 1.42 (95% confidence inter-
val [CI], 1.33 to 1.50) (n 
 28). Nonspecific binding of chicken
anti-3ABC antibody to matrix or MBP under these conditions
yielded an A450 value of0.1 (Fig. 3B).
Control sample limits and repeatability.PI limits (ranges) for
the high-positive-control (C), low-positive-control (C),
and negative-control (C) sera were determined to be as follows:
C, 87.8% (85.0 to 90.8%); C, 66.0% (60.0 to 72.8%); C,
23.2% (15.0 to 35.0%) (n 
 10). The absorbance limit for Amax
was 1.081 (0.85 to 1.71). Wells without test sera produced back-
ground A450 readings of0.06.
Evaluation of analytical sensitivity and specificity of c3B
cELISA. The limit of detection of the positive-control serum was
identified at a dilution of 1:80 when diluted with negative-control
serum or blocking buffer (Fig. 4A). The choice of diluents had no
effect on PI at the optimal dilution of competing antibody (Fig.
4B). At higher dilutions, the degree of inhibition was below the PI
cutoff value. Negative-control serum PI values were all below the
PI cutoff value, even at the highest dilution (1:350) of chicken
anti-3ABC antibody tested (Fig. 4C). Bovine, ovine, and porcine
sera from animals infected with BTV, VSV, or SVDV all tested
negative using the c3B cELISA.
Determinationofdiagnostic sensitivity andspecificityof c3B
cELISA. The DSe and DSp of the c3B cELISA were determined
using 289 sera (105 positive and 184 negative, as determined using
the AAHL 3ABC cELISA). The cross-classified data showed 93
true-positive, 14 false-positive, 12 false-negative, and 170 true-
negative sera. ROC curve analyses of these data gave an area under
the curve (AUC) of 0.944 and aYouden index (36) value of 0.8164,
indicating that the test has high discriminatory power (37) (Fig. 5A)
and a PI cutoff value for a positive sample of47% (Fig. 5B). At a
PI of 47%, the DSe andDSpwere 87.62% (95%CI, 79.8 to 93.2%)
and 94.02% (95%CI, 89.6 to 97.00%), respectively. Bayesian anal-
ysis of the c3B cELISA gave a sensitivity of 87.22% (95% proba-
bility interval, 81.37 to 92.37%) and a specificity of 93.15% (95%
probability interval, 89.59 to 96.19%) (Table 1).
Seven FMDV-infected, NSP-antibody-positive bovine serum
samples, representing the seven serotypes of FMDV, were ana-
lyzed, and all were detected using the c3B cELISA. All samples
produced PI values between 71 and 83% (cutoff value, 47%).
DISCUSSION
Immunoassays based on FMDV nonstructural proteins (NSPs)
have two significant advantages over those using structural pro-
teins, namely, the capacity to detectmultiple serotypes due to their
high sequence homology and the ability to differentiate infected
from vaccinated animals (12–14). The reference DIVA test ad-
opted by the OIE for FMDV is an ELISA that detects antibodies
against the NSP 3ABC (NCPanaftosa screening test) comple-
mented by an enzyme-linked immunoelectrotransfer blot assay
(12, 38). A problem associated with the use of 3ABC is the pres-
ence of vaccine-associated 3A protein, which may complicate
DIVA testing due to the presence of 3A-specific antibodies in sera
from some vaccinated cattle (15, 39, 40). Furthermore, due to its
FIG 3 Checkerboard titration of MBP-c3B antigen and chicken anti-3ABC
antibody by indirect ELISA. Sigmoidal dose-response curve (variable slope)
analyses of MBP-c3B (A) and MBP (B) titrated against a 2-fold dilution series
of chicken anti-3ABC antibody by indirect ELISA. Dilutions are indicated (B).
Values shown aremean	 standard deviation of absorbance at 450 nm for each
concentration of protein tested (n
 3).
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expression as insoluble inclusion bodies in E. coli and the presence
of the autocatalytic 3C protein segment, recombinant 3ABC is
difficult to produce (28, 41–43; our unpublished observations).
Recombinant 3A, 3B, and 3AB have also been shown to be insol-
uble when expressed as His-tagged fusion proteins (44); however,
others reported expression of proteins in soluble form taggedwith
6His (45), with the solubility-enhancing leader sequence His-
patch (HP) thioredoxin (46) or glutathione S-transferase (GST)
(47). This study described the expression of soluble c3B protein
N-terminally fused to the known solubility enhancer MBP and its
use in the development of a cELISA suitable for detection of anti-
bodies to NSPs from each of the seven FMDV serotypes.
Previously developed FMDV NSP ELISAs that used FMDV 3B
protein as the antigen have capitalized on one of the unique innate
properties of the protein, i.e., a triplet of highly conserved B-cell
epitopes, one each within the segments 3B1, 3B2, and 3B3 (17, 18,
40). Tests for the detection of FMDV-positive antisera have been
developed using synthetic 3B peptides; however, this is at a cost
premium and is limited by the length of peptides that can be pro-
duced. A lower-cost alternative is the use of recombinant 3B pep-
tides produced in E. coli (17, 40, 46, 48). By extension, the use of
tandem repeats of 3B peptides to effectively multiply the number
of potential antibody binding sites on the antigen has been used
successfully to differentiate infected and vaccinated animals (18,
48). In addition, others have developed DIVA tests by expressing
the entire 3B protein individually or as part of a larger FMDVNSP
protein, typically 3AB, 2C3AB, or 3ABC (for recent examples, see
references 31, 45, 49–51). In each case, however, the sequence used
was derived from a single FMDV strain. In contrast, our approach
to developing a 3B diagnostic assay was to generate a consensus 3B
(c3B) sequence to eliminate potential strain-specific deficiencies
in specificity by better mimicking the 3B epitopes of all serotypes.
Thus, c3B was representative of all FMDV 3B proteins, irrespec-
tive of serotype. It is worth noting that the GenBank database
FIG 4 Analytical sensitivity of c3B competition ELISA. (A) Analysis of the limit of detection for the positive-control serum serially diluted 2-fold in blocking
buffer (left) or negative-control bovine serum (right), performed using chicken anti-3ABC antibody diluted as indicated. (B) Comparison of percent inhibition
values for positive serum diluted 2-fold in blocking buffer or negative-control bovine serum, using chicken anti-3ABC antibody diluted 1:350. (C) Percent
inhibition of negative-control bovine serum serially diluted 2-fold with blocking buffer, using chicken anti-3ABC antibody diluted as indicated.
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contains significantly more sequence submissions for type O and
A serotypes than the other serotypes, and this is reflected in the
consensus sequence. The proportions of FMDV 3B gene se-
quences by serotype after the removal of redundant sequences
were as follows: O, 35.2%; A, 28%; SAT1, 8%; SAT2, 5.6%; SAT3,
2.4%; Asia 1, 17.6%; C, 3.2%. Predicted antigenic regions and
B-cell epitopes of c3B were consistent with epitopes of 3B deter-
mined experimentally (17, 18, 40). An additional epitope (VKKP
VA), not previously described, was predicted in the third repeat of
the c3B protein. It remains to be determined whether this predic-
tion translates into a biologically relevant immunogenic site.
The combination ofminimal predicted posttranslationalmod-
ifications, a lack of cysteine residues, and known linear epitopes
made c3B ideal for productionusing a bacterial expression system.
Recombinant c3B was generated using a synthetic codon-opti-
mized gene in BL21 E. coli. Previous studies that used E. coli-
expressed proteins to develop FMDVdiagnostic tests required the
addition of E. coli lysates to sample serum diluents, to preabsorb
nonspecific background reactivity (39, 52). It has been suggested
that this background reactivity may be due in part to inclusion of
the N-terminal 3A sequence, which shares sequence homology
with a transposase IS4 family protein fromE. coli (53). In addition,
10% (vol/vol) equine serum has been required in blocking buffers
tominimize background reactivity. The assay described here elim-
inated these additional requirements by using amylose resin to
affinity purify MBP-c3B, thereby removing potential E. coli pro-
tein contamination. Expression yielded approximately 14 mg of
affinity-purified MBP-c3B antigen per 100 ml of culture, i.e., suf-
ficient antigen to coat approximately 2,800 plates with 96 wells, at
50 ng/well. Others have reported yields for 3AB and 3B proteins of
3 and 1 mg/100 ml culture, respectively (44, 54). Coomassie blue
staining of MBP-c3B revealed a band at52 kDa, consistent with
its predicted molecular mass. In addition, antibodies specific for
3ABC and MBP produced similarly sized bands in immunoblot-
ting, confirming the identity ofMBP-c3B. Additional smaller pro-
tein bands were observed on stained gels and immunoblots, sug-
gesting partial degradation of MBP-c3B. Immunoblotting with
anti-MBP and anti-3ABC antibodies indicated that degradation
was due to cleavage of the c3B protein rather than MBP. The
observed pattern of 3B protein degradation was similar to that
shown in a study of a 6His-tagged 3B protein purified from
BL21 E. coli (45). Rabbit anti-3ABC antisera and chicken anti-
3ABC antibody did not cross-react with the MBP tag or any other
assay components in an indirect ELISA.
The c3B cELISA showed high analytical sensitivity by endpoint
dilution of positive control sera from 1:5 to 1:320. The analytical
specificity was 100%, as PI values observed using sera from ani-
mals (cattle, sheep, or pigs) infected with other clinically relevant
diseases were all below the 47% cutoff value. The c3B cELISA
detected the reference serum representatives of all seven FMDV
serotypes, demonstrating the assay’s potential as a pan-serotype
test. Future work will require testing of a more diverse population
of samples of each serotype. The test also discriminated between
infected and uninfected animals, based on a PI cutoff value deter-
mined using the maximum Youden index, which gives equal
weight to the sensitivity and specificity of the test. A validated test
would require modifications to the balance between DSe andDSp
FIG 5 Receiver operating characteristic (ROC) curve analysis of c3B competition ELISA. (A) ROC curve analysis of c3B cELISA results derived from 289 cattle
sera. Dotted lines, 95% confidence intervals. Circle (upper left corner), Youden index of 0.8164. AUC, area under the curve. (B) Plot-versus-criterion analysis for
the c3B cELISA. The data set from panel A was used to plot the sensitivity (solid line) or specificity (dashed line) at different cutoff values, and results indicated
an optimal PI cutoff value of47%. Respective 95% confidence intervals are shown.
TABLE 1 Bayesian latent class analysis of c3B and AAHL 3ABC cELISAs
ELISA and
parametera
Mean
(%) SD MC error
Minimum
(%)
Median
(%)
Maximum
(%)
c3B
DSe 87.22 0.03 2.75E05 81.37 87.34 92.37
DSp 93.15 0.02 1.83E05 89.59 93.24 96.19
AAHL
DSe 90.78 0.03 3.59E05 84.66 91.01 95.59
DSp 95.69 0.02 3.09E05 91.25 95.92 98.82
a DSe, diagnostic sensitivity; DSp, diagnostic specificity.
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according to the disease status of the country or region of the test’s
intended use. Using a cutoff value of 47% means that the DSe and
DSp of the c3B cELISA are slightly lower than those of the AAHL
cELISA. This may be explained by the fact that the AAHL cELISA
was validated using 2,500 samples, compared with the prototype
c3B cELISA presented here, which has been assessed using almost
10-fold fewer samples. The diagnostic sensitivity and specificity of
the c3B cELISA are anticipated to improve with the evaluation of
increasing numbers of samples during validation. In the absence
of a gold standard test, we showed, using Bayesian latent class
analysis, that theDSe andDSpof our test are similar to those of the
AAHL cELISA, with decreases of only 0.40% and 0.86%, respec-
tively.
Herein we have described a novel purified consensus 3B biore-
agent expressed in high yield and in soluble form in E. coli. We
describe its use as an effective pan-serotype FMDV diagnostic re-
agent in a cELISA format, and we provide preliminary assessment
of its analytical sensitivity and diagnostic sensitivity and specific-
ity. Future work will build on these data as part of a comprehen-
sive validation study encompassing testing of all serotypes, multi-
ple host species, ability to differentiate infected from vaccinated
animals, and performance against benchmark tests. We are cur-
rently seeking access to panels of sera for this purpose.
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